,target_label,summary
0,0,"The patient is a 43-year-old white male with a BMI of 29.65. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1,1,"The patient is a 63-year-old white male with a BMI of 28.53. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced both bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. Additionally, he has experienced an adverse effect of thrombosis."
2,0,"A female patient in the conventional surgery treatment arm, who has used narcotics for 3 days. She is experiencing symptoms but is still able to walk around. The pathology results indicate malignancy."
3,1,The patient is a male who is undergoing conventional surgery and has abdominal wall adhesions as well as bowel adhesions. He has used narcotics for 2 days and has symptoms but is still able to walk around. The pathology results indicate malignancy.
4,1,"The patient is a 35-year-old white male with a BMI of 32.96. He is receiving the FOLFOX treatment regimen and has been adherent to the chemotherapy cycles, completing 12 cycles so far. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of diarrhea and infection during the course of treatment."
5,0,The patient is a 61-year-old white female participating in the treatment arm involving 5FU/LV and radiation therapy. She has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. One notable adverse effect she is facing is fatigue.
6,0,"The patient is a 66-year-old white female with a BMI of 18.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
7,1,The patient is a 75-year-old white male with a BMI of 28.06. He is fully active and is receiving treatment with the FOLFOX regimen for colon cancer. His KRAS biomarker status is wild-type.
8,1,"The patient is a 55-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. He is currently experiencing adverse effects such as low levels of granulocytes/bands and white blood cells, as well as nausea."
9,0,The patient is a 42-year-old white female with a BMI of 25.22. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
10,1,"The patient is a 75-year-old white male with a BMI of 21.33. He is receiving treatment with FOLFOX for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker analysis shows a mutant status."
11,1,"The patient is a 72-year-old white male with a BMI of 22.79. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type, indicating a potentially better response to the treatment regimen."
12,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He experienced complications post-surgery and required 7 days of narcotic use for pain management. Despite having symptoms, he is still able to walk around. The pathology report indicates a malignant condition."
13,0,"The patient is a 52-year-old white female with a BMI of 36.47. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
14,1,The patient is a 64-year-old white female who is fully active and is receiving treatment with Sunitinib.
15,1,"The patient is a 66-year-old white male with a BMI of 25.5 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
16,0,The patient is a female who underwent laparoscopic-assisted colectomy. She did not require any narcotics for pain management post-surgery. Her histology shows symptoms but she is still able to move around. Pathology results indicate that the condition is malignant.
17,1,"The patient is a 42-year-old white male with a BMI of 21.22 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is mutant."
18,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
19,0,"The patient is a 55-year-old white male with a BMI of 25.45. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
20,0,The patient is a 65-year-old white female with a BMI of 24.46. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
21,1,"The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating an ambulatory performance status."
22,0,"The patient is a 56-year-old white male with a BMI of 25.88 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as a skin rash resembling acne."
23,1,The patient is a 71-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
24,1,"The patient is a 64-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing a common adverse effect known as granulocytes/bands."
25,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days following the procedure. Histologically, she was found to be in bed less than 50% of the time. Pathologically, the diagnosis was malignant."
26,0,"The patient is a 63-year-old white male with a BMI of 25.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
27,0,"The patient is a 39-year-old female of a race categorized as ""other"" with a BMI of 29.41. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
28,1,The patient is a 46-year-old white male participating in the ECF + Radiation treatment arm. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory).
29,1,"This patient is a 62-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has poorly differentiated histology and is experiencing adverse effects including low neutrophils/granulocytes, low leukocytes, nausea, anorexia, and fatigue."
30,0,"The patient is a 66-year-old white female with a BMI of 26.25 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced a bowel perforation and is also experiencing diarrhea as an adverse effect of the treatment."
31,0,"The patient is a 41-year-old white female with a BMI of 25.72. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
32,1,This patient is a 67-year-old white male with a BMI of 27.2. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
33,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
34,1,"The patient is a 60-year-old white male with a BMI of 30.83. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The patient's KRAS biomarker is mutant. Additionally, he has experienced an adverse effect in the form of an infarction."
35,1,"The patient is a 56-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and white blood cells."
36,1,"The patient is a 38-year-old white male with a BMI of 19.59. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. The patient has experienced bowel obstruction and perforation. He has completed 10 cycles of chemotherapy. Histologically, the cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the cancer is wild-type."
37,1,The patient is a 42-year-old white male with a BMI of 23.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
38,0,"The patient is a 63-year-old white female with a BMI of 29.91. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
39,0,The patient is a 41-year-old white male with a BMI of 23.39. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
40,1,"The patient is an 82-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she is showing adverse effects related to her lymphocytes."
41,0,"The patient is a 59-year-old white female with a BMI of 21.51. She is receiving treatment with the FOLFOX regimen for her bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Additionally, the KRAS biomarker testing showed that she has a mutant KRAS status."
42,0,"This patient is a 53-year-old white female with a BMI of 37.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type."
43,0,"The patient is a 63-year-old white female with a BMI of 29.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
44,0,The patient is a female who is undergoing conventional surgery and has abdominal wall adhesion as well as bowel adhesion. She has been using narcotics for 3 days and her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate that the condition is malignant.
45,1,The patient is a 39-year-old white male with a BMI of 25.1 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
46,0,"The patient is a 75-year-old white male with a BMI of 26.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
47,0,"The patient is a 63-year-old white male with a BMI of 25.96. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to ambulate. The KRAS biomarker testing showed that he has a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
48,0,"The patient is a 67-year-old white male with a BMI of 29.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, the patient's performance status is fully active. Additionally, his KRAS biomarker is wild-type."
49,0,"The patient is a 66-year-old white male with a BMI of 23.84. He is receiving treatment with FOLFOX + Cetuximab. He experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, his performance status is fully active. The KRAS biomarker indicates a mutant status."
50,0,"The patient is a 46-year-old white male with a BMI of 21.39. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
51,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
52,1,"This patient is a 65-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he is experiencing an adverse effect known as granulocytes/bands."
53,0,"The patient is a 68-year-old white female with a BMI of 31.81. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
54,0,"The patient is a 53-year-old white male with a BMI of 29.63. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
55,1,The patient is a 58-year-old white male with a fully active performance status. He is currently enrolled in the placebo treatment arm of the study.
56,1,"The patient is a 45-year-old white female with a BMI of 26.84 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect in the form of bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect during her treatment."
57,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days following the procedure. She was in bed less than 50% of the time. The pathology report indicated a malignant condition.
58,0,The patient is a 58-year-old black female with a fully active performance status who is receiving treatment with 5FU/LV and radiation therapy. She has well-differentiated histology and is experiencing adverse effects of low neutrophil/granulocyte levels and nausea.
59,0,"The patient is a 69-year-old white male with a BMI of 23.73. He is currently receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
60,1,"The patient is a 62-year-old white male with a BMI of 28.87. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
61,0,"The patient is a 55-year-old white female with a BMI of 24.77. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
62,0,"The patient is a female who is undergoing treatment with conventional surgery. She has used narcotics for 3 days. The histology of her condition is well differentiated, and the pathology indicates that it is malignant."
63,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery. She used narcotics for 4 days following the procedure. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated malignancy."
64,1,"This patient is a 55-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is currently experiencing a common adverse effect known as granulocytes/bands."
65,0,"The patient is a 70-year-old white male with a BMI of 29.26 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his 12 chemotherapy cycles. His cancer histology is poorly differentiated, but he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
66,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
67,1,The patient is a 47-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment with 5FU/LV + Radiation therapy. The histology shows poorly differentiated cells.
68,0,"The patient is a 45-year-old white female with a BMI of 22.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
69,1,"The patient is a 70-year-old white male with a BMI of 33.65. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of his 6 chemotherapy cycles. His histology shows poorly differentiated cells, but his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
70,0,"The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 29.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and the patient's performance status is fully active. The KRAS biomarker shows that the patient has a wild-type status."
71,0,"The patient is a 49-year-old white female with a BMI of 41.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
72,0,"The patient is a 74-year-old white male with a BMI of 25.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant form of the gene."
73,1,"This patient is a 44-year-old white female with a BMI of 26.67 who is currently receiving treatment with the FOLFOX regimen. She has a primary tumor diagnosis of colon cancer and her KRAS biomarker status is mutant. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
74,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. The histology report indicates that the tissue is well differentiated, and the pathology report shows that the condition is benign."
75,0,"The patient is a 76-year-old white female with a BMI of 27.0. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
76,0,The patient is a male who is undergoing conventional surgery for abdominal wall adhesion. He has experienced symptoms but is still able to walk around. The pathology results indicate a malignant condition. He has used narcotics for 4 days.
77,0,"The patient is a 75-year-old white female with a BMI of 34.45. She is currently receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
78,1,"The patient is a 75-year-old white male with a BMI of 28.54. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker indicates that he has a wild-type gene."
79,0,This patient is a 69-year-old white female with a BMI of 23.44. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
80,0,"The patient is a 60-year-old white female with a BMI of 25.49. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
81,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days following the procedure. His histology shows symptoms but he is still able to be ambulatory. The pathology results indicate that the cause of his symptoms is malignant.
82,0,"The patient is a 44-year-old white female with a BMI of 24.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type variant."
83,0,The patient is a 38-year-old white male with a BMI of 24.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is well-differentiated. His performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. He has experienced diarrhea as an adverse effect of the treatment.
84,1,The patient is a 75-year-old white male with a BMI of 29.24 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
85,0,The patient is a 60-year-old white female enrolled in the treatment arm receiving 5FU/LV + Radiation therapy. She has a performance status of experiencing symptoms but is still ambulatory. The histology of her condition is poorly differentiated. She is experiencing adverse effects of nausea and anorexia.
86,0,"The patient is a 75-year-old Black male with a BMI of 24.88. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate."
87,1,"The patient is a 76-year-old white male with a BMI of 28.0. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation after completing 3 cycles of chemotherapy. The histology shows well-differentiated cancer, and the patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
88,0,"The patient is a 47-year-old white female with a BMI of 30.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
89,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
90,0,"The patient is a 45-year-old white female with a BMI of 24.67. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
91,0,"The patient is a 56-year-old Black female with a BMI of 27.04. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
92,1,"The patient is a 72-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has also developed low white blood cell count as an adverse effect of the treatment."
93,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. There have been complications post-surgery. He used narcotics for 3 days. Histologically, he has symptoms but is still ambulatory. Pathology results indicate malignancy."
94,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she is able to walk around. The pathology report indicated that the cause of her symptoms was malignant.
95,0,"The patient is a 61-year-old white male with a BMI of 28.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
96,1,"The patient is a 71-year-old white male who is receiving treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood counts, specifically low granulocytes/bands and low white blood cells."
97,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 4 days post-surgery. She was in bed less than 50% of the time. The pathology report indicates malignancy.
98,0,"The patient is a 38-year-old white male with a BMI of 22.04. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory in terms of performance status. The KRAS biomarker indicates that he has a wild-type status. The patient has experienced a hypersensitivity adverse effect."
99,0,"The patient is a 76-year-old white female with a BMI of 33.72. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, she experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
100,1,This patient is a 52-year-old white female with a BMI of 20.2. She is fully active with a primary tumor diagnosis of colon cancer. The KRAS biomarker indicates that she has a wild-type status. She is currently receiving treatment with the FOLFOX regimen.
101,1,"The patient is a 65-year-old white male with a BMI of 26.59. He is undergoing treatment with the FOLFIRI regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer cells are wild-type."
102,1,"The patient is a 38-year-old white male with a BMI of 34.7. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment in the FOLFOX treatment arm."
103,1,"The patient is a 60-year-old white female with a BMI of 17.48. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
104,1,The patient is a 68-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated.
105,1,"The patient is a 66-year-old male of other race with a BMI of 25.43. He is fully active in terms of performance status. The primary tumor diagnosis is rectal, and the KRAS biomarker status is wild-type. The patient is receiving treatment with FOLFOX and Panitumumab."
106,0,The patient is a 64-year-old white female with a BMI of 27.78 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker shows that she has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
107,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 5 days. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
108,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 4 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
109,0,The patient is a female undergoing conventional surgery. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate malignancy.
110,1,"The patient is a 65-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. The patient has shown adverse effects related to his granulocytes/bands and lymphocytes."
111,0,"The patient is a 57-year-old Black female with a BMI of 22.48. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker indicates that it is mutant."
112,0,"The patient is a 36-year-old white female with a BMI of 34.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
113,1,"The patient is a 43-year-old white male who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. He has not yet started any chemotherapy cycles. Despite experiencing symptoms, he is still able to move around and be ambulatory."
114,1,"The patient is a 61-year-old white male with a BMI of 23.99. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
115,0,"This patient is a 49-year-old male of other race with a BMI of 27.7. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still ambulatory. Additionally, the KRAS biomarker analysis shows a mutant result."
116,0,"The patient is a 60-year-old white male with a BMI of 22.76 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor with a mutant KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect, which is a skin condition characterized by acne-like eruptions on the skin."
117,0,"The patient is a 72-year-old Black male with a BMI of 27.41. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
118,1,"The patient is a 62-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy and has a fully active performance status."
119,1,"The patient is a 73-year-old female of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes. Additionally, she has reported experiencing nausea as an adverse effect of the treatment."
120,0,The patient is a 60-year-old white female with a BMI of 22.7. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
121,0,"The patient is a 66-year-old white female with a BMI of 24.16. She is receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type KRAS gene."
122,1,"The patient is a 69-year-old white female with a BMI of 34.65 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) despite her condition. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
123,0,"The patient is a 48-year-old white female with a BMI of 36.91. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status, and she has also experienced thrombosis as an adverse effect."
124,1,The patient is a 74-year-old white male with a BMI of 22.57 who is currently undergoing treatment with the FOLFOX regimen. He has a fully active performance status and has been diagnosed with a primary tumor in the rectum.
125,1,The patient is a 74-year-old white male with a BMI of 19.84. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and is fully active in terms of performance status. The patient has a mutant KRAS biomarker and has undergone 12 cycles of chemotherapy. He is also experiencing diarrhea as an adverse effect of the treatment.
126,0,"The patient is a 40-year-old white female with a BMI of 40.77. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
127,1,"The patient is a 65-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
128,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and experienced complications post-surgery. He used narcotics for 2 days. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
129,1,The patient is a 72-year-old black male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology shows well-differentiated characteristics.
130,1,"The patient is a 67-year-old female of a race categorized as ""other"" who is receiving treatment with 5FU/LV + Radiation. She has a history of prior cancer. Despite this, she has a fully active performance status. The histology of her current condition is poorly differentiated. She is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
131,0,"The patient is a 62-year-old male of a race categorized as ""other"" who is currently receiving treatment with ECF chemotherapy in combination with radiation therapy. He has a fully active performance status and his cancer histology is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
132,0,"The patient is a 44-year-old white male with a BMI of 22.18. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
133,0,"The patient is a 46-year-old white male with a BMI of 33.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
134,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates a malignant condition.
135,0,"The patient is a 59-year-old white female with a BMI of 18.82. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a serious adverse effect, specifically a bowel obstruction, after completing 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite the adverse effects, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced hypersensitivity and infection as adverse effects during her treatment."
136,0,"The patient is a 38-year-old white male with a BMI of 25.28. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
137,0,"This patient is a 37-year-old white male with a BMI of 30.58. He is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced the adverse effect of thrombosis."
138,1,The patient is a 59-year-old Black male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology treatment arm.
139,0,"The patient is a 45-year-old white male with a BMI of 28.37. He is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
140,0,"The patient is a 54-year-old Black female with a BMI of 18.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
141,0,"The patient is a 72-year-old white male with a BMI of 25.44. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is currently receiving treatment with the FOLFOX regimen."
142,0,"The patient is a 44-year-old white female with a BMI of 39.93. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
143,0,"The patient is a 75-year-old white female with a BMI of 31.13. She is currently receiving treatment with FOLFOX chemotherapy regimen and has completed 1 cycle so far. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
144,0,The patient is a 67-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. She has a histology of poorly differentiated cancer. The patient is experiencing fatigue as an adverse effect of the treatment.
145,0,"The patient is a 44-year-old white female with a BMI of 28.52. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
146,0,"The patient is a 59-year-old white male participating in the treatment arm involving 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
147,0,"The patient is a 60-year-old white male with a BMI of 30.91. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he is experiencing a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
148,0,The patient is a 52-year-old white male with a BMI of 22.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
149,1,This patient is a 66-year-old white female who is fully active and is receiving treatment with Sunitinib.
150,0,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 4 days post-surgery. The histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
151,1,"This patient is a 59-year-old white female with a BMI of 25.33. She is receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type mutation."
152,1,"The patient is a 75-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed one cycle of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
153,0,"The patient is a 62-year-old white male with a BMI of 20.03. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
154,0,"This patient is a 65-year-old white male with a BMI of 26.2. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. His KRAS biomarker status is wild-type, indicating a potentially better response to the treatment regimen."
155,0,"The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 26.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment plan. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Histologically, her cancer is classified as well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
156,1,"The patient is a 71-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a performance status of fully active."
157,1,"The patient is a 61-year-old white male with a fully active performance status. He is receiving treatment with ECF and radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
158,1,"This patient is a 66-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has poorly differentiated histology and is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea, anorexia, and fatigue."
159,1,"The patient is a 67-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
160,0,"The patient is a 44-year-old white female with a BMI of 20.22. She is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. Her histology shows well-differentiated cancer cells. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type variant."
161,0,"The patient is a 60-year-old white male with a BMI of 30.37. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
162,0,"The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 33.36. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
163,1,"The patient is a 56-year-old white male with a BMI of 29.64. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
164,1,The patient is a 31-year-old white male with a BMI of 20.45. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
165,1,"The patient is a 70-year-old white female with a BMI of 31.8 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect in the form of a bowel perforation after completing 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
166,1,"The patient is a 71-year-old white male with a BMI of 23.8. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
167,0,"The patient is a 50-year-old female of a race other than specified, with a BMI of 45.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. The patient has experienced a hypersensitivity adverse effect."
168,1,"The patient is a 76-year-old female of other race with a BMI of 20.44. She is fully active in terms of performance status. The primary tumor diagnosis is rectal, and the KRAS biomarker is mutant. The patient is experiencing acne as an adverse effect."
169,0,"The patient is a 74-year-old white male with a BMI of 21.26. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
170,0,"The patient is a 60-year-old white male with a BMI of 37.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
171,1,"The patient is a 78-year-old white male with a BMI of 29.39. He is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker shows a wild-type status."
172,0,The patient is a 64-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her granulocytes/bands and white blood cells.
173,1,The patient is a 47-year-old white female with a BMI of 38.01 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker indicates that she has a wild-type status.
174,0,"The patient is a 46-year-old white female with a BMI of 36.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
175,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 5 days post-surgery. The histology results showed symptoms but she is still able to walk around. The pathology report indicated that the cause of her symptoms is malignant.
176,1,"The patient is a 24-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to ambulate."
177,0,"This patient is a 74-year-old white female with a BMI of 22.32 who is undergoing treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has completed 12 cycles of chemotherapy and has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to walk around. She has reported experiencing diarrhea as an adverse effect of her treatment."
178,0,"The patient is a 60-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and fatigue."
179,0,"The patient is a 55-year-old white female with a BMI of 23.02. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
180,0,"The patient is a 66-year-old white female with a BMI of 37.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a mutant form."
181,1,The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 6 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
182,0,The patient is a 42-year-old white male with a BMI of 38.41. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
183,0,The patient is a 67-year-old white male with a BMI of 33.33 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker status for this patient is mutant.
184,0,"The patient is a 67-year-old white male with a BMI of 28.69. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status."
185,0,"The patient is a 68-year-old white female with a BMI of 30.12. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
186,0,"The patient is a 68-year-old white male with a BMI of 27.69. He is currently receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
187,0,"The patient is a 40-year-old white male with a BMI of 27.52. He is receiving the FOLFIRI treatment regimen for his KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker. He has experienced an adverse effect of thrombosis."
188,1,The patient is a 70-year-old white female with a fully active performance status. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
189,1,"The patient is a 49-year-old white male with a BMI of 28.33 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker is mutant. The patient is experiencing dermatitis acneiform as an adverse effect, which presents as acne-like skin rash or inflammation."
190,0,"The patient is a 43-year-old white male with a BMI of 32.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and his histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
191,1,"The patient is a 72-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to low levels of granulocytes/bands and white blood cells."
192,1,"The patient is a 57-year-old white male with a BMI of 39.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
193,0,The patient is a male undergoing conventional surgery. He has used narcotics for 4 days. His histology shows symptoms but he is still able to walk. The pathology report indicates that the condition is malignant.
194,0,"The patient is a 49-year-old white male with a BMI of 36.06. He is receiving FOLFIRI treatment for his well-differentiated cancer, with a KRAS mutation. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. He is experiencing adverse effects of diarrhea and infection."
195,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
196,0,"The patient is a 73-year-old white male with a BMI of 22.75. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
197,0,"The patient is a 67-year-old white female with a BMI of 23.74. She is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
198,0,"The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 20.48. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
199,1,The patient is a 47-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
200,0,"The patient is a 69-year-old white male with a BMI of 30.55. He is in the FOLFOX treatment arm and has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
201,0,"The patient is a 43-year-old white female with a BMI of 36.59. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She experienced a bowel perforation and has undergone 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
202,1,"The patient is a 56-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects on his blood cells, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
203,1,"The patient is a 70-year-old white male with well-differentiated histology who is currently receiving treatment with ECF chemotherapy combined with radiation therapy. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). However, the patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
204,1,The patient is a 50-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
205,1,"The patient is a 59-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient has experienced a decrease in lymphocytes as an adverse effect of the treatment."
206,0,"The patient is a 64-year-old white male with a BMI of 24.62. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. Additionally, he has experienced a hypersensitivity adverse effect."
207,0,"The patient is a 74-year-old white male with a BMI of 29.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced an infection as an adverse effect of treatment."
208,1,"The patient is a 62-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She is undergoing a total of 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around and be active, indicating a relatively good performance status."
209,1,The patient is a 55-year-old white female with a BMI of 26.64. She is fully active with a primary tumor diagnosis of colon. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
210,0,"The patient is a 58-year-old white male with a BMI of 25.21. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
211,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
212,0,"The patient is a 56-year-old white male with a BMI of 23.99. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. The patient has been adherent to the treatment and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. Histologically, the patient's cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status."
213,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is ambulatory. The pathology report indicates that the cause of her symptoms is malignant.
214,0,The patient is a 55-year-old white male with a BMI of 26.83. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
215,0,"The patient is a 72-year-old white female with a BMI of 23.99. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
216,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
217,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 5 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates malignancy.
218,0,"The patient is a 70-year-old white male with a BMI of 28.94 who is receiving treatment with FOLFOX + Cetuximab. He has completed 9 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. He has reported experiencing diarrhea and infection as adverse effects of the treatment."
219,0,"The patient is a 66-year-old white male with a BMI of 21.81 who is receiving the FOLFOX treatment regimen. He has undergone 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
220,0,"The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has only used narcotics for 1 day. Despite having symptoms, she is still able to be ambulatory. The pathology results indicate malignancy."
221,1,"The patient is a 73-year-old white male with a BMI of 25.5. He is currently receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker is mutant."
222,0,"The patient is a 64-year-old white female with a BMI of 39.41. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
223,1,The patient is a 59-year-old white female who is part of the placebo treatment arm. She spends less than 50% of her time in bed and is experiencing fatigue as an adverse effect.
224,0,"The patient is a 66-year-old white male with a BMI of 31.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed a hypersensitivity reaction as an adverse effect to the treatment."
225,0,"The patient is a 70-year-old female of a race other than specified, with a BMI of 20.94. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. Unfortunately, she has experienced a serious adverse effect in the form of a bowel perforation. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
226,0,"The patient is a 74-year-old white male with a BMI of 27.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced an adverse effect in the form of an infection."
227,0,"The patient is a 36-year-old white male with a BMI of 30.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
228,0,"The patient is a 56-year-old male of a race other than Caucasian. He has a BMI of 21.38 and is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
229,1,The patient is a 62-year-old white male with a BMI of 23.63. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor.
230,1,"The patient is a 67-year-old white male with a BMI of 25.52. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker status is indeterminate."
231,0,"The patient is a 40-year-old white male with a BMI of 27.27. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed that he has a wild-type KRAS status."
232,1,The patient is a 56-year-old white female with a BMI of 26.67. She is fully active with a primary tumor diagnosis of rectal cancer. She is in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
233,1,"The patient is a 62-year-old male of a race categorized as ""other."" He is currently receiving treatment with 5FU/LV along with radiation therapy. Despite undergoing treatment, his performance status is noted as fully active. The histology of the patient's condition is well-differentiated."
234,0,"The patient is a 63-year-old white male with a BMI of 30.73. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
235,0,"The patient is a 54-year-old white male with a BMI of 31.37. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
236,0,"The patient is a 68-year-old white female with a BMI of 40.67. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
237,0,The patient is a 51-year-old white female with a BMI of 31.98. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
238,0,"The patient is a 63-year-old white male with a BMI of 30.08. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, the patient's performance status remains fully active. Additionally, his KRAS biomarker is wild-type."
239,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology showed symptoms but the patient was still ambulatory. The pathology report revealed that the cause of the symptoms was malignant.
240,0,"The patient is a 66-year-old white female with a BMI of 32.45. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's treatment arm is FOLFOX, and she has a mutant KRAS biomarker."
241,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 2 days and her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
242,0,"The patient is a 50-year-old white male with a BMI of 26.15. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
243,1,The patient is a 57-year-old black female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. She has a histology of poorly differentiated cancer and is experiencing fatigue as an adverse effect.
244,0,"This patient is a 36-year-old white male with a BMI of 30.43. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
245,1,"The patient is a 39-year-old white female with a BMI of 23.09. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS gene."
246,0,The patient is a 48-year-old white female with a BMI of 24.89. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
247,1,"The patient is a 77-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient has developed adverse effects related to her blood cells, specifically low granulocytes/bands and low white blood cell count."
248,1,"The patient is a 49-year-old white male with a BMI of 42.61. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
249,0,The patient is a 69-year-old white male with a BMI of 22.77. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
250,0,"The patient is a 51-year-old white female with a BMI of 28.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. She has experienced a hypersensitivity adverse effect."
251,0,"The patient is a 48-year-old white female with a BMI of 30.04. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects of hypersensitivity and diarrhea during her treatment."
252,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She only used narcotics for 1 day post-surgery. Despite experiencing symptoms, she is able to move around independently. The pathology report indicates malignancy."
253,0,The patient is a 40-year-old white female with a BMI of 22.34. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
254,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the cause of the symptoms is malignant.
255,0,"The patient is a 74-year-old white female with a BMI of 28.84. She is currently receiving the FOLFIRI treatment regimen and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
256,1,The patient is a 47-year-old white female who is fully active. She is currently receiving treatment with Sunitinib.
257,0,"The patient is a 66-year-old white female with a BMI of 32.34 who is receiving the FOLFOX treatment regimen. She has experienced serious adverse effects during her 8 cycles of chemotherapy, including diarrhea and infection. Her cancer histology is poorly differentiated, and her KRAS biomarker status is wild-type. Despite experiencing symptoms, she is still able to be ambulatory."
258,0,"This patient is a 41-year-old white female with a BMI of 32.98. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both a bowel obstruction and a bowel perforation. She is scheduled to undergo 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her medical challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
259,0,"The patient is a 67-year-old white male with a BMI of 33.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
260,0,The patient is a 51-year-old white female with a BMI of 34.91. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
261,1,"The patient is a 45-year-old white male with a BMI of 31.78. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient is experiencing diarrhea as an adverse effect."
262,1,The patient is a 53-year-old black female with a well-differentiated histology who is part of the treatment arm receiving ECF chemotherapy along with radiation. She has symptoms but is still able to walk around (ambulatory). The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
263,1,"The patient is a 31-year-old female of other race with a BMI of 20.14. She is receiving treatment with FOLFOX for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
264,1,"The patient is a 58-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
265,1,"The patient is a 56-year-old white female with a BMI of 19.92, who is fully active and receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. She has developed dermatitis acneiform as an adverse effect. This condition presents as red, inflamed bumps or pustules."
266,1,The patient is a 60-year-old white male with a BMI of 22.01. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
267,1,"The patient is a 60-year-old white female with a BMI of 25.26. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
268,0,The patient is a 53-year-old white female with a BMI of 24.61. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Her performance status is fully active. The KRAS biomarker shows a mutation.
269,0,"The patient is a 46-year-old white female with a BMI of 41.32. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is mutant."
270,0,"The patient is a 66-year-old white female with a BMI of 29.82 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker shows that she has a wild-type mutation. Additionally, she has developed thrombosis as an adverse effect."
271,0,"The patient is a 52-year-old white male with a BMI of 34.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
272,1,"The patient is a 64-year-old white male with a BMI of 36.4. He is receiving treatment with FOLFOX for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. The patient has a wild-type KRAS biomarker. He has also experienced a hypersensitivity adverse effect."
273,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
274,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She only used narcotics for 1 day post-surgery. The histology report indicates that she spends less than 50% of her time in bed. Additionally, the pathology report shows that the condition is malignant."
275,0,"The patient is a 46-year-old white male with a BMI of 30.04. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He is scheduled for 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and his performance status is fully active. The KRAS biomarker shows that he has a wild-type status."
276,1,The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands and nausea.
277,0,"The patient is a 40-year-old white male with a BMI of 30.48. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
278,1,The patient is a 54-year-old white male who is fully active. He is currently receiving treatment with Sunitinib.
279,0,"This patient is a 61-year-old white female with a BMI of 29.72. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both bowel obstruction and perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
280,1,"The patient is a 61-year-old white male with a BMI of 26.75. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
281,1,The patient is a 69-year-old white male with a BMI of 25.5 who is receiving treatment with FOLFOX for colon cancer. He has a mutant KRAS biomarker. His performance status indicates that he is in bed less than 50% of the time.
282,0,"The patient is a 65-year-old white female with a BMI of 27.68. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
283,1,"The patient is a 59-year-old white female with a BMI of 19.74 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory). Her primary tumor diagnosis is colon cancer, and her KRAS biomarker status is mutant."
284,0,"The patient is a 47-year-old Black female with a BMI of 36.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
285,1,"The patient is a 66-year-old white male with a BMI of 30.77. He is receiving treatment in the FOLFIRI chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
286,0,"The patient is a 49-year-old white female with a BMI of 20.57 who is receiving treatment with FOLFOX for well-differentiated histology. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. Despite experiencing a bowel obstruction and diarrhea as adverse effects, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
287,0,"The patient is a 59-year-old white female with a BMI of 19.68. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
288,0,"The patient is a 49-year-old white male with a BMI of 28.41. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He is scheduled to undergo 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
289,0,"The patient is a 69-year-old white female with a BMI of 26.45. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
290,0,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
291,0,"The patient is a 53-year-old white female with a BMI of 33.87. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed that she has a wild-type KRAS status."
292,0,The patient is a 56-year-old white female with a BMI of 24.08. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
293,1,"The patient is a 68-year-old white male with a BMI of 22.64. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
294,1,"The patient is a 62-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and lymphocytes, as well as experiencing nausea."
295,1,"The patient is a 56-year-old white male with a BMI of 21.54. He is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is rectal cancer."
296,1,The patient is a 68-year-old white male with a BMI of 23.82. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that the tumor is wild-type. The patient is receiving treatment with the FOLFOX regimen.
297,0,The patient is a 59-year-old white male with a BMI of 33.14. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
298,1,"The patient is a 76-year-old white male with a BMI of 24.66. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that he has a mutant KRAS status."
299,0,The patient is a 56-year-old white female with a BMI of 24.64. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
300,0,The patient is a male who underwent laparoscopic-assisted colectomy. He only used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
301,1,"The patient is a 54-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she has reported experiencing nausea as an adverse effect of the treatment."
302,0,"The patient is a 72-year-old white male with a BMI of 22.45 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a mutant KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment. This condition presents as acne-like skin eruptions, typically on the face and upper body, which can be red, inflamed, and sometimes itchy."
303,0,"The patient is a 54-year-old white female with a BMI of 27.96. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
304,0,The patient is a 47-year-old white female with a BMI of 23.43. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
305,1,The patient is a 71-year-old white female with a BMI of 28.58 who is fully active. She is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that she has a wild-type status.
306,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
307,0,"The patient is a 71-year-old white female with a BMI of 28.54. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has symptoms but is still ambulatory. The KRAS biomarker is mutant in her case. She has experienced adverse effects of thrombosis and infection during her treatment."
308,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology results indicate that the cause of the symptoms is malignant.
309,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and experienced complications post-surgery. She used narcotics for 2 days. The histology shows symptoms but she is ambulatory, and the pathology report indicates malignancy."
310,1,"The patient is a 45-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active (ambulatory)."
311,0,"The patient is a 56-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes, nausea, and anorexia."
312,0,"The patient is a 73-year-old white male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
313,0,"The patient is a 62-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and white blood cells."
314,0,"This patient is a 49-year-old white female with a BMI of 21.46. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is indeterminate."
315,1,The patient is a 52-year-old white male with a BMI of 26.23 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker for this patient is mutant.
316,0,"This patient is a 49-year-old white female with a BMI of 37.82. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
317,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. Pathology results indicate that the condition is malignant.
318,1,The patient is a 65-year-old white male with a BMI of 20.06 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory) and has been diagnosed with colon cancer. The KRAS biomarker indicates that he has a wild-type mutation.
319,1,"The patient is a 66-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing anorexia as an adverse effect, which means he is experiencing a loss of appetite."
320,0,The patient is a 48-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
321,0,"The patient is a 46-year-old white female with a BMI of 34.76. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
322,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 2 days. Her histology shows that she is in bed less than 50% of the time. The pathology report indicates malignancy.
323,1,"The patient is a 51-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
324,0,The patient is a 52-year-old white female with a BMI of 32.79. She is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
325,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is ambulatory. The pathology report indicates malignancy.
326,1,"The patient is a 60-year-old white male with a BMI of 25.69. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is mutant."
327,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
328,0,"The patient is a 62-year-old white male with a BMI of 27.18. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
329,0,"The patient is a 41-year-old white male with a BMI of 29.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
330,0,The patient is a 44-year-old white female with a BMI of 26.62. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type KRAS gene.
331,1,The patient is a 49-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
332,1,"The patient is a 52-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing an adverse effect on his leukocytes, indicating a decrease in white blood cell count."
333,0,"The patient is a 55-year-old white female with a BMI of 27.82. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
334,1,"The patient is a 50-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has reported experiencing nausea as an adverse effect of the treatment."
335,1,"The patient is a 54-year-old female of a race categorized as ""other"" who is undergoing treatment with Cisplatin + Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing adverse effects in the form of low granulocyte/band levels and nausea."
336,0,"The patient is a 51-year-old white female with a BMI of 29.16. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows that she has a wild-type status."
337,0,"The patient is a 52-year-old white male with a BMI of 25.88. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
338,0,"The patient is a 47-year-old white male with a BMI of 26.05. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing showed that he has a wild-type KRAS status."
339,0,"The patient is a 62-year-old white male with a BMI of 22.68. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
340,0,"The patient is a 75-year-old white female with a BMI of 29.14. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type. The patient has also experienced an infection as an adverse effect."
341,0,The patient is a 70-year-old white female with a BMI of 24.72. She is fully active with a primary tumor diagnosis of colon cancer. The KRAS biomarker indicates that she has a wild-type status. She is currently receiving treatment in the FOLFOX treatment arm.
342,1,"This patient is a 63-year-old white female with a BMI of 30.9. She is currently receiving treatment with FOLFOX and Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to move around independently. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
343,0,"The patient is a 45-year-old white female with a BMI of 26.25. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment in the FOLFOX treatment arm."
344,1,The patient is a 69-year-old white female with a BMI of 21.1. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is wild-type.
345,1,"The patient is a 39-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
346,0,The patient is a 47-year-old white female with a BMI of 24.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
347,1,The patient is a 50-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. He has a histology of poorly differentiated cancer. The patient is experiencing nausea and anorexia as adverse effects of the treatment.
348,0,"The patient is a 57-year-old white female with a BMI of 21.92. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
349,1,The patient is a 72-year-old white male participating in the placebo treatment arm. He is experiencing symptoms but is still able to walk around.
350,1,The patient is a 65-year-old white female with a BMI of 31.22. She is receiving treatment with FOLFIRI for her well-differentiated cancer with a KRAS mutation. She has completed 6 cycles of chemotherapy and has a fully active performance status. The patient has experienced hypersensitivity as an adverse effect to the treatment.
351,0,"The patient is a 44-year-old white male with a BMI of 35.79. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type."
352,0,"The patient is a 63-year-old white male with a BMI of 36.61. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
353,0,The patient is a 67-year-old white male with a BMI of 23.46. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
354,0,"The patient is a 43-year-old white female with a BMI of 35.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
355,0,"The patient is a 52-year-old white male with a BMI of 30.73. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
356,0,"The patient is a 40-year-old white male with a BMI of 30.84. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
357,0,The patient is a 48-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation therapy. The histology of his condition is poorly differentiated.
358,0,"The patient is a 62-year-old white female with a BMI of 28.42. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
359,0,"The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 2 days. The histology shows well-differentiated cells, and the pathology indicates a benign condition."
360,0,"The patient is a 54-year-old white female with a BMI of 22.37. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
361,1,"The patient is a 58-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects related to his granulocytes/bands and white blood cells."
362,1,"The patient is a 74-year-old white male with a BMI of 24.69. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
363,0,The patient is a 55-year-old white female with a BMI of 20.88. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
364,1,"The patient is a 68-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed one cycle of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, she has developed low white blood cell count as an adverse effect of the treatment."
365,0,"The patient is a 67-year-old white female with a BMI of 26.65. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
366,0,The patient is a 48-year-old white male with a BMI of 28.6. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
367,1,"The patient is a 65-year-old white female with a BMI of 35.55. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
368,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. There were complications during the treatment. He used narcotics for 3 days post-surgery. The histology results showed that the tissue was well-differentiated, and the pathology results indicated that the condition was benign."
369,0,"This patient is a 53-year-old white female with a BMI of 20.65. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
370,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 2 days. Despite the symptoms, she was able to remain ambulatory. The pathology report revealed malignant findings."
371,1,The patient is a 74-year-old white male with a BMI of 30.64 who is receiving treatment with FOLFOX + Cetuximab for well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
372,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days following the surgery. The histology report indicates that the tumor is well-differentiated, and the pathology report shows that the tumor is benign."
373,1,"The patient is a 74-year-old Black male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory. The histology of his current cancer is poorly differentiated. Additionally, he is experiencing adverse effects related to low levels of neutrophils/granulocytes."
374,0,"The patient is a 68-year-old white male with a BMI of 31.7. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. The patient has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker shows that it is wild-type."
375,0,"The patient is a 63-year-old white female with a BMI of 28.21. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
376,0,"The patient is a 61-year-old white female with a BMI of 33.31. She is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect."
377,1,"The patient is a 66-year-old white female with a BMI of 23.37. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis shows that she has a wild-type KRAS gene."
378,0,"The patient is a 67-year-old white female with a BMI of 44.95. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
379,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
380,0,The patient is a 47-year-old white male receiving treatment with Sunitinib. He is experiencing symptoms but is still able to walk around (ambulatory). He is also experiencing an adverse effect related to his neutrophils/granulocytes.
381,1,The patient is a 73-year-old white male with a BMI of 48.84 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect from the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker testing revealed a mutant result.
382,1,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He has used narcotics for 3 days. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
383,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 3 days post-surgery. The histology showed symptoms but the patient was still able to move around. The pathology results indicated that the condition was malignant.
384,0,"The patient is a 54-year-old white male with a BMI of 25.74. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
385,1,The patient is a female who is undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to be ambulatory. She has used narcotics for 3 days as part of her treatment.
386,0,The patient is a 55-year-old white female with a BMI of 30.83. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed a mutant result.
387,0,"The patient is a 39-year-old white female with a BMI of 17.92. She is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. She has completed 9 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker for this patient is wild-type."
388,0,"The patient is a 70-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as fatigue."
389,0,The patient is a 52-year-old white male with a BMI of 32.37 who is receiving treatment with FOLFOX and Panitumumab. He has a fully active performance status and has been diagnosed with a primary tumor in the rectum. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing an adverse effect in the form of a rash.
390,1,The patient is a 55-year-old white male with a BMI of 39.2 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
391,1,The patient is a 62-year-old white male with a BMI of 37.51 who is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. He has a performance status of being in bed less than 50% of the time. The patient is experiencing a rash as an adverse effect of the treatment.
392,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 4 days and is experiencing symptoms but is still able to walk around. The pathology report indicates malignancy.
393,0,"The patient is a 36-year-old white male with a BMI of 23.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
394,0,"The patient is a 63-year-old white male with a BMI of 22.93 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation. Despite this complication, he completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and his performance status indicates that he has symptoms but is still ambulatory. The KRAS biomarker testing revealed a wild-type result. Additionally, he has been experiencing diarrhea as an adverse effect of the treatment."
395,0,The patient is a 40-year-old white male with a BMI of 32.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
396,0,"The patient is a 44-year-old white male with a BMI of 26.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
397,1,"This patient is a 48-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory). She is experiencing adverse effects including low granulocytes/bands and low white blood cells, as well as nausea."
398,1,The patient is a 55-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and is experiencing symptoms but is still able to walk around. She is also experiencing nausea as an adverse effect of the treatment.
399,0,The patient is a male who is undergoing treatment with conventional surgery. He has been using narcotics for 7 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
400,0,"The patient is a 63-year-old white male with a BMI of 37.75. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
401,1,"The patient is a 48-year-old white male with a BMI of 25.61 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. He is experiencing dermatitis acneiform as an adverse effect, which presents as acne-like skin rash or inflammation."
402,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
403,0,"The patient is a 74-year-old Black male with a BMI of 21.14. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
404,0,"The patient is a 57-year-old white male with a BMI of 25.16. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
405,0,"The patient is a 76-year-old white female with a BMI of 24.71. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
406,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
407,1,"The patient is a 73-year-old white female with a BMI of 33.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
408,0,"The patient is a 75-year-old white male with a BMI of 30.36 who is receiving the FOLFOX treatment regimen for bowel obstruction. He has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite his condition, he has fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has been adherent to the prescribed treatment plan."
409,0,"The patient is a 62-year-old white male with a BMI of 30.36. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type KRAS gene."
410,1,"This patient is a 74-year-old black male with a well-differentiated histology who is part of the ECF + Radiation treatment arm. Despite experiencing symptoms, he is still able to ambulate. He is currently experiencing adverse effects such as low neutrophil and granulocyte levels, low leukocyte levels, nausea, anorexia, and fatigue."
411,0,"This patient is a 71-year-old white female with a BMI of 23.98. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
412,0,"The patient is a 56-year-old white male with a BMI of 32.46. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
413,0,"The patient is a 65-year-old white female with a BMI of 49.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
414,1,The patient is a 71-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around (ambulatory). She is also experiencing a side effect related to her platelet levels.
415,1,"The patient is a 42-year-old white male with a BMI of 23.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker. He has experienced an infection as an adverse effect during his treatment."
416,0,The patient is a 57-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status.
417,1,"The patient is a 59-year-old white male with a BMI of 21.6. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
418,1,"The patient is a 73-year-old white male with a BMI of 25.16 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker indicates that the patient has a wild-type gene. Additionally, the patient is experiencing a rash as an adverse effect of the treatment."
419,1,"The patient is a 68-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects related to his white blood cells, specifically a decrease in granulocytes/bands."
420,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has only used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
421,0,The patient is a 47-year-old white male with a BMI of 32.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker indicates that he has a mutant status.
422,0,"The patient is a 62-year-old white male with a BMI of 27.03. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to be ambulatory."
423,1,"The patient is a 68-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
424,0,"The patient is a 57-year-old white female with a BMI of 43.53. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. She has also experienced adverse effects of diarrhea and infection during her treatment."
425,0,"The patient is a 66-year-old white male with a BMI of 18.3. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. The patient experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis revealed a mutant status."
426,1,"The patient is a 66-year-old white male receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to walk around. He is currently experiencing adverse effects such as low granulocytes/bands and low white blood cell count, as well as nausea."
427,0,"The patient is a 63-year-old white female with a BMI of 24.34. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
428,1,The patient is a 64-year-old white male with a BMI of 26.12 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type.
429,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 2 days. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology report indicates malignancy."
430,0,"This patient is a 70-year-old white male with a BMI of 26.64. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
431,0,"The patient is a 43-year-old white male with a BMI of 25.77. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has experienced diarrhea as an adverse effect of the treatment."
432,1,"The patient is a 61-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and white blood cells."
433,0,"The patient is a 49-year-old white male with a BMI of 20.99. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
434,1,The patient is an 83-year-old white male with a BMI of 29.33. He is fully active with a primary tumor diagnosis of colon cancer. The treatment arm for this patient is FOLFOX combined with Panitumumab. The KRAS biomarker status for this patient is mutant.
435,0,"The patient is a 59-year-old white male with a BMI of 28.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type mutation."
436,0,"This patient is a 38-year-old Black female with a BMI of 37.2. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type status."
437,0,"The patient is a 46-year-old white male with a BMI of 29.44. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment."
438,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the surgery. The histology indicates that she spent less than 50% of her time in bed, and the pathology report shows that the tumor is malignant."
439,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. He is typically in bed less than 50% of the time. The pathology report indicates a malignant condition.
440,0,The patient is a 48-year-old white female with a BMI of 29.89. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
441,0,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to move around. She has used narcotics for 3 days.
442,1,The patient is a 65-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
443,1,The patient is a 53-year-old male of other race with a BMI of 22.4. He is fully active in terms of performance status. He has been diagnosed with a primary tumor in the rectum and has a wild-type KRAS biomarker. The patient is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
444,1,"The patient is a 70-year-old white male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory, indicating a relatively good performance status."
445,1,"The patient is a 50-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
446,0,The patient is a 76-year-old white male with a BMI of 31.97. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
447,1,"The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 6 days to manage his symptoms, but is still able to move around and be ambulatory."
448,0,The patient is a 34-year-old white male with a BMI of 31.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
449,0,The patient is a 58-year-old white male with a BMI of 19.41. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced hypersensitivity as an adverse effect.
450,1,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to be ambulatory. She has used narcotics for 4 days as part of her treatment.
451,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates a malignant condition.
452,1,"The patient is a 74-year-old white female with a BMI of 26.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
453,0,"The patient is a 51-year-old white female with a BMI of 26.8. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect."
454,1,"The patient is a 63-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also reported adverse effects including low white blood cell count and nausea."
455,1,"The patient is a 64-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around."
456,0,"The patient is a 57-year-old white male with a BMI of 24.91. He is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
457,0,"The patient is a 46-year-old white female with a BMI of 37.48. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
458,0,"The patient is a 41-year-old white female with a BMI of 39.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
459,0,The patient is a 64-year-old white male with a BMI of 37.51. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
460,1,"The patient is a 70-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
461,1,"The patient is a 70-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a performance status of fully active."
462,1,"The patient is a 63-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed adverse effects related to her white blood cells, specifically a decrease in granulocytes/bands."
463,0,"The patient is a 59-year-old white female with a BMI of 34.13. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene."
464,0,"The patient is a 63-year-old white male with a BMI of 25.76. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a serious adverse effect after the first chemotherapy cycle, specifically an infarction. The histology of his condition is well-differentiated, and his performance status is fully active. His KRAS biomarker status is wild-type."
465,0,"The patient is a 70-year-old white male with a BMI of 24.7. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker indicates that he has a wild-type KRAS gene."
466,1,"The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, indicating an abnormality in his white blood cell count."
467,1,"The patient is a 74-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. He is experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
468,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 4 days post-surgery. Despite experiencing symptoms, he is able to walk around. The pathology report indicates a malignant condition."
469,0,"This patient is a 68-year-old Black female with a BMI of 28.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 7 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an infection as an adverse effect of treatment."
470,0,The patient is a 63-year-old female of other race with a BMI of 22.07. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker shows a mutation. The patient is in the FOLFOX treatment arm.
471,1,"The patient is a 60-year-old white male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating a relatively good performance status."
472,1,The patient is a 58-year-old white male with a BMI of 30.22 who is receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a performance status of experiencing symptoms but is still able to be ambulatory. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
473,0,"The patient is a 57-year-old white female with a BMI of 25.59. She is receiving treatment in the FOLFIRI treatment arm and has been adherent to her chemotherapy. She is currently experiencing a bowel obstruction. So far, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
474,0,"The patient is a 41-year-old white female with a BMI of 29.71 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during the treatment. She has completed 8 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she has experienced adverse effects of thrombosis and diarrhea during the course of treatment."
475,0,"The patient is a 76-year-old white female with a BMI of 28.92. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
476,0,"The patient is a 68-year-old white female with a BMI of 27.33. She is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis revealed a mutant status."
477,0,"The patient is a 60-year-old white female with a BMI of 19.96. She is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and she has a mutant KRAS biomarker."
478,1,"The patient is a 41-year-old white male with a BMI of 31.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
479,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
480,0,"The patient is a 64-year-old white male with a BMI of 21.44. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a wild-type KRAS status."
481,0,"The patient is a 49-year-old white female with a BMI of 23.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
482,0,"The patient is a 40-year-old white female with a BMI of 57.73 who is receiving treatment with FOLFOX + Cetuximab. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status indicates that she is in bed less than 50% of the time. Her KRAS biomarker is wild-type. Additionally, she has experienced an infection as an adverse effect of treatment."
483,1,The patient is a 38-year-old white female with a BMI of 32.42. She is fully active with a primary tumor diagnosis of rectal cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
484,0,"The patient is a 34-year-old female of a race categorized as ""other"" with a BMI of 17.5. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
485,1,"This patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 5 days. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates that the condition is malignant."
486,0,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has been using narcotics for 5 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
487,0,"The patient is a 44-year-old white female with a BMI of 21.02. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
488,0,"The patient is a 61-year-old white female with a BMI of 25.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
489,0,"The patient is a 40-year-old female of a race other than specified, with a BMI of 21.64. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
490,1,"The patient is a 75-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient is experiencing adverse effects including low granulocytes/bands and nausea."
491,1,"The patient is a 69-year-old white female with a BMI of 31.64. She is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that her tumor is wild-type."
492,1,"The patient is a 55-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory). The patient has shown adverse effects with low levels of granulocytes/bands and lymphocytes."
493,1,"The patient is a 59-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. He is currently experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
494,0,"The patient is a 61-year-old white female with a BMI of 44.44. She is receiving the FOLFOX treatment arm for her cancer. She has experienced a serious adverse effect from the treatment. So far, she has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed that she has a mutant KRAS status."
495,0,The patient is a male who is receiving conventional surgery as part of his treatment. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
496,0,"The patient is a 75-year-old white female with a well-differentiated histology. She is part of the treatment arm receiving ECF chemotherapy along with radiation. Despite experiencing symptoms, she is still able to be ambulatory. The patient is also experiencing adverse effects such as low neutrophil/granulocyte levels and fatigue."
497,0,"The patient is a 66-year-old Black male with a BMI of 31.35. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
498,0,The patient is a 65-year-old white male with a BMI of 24.91 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that the patient has a mutant form of the gene.
499,1,The patient is a 59-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing nausea as an adverse effect of the treatment.
500,0,The patient is a 66-year-old white male with a BMI of 36.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
501,1,"The patient is a 54-year-old white male with a BMI of 27.47 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated, and he has a fully active performance status. The patient has a mutant KRAS biomarker and has experienced a serious adverse effect in the form of thrombosis."
502,1,"The patient is a 64-year-old white male with a BMI of 29.76. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
503,0,"The patient is a 56-year-old white male with a history of prior cancer. He is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to move around independently. The histology shows that the cancer is well-differentiated."
504,1,The patient is a 64-year-old white female with a BMI of 28.28. She is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker shows a mutant status.
505,0,The patient is a 68-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. The patient is also experiencing nausea as an adverse effect of the treatment.
506,0,The patient is a 55-year-old white female with a BMI of 22.89. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status.
507,0,"The patient is a 63-year-old white male with a BMI of 20.57. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
508,0,"The patient is a 63-year-old female of a race categorized as ""other"" with a BMI of 23.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
509,0,"The patient is a 44-year-old white male with a BMI of 25.6. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
510,1,"The patient is a 74-year-old female of other race with a BMI of 28.19. She is currently receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker status for this patient is wild-type."
511,0,"The patient is a 61-year-old male of a race categorized as ""other"" who is undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
512,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotic medication for 3 days post-surgery. The histology showed symptoms but the patient was still able to move around. The pathology results indicated a malignant condition.
513,0,"The patient is a 66-year-old white male with a BMI of 26.0. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene."
514,1,"The patient is a 54-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving ECF chemotherapy along with radiation therapy. His performance status is fully active, indicating that he is able to carry out daily activities without limitations. The histology of his condition is classified as poorly differentiated."
515,0,"The patient is a 41-year-old male of a race categorized as ""other"" with a BMI of 26.96. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
516,0,The patient is a 44-year-old white male with a BMI of 33.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
517,1,The patient is a 69-year-old white male with a BMI of 26.03. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
518,0,The patient is a 42-year-old white male with a BMI of 41.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
519,0,"The patient is a 49-year-old white male with a BMI of 29.67. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
520,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
521,1,"The patient is a 69-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
522,0,"The patient is a 46-year-old white female with a BMI of 25.82. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
523,0,"The patient is a 73-year-old white female with a BMI of 29.13. She is receiving the FOLFOX treatment arm for her poorly differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
524,0,"The patient is a 45-year-old white male with a BMI of 32.57. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the adverse effect, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
525,1,The patient is a 71-year-old white female with a BMI of 23.24 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory). She has been diagnosed with a primary colon tumor and has a mutant KRAS biomarker.
526,0,"The patient is a 42-year-old white female with a BMI of 21.23. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
527,0,"The patient is a 54-year-old white female with a BMI of 23.22 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has been adherent to her treatment, completing 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
528,0,"The patient is a 46-year-old white female with a BMI of 30.52. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, the KRAS biomarker shows that she has a wild-type status."
529,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but the patient was still able to be ambulatory. The pathology report indicated that the condition was malignant.
530,0,"The patient is a 70-year-old white male with a BMI of 23.53. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
531,0,"The patient is a 50-year-old white female with a high BMI of 53.84. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
532,0,The patient is a 51-year-old white male with a BMI of 33.49. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
533,1,This patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates malignancy.
534,0,"The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 20.33. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
535,1,The patient is a 61-year-old white male with a BMI of 38.61 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
536,0,"The patient is a 73-year-old white female with a BMI of 39.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
537,1,"The patient is a 61-year-old male of other race with a BMI of 24.0. He is currently receiving treatment with the FOLFOX regimen. His performance status is fully active, indicating that he is able to carry out all normal activities without any restrictions. The primary tumor diagnosis is rectal cancer."
538,1,"The patient is a 66-year-old white male with a BMI of 25.1. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
539,1,"The patient is a 51-year-old white female with a BMI of 32.47. She is currently receiving treatment with FOLFOX + Planitumumab for her rectal cancer. Despite experiencing symptoms, she is still fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. Additionally, she is experiencing dermatitis acneiform as adverse effect."
540,0,"The patient is a 69-year-old white male with a BMI of 24.43. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
541,0,"The patient is a 44-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
542,0,The patient is a 77-year-old white male with a BMI of 24.06. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status for this patient is wild-type.
543,1,"The patient is a 70-year-old white female with a BMI of 22.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
544,0,"The patient is a 66-year-old white female with a BMI of 34.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
545,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the symptoms, he was able to remain ambulatory. The pathology report revealed that the underlying cause was malignant."
546,0,"The patient is a 64-year-old white male with a BMI of 28.89. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows a mutant status."
547,0,"The patient is a 38-year-old male of a race categorized as ""other"" with a BMI of 23.39. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker analysis indicates a mutant status."
548,0,The patient is a 50-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around.
549,1,"The patient is a 71-year-old white female with a BMI of 32.46 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) despite her condition. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is mutant."
550,1,"The patient is a 61-year-old male of a race categorized as ""other"" who is currently receiving treatment with ECF chemotherapy in combination with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
551,0,"This patient is a 73-year-old white female who is fully active and is receiving treatment with 5FU/LV + Radiation for a poorly differentiated cancer. She has a history of prior cancer. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and fatigue."
552,1,The patient is a 70-year-old white male with a BMI of 24.08. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. The KRAS biomarker for this patient is mutant.
553,0,"The patient is a 43-year-old white male with a BMI of 28.37. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment in the FOLFOX treatment arm."
554,0,"The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 27.56. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel obstruction and has completed one cycle of chemotherapy. Histologically, the cancer is classified as well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. Additionally, the KRAS biomarker indicates that the cancer is wild-type."
555,0,"The patient is a 42-year-old white female with a BMI of 19.55. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
556,0,"The patient is a 67-year-old white male with a BMI of 22.75. He is receiving the FOLFOX treatment arm and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
557,1,The patient is a 50-year-old white male with a BMI of 45.15. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis shows that the patient has a mutant KRAS status.
558,0,The patient is a 73-year-old white male with a BMI of 28.55 who is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has completed 6 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
559,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 2 days. Histologically, he is experiencing symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
560,0,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 4 days post-surgery. The histology indicates that he spent less than 50% of his time in bed, and the pathology report shows that the tumor is malignant."
561,1,"The patient is a 75-year-old white male with a well-differentiated histology who is currently receiving treatment with 5FU/LV + Radiation. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). He is experiencing adverse effects such as low levels of neutrophils/granulocytes and leukocytes, as well as anorexia and fatigue."
562,1,"The patient is an 81-year-old white male undergoing treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. Additionally, the patient has developed a side effect known as granulocytes/bands."
563,1,"The patient is a 66-year-old white male with a BMI of 20.57. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
564,0,"The patient is a 53-year-old white male with a BMI of 23.59. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. His KRAS biomarker status is wild-type. The patient is experiencing dermatitis acneiform as an adverse effect, which is a skin condition characterized by acne-like eruptions on the skin."
565,1,The patient is a 46-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing adverse effects including low neutrophil/granulocyte levels and anorexia.
566,0,"The patient is a 65-year-old white female with a BMI of 43.42. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect after one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
567,0,The patient is a 40-year-old Black female with a BMI of 24.98. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
568,1,The patient is a 73-year-old white male with a BMI of 25.65. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is receiving treatment with the FOLFOX regimen. His KRAS biomarker status is mutant.
569,1,The patient is a 60-year-old white female with a BMI of 32.44. She is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
570,0,"The patient is a 40-year-old white male with a BMI of 33.1 who is undergoing treatment with FOLFOX chemotherapy. He has been adherent to his treatment regimen and has completed 6 cycles of chemotherapy. The patient has a history of bowel obstruction and perforation. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
571,0,"The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 22.95. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
572,0,"The patient is a 47-year-old white female with a BMI of 24.46. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
573,0,"This patient is a 53-year-old male of a race categorized as ""other"" who is receiving treatment with 5FU/LV + Radiation. He has a performance status indicating that he is in bed less than 50% of the time. The histology of his condition is poorly differentiated. Additionally, he is experiencing the adverse effect of fatigue."
574,0,"The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 19.84. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, her performance status is fully active, indicating that she is able to carry out daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
575,0,The patient is a 45-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
576,0,The patient is a 54-year-old white male with a BMI of 31.9. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. The histology of his cancer is well-differentiated. He has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status.
577,0,"The patient is a 50-year-old male of a race categorized as ""other"" who is participating in the treatment arm involving ECF chemotherapy combined with radiation therapy. He has a fully active performance status and has been diagnosed with well-differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
578,0,"The patient is a 73-year-old white male with a BMI of 27.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
579,0,"This patient is a 62-year-old female of a race categorized as ""other"" who is receiving treatment with 5FU/LV + Radiation. She has a fully active performance status and has been diagnosed with poorly differentiated histology. Additionally, she is experiencing an adverse effect related to neutrophils/granulocytes."
580,0,"The patient is a 41-year-old Black male with a BMI of 22.88. He is receiving the FOLFIRI treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker shows that he is wild-type."
581,0,"The patient is a 52-year-old white male with a BMI of 29.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
582,1,This patient is a 65-year-old white male with a BMI of 22.34. He is fully active with a primary tumor diagnosis of colon cancer. His KRAS biomarker status is wild-type. He is currently receiving treatment with the FOLFOX regimen.
583,0,"The patient is a 67-year-old white male with a BMI of 35.59. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
584,1,The patient is a 75-year-old white female with a BMI of 27.49 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
585,0,"The patient is a 46-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
586,0,The patient is a 59-year-old white female with a BMI of 24.45. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She has experienced an infection as an adverse effect during her treatment.
587,0,The patient is a female who underwent laparoscopic-assisted colectomy. She did not require any days of narcotic use post-surgery. The histology report indicates symptoms but the patient is still able to move around. The pathology report shows that the patient has a malignant condition.
588,0,"The patient is a 65-year-old white male with a BMI of 24.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
589,1,"The patient is a 60-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss (>5-10%). Despite this, her performance status is fully active. The patient has developed adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands and lymphocytes."
590,0,The patient is a 74-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation therapy. The histology of the cancer is well differentiated. The patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
591,0,The patient is a 54-year-old white male with a BMI of 32.54. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
592,0,The patient is a 59-year-old white female with a BMI of 23.92. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
593,0,"The patient is a 73-year-old white male with a BMI of 28.79. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
594,1,"The patient is a 72-year-old Black male with a BMI of 26.02. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a mutant KRAS status."
595,0,"The patient is a 42-year-old Black female with a BMI of 44.16. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. Additionally, she has a mutant KRAS biomarker."
596,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He used narcotics for 3 days post-surgery. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
597,1,The patient is a 75-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
598,1,The patient is a 51-year-old black male with a performance status of fully active. He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated. He is experiencing nausea as an adverse effect of the treatment.
599,0,"The patient is a 61-year-old white female with a BMI of 35.08. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a mutant status."
600,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the surgery. The histology report indicates that she spent less than 50% of her time in bed. The pathology report shows that the condition is malignant.
601,0,"The patient is a 63-year-old white male with a BMI of 23.31. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
602,0,"The patient is a 63-year-old white male with a BMI of 24.41. He is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
603,0,The patient is a 45-year-old white female with a BMI of 24.97 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that she has a wild-type status. She is experiencing an adverse effect of rash.
604,0,"The patient is a 61-year-old white female with a BMI of 36.58. She is receiving the FOLFOX treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type status. The patient is experiencing diarrhea as an adverse effect."
605,0,"The patient is a 56-year-old white female with a BMI of 35.77. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is indeterminate."
606,1,"The patient is a 57-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
607,0,"The patient is a 60-year-old white male with a BMI of 19.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker indicates a mutant status."
608,0,"The patient is a 66-year-old white female with a BMI of 37.0. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
609,0,The patient is a 58-year-old white female with a BMI of 22.59. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
610,0,The patient is a 56-year-old white male with a BMI of 33.9 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient has developed a rash as an adverse effect of the treatment.
611,1,"The patient is a 54-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. She has reported experiencing nausea as an adverse effect of the treatment."
612,0,The patient is a 56-year-old white male with a BMI of 20.27. He is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
613,0,"The patient is a 51-year-old white female with a BMI of 44.64. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
614,0,The patient is a 45-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
615,1,"The patient is a 76-year-old white male with a BMI of 27.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
616,0,"The patient is a 51-year-old white female with a BMI of 23.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
617,0,"The patient is a 72-year-old white female with a BMI of 24.61. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
618,0,"The patient is a 76-year-old white male with a BMI of 28.94. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
619,0,"The patient is a 42-year-old Black male with a BMI of 38.58. He is receiving the FOLFIRI treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
620,0,"The patient is a 64-year-old white female with a BMI of 24.65. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
621,1,The patient is a 32-year-old white female with a BMI of 24.09 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker shows that she has a wild-type status. The patient is experiencing an adverse effect of acne.
622,0,"The patient is a 44-year-old white male with a BMI of 21.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
623,1,The patient is a 76-year-old white female with a BMI of 32.3. She is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status for this patient is wild-type.
624,1,The patient is a 64-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
625,0,"The patient is a 75-year-old Black male with a BMI of 32.52 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. The histology of the cancer is poorly differentiated, and the patient's performance status is fully active. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
626,0,The patient is a 46-year-old white male with a BMI of 28.53. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
627,1,"The patient is a 52-year-old white female with a BMI of 18.81. She is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
628,1,"The patient is a 71-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
629,0,The patient is a 62-year-old white female with a BMI of 26.17 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
630,1,The patient is a 42-year-old white female with a BMI of 25.69 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. Her KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment.
631,1,"The patient is a 67-year-old male of other race who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to ambulate. The patient has developed adverse effects related to his white blood cells and granulocytes/bands."
632,0,"The patient is a 36-year-old white male with a BMI of 24.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
633,1,"This patient is a 66-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has undergone 8 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory)."
634,0,"The patient is a 68-year-old white female with a BMI of 17.54. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
635,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the procedure. They used narcotics for 2 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated malignancy.
636,0,"The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 24.71. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect."
637,1,"The patient is a 55-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient has developed adverse effects related to his granulocytes/bands and white blood cells."
638,0,"The patient is a 55-year-old white male with a BMI of 25.51. He is fully active and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
639,0,"The patient is a 65-year-old Black female with a BMI of 33.08. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
640,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 4 days post-surgery. The histology showed symptoms but the patient was still able to move around. The pathology results indicated a malignant condition.
641,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
642,0,"The patient is a 41-year-old Black male with a BMI of 23.34. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
643,0,"The patient is a 65-year-old white male with a BMI of 32.91. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a performance status of experiencing symptoms but still able to walk around. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, the patient has experienced an adverse effect of thrombosis."
644,0,"The patient is a 69-year-old white female with a BMI of 42.72. She is receiving treatment with FOLFOX + Cetuximab. She experienced a serious adverse effect and developed a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
645,0,"The patient is a 63-year-old white female with a BMI of 26.18. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates a mutant status."
646,0,The patient is a 69-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
647,0,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
648,0,The patient is a 43-year-old white female with a BMI of 21.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
649,0,The patient is a 75-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
650,0,"The patient is a 62-year-old white female with a BMI of 25.07. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
651,0,"The patient is a 53-year-old white female with a BMI of 27.54. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
652,0,"The patient is a 42-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant."
653,1,The patient is a 63-year-old white male with a BMI of 29.75. He is receiving treatment with FOLFOX and Panitumumab. His performance status indicates that he is in bed less than 50% of the time. The primary tumor diagnosis is colon cancer.
654,0,"The patient is a 69-year-old white female with a BMI of 23.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
655,0,"The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 19.15. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
656,0,"The patient is a 73-year-old white female with a BMI of 24.5. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
657,0,"The patient is a 65-year-old white female with a BMI of 29.78. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to move around independently. Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
658,1,"The patient is a 48-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology shows well-differentiated cancer cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as fatigue."
659,0,"The patient is a 56-year-old white female with a BMI of 30.11. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
660,0,"The patient is a 54-year-old white female with a BMI of 29.28. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker test results indicate that she has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
661,0,"The patient is a 50-year-old Black female with a BMI of 24.62. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
662,0,"The patient is a 43-year-old white female with a BMI of 21.76. She is receiving treatment in the FOLFOX regimen and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker shows that it is wild-type."
663,1,"The patient is a 63-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. The patient has developed adverse effects related to his white blood cells, specifically a decrease in granulocytes/bands."
664,0,This patient is a 64-year-old black female who is receiving treatment with Sunitinib. She is experiencing symptoms but is still able to move around independently.
665,0,"The patient is a 74-year-old white female with a BMI of 30.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
666,0,"The patient is a 41-year-old white female with a BMI of 33.83. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect during her chemotherapy cycles, which totaled 12. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
667,1,The patient is a 58-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
668,0,"The patient is a 43-year-old white female with a BMI of 23.84. She is receiving the FOLFOX + Cetuximab treatment regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
669,0,The patient is a 67-year-old white male with a BMI of 44.49. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
670,1,"The patient is a 54-year-old white male with a BMI of 27.06. He is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
671,1,"The patient is a 52-year-old white male with well-differentiated histology. He is part of the treatment arm receiving ECF chemotherapy along with radiation. Despite experiencing symptoms, he is still able to ambulate, indicating a relatively good performance status."
672,1,"The patient is a 54-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient has experienced a decrease in lymphocytes as an adverse effect of the treatment."
673,1,The patient is a 40-year-old white male with a BMI of 23.99. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
674,0,The patient is a 55-year-old white male with a BMI of 27.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
675,1,"The patient is a 40-year-old female of other race with a BMI of 19.13. She is currently receiving treatment with FOLFOX for a primary colon tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, the patient's KRAS biomarker status is mutant."
676,0,"The patient is a 69-year-old male of a race categorized as ""other"" with a BMI of 23.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer, and the patient's performance status is fully active. The KRAS biomarker shows wild-type status. The patient has experienced adverse effects of diarrhea and infection during the course of treatment."
677,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has used narcotics for 4 days. His histology shows that he is in bed less than 50% of the time, and the pathology indicates malignancy."
678,0,"The patient is a 45-year-old white female with a BMI of 29.76. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect during the treatment."
679,0,The patient is a 64-year-old white male with a BMI of 39.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
680,0,The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery but was able to remain ambulatory. She used narcotics for 2 days to manage pain. The pathology report indicated malignant findings.
681,0,"The patient is a 71-year-old white male with a BMI of 26.37. He is receiving treatment with FOLFOX + Cetuximab for his bowel obstruction. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his condition, he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
682,0,"The patient is a 69-year-old white male with a BMI of 31.38. He is currently receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
683,0,The patient is a 28-year-old white female with a BMI of 19.54 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. Her KRAS biomarker status is wild-type.
684,0,"The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 20.3. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated characteristics. In terms of performance status, she is fully active. Additionally, her KRAS biomarker status is wild-type."
685,0,"The patient is a 49-year-old white male with a BMI of 30.47. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
686,0,The patient is a 39-year-old white male with a BMI of 30.98. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
687,0,"The patient is a 59-year-old white male with a BMI of 25.25. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. His primary tumor diagnosis is rectal cancer, and he has a mutant KRAS biomarker."
688,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology results showed that the tissue was well-differentiated, and the pathology report indicated that the findings were benign."
689,0,The patient is a 58-year-old white male with a BMI of 46.04. He is enrolled in the FOLFOX + Cetuximab treatment arm and has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
690,1,The patient is a 45-year-old white female with a BMI of 26.64 who is fully active. She is receiving treatment in the FOLFOX arm for a diagnosis of rectal cancer. The KRAS biomarker analysis showed a mutant status.
691,1,"The patient is a 72-year-old female of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has reported adverse effects including low levels of granulocytes/bands and white blood cells, as well as experiencing nausea."
692,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is still able to move around. Pathology results indicate the presence of malignancy.
693,0,"The patient is a 53-year-old white male with a BMI of 20.22. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
694,0,"The patient is a 51-year-old white male with a BMI of 33.15. He is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of thrombosis and diarrhea."
695,0,"The patient is a 65-year-old white female with a BMI of 28.64. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
696,0,"The patient is a 35-year-old white male with a BMI of 32.65. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
697,0,"The patient is a 59-year-old white female with a BMI of 23.54. She is receiving treatment with FOLFOX for her well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. She has completed 12 cycles of chemotherapy and has adhered to her treatment regimen. Additionally, she has a wild-type KRAS biomarker and is currently dealing with a bowel obstruction."
698,0,"The patient is a 65-year-old Black female with a BMI of 24.1. She is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
699,0,"The patient is a 38-year-old white female with a BMI of 49.57 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to walk around. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
700,0,"The patient is a 46-year-old white male with a BMI of 33.76. He is receiving the FOLFIRI treatment arm for his KRAS mutant status. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
701,0,The patient is a 69-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
702,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 4 days post-surgery. The histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
703,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
704,0,"The patient is a 40-year-old white female with a BMI of 22.8. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect during her treatment. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the adverse effects, her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
705,0,"The patient is a 70-year-old white female with a BMI of 24.8. She is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
706,1,The patient is a 54-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
707,1,"The patient is a 41-year-old white female with a BMI of 43.12. She is undergoing treatment with FOLFOX chemotherapy and has completed 4 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
708,0,"The patient is a 43-year-old white female with a BMI of 28.79. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
709,0,The patient is a 49-year-old white female with well-differentiated histology who is currently receiving treatment with 5FU/LV + Radiation. She has symptoms but is still able to walk around (ambulatory). The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
710,1,"The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She required narcotic pain medication for 7 days post-surgery. Despite experiencing symptoms, she was still able to be ambulatory. The pathology results revealed a malignant condition."
711,1,The patient is a 61-year-old white male receiving treatment with ECF chemotherapy and radiation. He has well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
712,0,"The patient is a 62-year-old white male with a BMI of 31.77. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
713,0,"The patient is a 61-year-old white male with a BMI of 23.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
714,0,"The patient is a 62-year-old Black male with a BMI of 26.05. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker testing revealed a mutant result."
715,0,"The patient is a 58-year-old white female with a BMI of 21.93. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis shows that she has a mutant KRAS status."
716,0,"The patient is a 51-year-old female of a race classified as ""other"" with a BMI of 26.17. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing indicates that she has a wild-type KRAS status."
717,1,"The patient is a 66-year-old white female with a BMI of 50.45. She is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
718,1,"The patient is a 54-year-old white male with a BMI of 24.54. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
719,0,"The patient is a 58-year-old white female with a BMI of 26.7. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. Her histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker analysis revealed a mutant status."
720,1,"The patient is a 63-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
721,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
722,1,The patient is a 68-year-old white female with a fully active performance status. She is currently enrolled in the treatment arm that involves receiving a placebo.
723,1,"The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications post-surgery and required narcotic pain medication for 6 days. Despite having symptoms, the patient was able to remain ambulatory. The pathology report revealed that the underlying cause was malignant."
724,1,"The patient is a 66-year-old white male with a BMI of 29.92. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
725,0,"The patient is a 64-year-old white female with a BMI of 27.47. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
726,0,"The patient is a 34-year-old white male with a BMI of 32.01. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
727,0,"The patient is a 38-year-old female of a race categorized as ""other"" with a BMI of 22.1. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type."
728,1,"The patient is a 62-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
729,0,The patient is a 54-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
730,0,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
731,0,"The patient is a 72-year-old white male with a BMI of 30.0 who is receiving the FOLFOX treatment regimen. He has completed 8 cycles of chemotherapy and has been adherent to the treatment. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
732,1,The patient is a 63-year-old white male participating in the ECF + Radiation treatment arm. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory.
733,0,The patient is a 56-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low neutrophils/granulocytes and leukocytes.
734,0,"The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 28.69. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
735,1,"The patient is a 68-year-old white female who is part of the treatment arm receiving Cisplatin + Etoposide. She has not started chemotherapy yet (0 cycles completed). She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to move around and be ambulatory."
736,0,"The patient is a 48-year-old white male with a BMI of 30.75. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. Additionally, he has developed an infection as an adverse effect of the treatment."
737,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
738,0,"The patient is a 50-year-old white male with a BMI of 31.21. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
739,1,"The patient is a 65-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects on his blood cells, specifically on his granulocytes/bands, white blood cells, and lymphocytes."
740,1,"The patient is a 76-year-old white female with a BMI of 24.44. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates a mutant status."
741,1,"In this patient profile, the individual is a 51-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 6 chemotherapy cycles. Despite receiving this treatment regimen, the patient's performance status is fully active. An adverse effect noted in this case is a decrease in lymphocytes, which is a type of white blood cell that plays a crucial role in the immune system."
742,0,"The patient is a 50-year-old white female with a BMI of 34.79. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
743,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
744,1,"In this patient profile, the individual is a 52-year-old female of a race categorized as ""other."" She is undergoing treatment with a chemotherapy regimen consisting of Cisplatin and Etoposide. The patient has completed 8 cycles of chemotherapy and has a performance status of fully active. Additionally, she is experiencing an adverse effect known as granulocytes/bands."
745,0,"The patient is a 64-year-old white male with a BMI of 46.7. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that he has a wild-type mutation."
746,1,The patient is a 40-year-old white male with a BMI of 37.97. He is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
747,1,"This patient is a 66-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. She is experiencing adverse effects on her white blood cells and lymphocytes."
748,0,"The patient is a 51-year-old white male with a BMI of 27.28. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type."
749,0,The patient is a 48-year-old white male with a BMI of 28.54. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
750,1,"This patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. The histology report indicates that she spends less than 50% of her time in bed. Additionally, the pathology report shows that the condition is malignant."
751,1,"The patient is a 67-year-old white male who is receiving treatment with Sunitinib. He has symptoms but is still able to walk around, indicating that his performance status is somewhat compromised but he is still mobile."
752,1,"The patient is a 42-year-old white male with a BMI of 25.96 who is receiving the FOLFIRI treatment regimen. He has experienced a serious adverse effect during his 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates he has a wild-type status. Additionally, he has experienced diarrhea as an adverse effect."
753,0,"The patient is a 49-year-old white female with a BMI of 19.18. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type KRAS gene."
754,0,"The patient is a 72-year-old male of a race categorized as ""other"" with a BMI of 22.5. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
755,0,"The patient is a 45-year-old white female with a BMI of 26.49. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis showed a mutant status."
756,1,"The patient is a 76-year-old white male with a BMI of 22.94. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
757,0,The patient is a 41-year-old white female with a BMI of 25.09. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
758,1,The patient is a 58-year-old black female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
759,0,"The patient is a 72-year-old white female with a BMI of 26.96. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active, indicating that she is able to carry out her daily activities without limitations. The KRAS biomarker status is indeterminate, suggesting that further testing may be needed to determine its significance in her treatment plan."
760,0,"The patient is a 54-year-old white female with a BMI of 18.0. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
761,0,"The patient is a 41-year-old white female with a BMI of 30.48. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
762,0,"The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotic medication for 3 days post-surgery. The histology results showed that the tissue was well differentiated, and the pathology results indicated that the condition was benign."
763,1,The patient is a 76-year-old white male with a BMI of 25.65 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status.
764,0,"The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 38.79. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
765,0,"The patient is a 52-year-old white female with a BMI of 28.04. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. Additionally, the KRAS biomarker indicates that it is wild-type."
766,0,"The patient is a 44-year-old white male with a BMI of 22.83. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing indicates a mutant status."
767,0,The patient is a 55-year-old white female with a BMI of 25.0. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker for this patient is mutant.
768,0,"The patient is a 61-year-old Black male with a BMI of 28.21. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of thrombosis and infection."
769,1,"The patient is a 68-year-old white female with a BMI of 25.39 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
770,1,The patient is a 49-year-old white female with a BMI of 30.04 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory) and maintain her daily activities. The primary tumor diagnosis is in the rectal area.
771,1,The patient is a 61-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
772,1,"The patient is a white female, 80 years old, with a BMI of 22.97. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
773,0,"The patient is a 52-year-old white female with a BMI of 31.78. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
774,1,"The patient is a 61-year-old male of a race categorized as ""other"" who is undergoing treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around independently. The patient is currently experiencing adverse effects related to his granulocytes/bands and white blood cells."
775,0,"The patient is a 66-year-old white male with a BMI of 22.38. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that he has a wild-type status."
776,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 3 days following the procedure. Despite experiencing symptoms, he is able to walk around. The pathology report indicates malignancy."
777,1,The patient is a 45-year-old white female who is fully active. She is receiving treatment with Sunitinib.
778,0,"The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 32.49. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite his cancer treatment, he maintains a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
779,0,"The patient is a 37-year-old white female with a BMI of 32.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutation in the KRAS gene."
780,0,"The patient is a 62-year-old white male with a BMI of 24.59. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
781,0,The patient is a male undergoing laparoscopic-assisted colectomy treatment. He has bowel adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still ambulatory. Pathology results indicate a malignant condition.
782,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology indicates symptoms but she is still able to walk around. The pathology report shows that the condition is malignant.
783,0,"The patient is a 73-year-old Black female with a BMI of 27.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
784,1,"The patient is a 67-year-old white female with a BMI of 34.48. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis revealed that she has a mutant KRAS gene."
785,1,This patient is a 74-year-old white female with a BMI of 28.88 who is currently receiving treatment with FOLFOX and Panitumumab. She has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer.
786,1,"The patient is a 43-year-old white male with a BMI of 22.19. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
787,0,"The patient is a 42-year-old white male with a BMI of 32.23 who is receiving the FOLFOX treatment regimen. He has experienced serious adverse effects during the treatment, including thrombosis and infection. The patient has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
788,0,"The patient is a 67-year-old white male with a BMI of 26.35. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
789,0,The patient is a 41-year-old white female with a BMI of 18.78. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status.
790,0,"In this patient profile, the individual is a 60-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 8 chemotherapy cycles. Despite receiving this treatment regimen, the patient's performance status is fully active. An adverse effect noted in this case is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
791,0,"The patient is a 71-year-old white female with a BMI of 34.24. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
792,1,"The patient is a 62-year-old white male with a BMI of 20.57. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
793,0,"The patient is a 67-year-old white male with a BMI of 32.72. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
794,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
795,0,"The patient is a 38-year-old white male with a BMI of 26.92. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows a mutant status."
796,1,"This patient is a 51-year-old white female with a BMI of 28.18. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
797,0,"The patient is a 34-year-old white male with a BMI of 30.45. He is receiving treatment with FOLFOX and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
798,1,This patient is a 71-year-old white female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated.
799,1,The patient is a 57-year-old black female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active.
800,0,The patient is a 59-year-old white male with a BMI of 31.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker status is wild-type.
801,1,"This patient is a 66-year-old white female with a BMI of 23.66. She is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis for this patient is in the rectum."
802,0,The patient is a 76-year-old white male with a BMI of 29.48. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
803,1,The patient is a 49-year-old white male with a BMI of 26.89. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
804,0,"The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 26.4. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is mutant."
805,0,"The patient is a 69-year-old Black male who is part of the treatment arm receiving Cisplatin + Etoposide. He has not started any chemotherapy cycles yet. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around and be ambulatory."
806,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She has been using narcotics for 3 days. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology report indicates malignancy."
807,0,"The patient is a 40-year-old white female with a BMI of 30.72. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 11 chemotherapy cycles. Despite this, her performance status remains fully active. The KRAS biomarker status is indeterminate for this patient."
808,0,"The patient is a 66-year-old Black male with a BMI of 26.95. He is undergoing treatment with the FOLFOX regimen and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
809,1,The patient is a 67-year-old female of other race with a BMI of 33.53. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker is mutant in this case. The patient is receiving treatment in the FOLFOX treatment arm.
810,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is currently experiencing adverse effects related to his blood cells, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
811,1,"The patient is a 53-year-old white male with a BMI of 22.2. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis shows that the patient has a mutant KRAS gene."
812,1,"The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the procedure. They used narcotics for a total of 3 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
813,1,"The patient is a 45-year-old white female with a BMI of 32.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
814,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
815,0,"The patient is a 67-year-old white female with a BMI of 18.47. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
816,0,"The patient is a 58-year-old white male with a BMI of 34.19. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. He has reported experiencing diarrhea as an adverse effect of the treatment."
817,0,"The patient is a 60-year-old white male with a BMI of 20.9. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
818,1,The patient is a male who underwent laparoscopic-assisted colectomy and has bowel adhesions. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
819,0,"The patient is a 49-year-old white female with a BMI of 26.84. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has undergone 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory."
820,0,"The patient is a 49-year-old white female with a BMI of 27.53 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
821,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions and experienced complications post-surgery. He used narcotics for 4 days following the procedure. The histology shows symptoms but the patient is ambulatory, and the pathology indicates a malignant condition."
822,1,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
823,0,"The patient is a 66-year-old white female with a BMI of 24.84. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Additionally, the KRAS biomarker analysis indicates that she has a mutant KRAS status."
824,0,The patient is a 70-year-old white male who is part of the ECF + Radiation treatment arm. He has a performance status where he is in bed less than 50% of the time. The histology of his condition is poorly differentiated.
825,0,"The patient is a 56-year-old white female with a BMI of 22.85 who is currently receiving treatment with FOLFOX chemotherapy. She has completed one cycle of chemotherapy and has been diagnosed with poorly differentiated histology. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
826,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is able to move around. The pathology report indicates that the condition is malignant.
827,1,The patient is a 45-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
828,0,"The patient is a 46-year-old female of a race other than specified, with a BMI of 28.71. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker indicates that she is wild-type. The patient has experienced an infection as an adverse effect of her treatment."
829,1,"The patient is a 60-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy along with radiation. The histology of his cancer is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and loss of appetite."
830,1,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology indicates that the condition is malignant.
831,1,"The patient is a 54-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to move around and be ambulatory."
832,0,The patient is a 62-year-old Black female with a BMI of 24.05. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene.
833,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
834,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 5 days. Despite the symptoms, she was able to remain ambulatory. The pathology report revealed malignant findings."
835,0,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 8 days post-surgery. His histology indicates that he is in bed less than 50% of the time, and the pathology report shows that the tumor is malignant."
836,1,"This patient is a 74-year-old white female with a BMI of 28.76 who is currently receiving treatment with the FOLFOX regimen. She has a primary tumor diagnosis of colon cancer and has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to ambulate, indicating a performance status of symptoms but ambulatory."
837,1,"The patient is a 77-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
838,1,"The patient is a 61-year-old white male who is undergoing treatment with a combination of Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
839,1,"The patient is a 71-year-old white male who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. He has not started any chemotherapy cycles yet. Despite experiencing symptoms, he is still able to walk around."
840,1,"This patient is a 49-year-old white female with a BMI of 26.11. She is currently receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 4 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has also reported experiencing diarrhea as an adverse effect of her treatment."
841,0,"The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 26.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his condition is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
842,0,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of his condition is poorly differentiated.
843,0,"The patient is a 57-year-old white female with a BMI of 29.93. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
844,0,The patient is a 46-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing adverse effects of nausea and fatigue.
845,0,"The patient is a 75-year-old white male with a BMI of 28.18. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite his age, he has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced an adverse effect in the form of an infection."
846,1,The patient is a 72-year-old white male with well-differentiated histology who is part of the ECF + Radiation treatment arm. He has symptoms but is still able to walk around (ambulatory). The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
847,0,The patient is a 52-year-old black male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. The histology of the cancer is poorly differentiated.
848,0,"The patient is a 61-year-old white male with a BMI of 31.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, the patient has a fully active performance status. His KRAS biomarker status is wild-type."
849,0,The patient is a 59-year-old white female with a BMI of 44.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
850,0,"The patient is a 47-year-old white male with a BMI of 30.01. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced an adverse effect in the form of an infection."
851,0,The patient is a 59-year-old white male with a BMI of 23.42. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
852,1,"The patient is a 69-year-old white male who is undergoing treatment with Cisplatin + Etoposide. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. He has reported experiencing nausea as an adverse effect of the treatment."
853,0,"The patient is a 75-year-old white female with a BMI of 28.1. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
854,0,"The patient is a 57-year-old white female with a BMI of 29.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a wild-type KRAS status."
855,1,"The patient is a 65-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has shown adverse effects with low levels of granulocytes/bands and lymphocytes."
856,0,"The patient is a 39-year-old white female with a BMI of 23.86. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a mutant status."
857,0,"The patient is a 41-year-old white female with a BMI of 26.9. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
858,0,"The patient is a 65-year-old white female with a BMI of 24.22. She is enrolled in the FOLFOX treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not started any chemotherapy cycles yet. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker status is indeterminate."
859,0,The patient is a female who is undergoing conventional surgery for a malignant condition. She has not used any narcotics for pain relief and is experiencing symptoms but is still able to walk around.
860,1,"The patient is a 76-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around."
861,0,"The patient is a 50-year-old white female with a BMI of 28.05 who is undergoing treatment with FOLFOX chemotherapy. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to walk around. Additionally, the KRAS biomarker testing revealed a mutant status."
862,1,"The patient is a 52-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She is scheduled to undergo a total of 8 cycles of chemotherapy. Despite the treatment, her performance status is fully active, indicating that she is able to carry out her daily activities without any limitations."
863,0,The patient is a 45-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
864,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and experienced complications post-surgery. He used narcotics for 2 days. Histologically, he has symptoms but is still able to move around. Pathologically, the findings indicate malignancy."
865,1,The patient is a 66-year-old female of other race with a BMI of 32.89. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker shows a wild-type result. The patient is experiencing a rash as an adverse effect of the FOLFOX + Panitumumab treatment.
866,0,"The patient is a 62-year-old white male with a BMI of 32.65. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
867,1,"The patient is a 62-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. He has developed adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands and lymphocytes."
868,0,"The patient is a 43-year-old white female with a BMI of 23.98. She is currently undergoing treatment with FOLFIRI + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
869,1,The patient is a 51-year-old black male with a performance status of symptoms but still able to walk around. He is receiving treatment with ECF and radiation therapy. The histology shows poorly differentiated cancer. The patient is experiencing fatigue as an adverse effect of the treatment.
870,0,"The patient is a 69-year-old white male with a BMI of 24.98. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
871,0,"The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 6 days to manage his symptoms, but is still ambulatory."
872,0,The patient is a 58-year-old white female with a BMI of 20.94. She is fully active and is receiving treatment with FOLFOX for colon cancer. The KRAS biomarker indicates that the tumor is wild-type.
873,1,"The patient is a 61-year-old white male with a BMI of 20.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a mutant status."
874,1,"The patient is a 64-year-old white male with a BMI of 24.1. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
875,0,The patient is a 52-year-old white male with a performance status of having symptoms but still able to walk around. He is receiving treatment with 5FU/LV + Radiation therapy. The histology shows poorly differentiated cells.
876,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 1 day post-surgery. Despite experiencing symptoms, she is still able to move around. The pathology report revealed that the patient has a malignant condition."
877,0,"The patient is a 57-year-old white female with a BMI of 30.12. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker status is indeterminate for this patient."
878,1,"The patient is a 72-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 3 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate."
879,1,The patient is a 52-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of her cancer is poorly differentiated. She is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
880,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during the treatment. She used narcotics for 4 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
881,0,The patient is a 43-year-old white male with a BMI of 27.25 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 9 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
882,1,"This patient is a 59-year-old white female with a BMI of 50.78. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel perforation after completing 2 cycles of chemotherapy. Her cancer histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
883,1,"This patient is a 47-year-old white female with a BMI of 24.17 who is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. She has a performance status of experiencing symptoms but is still able to walk around (ambulatory). Additionally, her KRAS biomarker status is wild-type."
884,0,"The patient is a 68-year-old white female with a BMI of 23.43. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
885,0,"The patient is a 64-year-old white male with a BMI of 29.07. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
886,0,The patient is a 41-year-old white female with a BMI of 23.31. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
887,1,"The patient is a 64-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
888,0,"The patient is a 65-year-old white female with a BMI of 22.83. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her treatment, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
889,0,"The patient is a 64-year-old white female with a BMI of 21.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has the wild-type version of the gene."
890,1,"The patient is a 72-year-old white male with a BMI of 25.76. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
891,0,"The patient is a 71-year-old white female with a BMI of 20.81. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker indicates a mutant status."
892,1,The patient is a 57-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is well-differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
893,0,"The patient is a 58-year-old white male with a BMI of 34.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
894,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Histologically, she was in bed less than 50% of the time. Pathology results indicated a malignant condition."
895,0,"The patient is a 63-year-old white female with a BMI of 25.49. She is receiving treatment with FOLFOX chemotherapy. She has a bowel obstruction and has completed 11 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
896,0,"The patient is a 43-year-old white female with a BMI of 28.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
897,0,"The patient is a 58-year-old white male with a BMI of 26.82. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
898,0,"The patient is a 74-year-old white female with a BMI of 24.92. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cancer. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
899,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He only used narcotics for 1 day post-surgery. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
900,0,"This patient is a 62-year-old white female with a BMI of 18.4. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. Despite these challenges, her performance status is fully active. The patient has a mutant KRAS biomarker and is experiencing diarrhea as an adverse effect of her treatment."
901,1,The patient is a 45-year-old black female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. Her histology shows poorly differentiated characteristics.
902,0,"The patient is a 52-year-old white male with a BMI of 36.64. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
903,0,"The patient is a 44-year-old female of a race other than specified, with a BMI of 25.56. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
904,1,The patient is a 48-year-old white male who is currently receiving treatment with Sunitinib. He is experiencing symptoms but is still able to walk around.
905,0,"This patient is a 71-year-old white male with a BMI of 24.89. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of diarrhea, his performance status is fully active. Additionally, his KRAS biomarker is mutant."
906,0,"The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 26.8. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
907,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 5 days post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the underlying cause is malignant.
908,0,"The patient is a 63-year-old white male with a BMI of 29.92. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status."
909,0,"The patient is a 35-year-old white female with a BMI of 34.12. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS gene."
910,1,"The patient is a 46-year-old white female with a BMI of 37.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced an adverse effect of infection."
911,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
912,1,"The patient is a 45-year-old Black male receiving treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and lymphocytes."
913,0,"The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 25.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of the cancer is poorly differentiated. Despite the cancer diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker indicates that the patient has a wild-type KRAS gene."
914,1,"The patient is a 58-year-old white male with a BMI of 32.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
915,0,The patient is a 56-year-old white female with a BMI of 33.06 who is currently undergoing treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer.
916,1,"The patient is a 74-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed three cycles of chemotherapy and has a fully active performance status."
917,0,"The patient is a 59-year-old female of a race categorized as ""other"" who is currently receiving treatment in the ECF + Radiation arm. She has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
918,1,"The patient is a 34-year-old white male with a BMI of 30.49. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
919,0,"The patient is a 76-year-old white male with a BMI of 29.62. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
920,0,The patient is a 39-year-old white male with a BMI of 35.73. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is indeterminate.
921,0,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotics for 3 days.
922,1,The patient is a 60-year-old white male with a BMI of 21.73 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis shows a mutant status.
923,1,"The patient is a 58-year-old white female who is receiving treatment with a combination of Cisplatin and Etoposide. She is undergoing a total of 6 cycles of chemotherapy. Despite her treatment, she has a fully active performance status."
924,1,This patient is a 58-year-old white female with a BMI of 28.33. She is fully active and is receiving treatment with FOLFOX for a primary colon tumor. Her KRAS biomarker status is wild-type.
925,0,The patient is a 56-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a fully active performance status and has been diagnosed with poorly differentiated histology. She is experiencing adverse effects including low levels of neutrophils/granulocytes and fatigue.
926,0,"The patient is a 53-year-old white male with a BMI of 27.76. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
927,0,"The patient is a 58-year-old female of a race categorized as ""other."" She is part of the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite her age, she has a fully active performance status. The histology of her condition is classified as poorly differentiated."
928,0,"The patient is a 47-year-old Black male with a BMI of 30.32. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
929,0,"The patient is a 53-year-old white female with a BMI of 21.99. She is receiving the FOLFIRI treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
930,1,"The patient is an 80-year-old white male with a BMI of 36.66 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with colon cancer, and his KRAS biomarker status is wild-type."
931,0,"The patient is a 73-year-old white female with a BMI of 25.96. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status and has been adherent to the treatment. Unfortunately, she experienced a serious adverse effect in the form of a bowel perforation. Despite this, she completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type."
932,1,"The patient is a 58-year-old white female with a BMI of 26.37. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
933,0,"The patient is a 56-year-old white female with a BMI of 52.09. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
934,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
935,0,The patient is a 49-year-old white male with a BMI of 24.4 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a fully active performance status and has been identified as having a wild-type KRAS biomarker. The patient is experiencing an adverse effect of rash as a result of the treatment.
936,1,The patient is a 46-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. He has a histology of poorly differentiated cancer and is experiencing nausea as an adverse effect of the treatment.
937,1,"The patient is a 62-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to ambulate."
938,0,"The patient is a 69-year-old white male with a BMI of 37.06. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he is wild-type. He has also experienced diarrhea as an adverse effect of the treatment."
939,0,"The patient is a 69-year-old white male with a BMI of 23.44. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker testing revealed that he has a mutant KRAS gene."
940,1,"The patient is a 61-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 4 cycles of chemotherapy and has a performance status of fully active."
941,0,"The patient is a 56-year-old white female with a BMI of 31.52. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
942,1,"This patient is a 56-year-old white female with a BMI of 27.8 who is currently receiving treatment with FOLFOX and Panitumumab. She has a colon cancer diagnosis with a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
943,1,"The patient is a 62-year-old female of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation. She has a performance status that indicates she is experiencing symptoms but is still able to walk around. The histology of her condition is well-differentiated. She is also experiencing nausea as an adverse effect of her treatment."
944,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the procedure. Her histology indicates symptoms but she is still able to walk around. The pathology report shows that the condition is malignant.
945,1,"The patient is a 69-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
946,0,"The patient is a 61-year-old white female with a BMI of 35.74. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. Notably, her KRAS biomarker is wild-type."
947,0,The patient is a 57-year-old white female with a BMI of 28.65. She is fully active with a primary tumor diagnosis of colon cancer. The patient is enrolled in the FOLFOX treatment arm. Her KRAS biomarker status is mutant.
948,0,"The patient is a 49-year-old white female with a BMI of 25.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
949,1,"The patient is a 58-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 4 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to ambulate."
950,0,The patient is a 61-year-old white male with a BMI of 23.22. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
951,0,"The patient is a 65-year-old white female with a BMI of 41.3 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 3 cycles of chemotherapy. Her cancer histology is well differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has developed an infection as an adverse effect of the treatment."
952,0,"The patient is a 35-year-old Black male with a BMI of 31.18. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
953,0,"The patient is a 57-year-old white female with a BMI of 22.58. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
954,1,"The patient is a 72-year-old white male with a BMI of 28.37. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology. Despite being fully active with a wild-type KRAS biomarker, he is experiencing diarrhea as an adverse effect of the chemotherapy."
955,1,"The patient is a 56-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. His performance status indicates that he is in bed less than 50% of the time."
956,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology shows symptoms but she is able to walk around. The pathology report indicates that the condition is malignant.
957,1,"The patient is a 67-year-old white male with well-differentiated histology who is currently undergoing treatment with ECF and radiation. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
958,0,"The patient is a 76-year-old white male with a BMI of 33.02 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has completed 11 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
959,0,This patient is a 71-year-old white male who is part of the placebo treatment arm. His performance status indicates that he spends less than 50% of his time in bed.
960,1,"The patient is a 62-year-old white female with a BMI of 18.03. She is receiving treatment with FOLFOX for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed a mutant status."
961,0,The patient is a 57-year-old white male with a BMI of 23.71. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
962,0,"The patient is a 72-year-old white male with a BMI of 35.81. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
963,1,"The patient is a 64-year-old white male with a BMI of 37.26. He is currently receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
964,1,"This patient is a 74-year-old white male with a BMI of 29.38. He is currently receiving treatment in the FOLFOX + Panitumumab treatment arm. Despite experiencing symptoms, he is still able to ambulate. The patient has been diagnosed with a primary colon tumor and has a wild-type KRAS biomarker."
965,1,"The patient is a 61-year-old white male with a BMI of 29.07. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
966,1,The patient is a 62-year-old white female with a BMI of 22.2. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is mutant.
967,1,"The patient is a 75-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is currently experiencing adverse effects related to her granulocytes/bands and white blood cells."
968,0,"The patient is a 66-year-old male of a race categorized as ""other."" He is currently receiving treatment in the 5FU/LV + Radiation arm. Despite experiencing symptoms, he is still able to move around independently. The histology indicates that the cancer is poorly differentiated."
969,0,The patient is a 41-year-old white female with a BMI of 34.22. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She is experiencing a bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status indicates that she is in bed less than 50% of the time. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect.
970,0,The patient is a 67-year-old white male with a BMI of 32.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
971,1,"The patient is a 61-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
972,1,The patient is a 68-year-old white male participating in the placebo treatment arm. He has symptoms but is still able to move around independently.
973,1,"The patient is a 67-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
974,1,"The patient is a 76-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with decreased levels of granulocytes/bands and lymphocytes."
975,0,"The patient is a 58-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 4 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory). She is experiencing adverse effects related to her granulocytes/bands and white blood cells."
976,0,The patient is a 41-year-old white male with a BMI of 25.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
977,0,"The patient is a 60-year-old white male with a BMI of 29.76. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's treatment arm is FOLFOX, and his KRAS biomarker status is wild-type."
978,0,"The patient is a 34-year-old white male with a BMI of 25.66. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
979,0,The patient is a 60-year-old white male with a BMI of 23.72. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. The KRAS biomarker analysis showed a mutant status.
980,1,"The patient is a 75-year-old Black male with a history of prior cancer. He is currently receiving treatment with ECF and radiation. Despite experiencing adverse effects on his neutrophils/granulocytes and leukocytes, his performance status remains fully active. The histology of his cancer is well-differentiated."
981,1,"The patient is a 55-year-old white male with a BMI of 31.45. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed a mutant result. The patient experienced a hypersensitivity adverse effect during treatment."
982,1,This patient is a 49-year-old white female with a BMI of 25.64. She is fully active with a primary tumor diagnosis of colon. She is in the FOLFOX + Panitumumab treatment arm and has a wild-type KRAS biomarker.
983,0,The patient is a 72-year-old white male with a BMI of 23.15. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
984,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, along with some complications. He used narcotics for 5 days post-surgery. The histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
985,0,"The patient is a 71-year-old white male with a BMI of 30.48. He is undergoing treatment with FOLFOX chemotherapy regimen and has experienced both bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his bowel issues, his performance status is fully active. His KRAS biomarker status is wild-type."
986,0,The patient is a 65-year-old white male with a BMI of 38.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that he has a mutant form of the gene.
987,0,"The patient is a 63-year-old white female with a BMI of 25.8. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
988,1,"The patient is a 68-year-old white male receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing nausea as an adverse effect of the treatment."
989,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 1 day following the procedure. The histology results indicate that the tissue is well-differentiated, and the pathology report shows that the condition is benign."
990,1,The patient is a 48-year-old Black female with a BMI of 20.16. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy. She has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is mutant.
991,0,"The patient is a 59-year-old white male with a BMI of 23.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
992,0,"The patient is a 77-year-old white male with a BMI of 25.04 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory) despite his condition. He has been diagnosed with colon cancer, and his KRAS biomarker status is mutant."
993,1,"The patient is a 71-year-old white male who is currently undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy and has a performance status of fully active."
994,0,The patient is a 74-year-old Black female with a performance status indicating symptoms but still able to walk around (ambulatory). She is receiving treatment in the ECF + Radiation arm. The histology shows poorly differentiated characteristics.
995,1,"The patient is a 61-year-old male of other race with a BMI of 26.26. He is currently receiving treatment with FOLFOX and Panitumumab for a colon tumor. His performance status indicates that he is experiencing symptoms but is still able to walk around. Additionally, the KRAS biomarker testing revealed a mutant status."
996,1,The patient is a 54-year-old white male who is fully active and is receiving treatment with Sunitinib. He is experiencing adverse effects related to his neutrophils/granulocytes and leukocytes.
997,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. He spends less than 50% of his time in bed. The pathology report indicates a malignant condition.
998,1,"The patient is a 58-year-old white female receiving treatment with Cisplatin, Etoposide, and Paclitaxel. She has completed 3 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She has developed low white blood cell count as an adverse effect of the treatment, and she is also experiencing nausea."
999,0,"The patient is a 73-year-old white female with a BMI of 20.93. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1000,1,"The patient is a 64-year-old white female with a BMI of 23.06. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1001,1,The patient is a 58-year-old male of other race with a BMI of 20.43. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that the patient has a mutant KRAS status. The patient is receiving treatment in the FOLFOX + Panitumumab treatment arm.
1002,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He experienced complications following the surgery and used narcotics for 5 days. Despite having symptoms, he is able to walk around. The pathology report indicates a malignant condition."
1003,1,"The patient is a 42-year-old white female with a BMI of 24.54. She is enrolled in the FOLFIRI treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1004,0,"The patient is a 57-year-old male of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows that the cancer cells are well-differentiated. Additionally, the patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
1005,0,The patient is a 45-year-old white female with a BMI of 33.73. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1006,1,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 6 days and his histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
1007,1,"The patient is a 53-year-old white female with a BMI of 34.48. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to move around. The KRAS biomarker analysis showed that she has a mutant KRAS status."
1008,1,"The patient is a 64-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects related to his granulocytes/bands and white blood cells."
1009,0,"The patient is a 62-year-old white male with a BMI of 29.36. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
1010,0,The patient is a 54-year-old white male with a BMI of 22.63. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status.
1011,0,"The patient is a 64-year-old male of a race categorized as ""other"" with a BMI of 22.32. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. The patient experienced a bowel perforation and has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
1012,1,"The patient is a 56-year-old male of a race categorized as ""other"" who is undergoing treatment with Cisplatin + Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands."
1013,0,"The patient is a 58-year-old white female with a BMI of 28.28. She is currently receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
1014,0,"The patient is a 46-year-old white male with a BMI of 32.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
1015,1,This patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she was still able to be ambulatory. The pathology report indicated that the cause of her symptoms was malignant.
1016,1,"The patient is a 53-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around. The patient is experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
1017,0,The patient is a 46-year-old white female with a BMI of 28.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
1018,1,"The patient is a 59-year-old white male with a BMI of 30.32. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
1019,0,"The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 21.82. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite his treatment, he maintains a fully active performance status. Additionally, the patient's KRAS biomarker is identified as mutant."
1020,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
1021,0,"The patient is a 71-year-old white male with a BMI of 30.91. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of his cancer is well-differentiated. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed that he has a mutant KRAS status."
1022,1,"The patient is a 41-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient has experienced a decrease in lymphocytes as an adverse effect of the treatment."
1023,1,"The patient is a 57-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. He is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
1024,0,"The patient is a 55-year-old white female with a BMI of 23.26. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1025,1,"The patient is a 58-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. She is experiencing adverse effects such as low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
1026,0,The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery. He used narcotics for one day. The histology showed symptoms but the patient was still able to be ambulatory. The pathology report indicated a malignant condition.
1027,1,The patient is a 70-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of his cancer is poorly differentiated. He is experiencing an adverse effect related to his neutrophils/granulocytes.
1028,1,"The patient is a 73-year-old white female with a BMI of 27.54. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
1029,0,"The patient is a 76-year-old white female with a BMI of 26.52. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1030,1,"The patient is a 38-year-old white male with a BMI of 29.86. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed one cycle of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced adverse effects including infection and infarction."
1031,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days post-surgery. Their histology shows that they are in bed less than 50% of the time, and their pathology indicates a malignant condition."
1032,0,"The patient is a 49-year-old white female with a BMI of 35.63. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1033,0,"The patient is a 70-year-old white male with a BMI of 32.88. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
1034,1,The patient is a 69-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active.
1035,1,"The patient is a 63-year-old white female with a BMI of 24.04. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment in the FOLFOX + Panitumumab arm, and her KRAS biomarker status is wild-type."
1036,0,"The patient is a female who underwent conventional surgery and has abdominal wall and bowel adhesions. She experienced complications post-surgery and required 4 days of narcotic use for pain management. Despite having symptoms, she is able to walk around. The pathology report indicates malignancy."
1037,0,"The patient is a 67-year-old white male with a BMI of 38.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
1038,0,"This patient is a 41-year-old white male with a BMI of 29.23. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced the adverse effect of thrombosis."
1039,1,"The patient is a 72-year-old white male with a BMI of 19.13 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a rash as an adverse effect of the treatment."
1040,1,The patient is a 66-year-old black male who is fully active and is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
1041,0,"This patient is a 64-year-old white male with a BMI of 23.56. He is receiving treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel complications, his performance status is fully active. His KRAS biomarker status is wild-type."
1042,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required 3 days of narcotic pain medication. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
1043,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 3 days. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology results show that the condition is malignant."
1044,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesion as well as bowel adhesion. There have been complications following the surgery. The patient used narcotics for 4 days post-surgery. Despite experiencing symptoms, the patient is able to walk around. The pathology report indicates a malignant condition."
1045,0,"The patient is a 60-year-old white female with a high BMI of 47.51. She is receiving the FOLFOX treatment arm for her chemotherapy, with a planned 12 cycles. Her cancer histology is poorly differentiated. Despite her health challenges, she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type status."
1046,1,"The patient is a 62-year-old white male with a BMI of 27.66. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed that the patient has a mutant KRAS status."
1047,0,The patient is a 56-year-old Black female with a BMI of 37.47. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
1048,0,"The patient is a 73-year-old white female with a BMI of 36.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1049,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 3 days post-surgery. The histology shows symptoms but the patient is ambulatory. The pathology report indicates malignancy.
1050,1,"The patient is a 63-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
1051,0,"The patient is a 67-year-old white female with a BMI of 27.26. She is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment."
1052,0,"The patient is a 70-year-old white male with a BMI of 37.3. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1053,0,"The patient is a 50-year-old white female with a BMI of 24.49. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1054,1,"The patient is a 57-year-old white male undergoing treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects on his blood cells, specifically decreased granulocytes/bands and lymphocytes."
1055,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 2 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology report indicated that the condition was malignant.
1056,0,"The patient is a 67-year-old white female with a BMI of 27.32. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
1057,0,The patient is a 72-year-old white female with a BMI of 20.73. She is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker status is wild-type.
1058,1,"The patient is a 64-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects including low levels of granulocytes/bands and lymphocytes, as well as nausea."
1059,1,"The patient is a 55-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 6 chemotherapy cycles. She is experiencing symptoms but is still able to walk around. Additionally, she is experiencing adverse effects on her white blood cells and lymphocytes."
1060,0,The patient is a 39-year-old white female with a BMI of 20.28. She is undergoing treatment with FOLFOX chemotherapy and has completed 11 cycles so far. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
1061,0,"The patient is a 59-year-old white female with a BMI of 19.63. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1062,0,"The patient is a 50-year-old white male with a BMI of 26.7. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
1063,1,The patient is a 67-year-old white male with a BMI of 27.78 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that the tumor is wild-type.
1064,1,"The patient is a 75-year-old white male with a BMI of 21.38. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
1065,0,"The patient is a 74-year-old white female with a BMI of 20.62. She is receiving the FOLFOX treatment arm for her bowel perforation. She has undergone 12 chemotherapy cycles and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that she has a wild-type status."
1066,0,"This patient is a 44-year-old white male with a BMI of 25.86. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1067,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions and experienced complications post-surgery. He used narcotics for 6 days. Despite having symptoms, he is able to walk around. The pathology report indicated malignancy."
1068,0,The patient is a 44-year-old white male with a BMI of 27.14 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
1069,1,The patient is a 55-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
1070,1,The patient is a 75-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
1071,1,"The patient is a 36-year-old white female with a BMI of 29.41 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
1072,0,"The patient is a 74-year-old white male with a BMI of 27.71. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1073,1,"The patient is a 56-year-old white female with a BMI of 38.66. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1074,0,The patient is a 42-year-old white male with a BMI of 26.89. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1075,0,"The patient is a 69-year-old white female with a BMI of 33.19. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
1076,0,"The patient is a 61-year-old white male with a BMI of 22.86. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
1077,1,"The patient is a 62-year-old white male with a BMI of 26.3. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1078,0,"The patient is a 48-year-old white female with a BMI of 33.9. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
1079,0,"The patient is a 68-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed treatment. However, he experienced a serious adverse effect after completing one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. Additionally, the KRAS biomarker analysis revealed a mutant status."
1080,0,The patient is a 62-year-old white male with a BMI of 28.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
1081,1,"The patient is a 77-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
1082,1,"The patient is a 51-year-old Black female with a history of prior cancer. She is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, she is still able to walk around (ambulatory). The histology of her cancer is poorly differentiated."
1083,0,"The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 22.83. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker shows that the patient has a wild-type status."
1084,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. She is experiencing symptoms but is still able to move around. The pathology report indicates that the patient has a malignant condition.
1085,0,The patient is a 61-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
1086,0,"The patient is a 70-year-old white male with a BMI of 25.45. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The patient's KRAS biomarker is mutant. He is experiencing diarrhea as an adverse effect of the treatment."
1087,0,"The patient is a 54-year-old white male with a BMI of 33.46. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
1088,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have only used narcotics for 1 day. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
1089,1,"The patient is a 72-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she has reported experiencing nausea as an adverse effect of the treatment."
1090,0,"The patient is a 61-year-old white male with a BMI of 17.51. He is receiving the FOLFOX treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, his performance status is fully active. The KRAS biomarker indicates a wild-type status."
1091,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1092,0,"The patient is a 59-year-old white male with a BMI of 40.01. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
1093,0,"The patient is a 46-year-old white female with a BMI of 23.43. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1094,0,"The patient is a 58-year-old white male with a BMI of 22.44. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1095,0,"The patient is a 49-year-old white female with a BMI of 26.45. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1096,0,"The patient is a 75-year-old white male with a BMI of 22.8. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1097,0,"The patient is a 64-year-old white female with a BMI of 24.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1098,0,"The patient is a 49-year-old white female with a BMI of 31.24. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1099,0,The patient is a 69-year-old white male with a BMI of 26.76. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1100,0,The patient is a 65-year-old white female with a BMI of 26.65 who is enrolled in the FOLFOX + Panitumumab treatment arm. She has a fully active performance status and has been diagnosed with a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing an adverse effect of rash as a result of the treatment.
1101,0,"The patient is a 63-year-old white female with a BMI of 21.47. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1102,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
1103,1,"The patient is a 51-year-old white female with a BMI of 25.77. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a serious adverse effect during the treatment, specifically thrombosis and diarrhea. She completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Her KRAS biomarker is wild-type."
1104,0,The patient is a 47-year-old white male with a BMI of 28.59. He is receiving the FOLFIRI treatment regimen for his well-differentiated cancer with a KRAS mutation. He has completed 12 cycles of chemotherapy and has a fully active performance status.
1105,0,"The patient is a 72-year-old white male with a BMI of 27.58. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1106,1,"The patient is a 55-year-old white male with a BMI of 21.56. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker shows that he has a wild-type status."
1107,0,"The patient is a 75-year-old white female with a BMI of 28.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has the wild-type variant."
1108,1,"The patient is a 60-year-old Black male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. He has a fully active performance status but is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
1109,1,The patient is a 56-year-old white male with a BMI of 35.28 who is receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker indicates that the patient has a wild-type gene.
1110,1,The patient is a 58-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
1111,0,"The patient is a 58-year-old white male with a BMI of 37.54 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has developed thrombosis as an adverse effect."
1112,0,"The patient is a 67-year-old male of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating a reasonable performance status."
1113,0,"The patient is a 46-year-old Black female with a BMI of 27.13. She is currently receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. The KRAS biomarker status is indeterminate."
1114,0,"The patient is a 54-year-old white male with a BMI of 28.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1115,1,The patient is a 70-year-old white female with a BMI of 22.48. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed one cycle of chemotherapy. The histology shows well-differentiated cells. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker test revealed a mutant result.
1116,0,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They used narcotics for 2 days following the procedure. The histology results showed symptoms but the patient is still ambulatory. The pathology report indicated that the cause of the symptoms was malignant in nature.
1117,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology shows symptoms but the patient is ambulatory. The pathology report indicates malignancy.
1118,0,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotics for 2 days.
1119,1,"The patient is a 71-year-old white female with a BMI of 33.8 who is undergoing treatment with FOLFOX + Cetuximab for colorectal cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated, and her performance status is fully active. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1120,0,"The patient is a 66-year-old white male with a BMI of 29.25. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
1121,0,"The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 26.37. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1122,1,The patient is a 56-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects of nausea and fatigue.
1123,1,"The patient is a 75-year-old white female with a BMI of 31.87. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She has experienced diarrhea as an adverse effect during her treatment."
1124,1,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and has only used narcotics for 1 day. Despite experiencing symptoms, he is still able to be ambulatory. The pathology results indicate malignancy."
1125,1,"This patient is a 56-year-old white female with a well-differentiated histology who is receiving treatment with 5FU/LV and radiation. She has symptoms but is still able to be ambulatory. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
1126,1,"The patient is a 75-year-old white male with a BMI of 26.99. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
1127,0,"The patient is a 53-year-old white female who is fully active and is receiving treatment with Sunitinib. She is experiencing an adverse effect related to her neutrophils/granulocytes. This may indicate a decrease in these types of white blood cells, which are important for fighting infections"
1128,1,"The patient is a 65-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory."
1129,1,The patient is a 69-year-old white male with a BMI of 24.46 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. The KRAS biomarker indicates that he has a wild-type mutation. The patient is experiencing a rash as an adverse effect of the treatment.
1130,0,"The patient is a 68-year-old white female with a BMI of 24.84. She is undergoing treatment with the FOLFIRI + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1131,0,"This patient is a 40-year-old white female with a BMI of 20.96. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Despite being fully active with a good performance status, she has experienced a serious adverse effect during her 12 chemotherapy cycles. The patient's KRAS biomarker is mutant, and she has also experienced diarrhea as an adverse effect of her treatment."
1132,0,"The patient is a 60-year-old white male with a BMI of 31.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. The patient has experienced a hypersensitivity adverse effect."
1133,1,"The patient is a 63-year-old white female with a history of prior cancer. She is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, she is still able to walk around (ambulatory). The histology of her cancer is poorly differentiated."
1134,0,"The patient is a 34-year-old Black female with a BMI of 33.46. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including hypersensitivity and diarrhea."
1135,1,"The patient is a 50-year-old white male with a BMI of 19.66 who is currently receiving treatment with the FOLFOX regimen. He has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that the patient has a mutant KRAS gene."
1136,1,"The patient is a 64-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still ambulatory. His histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
1137,0,"The patient is a 52-year-old white male with a BMI of 24.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1138,1,"The patient is a 46-year-old white male with a BMI of 36.59. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker is mutant. Additionally, the patient has experienced thrombosis as an adverse effect."
1139,0,"The patient is a 45-year-old white female with a BMI of 33.49. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1140,1,The patient is a 65-year-old white male with a BMI of 26.68. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
1141,1,"The patient is a 68-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed one cycle of chemotherapy. She has experienced weight loss greater than 5-10%. Despite this, she has a fully active performance status. The patient has reported adverse effects including low levels of granulocytes/bands and white blood cells, as well as experiencing nausea."
1142,0,The patient is a 55-year-old Black female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation therapy. The histology shows poorly differentiated cells.
1143,0,The patient is a 67-year-old white male with a BMI of 34.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1144,0,The patient is a 64-year-old white female with a BMI of 23.83. She is fully active with a primary tumor diagnosis of colon. She is in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
1145,0,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
1146,0,"The patient is a 63-year-old white male with a BMI of 21.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1147,1,"The patient is a 63-year-old white male with a BMI of 31.28. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed regimen. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1148,1,"The patient is a 49-year-old white female with a BMI of 24.89. She is fully active with a primary tumor diagnosis of rectal cancer. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab (a targeted therapy). Her KRAS biomarker status is wild-type, indicating that she may respond well to the treatment regimen."
1149,1,The patient is a 62-year-old white female who is fully active. She is currently receiving treatment in the placebo arm of the study.
1150,1,"The patient is a 38-year-old white female with a BMI of 19.84. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1151,0,"The patient is a 37-year-old white female with a BMI of 29.26. She is currently receiving treatment with the FOLFOX regimen. Her performance status is fully active, indicating that she is able to carry out normal daily activities without any limitations. The primary tumor diagnosis is colon cancer."
1152,0,"The patient is a 62-year-old white female with a BMI of 40.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient's KRAS biomarker status is mutant."
1153,1,"The patient is a 57-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as fatigue."
1154,0,"The patient is a 38-year-old white male with a BMI of 25.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1155,0,"The patient is a 63-year-old white male with a BMI of 31.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1156,0,"The patient is a 73-year-old white male with a BMI of 30.64. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
1157,0,"The patient is a 51-year-old white female with a BMI of 36.91. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1158,0,"The patient is a 40-year-old white female with a BMI of 29.51. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1159,0,The patient is a 63-year-old white female with a BMI of 25.89. She is fully active with a primary tumor diagnosis of rectal cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
1160,1,"The patient is a 37-year-old white male who is undergoing treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects on his blood cells, specifically on his granulocytes/bands, white blood cells, and lymphocytes."
1161,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is able to walk around. The pathology report indicates that the condition is malignant.
1162,0,"The patient is a 67-year-old female of a race classified as ""other"" with a BMI of 26.78. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 4 cycles so far. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
1163,1,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
1164,0,The patient is a 74-year-old white male who is fully active and has received prior chemotherapy and radiation treatment. He is currently enrolled in the ECF + Radiation treatment arm. The histology of his condition is poorly differentiated. He is experiencing an adverse effect of low leukocyte levels.
1165,0,The patient is a 41-year-old white female with a BMI of 23.29. She is receiving treatment in the FOLFOX chemotherapy arm and has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
1166,0,"The patient is a 59-year-old black male with a BMI of 30.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
1167,1,The patient is a 74-year-old white male with a BMI of 27.34 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
1168,0,"The patient is a 56-year-old white female with a BMI of 26.44. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1169,0,The patient is a 50-year-old white female with a BMI of 23.45. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1170,0,The patient is a 58-year-old white male with a BMI of 31.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1171,0,The patient is a 73-year-old white male with a BMI of 25.2. He is receiving treatment with the FOLFIRI regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status.
1172,1,"The patient is a 51-year-old white female with a BMI of 20.96. She is fully active and is receiving treatment with the FOLFOX regimen. The primary tumor diagnosis is colon cancer, and the KRAS biomarker is mutant."
1173,1,"In this patient profile, the individual is a 62-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 6 chemotherapy cycles. Despite the treatment, the patient's performance status is fully active. An adverse effect noted is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
1174,1,The patient is a 63-year-old white female who is fully active. She is receiving treatment with Sunitinib.
1175,0,"The patient is a 67-year-old white male with a BMI of 28.47. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has experienced diarrhea as an adverse effect."
1176,1,"The patient is a 68-year-old white male who has received prior chemotherapy. He is currently in the treatment arm receiving 5FU/LV + Radiation. Despite experiencing symptoms, he is still able to ambulate. The histology shows well-differentiated characteristics."
1177,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to move around independently. The pathology report indicates malignancy."
1178,0,"The patient is a 66-year-old white male with a BMI of 22.44. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
1179,0,"The patient is a 44-year-old white female with a BMI of 26.12. She is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1180,1,The patient is a 72-year-old white male with a BMI of 30.32. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
1181,1,"The patient is a 58-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory)."
1182,0,"The patient is a 47-year-old white female with a BMI of 34.93. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1183,0,The patient is a 60-year-old white male with a BMI of 23.55. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. His KRAS biomarker status is wild-type.
1184,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He used narcotics for 2 days post-surgery. Despite experiencing symptoms, he is able to walk around. The pathology report indicates malignancy."
1185,0,"The patient is a 49-year-old white female with a BMI of 21.14. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1186,0,"The patient is a male who underwent conventional surgery as part of his treatment. He used narcotic medication for 6 days following the surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that the tumor was benign."
1187,1,The patient is a 45-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around. His histology shows well-differentiated cells. The patient is experiencing anorexia and fatigue as adverse effects of the treatment.
1188,1,The patient is a 37-year-old white male with a BMI of 26.68. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS status.
1189,0,The patient is a 71-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has symptoms but is still able to walk around.
1190,1,The patient is a 59-year-old white male with a BMI of 25.97 who is receiving treatment with FOLFOX for colon cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
1191,0,"This patient is a 73-year-old white male with a BMI of 26.07. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory."
1192,0,"The patient is a 61-year-old male of a race other than specified, with a BMI of 27.02. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1193,0,"The patient is a 47-year-old white male with a BMI of 26.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
1194,0,"The patient is a 58-year-old white male with a BMI of 24.78. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1195,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
1196,0,The patient is a 41-year-old white male with a BMI of 29.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker status is indeterminate.
1197,0,"The patient is a 70-year-old white female with a well-differentiated histology. She is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status."
1198,0,"The patient is a 42-year-old white male with a BMI of 30.51. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. His KRAS biomarker is wild-type, and he has also experienced a hypersensitivity adverse effect."
1199,0,The patient is a 55-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
1200,1,"The patient is a 53-year-old white male with a BMI of 23.95. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1201,0,"The patient is a 72-year-old white male with a BMI of 25.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1202,1,"The patient is a 74-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to be ambulatory. The patient has developed adverse effects including low granulocytes/bands and low white blood cell count."
1203,0,The patient is a 67-year-old white male with a BMI of 23.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1204,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 2 days post-surgery. The histology results indicate that she spends less than 50% of her time in bed, and the pathology report shows that the tumor is malignant."
1205,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
1206,1,"The patient is a 65-year-old white female with a history of prior cancer. She is currently receiving treatment with ECF chemotherapy in combination with radiation therapy. Despite experiencing adverse effects such as low neutrophil/granulocyte levels and fatigue, her performance status remains fully active. Additionally, her cancer histology is poorly differentiated."
1207,0,"The patient is a 76-year-old white male with a BMI of 26.21. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
1208,0,The patient is a 51-year-old white male with a BMI of 28.1. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
1209,1,"The patient is a 72-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around."
1210,1,"The patient is a 75-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
1211,0,The patient is a 41-year-old white female with a BMI of 20.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1212,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions present. He used narcotics for 1 day. His histology shows symptoms but he is still able to be ambulatory. Pathology results indicate a malignant condition.
1213,0,The patient is a 58-year-old white male with a BMI of 28.04. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. He has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
1214,0,"The patient is a 63-year-old Black male who is receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytopenia, which is indicated by a decrease in the number of granulocytes (a type of white blood cell) and bands (immature white blood cells) in the blood."
1215,0,"The patient is a 45-year-old white male with a BMI of 28.05. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1216,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the surgery. The histology results showed symptoms but the patient is still ambulatory. The pathology report indicated that the condition is malignant.
1217,0,"The patient is a 56-year-old white female with a BMI of 25.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
1218,0,"The patient is a 35-year-old white male with a BMI of 24.4. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. His KRAS biomarker is wild-type. He has also experienced a hypersensitivity adverse effect."
1219,0,"The patient is a 67-year-old white male with a BMI of 28.56. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient experienced a bowel perforation during the course of treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. His KRAS biomarker status is wild-type."
1220,0,"The patient is a 57-year-old white male with a BMI of 40.68. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1221,1,"The patient is a 56-year-old white female with a BMI of 22.07. She is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and her KRAS biomarker status is mutant."
1222,1,"The patient is a 64-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. He has also developed adverse effects related to his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
1223,0,"The patient is a 64-year-old white male with a BMI of 26.44. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status in this patient."
1224,1,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has been using narcotics for 3 days. The histology shows symptoms but he is still able to walk around. The pathology indicates a malignant condition.
1225,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the procedure. Her histology indicates symptoms but she is still able to walk around. The pathology results show that the condition is malignant.
1226,1,The patient is a 70-year-old white male with a BMI of 29.73. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
1227,1,"The patient is a 63-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects related to his blood cell counts, specifically having low levels of granulocytes/bands, white blood cells, and lymphocytes."
1228,1,"This patient is a 57-year-old white female with a BMI of 32.13. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
1229,1,The patient is a 69-year-old white female who is fully active and is receiving treatment with Sunitinib.
1230,0,"The patient is a 67-year-old white male with a BMI of 24.78. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1231,1,The patient is a 74-year-old white male with a BMI of 26.99. He is fully active with a primary tumor diagnosis of colon. The patient is in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
1232,1,"In this patient profile, the individual is a 57-year-old white female who is fully active. She is receiving treatment with a placebo. It is noted that she is experiencing an adverse effect related to her neutrophils/granulocytes. This means that there is a decrease in the levels of neutropenia. This condition increases her risk of infections."
1233,0,"The patient is a 42-year-old white female with a BMI of 21.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
1234,0,"The patient is a 56-year-old white male with a BMI of 21.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
1235,0,"The patient is a 74-year-old white male with a BMI of 21.46. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type. He has also experienced diarrhea as an adverse effect of the treatment."
1236,0,"The patient is a 64-year-old white female with a BMI of 33.81. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
1237,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. He is typically out of bed more than 50% of the time. The pathology report indicated a malignant condition.
1238,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days following the surgery. The histology results show symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1239,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology shows symptoms but the patient is ambulatory. The pathology report indicates a malignant condition.
1240,0,"The patient is a 57-year-old white female with a BMI of 44.06. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. Unfortunately, she has experienced an infection as an adverse effect of her treatment."
1241,1,"The patient is a 59-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands and lymphocytes."
1242,0,"The patient is a 56-year-old white male with a BMI of 27.44. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1243,1,"The patient is a 73-year-old white male with a BMI of 21.73 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is wild-type."
1244,0,"The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 33.09. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
1245,1,"The patient is a 58-year-old white female with a fully active performance status who is receiving treatment with ECF and radiation therapy. She has well-differentiated histology and is experiencing adverse effects including low levels of neutrophils/granulocytes, nausea, and fatigue."
1246,0,"The patient is a female who underwent laparoscopic-assisted colectomy and has abdominal wall adhesions. She has been using narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology report indicates malignancy."
1247,0,"This patient is a 58-year-old white male with a BMI of 33.49. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
1248,1,The patient is a 46-year-old white female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. Her histology shows poorly differentiated cells. She is experiencing an adverse effect related to neutrophils/granulocytes.
1249,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate malignancy.
1250,1,"The patient is a 53-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. The patient has shown adverse effects with decreased levels of granulocytes/bands and lymphocytes."
1251,0,"The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 25.4. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not yet started chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1252,0,"The patient is a 44-year-old white male with a BMI of 29.03. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1253,0,"The patient is a 48-year-old male of a race other than Caucasian, with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
1254,1,"The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 4 days. The histology of the tumor is well differentiated, and the pathology report indicates that it is malignant."
1255,0,"The patient is a 42-year-old white male with a BMI of 25.16. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1256,0,"The patient is a 55-year-old white male with a BMI of 28.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
1257,0,"The patient is a male who is undergoing conventional surgery for a malignant condition. He has been using narcotics for 5 days to manage his symptoms, but is still able to move around and be ambulatory."
1258,0,"The patient is a 34-year-old white female with a BMI of 23.23. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1259,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the procedure. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1260,0,"The patient is a 51-year-old white male with a well-differentiated histology. He is currently receiving treatment with 5FU/LV + Radiation in the clinical trial. Despite experiencing symptoms, he is still able to walk around and be active, indicating a relatively good performance status."
1261,0,"The patient is a 55-year-old white male with a BMI of 24.04. He is in the FOLFOX treatment arm and has not yet started chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status."
1262,0,"The patient is a 55-year-old white male with a BMI of 25.73. He is currently receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the patient has a mutant KRAS biomarker."
1263,0,"The patient is a 60-year-old white male with a BMI of 28.4. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that the patient has a mutant KRAS status."
1264,0,"The patient is a 55-year-old white male with a BMI of 27.17. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type."
1265,0,"The patient is a 70-year-old white female with a BMI of 29.82. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate."
1266,1,The patient is a female who is undergoing conventional surgery as part of her treatment. She has only used narcotics for 1 day. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1267,0,"The patient is a 60-year-old white male with a BMI of 29.34. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient completed 12 chemotherapy cycles and has well-differentiated histology. His performance status is fully active, and his KRAS biomarker is wild-type."
1268,0,"The patient is a 66-year-old white male with a BMI of 24.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status remains fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
1269,1,"The patient is a 47-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status."
1270,1,"The patient is a 76-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. The patient is showing adverse effects related to his blood cell counts, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
1271,0,The patient is a 42-year-old Black female with a BMI of 38.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1272,1,"The patient is a 72-year-old white male with a BMI of 25.47. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1273,0,"The patient is a 51-year-old white female with a BMI of 40.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1274,1,The patient is a 65-year-old white male with a BMI of 32.1. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS status.
1275,0,"The patient is a 40-year-old white female with a BMI of 29.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1276,0,"The patient is a 53-year-old white female with a BMI of 42.06. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of her treatment."
1277,0,"This patient is a 74-year-old white male with a BMI of 23.76. He is receiving treatment with FOLFOX and has been adherent to the treatment. He has experienced a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker is mutant in this patient. He has also experienced adverse effects in the form of thrombosis and diarrhea."
1278,1,"The patient is a 71-year-old white female with a BMI of 30.69. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status."
1279,0,"The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 26.4. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
1280,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days post-surgery. The histology indicates that she spends less than 50% of her time in bed, and the pathology results show that the condition is malignant."
1281,0,"The patient is a 53-year-old white female with a BMI of 25.0. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
1282,0,"This patient is a 55-year-old white female with a BMI of 32.98. She is enrolled in the FOLFOX treatment arm and has been adherent to her treatment. She has experienced a bowel perforation and has not yet undergone any chemotherapy cycles. Her histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
1283,1,"The patient is a 71-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
1284,0,The patient is a 54-year-old white male with a BMI of 28.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1285,0,"The patient is a 53-year-old white female with a BMI of 29.52. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows poorly differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
1286,0,The patient is a 66-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around. His histology shows poorly differentiated cells. The patient is experiencing nausea and anorexia as adverse effects.
1287,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1288,1,"The patient is a 41-year-old white male with a BMI of 31.61. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
1289,1,"This patient is a 27-year-old white female with a BMI of 19.38 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and her KRAS biomarker status is wild-type."
1290,1,"The patient is a 68-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has experienced weight loss greater than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also shown adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
1291,0,"The patient is a 44-year-old white female with a BMI of 33.32. She is receiving the FOLFOX treatment arm for her cancer. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker shows that it is wild-type."
1292,0,"The patient is a 74-year-old white female with a BMI of 24.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
1293,0,"The patient is a 62-year-old Black female with a BMI of 42.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
1294,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 3 days post-surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the condition was malignant.
1295,0,"The patient is a 40-year-old white male with a BMI of 35.49. He is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 3 cycles so far. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1296,1,The patient is a 46-year-old white female with a BMI of 20.58 who is fully active. She is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker testing revealed a mutant status.
1297,1,The patient is a 54-year-old male of other race with a BMI of 30.11. He is fully active with a primary tumor diagnosis of colon. The KRAS biomarker shows a mutation. The patient is currently on the FOLFOX treatment arm.
1298,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology indicates symptoms but she is still able to move around. The pathology report shows that the condition is malignant.
1299,1,"The patient is a 70-year-old white female with a BMI of 27.63. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk and move around (ambulatory). The KRAS biomarker analysis shows that she has a wild-type KRAS gene."
1300,0,The patient is a 53-year-old white male with a BMI of 26.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1301,1,"The patient is a 74-year-old white female with a BMI of 22.02. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1302,0,"The patient is a 69-year-old white female with a BMI of 24.98. She is currently receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1303,0,The patient is a 71-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of low neutrophil/granulocyte levels and nausea.
1304,0,The patient is a 76-year-old white male with a BMI of 30.44. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
1305,1,"The patient is a 53-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects such as low levels of granulocytes/bands and lymphocytes, as well as experiencing nausea."
1306,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results show that the tumor is well-differentiated, and the pathology report indicates that it is malignant."
1307,0,"The patient is a 49-year-old white male with a BMI of 32.07. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
1308,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the cause of her symptoms was malignant.
1309,0,"The patient is a 55-year-old white female with a BMI of 45.12. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker indicates that it is wild-type."
1310,1,"The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 2 days. Their histology shows that they are in bed less than 50% of the time, and their pathology indicates a malignant condition."
1311,0,"The patient is a 59-year-old white male with a BMI of 46.18. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type mutation."
1312,0,"The patient is a 44-year-old white female with a BMI of 25.62 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker is mutant. She is also experiencing diarrhea as an adverse effect of the treatment."
1313,1,The patient is a female undergoing laparoscopic-assisted colectomy. She has used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates a malignant condition.
1314,1,"The patient is a 76-year-old white male with a BMI of 25.2 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
1315,1,The patient is a 50-year-old white male with a BMI of 30.86. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type.
1316,0,"The patient is a 67-year-old white female with a BMI of 26.24. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation. Additionally, she has experienced diarrhea as an adverse effect."
1317,0,This patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1318,0,"The patient is a 76-year-old white female with a BMI of 27.18. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1319,0,"This patient is a 50-year-old white female with a BMI of 23.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 5 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is symptomatic but she is still able to be ambulatory. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
1320,1,"This patient is a 62-year-old white female with a BMI of 28.59 who is fully active. She is receiving treatment with FOLFOX for her colon cancer, and her KRAS biomarker status is wild-type."
1321,0,The patient is a 47-year-old white male with a BMI of 27.25. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1322,0,The patient is a 42-year-old white female with a BMI of 21.56. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
1323,1,"The patient is a 50-year-old white male with a BMI of 32.38. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows poorly differentiated cancer, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1324,0,"The patient is a 76-year-old white male with a BMI of 24.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1325,1,"The patient is a 62-year-old white male with a BMI of 37.04. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis shows that he has a wild-type status."
1326,1,The patient is a 68-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated.
1327,1,"The patient is a 57-year-old white female with a BMI of 29.45. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
1328,0,"The patient is a 62-year-old white female with a BMI of 29.73. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment in the FOLFOX treatment arm."
1329,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. There have been complications post-surgery. He used narcotics for 2 days. Despite experiencing symptoms, he is able to move around independently. The pathology report indicates malignancy."
1330,0,"This patient is a 58-year-old white female with a BMI of 40.74. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. It is important to note that her KRAS biomarker is wild-type."
1331,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
1332,0,"The patient is a 58-year-old Black male with a BMI of 23.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1333,1,"The patient is a 77-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has undergone 2 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he is experiencing a decrease in lymphocytes as an adverse effect of the treatment."
1334,1,The patient is a 65-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around. He is experiencing a side effect known as granulocytes/bands.
1335,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
1336,0,"The patient is a 63-year-old white male with a BMI of 28.51. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
1337,0,"The patient is a 43-year-old white male with a BMI of 39.12. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment for 12 cycles. The histology shows well-differentiated cancer cells, and the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1338,0,"The patient is a 61-year-old white female with a BMI of 21.01. She is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1339,0,"The patient is a 43-year-old white female with a BMI of 28.37. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1340,0,"The patient is a 41-year-old white male with a BMI of 21.71. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has experienced diarrhea as an adverse effect of the treatment."
1341,1,"The patient is a 43-year-old white male with a BMI of 38.42. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1342,1,"The patient is a 61-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
1343,0,"The patient is a 59-year-old white male with a BMI of 26.24. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1344,1,"The patient is a 55-year-old Black female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. The patient has experienced adverse effects on her blood cells, specifically a decrease in granulocytes/bands and lymphocytes."
1345,0,"The patient is a 74-year-old white female with a BMI of 22.38 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. However, she has experienced a serious adverse effect, specifically diarrhea, during her 4 chemotherapy cycles. Her histology shows poorly differentiated cells, but her performance status is fully active. The KRAS biomarker indicates she has a wild-type status."
1346,0,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They have been using narcotics for 5 days post-surgery. The histology shows symptoms but the patient is still able to move around. The pathology report indicates that the cause of the symptoms is malignant.
1347,0,"The patient is a 71-year-old white male with a BMI of 27.93. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, the patient has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
1348,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the condition was malignant.
1349,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has experienced complications post-surgery. She used narcotic medication for 3 days. The histology shows symptoms but she is still ambulatory. Pathology results indicate a malignant condition.
1350,1,"The patient is a 59-year-old white male with a BMI of 25.56 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. His KRAS biomarker status is wild-type. He is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
1351,1,The patient is a 48-year-old white male enrolled in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to his neutrophils/granulocytes and leukocytes.
1352,0,The patient is a 68-year-old white male with a BMI of 27.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
1353,1,"This patient is a 35-year-old white female with a BMI of 15.81. She is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker for this patient is mutant."
1354,0,The patient is a 66-year-old white female with a BMI of 40.68. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1355,0,"The patient is a 64-year-old white female with a BMI of 36.43. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1356,0,"The patient is a 37-year-old white male with a BMI of 23.24. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1357,0,"The patient is a 66-year-old white male with a BMI of 26.7. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1358,1,"The patient is a 55-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects related to her granulocytes/bands and white blood cells."
1359,0,"The patient is a 42-year-old white male with a BMI of 26.73. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status. The patient has experienced an adverse effect in the form of an infarction."
1360,0,"The patient is a 74-year-old white male with a BMI of 27.25. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1361,1,The patient is a 55-year-old white male with a BMI of 34.29 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
1362,1,"The patient is a 61-year-old white female with a BMI of 23.66. She is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
1363,0,"The patient is a 67-year-old Black female with a BMI of 43.08. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1364,0,The patient is a 70-year-old black male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
1365,1,"The patient is a 70-year-old white male with a BMI of 31.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
1366,1,The patient is a 48-year-old black female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing an adverse effect on her leukocytes.
1367,1,"The patient is a 59-year-old male of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and anorexia."
1368,0,"The patient is a 71-year-old white male with a BMI of 25.31. He is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker status is indeterminate."
1369,0,"The patient is a 69-year-old female of a race categorized as ""other"" with a BMI of 21.3. She is currently receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a performance status of fully active, indicating she is able to carry out normal daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
1370,1,"The patient is a 45-year-old white female with a BMI of 26.5. She is fully active and is receiving treatment with the FOLFOX regimen. She has been diagnosed with a primary tumor in the colon, and her KRAS biomarker status is mutant."
1371,1,The patient is a 53-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
1372,1,The patient is a 45-year-old white female with a fully active performance status. She is currently in the treatment arm receiving a placebo.
1373,0,"The patient is a 42-year-old white female with a BMI of 25.37. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1374,1,The patient is a 47-year-old white male who is receiving treatment with Sunitinib. He is experiencing symptoms but is still able to walk around.
1375,1,"The patient is a 53-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. He is also experiencing nausea as an adverse effect of the treatment."
1376,1,The patient is a 60-year-old white female with a BMI of 24.85 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing acne as an adverse effect of the treatment.
1377,0,"The patient is a 58-year-old white female with a BMI of 26.82. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has completed 12 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect."
1378,1,"The patient is a 59-year-old white male with a BMI of 32.28. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient has experienced adverse effects of thrombosis and hypersensitivity during treatment."
1379,0,"This patient is a 51-year-old white female who is receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects including low granulocytes/bands and low white blood cells, as well as nausea."
1380,1,The patient is a 54-year-old white male with a BMI of 30.42. He is fully active with a primary tumor diagnosis of colon cancer. The patient is receiving treatment with the FOLFOX regimen. His KRAS biomarker status is mutant.
1381,0,"The patient is a 70-year-old white female with a BMI of 32.05. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1382,0,The patient is a 54-year-old white female with a BMI of 26.04. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
1383,1,The patient is a 77-year-old white male with a BMI of 16.85. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
1384,1,"The patient is a 54-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
1385,0,"The patient is a 43-year-old white female with a BMI of 47.26. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
1386,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating an ambulatory performance status."
1387,0,"The patient is a 51-year-old white female with a BMI of 24.26. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the treatment, her performance status remains fully active. The KRAS biomarker analysis indicates a mutant status."
1388,0,"The patient is a 76-year-old white female with a BMI of 25.24. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
1389,1,"The patient is a 48-year-old white male with a BMI of 31.91. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction after completing 4 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker status is wild-type."
1390,1,This patient is a 73-year-old white female with a BMI of 20.19. She is fully active and is receiving treatment with FOLFOX and Panitumumab for her colon cancer. The KRAS biomarker indicates that she has a mutant form of the gene.
1391,0,"This patient is a 47-year-old white female who has not yet started chemotherapy treatment. She is assigned to the treatment arm receiving Cisplatin and Etoposide. Despite not having undergone any chemotherapy cycles yet, her performance status is noted as fully active."
1392,0,"The patient is a 69-year-old white male with a BMI of 27.26. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1393,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is ambulatory. The pathology report indicates that the cause of his symptoms is malignant.
1394,1,"The patient is a 48-year-old white female with a BMI of 21.8. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
1395,0,The patient is a female who underwent conventional surgery and experienced complications. She used narcotics for 20 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
1396,0,"The patient is a 47-year-old white female with a BMI of 31.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing indicates that she has a wild-type KRAS gene. The patient has developed an infection as an adverse effect of the treatment."
1397,0,"The patient is a 50-year-old male of a race other than specified, with a BMI of 45.41. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 5 cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1398,0,"This patient is a 51-year-old female of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV + Radiation. She has a performance status of experiencing symptoms but is still able to be ambulatory. The histology of her condition is poorly differentiated. Additionally, she is experiencing an adverse effect related to her neutrophils/granulocytes."
1399,0,"The patient is a 65-year-old white male with a BMI of 35.03. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea during his treatment."
1400,0,"The patient is a 56-year-old white male with a BMI of 36.62 who is receiving treatment with FOLFIRI + Cetuximab. He has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene. Additionally, he has experienced an adverse effect of thrombosis."
1401,0,"The patient is a 54-year-old white male with a BMI of 35.42. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1402,0,"The patient is a 62-year-old white female with a BMI of 31.57. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker shows that it is wild-type."
1403,1,"The patient is a 55-year-old male of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10% and has symptoms but is still able to walk around (ambulatory)."
1404,1,The patient is a 75-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects of low granulocytes/bands and nausea.
1405,0,"The patient is a male who underwent conventional surgery and has bowel adhesions. They experienced complications during treatment and used narcotics for 4 days. Their histology shows that they spent less than 50% of their time in bed, and the pathology results indicate malignancy."
1406,1,"The patient is a 69-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes, which are important white blood cells for fighting infections, and fatigue."
1407,0,"The patient is a 49-year-old white male with a BMI of 41.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, indicating he is able to carry out normal daily activities without limitations. The KRAS biomarker analysis reveals that the patient has a wild-type KRAS gene."
1408,1,The patient is a 72-year-old black male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
1409,0,"The patient is a 51-year-old white male with a BMI of 19.63. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing an infection, the patient's performance status remains fully active. Additionally, his KRAS biomarker indicates a wild-type status."
1410,0,"The patient is a 72-year-old white male with a BMI of 29.49. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1411,0,The patient is a male who underwent laparoscopic-assisted colectomy. He only used narcotics for 1 day post-surgery. The histology results showed symptoms but the patient is still able to be ambulatory. The pathology report indicated that the cause of the symptoms was malignant.
1412,1,"In this patient profile, the individual is a 48-year-old white female who is receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is a decrease in lymphocytes, which is a type of white blood cell important for the immune system's function."
1413,1,The patient is a 69-year-old white female with a BMI of 27.02. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
1414,0,"The patient is a 41-year-old white male with a BMI of 27.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
1415,0,"This patient is a 66-year-old white female with a BMI of 34.84 who is undergoing treatment with FOLFOX + Cetuximab for a well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status remains fully active. The KRAS biomarker indicates she is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
1416,1,"The patient is a 59-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
1417,0,"The patient is a 75-year-old white male with a BMI of 31.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1418,0,"The patient is a 58-year-old white female with a BMI of 30.77. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
1419,1,The patient is a 69-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. The patient is also experiencing nausea as an adverse effect of the treatment.
1420,0,"The patient is a 64-year-old Black female with a BMI of 31.68. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1421,1,"The patient is a 54-year-old white male with a BMI of 26.57. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the patient has a mutant KRAS biomarker."
1422,1,"The patient is a 67-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects related to her blood cells, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
1423,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 5 days. His histology shows symptoms but he is still able to move around. The pathology report indicates malignancy.
1424,0,"The patient is a 60-year-old white female with a BMI of 20.19. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1425,1,"The patient is a 70-year-old Black male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around."
1426,1,"The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and is experiencing symptoms but is still able to walk around (ambulatory). He is also experiencing a side effect known as granulocytes/bands, indicating an abnormality in his white blood cell count."
1427,1,The patient is a 47-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. The histology of the patient's condition is poorly differentiated.
1428,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days following the procedure. The histology results showed symptoms but the patient is still able to walk around. The pathology report indicated that the condition is malignant.
1429,0,"The patient is a 52-year-old white female with a BMI of 28.26. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1430,0,The patient is a 69-year-old white male with a BMI of 27.95 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1431,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. Pathology results indicate a malignant condition.
1432,1,"The patient is a 68-year-old white male with a BMI of 23.38 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has mutant KRAS biomarker status. Despite experiencing symptoms, he is still able to be ambulatory. The patient is also experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
1433,0,"The patient is a 49-year-old white female with a BMI of 26.56. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1434,0,The patient is a 52-year-old white male with a BMI of 36.37. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1435,1,"The patient is a 74-year-old white female with a BMI of 33.28 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) despite her condition. The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that the tumor is wild-type."
1436,0,The patient is a 72-year-old white male with a BMI of 24.56. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. His KRAS biomarker status is wild-type.
1437,1,"This patient is a 48-year-old white female with a BMI of 35.02. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has developed an infection as an adverse effect of her treatment."
1438,0,The patient is a 42-year-old white female with a BMI of 23.46. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1439,1,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
1440,1,The patient is a 55-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows well-differentiated cells.
1441,0,"The patient is a 49-year-old white female with a BMI of 21.64. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is identified as mutant."
1442,0,The patient is a 46-year-old white female with a BMI of 25.45. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
1443,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has bowel adhesions and has only used narcotics for 1 day. His histology shows symptoms but he is still able to move around. The pathology results indicate a malignant condition.
1444,0,"The patient is a 38-year-old female of a race categorized as ""other"" with a BMI of 20.62. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
1445,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 7 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated that the condition was malignant.
1446,0,"The patient is a 67-year-old white male with a BMI of 25.86. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows a mutation in the KRAS gene."
1447,0,"The patient is a 74-year-old white male with a BMI of 35.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1448,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 6 days post-surgery. Their histology indicates that they are in bed less than 50% of the time, and their pathology report shows that the condition is malignant."
1449,1,"The patient is a 62-year-old white female participating in the treatment arm receiving 5FU/LV + Radiation. She has a performance status of symptoms but is still able to ambulate. Her histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
1450,0,"The patient is a 64-year-old white female with a BMI of 20.72. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1451,0,"The patient is a 63-year-old white female with a BMI of 30.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1452,0,"The patient is a 66-year-old white male with a BMI of 28.09. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
1453,0,"The patient is a 67-year-old white male with a BMI of 25.58. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
1454,1,"The patient is a 78-year-old white male with a BMI of 26.26. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1455,0,"The patient is a 64-year-old white male with a BMI of 27.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant, and he has also experienced a hypersensitivity adverse effect."
1456,0,"The patient is a 66-year-old white male with a BMI of 30.94. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1457,0,The patient is a 65-year-old Black female with a BMI of 30.15. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment plan. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker is wild-type.
1458,0,"The patient is a 42-year-old white male with a BMI of 27.84. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1459,1,"The patient is a 51-year-old white female with a fully active performance status who is receiving treatment with ECF and radiation. She has a histology of poorly differentiated cancer. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and fatigue."
1460,1,The patient is a 59-year-old white male with a BMI of 26.18 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis shows that he has a mutant KRAS status.
1461,0,"The patient is a 69-year-old white female with a BMI of 26.56. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1462,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 6 days post-surgery. The histology showed symptoms but the patient was still able to move around. The pathology results indicated that the condition was malignant.
1463,0,"The patient is a 63-year-old white male with a BMI of 29.07. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1464,0,"This patient is a 66-year-old white male with a BMI of 25.0. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to move around independently. The KRAS biomarker testing revealed a mutant status."
1465,0,"The patient is a 46-year-old white female with a BMI of 25.16. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1466,1,The patient is a 70-year-old white male with a BMI of 21.52. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that he has a wild-type status. He is currently receiving treatment with the FOLFOX regimen.
1467,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 3 days post-surgery. The histology showed symptoms but the patient was still ambulatory. The pathology results indicated malignancy.
1468,0,"The patient is a 69-year-old white male with a BMI of 23.02. He is receiving treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has a bowel obstruction and has completed 4 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is ambulatory. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
1469,0,"The patient is a 67-year-old white male with a BMI of 30.4. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene."
1470,0,"The patient is a 68-year-old white female with a BMI of 21.49. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1471,1,The patient is a 51-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated.
1472,0,The patient is a 63-year-old white male with a BMI of 28.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1473,0,The patient is a 60-year-old white female with a BMI of 20.7 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The patient has a wild-type KRAS biomarker. She is experiencing a rash as an adverse effect of the treatment.
1474,1,"The patient is a 55-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She is scheduled to undergo a total of 8 cycles of chemotherapy. Despite her treatment, she has a fully active performance status."
1475,0,"The patient is a 71-year-old male of a race categorized as ""other"" with a BMI of 26.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the patient's KRAS biomarker indicates a mutant status."
1476,1,"The patient is a 60-year-old female of a race other than specified, undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5 to 10%. Despite experiencing symptoms, she is still able to ambulate."
1477,1,"The patient is a 50-year-old white female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
1478,1,"The patient is a 73-year-old white female with a low BMI of 16.12. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction after completing 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker shows that it is wild-type. Additionally, she is also experiencing diarrhea as an adverse effect of the treatment."
1479,1,The patient is a 65-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology shows well-differentiated cells.
1480,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. He is typically out of bed more than 50% of the time. The pathology report indicated a malignant condition.
1481,0,"The patient is a 52-year-old female of a race other than specified, with a BMI of 21.83. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1482,1,"The patient is a 68-year-old white female with a BMI of 37.82. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1483,1,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days following the procedure. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
1484,1,"This patient is a 76-year-old white female with a BMI of 19.74. She is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to walk around. Additionally, her KRAS biomarker status is wild-type, which may impact her response to treatment."
1485,0,"This patient is a 73-year-old white male with a BMI of 25.93. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
1486,0,"The patient is a 70-year-old white male with a BMI of 27.84. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
1487,1,"The patient is a 48-year-old female of other race with a BMI of 22.2. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is in the colon."
1488,1,"The patient is a 57-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes."
1489,0,"The patient is a 74-year-old white female with a BMI of 33.15. She is receiving the FOLFIRI treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker shows that she has a wild-type mutation."
1490,0,"The patient is a 43-year-old white male with a BMI of 37.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1491,0,The patient is a 73-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
1492,0,"The patient is a 39-year-old white female with a BMI of 28.55. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1493,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is able to move around. The pathology report indicates that the condition is malignant.
1494,0,"The patient is a 58-year-old white female with a BMI of 22.61. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1495,1,"The patient is a 35-year-old white male with a BMI of 37.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1496,1,"The patient is a 67-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her white blood cells and lymphocytes."
1497,1,"This patient is a male who underwent conventional surgery as part of their treatment. They have used narcotics for 5 days. Their histology indicates that they are in bed less than 50% of the time, and their pathology results show that the condition is malignant."
1498,0,"The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 23.02. He is currently receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite undergoing treatment, the patient maintains a fully active performance status. Additionally, the KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1499,0,"The patient is a 35-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
1500,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
1501,0,"The patient is a 76-year-old white male with a BMI of 26.39. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1502,1,"The patient is a 57-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. He is showing adverse effects such as low levels of granulocytes/bands and white blood cells, as well as experiencing nausea."
1503,1,The patient is a male undergoing conventional surgery with abdominal wall and bowel adhesions present. They have been using narcotics for 4 days and are experiencing symptoms but are still able to move around. The pathology report indicates malignancy.
1504,0,"The patient is a 69-year-old white male with a BMI of 30.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
1505,1,"The patient is a 72-year-old male of a race categorized as ""other"" who is receiving treatment with 5FU/LV and radiation. He has a history of prior cancer. Despite this, he is fully active in terms of performance status. The histology of his current condition is poorly differentiated. He is experiencing nausea as an adverse effect of his treatment."
1506,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 5 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
1507,0,"The patient is a 40-year-old white male with a BMI of 24.13. He is receiving the FOLFOX treatment arm for his cancer, with a planned 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1508,0,The patient is a 67-year-old white male with a BMI of 29.14. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. His KRAS biomarker status is wild-type.
1509,0,"The patient is a 41-year-old white male with a BMI of 35.3. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment regimen. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status for this patient is indeterminate."
1510,1,This patient is a 56-year-old white female with a performance status of symptoms but still able to walk around (ambulatory). She is receiving treatment in the ECF + Radiation arm and has been diagnosed with poorly differentiated histology. The patient is experiencing nausea as an adverse effect of the treatment.
1511,1,"The patient is a female undergoing conventional surgery for a malignant condition. She has been using narcotics for 5 days post-surgery. Despite experiencing symptoms, she is still able to move around and be ambulatory."
1512,0,The patient is a 54-year-old white male with a BMI of 27.84 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis shows that the patient has a mutant KRAS status.
1513,0,"The patient is a 48-year-old white male with a BMI of 24.62. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1514,0,"The patient is a 63-year-old white female with a BMI of 37.45. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
1515,0,The patient is a 44-year-old white male with a BMI of 28.16. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1516,0,"The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 21.79. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
1517,1,"The patient is a 57-year-old male of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing adverse effects related to his blood cell counts, specifically showing low levels of granulocytes/bands and lymphocytes."
1518,0,"The patient is a 71-year-old white female with a BMI of 24.88. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab for her poorly differentiated histology. She has not started any chemotherapy cycles yet. Despite her age, she has a fully active performance status. Her KRAS biomarker status is indeterminate."
1519,0,"The patient is a 43-year-old white female with a BMI of 22.55. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1520,0,"The patient is a 42-year-old white male with a BMI of 34.29. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1521,0,The patient is a male who underwent conventional surgery as part of his treatment. He experienced complications following the surgery. He used narcotics for 3 days post-surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
1522,1,"The patient is a 75-year-old white female with a BMI of 26.33. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1523,0,The patient is a 55-year-old white female with a BMI of 29.63. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
1524,0,"The patient is a 63-year-old white male with a BMI of 31.26. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
1525,1,"The patient is a 68-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
1526,0,The patient is a male who is undergoing conventional surgery for a malignant condition. He has been using narcotics for 3 days and is experiencing symptoms but is still able to walk around.
1527,0,"The patient is a 47-year-old white female with a BMI of 26.67. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 10 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
1528,0,"The patient is a 62-year-old white male with a BMI of 19.49. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
1529,1,The patient is a 53-year-old white female with symptoms but is still able to move around independently. She is currently receiving treatment with a placebo.
1530,0,"The patient is a 57-year-old female of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation. She has previously undergone chemotherapy. Despite experiencing symptoms, she is still able to move around (ambulatory). The histology shows that the cancer cells are well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
1531,0,"The patient is a 51-year-old white male with a BMI of 24.92. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. He has experienced an adverse effect in the form of an infection."
1532,1,"The patient is a 76-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around. She has developed adverse effects related to her granulocytes/bands and white blood cells."
1533,1,"The patient is a 70-year-old white female with a BMI of 20.08. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1534,1,"The patient is a 65-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around. Additionally, she is showing adverse effects related to low levels of granulocytes/bands."
1535,1,The patient is a 50-year-old white male with a BMI of 24.77 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has symptoms but is still able to walk around. The KRAS biomarker indicates that the patient has a mutant form of the gene.
1536,1,"The patient is a 67-year-old white male with a BMI of 23.67. He is fully active with a primary tumor diagnosis of colon cancer. His KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1537,0,"The patient is a 45-year-old Black female with a BMI of 31.95. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1538,0,The patient is a female who underwent laparoscopic-assisted colectomy. She only used narcotics for 1 day following the procedure. Her histology shows symptoms but she is still able to move around. The pathology results indicate that the cause of her symptoms is malignant.
1539,0,The patient is a 45-year-old white male with a BMI of 38.82. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced hypersensitivity as an adverse effect.
1540,1,"The patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 9 days. Her histology indicates that she is in bed less than 50% of the time, and her pathology results show that she has a malignant condition."
1541,0,"The patient is a 59-year-old white male with a BMI of 37.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1542,0,"The patient is a 62-year-old white female with a BMI of 32.89. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1543,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 5 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate that the condition is malignant.
1544,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
1545,0,"The patient is a 44-year-old white male with a BMI of 27.86. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1546,0,The patient is a 73-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. He has a histology of poorly differentiated cancer. He is experiencing adverse effects of nausea and anorexia.
1547,0,The patient is a 49-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology shows well-differentiated characteristics. The patient is experiencing adverse effects related to neutrophils/granulocytes and leukocytes.
1548,1,"The patient is a 38-year-old white female with a BMI of 22.8. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
1549,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions and experienced complications post-surgery. She used narcotics for 6 days. Despite having symptoms, she is able to be ambulatory. The pathology report indicated malignancy."
1550,0,"The patient is a 47-year-old white male with a well-differentiated histology who is currently receiving treatment with 5FU/LV + Radiation. Despite experiencing symptoms, he is still able to be ambulatory. He is also experiencing adverse effects such as low levels of neutrophils/granulocytes and leukocytes, as well as a loss of appetite (anorexia)."
1551,0,"The patient is a 42-year-old white female with a BMI of 27.55. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
1552,0,This patient is a 73-year-old black male receiving treatment with ECF chemotherapy combined with radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology of his condition is well-differentiated. He is experiencing an adverse effect related to his neutrophils/granulocytes.
1553,0,The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 4 days and is experiencing symptoms but is still able to walk around. The pathology results indicate malignancy.
1554,0,The patient is a 59-year-old white male with a BMI of 28.07. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. His KRAS biomarker status is wild-type.
1555,0,"The patient is a 62-year-old white female with a BMI of 31.79. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
1556,0,"The patient is a 59-year-old white male with a BMI of 20.25. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1557,0,"The patient is a 58-year-old white female with a BMI of 22.23. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
1558,0,"The patient is a 37-year-old white female with a BMI of 24.44 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory). She has been diagnosed with a primary tumor in the colon, and her KRAS biomarker status is mutant."
1559,0,The patient is a 50-year-old white male with a BMI of 23.31. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status is wild-type.
1560,0,"The patient is a 51-year-old Black female with a BMI of 35.58. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and her KRAS biomarker is wild-type."
1561,1,"The patient is a 58-year-old white male with a BMI of 30.98 who is undergoing treatment with the FOLFIRI regimen. He has been adherent to the treatment and has completed 12 cycles of chemotherapy. The patient has experienced a serious adverse effect in the form of bowel obstruction and has also reported experiencing thrombosis and diarrhea as additional adverse effects. His histology shows well-differentiated cancer, and his KRAS biomarker is wild-type. Despite experiencing symptoms, the patient is still ambulatory and able to move around."
1562,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 4 days. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
1563,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
1564,0,"The patient is a 63-year-old white female with a BMI of 24.93. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker indicates a mutant status."
1565,0,"The patient is a 43-year-old white female with a BMI of 23.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
1566,0,"The patient is a 51-year-old white male with a BMI of 30.86. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
1567,0,"The patient is a 57-year-old white female with a BMI of 23.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1568,1,"The patient is a 69-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to ambulate."
1569,1,The patient is a 62-year-old white male with a BMI of 24.59. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1570,0,"This patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 2 days. Her histology shows that she is in bed less than 50% of the time, and her pathology indicates that she has a malignant condition."
1571,0,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 9 days post-surgery. The histology results show that he spent less than 50% of his time in bed, and the pathology report indicates a malignant condition."
1572,0,The patient is a 68-year-old white male with a BMI of 24.1. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation.
1573,1,The patient is a 57-year-old white male with a BMI of 27.68. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
1574,0,The patient is a 62-year-old white female with a BMI of 25.71. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. Her KRAS biomarker status is wild-type.
1575,0,"The patient is a 59-year-old white female with a BMI of 29.5. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1576,0,"The patient is a 74-year-old white male with a BMI of 33.58. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1577,0,"The patient is a 65-year-old white male with a BMI of 24.31. He is in the FOLFIRI treatment arm for his KRAS mutant status. He has not started chemotherapy cycles yet. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker status is indeterminate."
1578,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She has been using narcotics for 7 days. The histology shows symptoms but she is still able to be ambulatory. The pathology report indicates malignancy.
1579,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 25.33. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status. Additionally, her KRAS biomarker status is wild-type."
1580,0,"The patient is a 57-year-old Black female with a BMI of 26.58. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1581,1,"The patient is a 49-year-old white female with a BMI of 35.42. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment in the FOLFOX + Panitumumab arm, and her KRAS biomarker status is wild-type."
1582,0,"The patient is a 72-year-old white male with a BMI of 27.18. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1583,1,The patient is a 48-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. His histology shows poorly differentiated cells. He is experiencing an adverse effect related to neutrophils/granulocytes.
1584,0,"The patient is a 71-year-old white male with a BMI of 27.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
1585,0,"The patient is a 51-year-old white male with a BMI of 26.73. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1586,0,"The patient is a 67-year-old black female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer. The patient is experiencing adverse effects including low white blood cell count (leukocytes), nausea, and loss of appetite (anorexia)."
1587,1,The patient is a 59-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status.
1588,0,The patient is a 72-year-old white male with a BMI of 25.59. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He experienced a serious adverse effect during the treatment. He completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker indicates he is wild-type. He also experienced adverse effects of thrombosis and diarrhea during the treatment.
1589,1,The patient is a 49-year-old white female with a BMI of 21.99. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker analysis showed that she has a mutant KRAS status.
1590,1,The patient is a 71-year-old male of other race with a BMI of 26.23. He is fully active in terms of performance status. He is receiving treatment with FOLFOX for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
1591,0,"This patient is a 43-year-old white male with a BMI of 30.49 who is receiving the FOLFOX treatment regimen for their cancer. They have experienced a bowel obstruction and have completed 12 cycles of chemotherapy. The histology of their cancer is well differentiated. Despite the bowel obstruction, the patient's performance status is fully active. Their KRAS biomarker status is indeterminate."
1592,0,"The patient is a 43-year-old white female with a BMI of 20.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she has a wild-type status. The patient has experienced an infection as an adverse effect during her treatment."
1593,0,"The patient is a 61-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is mutant. Additionally, she has experienced an infection as an adverse effect."
1594,0,"The patient is a 60-year-old male of a race categorized as ""other"" who is receiving treatment with ECF chemotherapy combined with radiation. His performance status indicates that he is in bed less than 50% of the time. The histology of his condition is described as poorly differentiated."
1595,0,"The patient is a 73-year-old white male with a BMI of 27.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1596,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the condition is malignant.
1597,1,"The patient is a 75-year-old white male with a BMI of 23.78. He is currently receiving treatment with the FOLFOX regimen for his colon cancer. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
1598,0,"The patient is a 42-year-old white female with a BMI of 45.79. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1599,0,"The patient is a 49-year-old white female with a BMI of 39.82. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type."
1600,0,The patient is a female who underwent laparoscopic-assisted colectomy. She only used narcotics for 1 day post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the cause of her symptoms is malignant.
1601,0,This patient is a 69-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated. She is experiencing an adverse effect related to her neutrophils/granulocytes.
1602,1,"The patient is a 49-year-old Black male with a BMI of 27.08. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed a mutant status."
1603,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to move around. The pathology report indicates malignancy.
1604,1,The patient is a 71-year-old white female with a BMI of 25.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel perforation and has completed 1 cycle of chemotherapy. The histology shows well-differentiated cells. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker indicates that she has a wild-type status.
1605,1,The patient is a 62-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
1606,0,The patient is a 58-year-old white male with a BMI of 31.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1607,0,"The patient is a 71-year-old white male with a BMI of 34.58. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1608,0,"The patient is a 38-year-old white male with a BMI of 35.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. He has experienced an infection as an adverse effect during his treatment."
1609,0,"The patient is a 59-year-old white male with a BMI of 30.81. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the course of his 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1610,1,The patient is a 74-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
1611,1,"The patient is a 43-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory)."
1612,0,The patient is a 72-year-old white female with a BMI of 28.45 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment.
1613,0,"The patient is a 52-year-old white female with a BMI of 20.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1614,0,"The patient is a 46-year-old white male with a BMI of 26.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1615,0,"The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 25.01. He is currently receiving treatment in the FOLFIRI treatment arm for his KRAS mutant status. Despite experiencing bowel obstruction and perforation, he has maintained good adherence to his treatment. He has completed two cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel issues, his performance status is fully active. It is noted that his KRAS biomarker is wild-type."
1616,0,The patient is a 64-year-old white male with a BMI of 22.49. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. The patient has a fully active performance status. His KRAS biomarker is wild-type. He has experienced an infection as an adverse effect during his treatment.
1617,1,The patient is a 68-year-old white male who is part of the placebo treatment arm. His performance status indicates that he spends less than 50% of his time in bed.
1618,0,"The patient is a 75-year-old white female with a BMI of 24.71. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1619,0,"The patient is a 64-year-old white female with a BMI of 25.97. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis showed that she has a wild-type KRAS status."
1620,0,"The patient is a 70-year-old white female with a BMI of 23.63. She is receiving FOLFIRI treatment for her poorly differentiated cancer, and her KRAS biomarker is wild-type. Despite being fully active, she has experienced a serious adverse effect of diarrhea during her 12 chemotherapy cycles."
1621,0,"The patient is a 70-year-old male of a race categorized as ""other"" with a BMI of 28.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1622,0,"The patient is a 74-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving 5FU/LV + Radiation therapy. Despite his age, he has a fully active performance status. The histology indicates that the cancer cells are well-differentiated."
1623,0,"The patient is a 68-year-old white female with a BMI of 19.37. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1624,0,"The patient is a 46-year-old white female with a BMI of 40.82. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. Additionally, she has experienced an adverse effect of thrombosis."
1625,0,"The patient is a 38-year-old white female with a BMI of 22.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1626,0,The patient is a 61-year-old white female with a BMI of 23.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type gene.
1627,0,"The patient is a 41-year-old male of a race categorized as ""other"" with a BMI of 24.38. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel issues, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
1628,0,"The patient is a 36-year-old white female with a BMI of 29.09. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1629,0,"The patient is a 60-year-old white male with a BMI of 31.83. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1630,0,The patient is a 45-year-old Black female with a BMI of 33.77. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is mutant. The patient has experienced an infarction as an adverse effect.
1631,0,"This patient is a 72-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of his cancer is poorly differentiated. Additionally, he is experiencing an adverse effect on his leukocytes, which may indicate a decrease in white blood cell count."
1632,0,The patient is a female who is undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotics for 2 days.
1633,1,"The patient is a 78-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 3 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
1634,1,"The patient is a 71-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects related to her granulocytes/bands and white blood cells."
1635,1,"The patient is a 59-year-old white male with a BMI of 26.89. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a mutant KRAS status."
1636,1,"The patient is a 45-year-old white female with a BMI of 23.77. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1637,0,"The patient is a 47-year-old white male with a BMI of 30.19. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled to undergo 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1638,1,The patient is a 45-year-old white female with a BMI of 22.68 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. Her KRAS biomarker status is wild-type.
1639,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days post-surgery. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the tumor is malignant.
1640,0,"The patient is a 64-year-old white female with a BMI of 25.37. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1641,0,"The patient is a 50-year-old white male with a BMI of 28.8 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect and developed a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite these challenges, the patient has a fully active performance status. The KRAS biomarker indicates that the cancer is wild-type."
1642,1,"The patient is a 65-year-old female of other race with a BMI of 23.13. She is currently receiving treatment with the FOLFOX regimen combined with Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is rectal, and the KRAS biomarker indicates a mutant status."
1643,0,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 2 days post-surgery. The histology results show that he spent less than 50% of his time in bed, and the pathology report indicates a malignant condition."
1644,0,"The patient is a 44-year-old white male with a BMI of 23.97. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type."
1645,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1646,1,The patient is a 39-year-old white male with a BMI of 33.11 who is receiving treatment with FOLFOX for a rectal tumor. He has symptoms but is still able to walk around (ambulatory). His KRAS biomarker status is wild-type.
1647,0,"The patient is a 41-year-old white female with a BMI of 24.66. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
1648,1,The patient is a 56-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still being able to walk around. The histology shows poorly differentiated cells. The patient is experiencing nausea as an adverse effect.
1649,0,"The patient is a 45-year-old white male with a BMI of 40.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status. Additionally, the patient has experienced a hypersensitivity adverse effect."
1650,0,"The patient is a 63-year-old white female with a BMI of 19.89. She is currently receiving treatment with FOLFOX for her well-differentiated histology. She has experienced a bowel obstruction and is in her first cycle of chemotherapy. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She is also experiencing diarrhea as an adverse effect of her treatment."
1651,1,"The patient is a 54-year-old white female with a BMI of 23.07. She is receiving treatment with FOLFOX for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
1652,1,"The patient is a 52-year-old white male with a BMI of 26.03 who is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
1653,0,The patient is a 63-year-old white male with a fully active performance status who is receiving treatment in the placebo arm of the study.
1654,1,"The patient is a 61-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects on his blood cells, specifically a decrease in granulocytes/bands and lymphocytes."
1655,0,"The patient is a 40-year-old white male with a BMI of 25.35. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1656,0,The patient is a 55-year-old white male with a BMI of 29.22. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. His KRAS biomarker status is wild-type.
1657,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates a malignant condition."
1658,0,"The patient is a 49-year-old male of a race other than Caucasian, with a BMI of 40.3. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1659,0,"The patient is a 45-year-old white female with a BMI of 23.84. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1660,1,"The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has used narcotics for 3 days. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
1661,1,"The patient is a 64-year-old female of a race categorized as ""other"" who is receiving treatment with ECF chemotherapy combined with radiation therapy. She has a performance status indicating that she is in bed less than 50% of the time. The histology of her condition is well-differentiated. Additionally, she is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
1662,1,"The patient is a 71-year-old white male with a BMI of 28.73. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that the tumor is wild-type."
1663,1,"This patient is a 47-year-old white male with a BMI of 29.66. He is receiving treatment with FOLFOX and Panitumumab for a colon tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, his KRAS biomarker status is wild-type."
1664,0,"The patient is a 72-year-old white female with a BMI of 27.18. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
1665,1,"The patient is a 51-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 10 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around, indicating an ambulatory performance status."
1666,0,"The patient is a 54-year-old white male with a BMI of 20.98. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
1667,0,"The patient is a 71-year-old white male with a BMI of 27.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1668,0,"The patient is a 63-year-old male of a race categorized as ""other"" who is currently undergoing treatment with 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes, low levels of leukocytes, and is also experiencing nausea."
1669,0,"The patient is a 53-year-old Black male with a BMI of 22.22 who is undergoing treatment with FOLFOX chemotherapy. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite the adverse effect, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, he has experienced diarrhea as an adverse effect during the treatment."
1670,0,The patient is a 73-year-old white male with a BMI of 32.28. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
1671,1,The patient is a 30-year-old female of other race with a BMI of 27.38. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is wild-type.
1672,1,The patient is a 73-year-old white male with a BMI of 22.09. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
1673,0,"The patient is a 46-year-old Black female with a BMI of 38.79. She is receiving the FOLFOX treatment arm and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1674,0,"The patient is a 54-year-old white male with a BMI of 34.51. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type."
1675,0,The patient is a 63-year-old white male with a BMI of 21.24. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. He has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status.
1676,0,"This patient is a female who is receiving conventional surgery as treatment. She has used narcotics for 2 days. Her histology shows that she is in bed less than 50% of the time, and her pathology indicates a malignant condition."
1677,0,"The patient is a 68-year-old white male with a BMI of 28.8. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1678,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications during treatment. She used narcotics for 3 days post-surgery. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated malignancy."
1679,1,"The patient is a 62-year-old white male with a BMI of 24.97. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
1680,1,The patient is a 65-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated. The patient is experiencing nausea and fatigue as adverse effects.
1681,1,The patient is a 65-year-old white female with a BMI of 24.62. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
1682,1,"The patient is a 71-year-old white female with a BMI of 19.72. She is currently receiving treatment with FOLFOX for her rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1683,1,The patient is a 63-year-old white female with a BMI of 39.82 who is receiving treatment with FOLFOX and Panitumumab for rectal cancer. She has a performance status of being in bed less than 50% of the time. The KRAS biomarker is wild-type. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment. This condition presents as acne-like skin irritation and inflammation.
1684,0,The patient is a 47-year-old white female with a BMI of 45.14 who is currently receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has completed 3 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
1685,0,"The patient is a 61-year-old white male with a BMI of 37.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
1686,0,"The patient is a 60-year-old female of a race other than Caucasian, with a BMI of 27.44. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Unfortunately, she has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1687,1,"The patient is a 41-year-old white male undergoing treatment with a combination of Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and perform daily activities, indicating a relatively good performance status."
1688,0,"The patient is a 37-year-old white male with a BMI of 23.23. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1689,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days following the surgery. The histology results showed that the tumor was well-differentiated, and the pathology results indicated that it was benign."
1690,1,"The patient is a 66-year-old white female with a BMI of 20.32. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her treatment, she has a fully active performance status. Her KRAS biomarker is wild-type."
1691,1,The patient is a 57-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving 5FU/LV chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated.
1692,1,"The patient is a 40-year-old white female with a BMI of 30.79. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1693,0,"The patient is a 62-year-old white female with a BMI of 27.97. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1694,1,"The patient is a 46-year-old female of other race with a BMI of 24.3. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is in the colon, and the KRAS biomarker shows that it is wild-type."
1695,1,The patient is a 49-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. The histology shows poorly differentiated cells.
1696,0,"The patient is a 50-year-old white female with a BMI of 26.33. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1697,1,"The patient is a 52-year-old white male with a BMI of 20.9. He is currently receiving treatment with FOLFOX for his rectal cancer. Despite experiencing symptoms, he is still able to move around independently. The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
1698,0,"The patient is a 47-year-old white male with a BMI of 32.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1699,1,"The patient is a 38-year-old white male with a BMI of 36.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 chemotherapy cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
1700,0,"The patient is a 61-year-old white male with a BMI of 27.87. He is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. He has experienced adverse effects of hypersensitivity and diarrhea during his treatment."
1701,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 9 days following the procedure. The histology results showed well-differentiated cells, and the pathology results indicated a benign condition."
1702,0,"In this patient profile, the individual is a 56-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving ECF chemotherapy along with radiation. His performance status is fully active, indicating that he is able to carry out daily activities without limitations. The histology of his condition is well-differentiated. An adverse effect noted in this case is the presence of neutrophils/granulocytes."
1703,0,The patient is a 42-year-old white male with a BMI of 41.6. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1704,0,"The patient is a 67-year-old white female with a BMI of 27.1 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect from the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
1705,0,"The patient is a 43-year-old white male with a BMI of 30.27. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant result."
1706,0,The patient is a 54-year-old white female with a BMI of 26.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1707,1,The patient is a 72-year-old white male with a BMI of 29.73 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer.
1708,0,"The patient is a 45-year-old white male with a BMI of 24.42. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
1709,0,"The patient is a 55-year-old white male with a BMI of 29.2. He is undergoing treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
1710,0,The patient is a 57-year-old white male with a BMI of 29.15. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
1711,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has been using narcotics for 4 days. Despite experiencing symptoms, he is still able to walk around. The pathology report indicates malignancy."
1712,0,The patient is a 55-year-old white male with a BMI of 28.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1713,0,"The patient is a 47-year-old white female with a BMI of 35.71. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
1714,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has used narcotics for 2 days and is experiencing symptoms but is still able to walk around. The pathology report indicates a malignant condition.
1715,1,The patient is a 55-year-old Black male with a BMI of 31.62. He is enrolled in the treatment arm receiving FOLFIRI + Cetuximab for his cancer treatment. He has been adherent to the treatment plan. The patient has not started any chemotherapy cycles yet. His cancer histology is well differentiated. He has a fully active performance status. The KRAS biomarker analysis showed a mutant status.
1716,1,"The patient is a 56-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. The patient has also experienced adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
1717,0,"The patient is a 45-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. Additionally, the patient is experiencing an adverse effect related to neutrophils/granulocytes."
1718,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
1719,1,The patient is a 59-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
1720,0,"The patient is a 57-year-old white female with a BMI of 23.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
1721,0,The patient is a 40-year-old white male with a BMI of 23.89. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
1722,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the cause of her symptoms was malignant.
1723,1,The patient is a 64-year-old white male with a BMI of 16.69. He is receiving treatment with FOLFOX for colon cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
1724,0,"The patient is a 40-year-old white female with a BMI of 41.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1725,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 2 days. She spends less than 50% of her time in bed. The histology report indicates malignant pathology.
1726,1,"The patient is a 67-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1727,0,"The patient is a 60-year-old white female with a BMI of 34.62. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer cells are wild-type."
1728,1,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
1729,1,The patient is a 67-year-old white male receiving treatment with FOLFOX for rectal cancer. He has a BMI of 21.76 and is fully active in terms of performance status.
1730,0,The patient is a 43-year-old white male with a BMI of 30.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
1731,1,The patient is a 61-year-old white female with a BMI of 22.84 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing acne as an adverse effect of the treatment.
1732,1,The patient is a 70-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
1733,0,The patient is a 48-year-old white female with a BMI of 21.73. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
1734,0,The patient is a 51-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
1735,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 4 days post-surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
1736,0,"The patient is a 41-year-old white male with a BMI of 28.63. He is receiving the FOLFOX treatment regimen and has a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1737,1,"The patient is a 65-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time."
1738,1,The patient is a 59-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
1739,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She used narcotics for 1 day. The histology shows symptoms but she is still able to be ambulatory. The pathology report indicates a malignant condition.
1740,0,"The patient is a 48-year-old white female with a BMI of 21.6. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1741,0,"The patient is a 53-year-old white male with a BMI of 29.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
1742,0,The patient is a 57-year-old female of other race with a BMI of 32.98. She is fully active in terms of performance status. She has been diagnosed with a primary tumor in the rectum and her KRAS biomarker status is wild-type. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
1743,1,"The patient is a 61-year-old white female with a BMI of 17.23. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type mutation."
1744,0,"The patient is a 43-year-old white female with a BMI of 56.6. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
1745,0,The patient is a 36-year-old white male with a BMI of 23.14. He is receiving treatment in the FOLFOX treatment arm and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a mutant form of the gene.
1746,1,"The patient is a 58-year-old white male with a BMI of 26.3 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
1747,0,"The patient is a 47-year-old white female with a BMI of 34.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of hypersensitivity and infection during the course of treatment."
1748,1,The patient is a 46-year-old white male with a performance status indicating symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
1749,0,"The patient is a 38-year-old white male with a BMI of 23.11 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 9 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effects, he maintains a fully active performance status. His KRAS biomarker status is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
1750,1,"The patient is a 41-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active."
1751,0,"The patient is a 54-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1752,0,"The patient is a 52-year-old female of a race other than specified, with a BMI of 34.51. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is mutant in this case."
1753,0,"The patient is a 63-year-old white male with a BMI of 35.49. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
1754,0,"The patient is a 61-year-old white female with a BMI of 24.7. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1755,1,"The patient is a 66-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has experienced significant weight loss (>5/10%). Despite having symptoms, he is still able to be ambulatory. The patient has experienced adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
1756,0,"The patient is a 43-year-old white female with a BMI of 36.1. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her treatment. She experienced a bowel perforation during her treatment. She has completed 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
1757,0,The patient is a 40-year-old white male with a BMI of 42.07. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker analysis shows a mutant status.
1758,0,The patient is a 52-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
1759,1,The patient is a 68-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology of his condition is poorly differentiated. He is experiencing an adverse effect related to neutrophils/granulocytes.
1760,0,"The patient is a 74-year-old white male with a BMI of 30.01. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1761,1,"The patient is a 36-year-old white male with a BMI of 30.99 who is receiving the FOLFIRI treatment regimen. He has been adherent to his treatment and has completed 11 cycles of chemotherapy. The patient's histology shows poorly differentiated cancer cells. Despite experiencing a bowel perforation, his performance status remains fully active. The KRAS biomarker testing revealed a mutant status. The patient has also experienced diarrhea as an adverse effect of the treatment."
1762,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1763,1,"The patient is a 63-year-old white female with a BMI of 22.77 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. Her KRAS biomarker status is wild-type. She is experiencing dermatitis acneiform as an adverse effect, which is a skin condition characterized by acne-like eruptions on the skin."
1764,0,"The patient is a 51-year-old Black male with a BMI of 29.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to the treatment. He has a bowel obstruction and has not yet undergone any chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1765,0,"The patient is a 42-year-old white male with a BMI of 27.12 who is receiving treatment with FOLFOX for bowel obstruction. He has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
1766,0,"The patient is a 51-year-old white female with a BMI of 31.48. She is receiving treatment with the FOLFOX regimen and has a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
1767,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 6 days. Despite experiencing symptoms, he is still able to walk around. The pathology report indicates that the patient has a malignant condition."
1768,0,"The patient is a 74-year-old white male with a BMI of 24.86. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1769,1,The patient is a 47-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status.
1770,1,"The patient is a 46-year-old white male with a BMI of 21.63. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1771,0,The patient is a 51-year-old white male with a BMI of 25.0. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
1772,0,"The patient is a 65-year-old white male with a BMI of 27.46. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a wild-type result. The patient has experienced an adverse effect of thrombosis."
1773,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still ambulatory. The pathology report indicates malignancy.
1774,0,"This patient is a 63-year-old white female with a BMI of 26.24. She is receiving the FOLFIRI treatment regimen for her KRAS mutant cancer. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her bowel obstruction, her performance status is fully active. The patient has a mutant KRAS biomarker and is experiencing diarrhea as an adverse effect of her treatment."
1775,0,"The patient is a 44-year-old white male with a BMI of 34.85. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient's KRAS biomarker indicates a mutant status."
1776,0,The patient is a 55-year-old white female with a BMI of 26.37. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
1777,1,The patient is a 54-year-old white female receiving treatment with FOLFOX for colon cancer. She has a BMI of 24.22 and is experiencing symptoms but is still able to walk around (ambulatory).
1778,0,The patient is a 53-year-old white male with a BMI of 23.89. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status.
1779,1,"The patient is a 68-year-old white male with a BMI of 26.81. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1780,0,"This patient is a 64-year-old white female with a BMI of 25.54. She is receiving the FOLFIRI treatment regimen for her KRAS mutant cancer. She has experienced a serious adverse effect from the treatment. So far, she has completed 10 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her treatment, she has a fully active performance status. The KRAS biomarker status is currently indeterminate."
1781,1,"The patient is a 51-year-old white female with a BMI of 26.33. She is undergoing treatment with FOLFOX chemotherapy regimen and has completed 8 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
1782,0,"The patient is a 44-year-old white female with a BMI of 24.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
1783,1,"The patient is a 71-year-old white female with a BMI of 24.24. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
1784,0,"The patient is a 76-year-old white male with a BMI of 28.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. Unfortunately, he experienced serious adverse effects in the form of bowel obstruction and perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker status is wild-type."
1785,0,"The patient is a 45-year-old white male with a BMI of 31.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
1786,1,"The patient is a 47-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes."
1787,0,"The patient is a 57-year-old white female with a BMI of 36.07. She is receiving the FOLFOX treatment arm for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker test showed that she has a mutant KRAS status."
1788,0,"The patient is a 45-year-old white male with a BMI of 31.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
1789,1,"The patient is a male undergoing conventional surgery. He has used narcotics for 3 days. His histology shows that he is in bed less than 50% of the time, and his pathology indicates a malignant condition."
1790,1,"The patient is a 73-year-old white male with a BMI of 28.98. He is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
1791,1,The patient is a 46-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around (ambulatory). The histology of his condition is poorly differentiated.
1792,0,"The patient is a 41-year-old white female with a BMI of 18.99. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
1793,1,The patient is a male who underwent laparoscopic-assisted colectomy and has abdominal wall adhesions. He only used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the underlying cause is malignant.
1794,0,The patient is a 60-year-old black female with a well-differentiated histology who is part of the treatment arm receiving ECF chemotherapy along with radiation. She has a fully active performance status but is experiencing fatigue as an adverse effect of the treatment.
1795,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days following the procedure. The histology results showed that the tumor was well-differentiated, and the pathology report confirmed that it was malignant."
1796,1,"The patient is a 45-year-old male of a race categorized as ""other."" He is fully active and is receiving treatment with 5FU/LV plus radiation therapy. The histology indicates that the cancer is poorly differentiated."
1797,0,"The patient is a 61-year-old white male with a BMI of 26.14. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
1798,1,The patient is a male who is undergoing treatment with conventional surgery. He has been using narcotics for 6 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
1799,0,"The patient is a 62-year-old white female with a BMI of 29.64. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate."
1800,0,"The patient is a 76-year-old white female with a BMI of 26.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
1801,0,The patient is a female undergoing laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She has been using narcotics for 6 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate a malignant condition.
1802,0,"The patient is a 53-year-old male of a race categorized as ""other."" He is currently receiving treatment with 5FU/LV + Radiation therapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The histology of his condition is poorly differentiated. Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
1803,1,The patient is a 50-year-old white male with a BMI of 25.78. He is receiving treatment with FOLFOX and Panitumumab for a colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows a mutant status.
1804,0,The patient is a 74-year-old white male with a BMI of 23.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
1805,0,"The patient is a 51-year-old white male with a BMI of 25.63. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
1806,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1807,1,"The patient is a 69-year-old white female with a BMI of 28.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
1808,0,"The patient is a 62-year-old white female with a BMI of 42.9. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
1809,1,"The patient is a 66-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. He has also reported adverse effects including low lymphocyte levels and nausea."
1810,1,"The patient is a 50-year-old white female who has previously undergone chemotherapy and radiation treatment. She is currently enrolled in the ECF + Radiation treatment arm. Despite experiencing symptoms, she is still able to be ambulatory. The histology of her condition is poorly differentiated."
1811,0,"The patient is a 63-year-old white female with a BMI of 23.93. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1812,0,"The patient is a 74-year-old Black female with a BMI of 29.2. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker indicates that she has a wild-type status."
1813,0,"The patient is a 46-year-old white male with a BMI of 31.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
1814,0,"The patient is a 66-year-old Black female with a BMI of 36.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the cancer is wild-type."
1815,1,This patient is a 71-year-old white female with a BMI of 19.84. She is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. Her KRAS biomarker status is wild-type.
1816,1,"The patient is a 64-year-old male of other race with a BMI of 20.8. He has a fully active performance status and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal, and his KRAS biomarker status is wild-type."
1817,0,"The patient is a 63-year-old Black female with a BMI of 30.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
1818,0,"The patient is a 43-year-old female of a race other than specified, with a BMI of 22.7. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 11 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced an infection as an adverse effect of treatment."
1819,0,"The patient is a 67-year-old white male with a BMI of 23.24. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active, indicating that he is able to carry out daily activities without limitations. Additionally, his KRAS biomarker status is wild-type."
1820,0,"The patient is a 56-year-old white male with a BMI of 21.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. His performance status is fully active, and his KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of his treatment."
1821,0,The patient is a 58-year-old white female with a BMI of 28.55. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1822,0,"The patient is a 74-year-old white male with a BMI of 20.28. He is undergoing treatment with the FOLFIRI regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
1823,1,The patient is a 54-year-old white male enrolled in the ECF + Radiation treatment arm. He has a performance status of experiencing symptoms but is still able to walk around. His histology shows poorly differentiated cells. The patient is experiencing nausea as an adverse effect of the treatment.
1824,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days post-surgery. Her histology indicates that she is in bed less than 50% of the time, and her pathology report shows that the condition is malignant."
1825,1,The patient is a 47-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing fatigue as an adverse effect.
1826,1,"In this patient profile, the individual is a 67-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is a decrease in lymphocytes, which are a type of white blood cell that plays a crucial role in the immune system."
1827,1,"The patient is a 74-year-old white male who is currently undergoing treatment with a combination of Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating that his performance status is relatively good."
1828,0,"The patient is a 63-year-old white female with a BMI of 23.81. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1829,0,"The patient is a 41-year-old white female with a BMI of 23.8. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1830,1,The patient is a 68-year-old white male who is receiving treatment with Sunitinib. His performance status indicates that he is spending less than 50% of his time in bed.
1831,1,The patient is a 67-year-old white female with a BMI of 18.47. She is fully active with a primary tumor diagnosis of colon cancer. The patient is enrolled in the FOLFOX treatment arm. The KRAS biomarker indicates a mutant status.
1832,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the cause of the symptoms is malignant.
1833,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 23 days. The histology shows that she is in bed less than 50% of the time. The pathology indicates that the condition is malignant.
1834,1,The patient is a 55-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to low levels of granulocytes/bands and lymphocytes.
1835,1,"The patient is a 67-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. She has reported adverse effects including low levels of granulocytes/bands and nausea."
1836,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has been using narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate malignancy.
1837,1,"The patient is a 49-year-old white male with a BMI of 25.26. He is fully active and is receiving treatment in the FOLFOX + Panitumumab treatment arm. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
1838,0,"The patient is a 54-year-old white female with a BMI of 34.97. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced thrombosis as an adverse effect."
1839,0,The patient is a male who is receiving conventional surgery as part of their treatment. They have used narcotics for 5 days. The histology shows symptoms but the patient is still able to walk around. The pathology indicates that the condition is malignant.
1840,0,"The patient is a 37-year-old white female with a BMI of 23.74. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1841,1,The patient is a 49-year-old white female with a BMI of 18.52. She is fully active and is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that she has a wild-type status.
1842,0,The patient is a 66-year-old white female with a BMI of 29.74. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
1843,1,"The patient is a 61-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has undergone 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to move around independently."
1844,1,The patient is a 38-year-old white male with a BMI of 29.76. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates well-differentiated cancer. The patient has a fully active performance status and the KRAS biomarker is wild-type.
1845,1,"The patient is a 59-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood cell counts, specifically low levels of granulocytes/bands and lymphocytes."
1846,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1847,0,"The patient is a 44-year-old white male with a BMI of 28.96 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
1848,1,"The patient is a 71-year-old white male undergoing treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, he maintains a fully active performance status. The patient has reported experiencing nausea as an adverse effect of the treatment."
1849,0,The patient is a 78-year-old male of other race with a BMI of 27.99. He is fully active in terms of performance status. He has been diagnosed with a primary tumor in the colon and his KRAS biomarker status is wild-type. The patient is currently undergoing treatment with the FOLFOX regimen.
1850,1,"The patient is a 68-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
1851,0,"The patient is a 61-year-old white male with a BMI of 37.27. He is receiving treatment with FOLFIRI + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
1852,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has been using narcotics for 6 days. His histology shows symptoms but he is still able to move around. The pathology report indicates malignancy.
1853,0,"This patient is a 49-year-old white male with a BMI of 26.07. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
1854,0,The patient is a 74-year-old white male with a BMI of 23.46. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
1855,1,The patient is a 39-year-old white female with a BMI of 25.71 who is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. She has a fully active performance status. The KRAS biomarker shows a mutant status. The patient is experiencing a rash as an adverse effect of the treatment.
1856,0,"The patient is a 42-year-old white male with a BMI of 27.08. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has been adherent to the treatment. However, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
1857,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the patient has a malignant condition.
1858,1,"The patient is a 62-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects related to her blood cell counts, with low levels of granulocytes/bands, white blood cells, and lymphocytes. Additionally, she is experiencing nausea as a side effect of the treatment."
1859,0,"The patient is a 74-year-old white female with a BMI of 22.54. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
1860,0,The patient is a 53-year-old white female with a BMI of 21.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
1861,1,"The patient is a 66-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. He has reported experiencing nausea as an adverse effect of the treatment."
1862,1,"The patient is a 64-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
1863,0,"The patient is a 50-year-old Caucasian woman with a BMI of 18.99. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
1864,1,"The patient is a 54-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around and be ambulatory."
1865,0,"The patient is a 48-year-old white female with a BMI of 31.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
1866,1,The patient is a 56-year-old white female with a BMI of 24.34. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker for this patient is mutant.
1867,1,"The patient is a 60-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects related to her granulocytes/bands and white blood cells."
1868,0,"The patient is a 62-year-old white male with a BMI of 27.84. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type status."
1869,0,"This patient is a 47-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology of the patient's condition is well differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
1870,0,"The patient is a 74-year-old white male with a BMI of 22.1. He is receiving the FOLFOX treatment regimen and has been adherent to the therapy for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status. The patient has also experienced thrombosis as an adverse effect of the treatment."
1871,0,"The patient is a 41-year-old white female with a BMI of 23.05. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
1872,0,"The patient is a 36-year-old white female with a BMI of 20.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
1873,0,"The patient is a 67-year-old white female with a BMI of 35.01. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite having symptoms, she is still ambulatory. Additionally, the patient has a mutant KRAS biomarker."
1874,0,The patient is a 73-year-old white male with a BMI of 27.69. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status is wild-type.
1875,0,"The patient is a 71-year-old white male with a history of prior cancer. He is currently receiving treatment with ECF chemotherapy combined with radiation therapy. Despite experiencing adverse effects on his neutrophils/granulocytes and leukocytes, his performance status remains fully active. The histology of his current cancer is poorly differentiated."
1876,0,"The patient is a 68-year-old Black male with a BMI of 29.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an adverse effect of thrombosis."
1877,1,"This patient is a 76-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around. She is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes. Additionally, she is also experiencing nausea as a side effect of the treatment."
1878,0,"The patient is a 61-year-old white male with a BMI of 26.94. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1879,0,"The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 40.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
1880,0,"The patient is a 46-year-old white female with a BMI of 25.21. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1881,0,"This patient is a 35-year-old white female with a BMI of 21.33. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
1882,1,"The patient is a 62-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite this, her performance status remains fully active. She has also developed a side effect known as granulocytes/bands."
1883,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 1 day post-surgery. Her histology shows symptoms but she is able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
1884,0,"The patient is a 67-year-old Black male with a BMI of 42.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age and BMI, his performance status is fully active, indicating he is able to carry out daily activities without limitations. The KRAS biomarker analysis revealed that he has a wild-type KRAS gene."
1885,1,The patient is a 43-year-old white female with a BMI of 23.01. She is fully active and is receiving treatment with the FOLFOX regimen for colon cancer.
1886,0,"The patient is a 34-year-old white female with a BMI of 29.98. She is receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing indicates she has a wild-type mutation. The patient has experienced an infection as an adverse effect of the treatment."
1887,0,"The patient is a 53-year-old Black female with a BMI of 34.44. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
1888,0,"The patient is a 63-year-old Black female with a BMI of 19.9. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 12 chemotherapy cycles. The histology of her condition is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker status is intermediate."
1889,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She used narcotics for 3 days post-surgery. She is typically out of bed more than 50% of the time. The pathology report indicates malignancy.
1890,0,"The patient is a 59-year-old white female with a BMI of 19.96. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
1891,0,"The patient is a male undergoing treatment with conventional surgery. He has used narcotics for 2 days. His histology shows well-differentiated cells, and his pathology indicates a benign condition."
1892,1,The patient is a 47-year-old white male with a BMI of 26.72 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker status is wild-type.
1893,1,"The patient is a 55-year-old white male receiving treatment with a combination of Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around, indicating that his performance status is relatively good."
1894,0,"The patient is a 41-year-old white male with a BMI of 34.62. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1895,1,"The patient is a 57-year-old white male with a BMI of 30.49. He is currently receiving treatment in the FOLFIRI chemotherapy arm and has completed one cycle of treatment. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient's KRAS biomarker indicates a mutant status."
1896,0,"The patient is a 55-year-old white female with a BMI of 21.84. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1897,0,"The patient is a 63-year-old white male with a BMI of 35.99. He is receiving the FOLFOX treatment arm for his cancer. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1898,0,"The patient is a 42-year-old Black male with a BMI of 34.94. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
1899,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 22.68. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type."
1900,0,"The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 21.04. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1901,0,The patient is a 35-year-old white male with a BMI of 26.56. He is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
1902,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, as well as experiencing complications. He used narcotics for 3 days post-surgery. Despite having symptoms, he is ambulatory. The pathology report indicates malignancy."
1903,0,"The patient is a 66-year-old white male with a BMI of 27.28. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker is wild-type, and he is receiving treatment with the FOLFOX regimen."
1904,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery but only required one day of narcotic use for pain management. Despite the complications, she was able to remain ambulatory with symptoms. The pathology report indicated a malignant condition."
1905,1,The patient is a 58-year-old black female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. She has poorly differentiated histology and is experiencing adverse effects of nausea and anorexia.
1906,0,"The patient is a 66-year-old white male with a BMI of 27.43. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1907,0,The patient is a 46-year-old Black male with a BMI of 31.94. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1908,1,The patient is a 66-year-old white male with a BMI of 20.62 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker shows that he has a wild-type gene. The patient is experiencing a rash as an adverse effect of the treatment.
1909,0,"The patient is a 64-year-old white female with a BMI of 25.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
1910,0,The patient is a 50-year-old white female with a BMI of 36.54. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1911,1,"This patient is a 45-year-old white male with a BMI of 32.96. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
1912,0,"The patient is a 47-year-old white female with a BMI of 19.96. She is receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1913,0,"This patient is a 49-year-old Black male with a BMI of 31.35. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1914,1,"The patient is a 65-year-old white female with a BMI of 36.88. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
1915,1,"The patient is a 61-year-old white male with a BMI of 23.15 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker shows that the tumor is wild-type."
1916,0,"The patient is a 54-year-old female of a race categorized as ""other"" with a BMI of 24.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1917,0,"The patient is a 68-year-old white male with a BMI of 27.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
1918,0,"The patient is a 71-year-old white female with a BMI of 28.76. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1919,1,"The patient is a 63-year-old white male with a BMI of 27.95. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
1920,1,This patient is a 66-year-old white female who is part of the placebo treatment arm. She has a performance status that indicates she is in bed less than 50% of the time.
1921,0,"The patient is a 63-year-old white male with a BMI of 29.09. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
1922,0,"The patient is a 54-year-old white male with a BMI of 33.3. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 8 cycles so far. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
1923,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
1924,0,"The patient is a 53-year-old white male with a BMI of 31.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
1925,1,"The patient is a 73-year-old white male with a BMI of 31.06. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
1926,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1927,1,"The patient is a 67-year-old male of other race with a BMI of 23.01. He is currently receiving treatment with FOLFOX for a colon cancer diagnosis. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
1928,1,"The patient is a 64-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing a common adverse effect known as granulocytes/bands."
1929,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
1930,1,"The patient is a 66-year-old white male with a BMI of 24.72. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the patient has a mutant KRAS biomarker."
1931,1,"The patient is a 38-year-old white female with a BMI of 27.4. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
1932,0,"The patient is a 73-year-old female of a race categorized as ""other"" with a BMI of 19.26. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
1933,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
1934,1,"The patient is a 67-year-old male of a race other than specified, who is currently receiving treatment with 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes."
1935,1,This patient is a 69-year-old white female with a BMI of 27.37. She is fully active and is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis shows that she has a mutant KRAS status.
1936,0,The patient is a 58-year-old white male with a BMI of 29.72. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. His KRAS biomarker status is wild-type.
1937,0,"The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 3 days. The histology shows that the tumor is well differentiated, and the pathology report indicates that the tumor is benign."
1938,0,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 6 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
1939,0,"The patient is a 40-year-old white female with a BMI of 25.59. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the course of her 12 chemotherapy cycles. The histology of her cancer is well differentiated. Despite the treatment, her performance status remains fully active. Additionally, her KRAS biomarker is identified as mutant."
1940,1,"The patient is a 47-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also developed a decrease in lymphocytes as an adverse effect of the treatment."
1941,0,"The patient is a 49-year-old female of a race other than specified, with a BMI of 25.06. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite her treatment, she has a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
1942,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 4 days. The histology report indicates that she spent less than 50% of her time in bed, and the pathology report revealed a malignant condition."
1943,1,The patient is a 60-year-old white male with a BMI of 30.45. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker status is wild-type.
1944,0,"The patient is a 57-year-old white male with a BMI of 28.54. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infarction."
1945,0,"The patient is a 58-year-old Black female with a BMI of 29.48. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
1946,0,"The patient is a 60-year-old white male with a BMI of 26.36. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1947,0,The patient is a 41-year-old white male with a BMI of 30.56. He is receiving the FOLFIRI treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
1948,1,"The patient is a 54-year-old white male with a BMI of 24.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a serious adverse effect after one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type."
1949,1,The patient is a 53-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. He is also experiencing adverse effects of low neutrophils/granulocytes and fatigue.
1950,0,The patient is a 44-year-old white male with a BMI of 22.86. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
1951,0,"The patient is a 42-year-old white female with a BMI of 36.04. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
1952,0,"The patient is a 42-year-old white male with a BMI of 30.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1953,0,"This patient is a 68-year-old black male who is fully active and is receiving treatment with ECF chemotherapy and radiation therapy. He is experiencing fatigue as an adverse effect of his treatment. Fatigue is a common side effect that can cause feelings of tiredness, weakness, and lack of energy. It can impact a person's ability to carry out daily activities and may require adjustments in their routine to manage effectively."
1954,1,"The patient is a 44-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the patient has developed a decrease in lymphocyte count as an adverse effect of the treatment."
1955,0,"The patient is a 50-year-old white female with a BMI of 27.14. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is mutant."
1956,0,"This patient is a 61-year-old white female with a BMI of 25.81 who is currently receiving treatment with FOLFOX for a diagnosis of rectal cancer. She has symptoms but is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type, indicating a better prognosis for response to treatment."
1957,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 5 days post-surgery. He is experiencing symptoms but is still able to be ambulatory. The pathology report indicates that the cause of the symptoms is malignant.
1958,0,"The patient is a 47-year-old female of a race other than specified. She has a BMI of 19.04 and is receiving treatment with the FOLFOX + Cetuximab regimen. She is scheduled for 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker testing shows that the patient has a wild-type KRAS status."
1959,0,The patient is a 59-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
1960,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is ambulatory. The pathology report indicates malignancy.
1961,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
1962,0,"The patient is a 64-year-old white female with a BMI of 22.22. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that it is wild-type."
1963,1,"The patient is a 60-year-old white female with a BMI of 25.8 who is currently receiving treatment with FOLFOX and Panitumumab. She has symptoms but is still able to walk around (ambulatory). She has been diagnosed with a primary colon tumor, and her KRAS biomarker status is mutant."
1964,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the surgery. The histology results showed symptoms but the patient is still able to walk around. The pathology results indicated that the condition is malignant.
1965,0,"The patient is a 62-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
1966,0,"The patient is a 39-year-old white male with a BMI of 27.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
1967,0,"The patient is a 52-year-old white female with a BMI of 25.14 who is receiving treatment with FOLFOX + Cetuximab. She has completed 11 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
1968,0,"The patient is a 59-year-old white male with a BMI of 35.35. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation."
1969,0,The patient is a male who is receiving conventional surgery as part of their treatment. They have used narcotics for 7 days. Their histology shows symptoms but they are still able to walk around. The pathology report indicates that the condition is malignant.
1970,1,The patient is a 65-year-old white female who is fully active. She is currently receiving treatment with Sunitinib.
1971,1,This patient is a 67-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. She is experiencing an adverse effect of low neutrophils/granulocytes.
1972,1,The patient is a 48-year-old white male receiving treatment with 5FU/LV and radiation. He has a performance status of being in bed less than 50% of the time. The histology shows well-differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
1973,0,The patient is a 76-year-old white female with a BMI of 18.29. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
1974,0,"The patient is a 43-year-old white female with a BMI of 33.63. She is receiving the FOLFIRI treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
1975,0,"The patient is a 74-year-old white male with a BMI of 27.68 who is receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a performance status of symptoms but is still able to walk around. The KRAS biomarker shows that he has a wild-type mutation. The patient is experiencing dermatitis acneiform as an adverse effect, which presents as a skin rash resembling acne."
1976,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the condition is malignant.
1977,0,"The patient is a 42-year-old white female with a BMI of 37.9. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
1978,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesion and bowel adhesion. There were complications during the treatment. The patient used narcotics for 17 days. The histology results show that the tissue is well differentiated, and the pathology indicates that the condition is benign."
1979,0,"The patient is a 68-year-old white male who has previously undergone chemotherapy and radiation treatment. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to move around. The histology shows that the cancer cells are well differentiated. The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes."
1980,1,The patient is a 50-year-old white female with a BMI of 28.35 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker testing revealed a mutant status.
1981,0,"The patient is a 64-year-old white female with a BMI of 25.68. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
1982,0,"The patient is a 42-year-old white male with a BMI of 27.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and the KRAS biomarker indicates that he has a wild-type mutation."
1983,1,"The patient is a 59-year-old white male with a BMI of 26.94. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
1984,1,"The patient is a 62-year-old white male with a BMI of 24.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates a mutant status."
1985,1,This patient is a 55-year-old white female with a BMI of 40.21. She is fully active and her primary tumor diagnosis is colon cancer. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. Her KRAS biomarker status is wild-type.
1986,0,"The patient is a 48-year-old white male with a BMI of 27.28. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
1987,0,"The patient is a 64-year-old white male with a BMI of 35.68. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
1988,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has used narcotics for 2 days. The histology shows well-differentiated cells, and the pathology indicates malignancy."
1989,0,"The patient is a 57-year-old Black female with a BMI of 25.16. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to move around independently (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
1990,1,"The patient is a 50-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
1991,1,The patient is a female who is undergoing treatment with conventional surgery. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
1992,0,"The patient is a 64-year-old white male with a BMI of 27.45. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
1993,0,"The patient is a 67-year-old white female with a BMI of 33.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
1994,0,"The patient is a 56-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
1995,1,"The patient is a 75-year-old white male with a BMI of 29.07. He is currently undergoing treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that he has a mutant KRAS status."
1996,0,The patient is a 64-year-old white female with a BMI of 32.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type.
1997,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 4 days. Despite the symptoms, he was still able to be ambulatory. The pathology report revealed malignant findings."
1998,1,"The patient is a 75-year-old white male with a BMI of 29.6. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect after one cycle of chemotherapy. His histology shows well-differentiated cancer, and he has symptoms but is still able to be ambulatory. The KRAS biomarker indicates a mutation. Additionally, he is experiencing diarrhea as an adverse effect of the treatment."
1999,1,"The patient is a 74-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV and radiation therapy. He has a histology of poorly differentiated cancer. The patient is experiencing adverse effects including nausea, anorexia, and fatigue."
2000,1,"The patient is a 50-year-old black male with a well-differentiated histology. He is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to ambulate, indicating a relatively good performance status."
2001,1,"The patient is a 63-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. He is experiencing an adverse effect known as granulocytes/bands, which indicates a decrease in a type of white blood cell called granulocytes."
2002,0,"The patient is a 39-year-old white male with a BMI of 22.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type gene."
2003,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 11 days. Her histology shows symptoms but she is still able to move around. The pathology report indicates a malignant condition.
2004,1,The patient is a 71-year-old male of other race with a BMI of 25.96. He is fully active with a primary tumor diagnosis of rectal cancer and is receiving treatment with the FOLFOX regimen.
2005,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is able to walk around. Pathology results indicate a malignant condition.
2006,0,"The patient is a 73-year-old white female with a BMI of 20.19. She is receiving treatment in the FOLFIRI treatment arm for her KRAS mutant status. She has been adherent to her treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active."
2007,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes."
2008,1,The patient is a 70-year-old white male with a BMI of 26.4. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker indicates that the patient has a mutant form of the gene.
2009,1,"The patient is a 47-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to be ambulatory. The patient has developed adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2010,0,"The patient is a 34-year-old white male with a BMI of 28.4. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite the treatment, he maintains a fully active performance status. His KRAS biomarker status is wild-type."
2011,0,The patient is a 33-year-old white female with a BMI of 19.47. She is fully active and is receiving treatment with FOLFOX and Panitumumab for her colon cancer. The KRAS biomarker analysis shows that she has a mutant KRAS status.
2012,1,"The patient is a 75-year-old white male with a BMI of 23.62. He is currently receiving treatment with FOLFOX and Panitumumab for a colon cancer diagnosis. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker for this patient is mutant."
2013,0,"The patient is a 43-year-old white female with a BMI of 16.19. She is currently receiving treatment with FOLFOX + Cetuximab for her cancer. She is experiencing a bowel obstruction and has completed one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2014,0,"The patient is a 57-year-old white male with a BMI of 49.43. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status. Additionally, the patient has experienced an adverse effect of thrombosis."
2015,1,"The patient is a 72-year-old white male with a BMI of 25.28. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with colon cancer, and his KRAS biomarker status is mutant."
2016,0,The patient is a 43-year-old white female with a BMI of 33.86. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
2017,0,"The patient is a 34-year-old white female with a BMI of 24.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2018,0,The patient is a 61-year-old Black male with a BMI of 25.1. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status.
2019,0,"The patient is a 67-year-old white female with a BMI of 27.14. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker shows a mutant status."
2020,0,"The patient is a 67-year-old white female with a BMI of 29.74. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
2021,1,The patient is a 60-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects of low white blood cells and nausea.
2022,0,"The patient is a 55-year-old white male with a BMI of 22.44. He is currently receiving FOLFOX treatment for bowel obstruction and has completed 3 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates that the cancer is wild-type."
2023,1,"This patient is a 60-year-old white male with a BMI of 19.03. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2024,0,"This patient is a 42-year-old white female with a BMI of 22.68. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2025,0,"The patient is a 51-year-old white female with a BMI of 24.13. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2026,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesion as well as bowel adhesion. She experienced complications post-surgery and required narcotic use for 5 days. Despite having symptoms, she is able to walk around. The pathology report indicated malignancy."
2027,1,"The patient is a 68-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to ambulate. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
2028,0,"The patient is a 37-year-old white male with a BMI of 30.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
2029,1,"The patient is a 44-year-old white male with a BMI of 23.99. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed a mutant status."
2030,1,"The patient is a 54-year-old white male enrolled in the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
2031,1,The patient is a 70-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of decreased neutrophils/granulocytes and leukocytes.
2032,0,The patient is a 58-year-old white female with a BMI of 21.11. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
2033,0,The patient is a 74-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
2034,0,"This patient is a 61-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy along with radiation. The histology of his cancer is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
2035,0,"The patient is a 64-year-old white female with a BMI of 38.86. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of treatment."
2036,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 1 day following the surgery. The histology results showed that the tumor was well differentiated, and the pathology report indicated that it was benign."
2037,0,The patient is a 66-year-old white female with a BMI of 23.13. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene.
2038,0,"The patient is a 44-year-old white male with a BMI of 37.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2039,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 4 days. Despite experiencing symptoms, he is still able to move around. The pathology results indicate that the patient has a malignant condition."
2040,0,"The patient is a 42-year-old white male with a BMI of 29.0. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2041,1,"The patient is a 44-year-old white female with a BMI of 26.95. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2042,1,The patient is a 66-year-old white male with a BMI of 26.96 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis shows that the patient has a mutant KRAS status.
2043,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She used narcotics for 2 days post-surgery. Despite having symptoms, she is able to walk around. The pathology report indicates malignancy."
2044,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 3 days following the procedure. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2045,0,"The patient is a 75-year-old white male with a BMI of 35.33. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced hypersensitivity as an adverse effect."
2046,1,"The patient is a 63-year-old white male with a BMI of 24.91. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
2047,1,"The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 8 days post-surgery. Despite experiencing symptoms, she is still able to walk around. The pathology results indicated that the condition is malignant."
2048,0,"The patient is a 74-year-old male of a race categorized as ""other"" with a BMI of 23.6. He is receiving the FOLFOX treatment arm for his condition. The patient has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows that the cancer cells are well-differentiated. Despite his age, the patient has a fully active performance status. Additionally, his KRAS biomarker indicates that it is wild-type."
2049,0,"The patient is a 55-year-old Black male with a BMI of 30.77. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
2050,1,"The patient is a 60-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed."
2051,0,"The patient is a 58-year-old white male with a BMI of 28.3. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory based on his performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2052,0,"The patient is a 49-year-old white female with a BMI of 25.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel perforation. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant result."
2053,1,The patient is a 68-year-old white female with a BMI of 21.72. She is receiving treatment with FOLFOX and Panitumumab for colon cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis shows a mutant status.
2054,0,"The patient is a 73-year-old white male with a BMI of 31.14. He is currently receiving the FOLFIRI treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2055,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
2056,1,"The patient is a 79-year-old white male with a BMI of 16.07. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
2057,0,"The patient is a 67-year-old white male with a BMI of 30.27. He is currently undergoing treatment with the FOLFOX regimen and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient's performance status is fully active, indicating that he is able to carry out his daily activities without limitations. The KRAS biomarker status is indeterminate, meaning further testing may be needed to determine its significance in his treatment plan."
2058,1,The patient is a 50-year-old white female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. Her histology shows poorly differentiated characteristics.
2059,0,"The patient is a 61-year-old white female with a BMI of 25.71. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2060,0,"The patient is a 51-year-old white male with a BMI of 42.09. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates poorly differentiated cancer. Despite this, the patient has a fully active performance status. The KRAS biomarker shows that the patient has a wild-type status."
2061,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 3 days. The histology shows that he is in bed less than 50% of the time, and the pathology report indicates malignancy."
2062,0,The patient is a 62-year-old white male with a BMI of 28.0 who is fully active. He is receiving treatment with the FOLFOX regimen for colon cancer.
2063,1,"The patient is a 40-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy and has a fully active performance status."
2064,0,The patient is a 67-year-old white female with a BMI of 22.7. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2065,1,This patient is a 58-year-old white female who is part of the placebo treatment arm. Her performance status indicates that she spends less than 50% of her time in bed.
2066,1,"The patient is a 57-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around. She is experiencing adverse effects including low levels of granulocytes/bands and nausea."
2067,1,The patient is a 67-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2068,1,"The patient is a 69-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to ambulate. The patient has also developed adverse effects including low granulocytes/bands and low white blood cell count."
2069,0,"The patient is a 76-year-old white male with a BMI of 31.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). Additionally, his KRAS biomarker indicates that it is wild-type."
2070,0,"In this patient profile, the individual is a 59-year-old white female who is fully active. She is receiving treatment with Sunitinib. One of the adverse effects she is experiencing is a decrease in neutrophils/granulocytes, which are types of white blood cells that help fight infections and play a crucial role in the immune response."
2071,1,The patient is a 67-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy and is experiencing symptoms but is still able to walk around. She is also experiencing a decrease in lymphocytes as an adverse effect of the treatment.
2072,0,"The patient is a 58-year-old white female with a BMI of 33.92. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2073,0,"The patient is a 43-year-old female of a race classified as ""other"" with a BMI of 20.4. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutation."
2074,0,This patient is a female who is part of the conventional surgery treatment arm. She has been using narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
2075,0,"This patient is a 75-year-old white female with a BMI of 27.06. She is enrolled in the FOLFIRI + Cetuximab treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not started any chemotherapy cycles yet. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is indeterminate."
2076,0,"The patient is a 64-year-old white male with a BMI of 24.48. He is undergoing treatment with FOLFIRI for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker is wild-type."
2077,1,"The patient is a 35-year-old white female with a BMI of 21.65. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2078,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotic medication for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2079,1,The patient is a male undergoing laparoscopic-assisted colectomy. He has bowel adhesions present. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates the presence of malignancy.
2080,1,"The patient is a 57-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and perform daily activities."
2081,0,"The patient is a 65-year-old white female with a BMI of 24.34. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
2082,0,"The patient is a 41-year-old Black female with a BMI of 37.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2083,0,"This patient is a 72-year-old white female with a BMI of 23.5. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2084,0,"The patient is a 43-year-old white male with a BMI of 27.65. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2085,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
2086,0,"The patient is a 45-year-old white female with a BMI of 30.11. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2087,1,"The patient is a 50-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Her performance status indicates that she is spending less than 50% of her time in bed. The patient has also experienced adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
2088,0,"The patient is a 68-year-old white male with a BMI of 36.04. He is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis indicates a wild-type status."
2089,0,The patient is a female undergoing laparoscopic-assisted colectomy. She has been using narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2090,0,"The patient is a 70-year-old female of a race other than Caucasian. She has a BMI of 24.58 and is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect from the treatment. So far, she has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is indeterminate."
2091,1,"The patient is a 72-year-old white female with a BMI of 30.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
2092,0,"The patient is a 64-year-old white female with a BMI of 22.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2093,0,"The patient is a 70-year-old white female with a BMI of 29.68. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
2094,0,"The patient is a 58-year-old male of a race categorized as ""other"" with a BMI of 27.5. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed treatment. The patient has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2095,1,"The patient is a 59-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects on her blood cells, specifically showing low levels of granulocytes/bands, white blood cells, and lymphocytes."
2096,1,The patient is a 56-year-old white female with a BMI of 30.11. She is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
2097,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions present. He has used narcotics for 2 days. The histology shows symptoms but he is still able to be ambulatory. The pathology report indicates a malignant condition.
2098,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 2 days. Her histology shows symptoms but she is ambulatory. The pathology report indicates a malignant condition.
2099,1,"The patient is a 64-year-old white female with a BMI of 24.91.She is currently receiving treatment with FOLFOX + Planitumumab for her colon cancer. Despite experiencing symptoms, she is still fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. Additionally, she is experiencing dermatitis acneiform as an adverse effect ."
2100,1,"The patient is a 59-year-old white male with a BMI of 28.46. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He is experiencing a bowel obstruction and has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
2101,0,"The patient is a 54-year-old Black female with a BMI of 26.36. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2102,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2103,0,"The patient is a 41-year-old white male with a BMI of 23.5. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2104,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
2105,1,The patient is a 69-year-old white male participating in the treatment arm involving 5FU/LV chemotherapy combined with radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology indicates that the cancer cells are well-differentiated.
2106,1,"The patient is a 71-year-old white male with a BMI of 29.05 who is receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has mutant KRAS biomarker status. Despite experiencing symptoms, he is still able to ambulate. The patient is also experiencing dermatitis acneiform as an adverse effect of treatment. This condition presents as acne-like skin rash or inflammation."
2107,0,"The patient is a 52-year-old white male with a BMI of 21.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2108,0,"The patient is a 54-year-old Black male with a BMI of 22.82. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2109,0,"The patient is a 67-year-old white female with a BMI of 29.61. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2110,1,"This patient is a 76-year-old white female with a BMI of 36.69 who is receiving the FOLFOX treatment regimen for her well-differentiated cancer. She has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
2111,0,The patient is a 64-year-old white female with a BMI of 25.59 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a fully active performance status. The KRAS biomarker is mutant. The patient is experiencing an adverse effect of rash.
2112,1,The patient is a 48-year-old white female with a BMI of 29.96. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is wild-type.
2113,0,"The patient is a 66-year-old Black male with a BMI of 34.31. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
2114,0,"This patient is a 74-year-old white female with a BMI of 23.42. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to ambulate. Additionally, her KRAS biomarker status is wild-type."
2115,1,The patient is a 72-year-old white female enrolled in the placebo treatment arm. She is experiencing symptoms but is still able to move around. She has reported feeling fatigued as an adverse effect of her treatment.
2116,0,"The patient is a 61-year-old white male with a BMI of 48.88 who is undergoing treatment with FOLFOX + Cetuximab. He has been adherent to his treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated, and he has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed a bowel perforation and is experiencing diarrhea as an adverse effect of the treatment."
2117,1,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2118,0,The patient is a 62-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology of the cancer is poorly differentiated. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
2119,0,"The patient is a 67-year-old white male with a BMI of 24.31. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced a hypersensitivity adverse effect."
2120,0,"The patient is a 44-year-old white female with a BMI of 41.87. She is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. She has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite her cancer diagnosis, she has a fully active performance status."
2121,0,"The patient is a 72-year-old white male with a BMI of 21.32. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has completed 11 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2122,1,"The patient is a 55-year-old male of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed an adverse effect related to his lymphocytes."
2123,0,"The patient is a 45-year-old white female with a BMI of 21.94. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2124,0,"The patient is a 44-year-old white male with a BMI of 21.92. He is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
2125,0,"The patient is a 66-year-old white female with a BMI of 24.1. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2126,1,The patient is a 53-year-old white female with a BMI of 17.72 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a mutant KRAS status.
2127,0,"The patient is a 73-year-old white male with a BMI of 26.49. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker indicates a mutant status. The patient is also experiencing diarrhea as an adverse effect of the treatment."
2128,1,The patient is a 60-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of low neutrophils/granulocytes and low leukocytes.
2129,0,"The patient is a 56-year-old white male with a BMI of 26.83 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect after completing one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker status is indeterminate."
2130,0,The patient is a 49-year-old white male with a BMI of 22.79. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. He has a fully active performance status. The KRAS biomarker testing showed a mutant result.
2131,1,"The patient is an 81-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to move around. He is experiencing adverse effects such as low white blood cell count and nausea."
2132,1,"The patient is a 61-year-old Black female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to ambulate."
2133,0,"The patient is a 57-year-old white male with a BMI of 33.64. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
2134,1,"The patient is a 77-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. He is experiencing adverse effects such as low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
2135,1,The patient is a 57-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated.
2136,1,"The patient is a 39-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects related to her granulocytes/bands and white blood cells."
2137,0,This patient is a 71-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
2138,1,"The patient is a 59-year-old white male with a BMI of 45.54 who is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, the patient is still able to ambulate. The primary tumor diagnosis for this patient is rectal cancer."
2139,1,"The patient is a 72-year-old white male with a BMI of 31.14. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the KRAS biomarker analysis revealed a mutant status."
2140,1,"In this patient profile, the individual is a 54-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. An adverse effect noted is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
2141,0,The patient is a 75-year-old Black female with a BMI of 33.16. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis revealed that she has a wild-type KRAS status.
2142,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days post-surgery. The histology results show that she spent less than 50% of her time in bed, and the pathology report indicates that the tumor is malignant."
2143,0,The patient is a 74-year-old white male with a BMI of 30.04. He is fully active with a primary tumor diagnosis of colon cancer. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
2144,0,"The patient is a 72-year-old white male with a BMI of 27.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker is wild-type."
2145,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates the presence of malignancy.
2146,1,"The patient is a 75-year-old female of other race who is undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, which indicates an abnormal level of a type of white blood cell in the body."
2147,0,"The patient is a 69-year-old white female with a BMI of 28.1. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
2148,1,"The patient is a 50-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
2149,1,"The patient is a female who underwent conventional surgery and experienced complications. She used narcotics for 3 days post-surgery. Despite having symptoms, she is still able to walk around. The pathology report revealed a malignant condition."
2150,1,"The patient is a 72-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient is showing adverse effects including low granulocytes/bands and low white blood cells, as well as experiencing nausea."
2151,0,"The patient is a 68-year-old white female with a BMI of 21.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
2152,1,"The patient is a 58-year-old white female with a BMI of 23.18. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2153,1,The patient is a 70-year-old white male with a BMI of 31.53. He is currently in bed less than 50% of the time due to his performance status. He has been diagnosed with a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. He is receiving treatment with FOLFOX and Panitumumab.
2154,0,"The patient is a 43-year-old white female with a BMI of 26.01. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene. The patient has experienced an adverse effect of thrombosis."
2155,1,This patient is a 60-year-old white female with a BMI of 27.73. She is fully active and is receiving treatment with FOLFOX chemotherapy combined with Panitumumab for a primary tumor diagnosis of rectal cancer.
2156,0,"The patient is a 42-year-old white female with a BMI of 39.62 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her chemotherapy cycles, which total 12. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
2157,0,"The patient is a 46-year-old Black male with a BMI of 18.44. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He is currently experiencing a bowel obstruction. So far, he has completed 8 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2158,1,"The patient is a 59-year-old male of a race categorized as ""other"" who is currently receiving treatment in the ECF + Radiation arm. He has a performance status of experiencing symptoms but is still able to walk around. The histology of his condition is poorly differentiated. He is experiencing fatigue as an adverse effect of his treatment."
2159,1,"The patient is a 56-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes."
2160,0,"The patient is a 58-year-old white female with a BMI of 39.74. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 9 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2161,0,"The patient is a 57-year-old white male with a BMI of 32.53. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2162,0,"The patient is a 67-year-old female of a race categorized as ""other."" She has a BMI of 26.21 and is currently receiving the FOLFOX treatment regimen. She has completed 7 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Her KRAS biomarker status is wild-type."
2163,0,The patient is a 52-year-old Black male with a BMI of 24.62. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
2164,1,The patient is a 77-year-old white male with a BMI of 26.37. He is fully active with a primary tumor diagnosis of colon cancer. He is in the treatment arm receiving FOLFOX chemotherapy along with Panitumumab. His KRAS biomarker status is wild-type.
2165,0,"The patient is a 40-year-old white female with a BMI of 28.73. She is receiving the FOLFOX treatment arm and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2166,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She used narcotics for 3 days post-surgery. Histologically, she is experiencing symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
2167,0,"The patient is a 69-year-old white female with a BMI of 25.66. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker analysis shows that she has a mutant KRAS status."
2168,1,"The patient is a 70-year-old white male with a well-differentiated histology who is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, the patient is still able to walk around. The patient is also experiencing adverse effects such as low levels of neutrophils/granulocytes and leukocytes, as well as a loss of appetite (anorexia)."
2169,0,"The patient is a 71-year-old white female with a BMI of 26.0. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea during her treatment."
2170,0,The patient is a female who is undergoing conventional surgery for a malignant pathology. She has experienced symptoms but is still able to be ambulatory. She has used narcotics for 3 days as part of her treatment.
2171,1,The patient is a 73-year-old male of other race with a BMI of 25.51. He is fully active with a primary tumor diagnosis of rectal cancer and is currently receiving treatment with the FOLFOX regimen.
2172,0,"The patient is a 46-year-old white female with a BMI of 26.0 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
2173,0,The patient is a 49-year-old white female with a BMI of 21.4. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2174,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days post-surgery. Her histology indicates that she is in bed less than 50% of the time, and her pathology report shows that the tumor is malignant."
2175,0,The patient is a 54-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology shows well-differentiated cells.
2176,1,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
2177,0,"The patient is a 62-year-old white female with a BMI of 38.98. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker status is wild-type."
2178,0,"The patient is a 45-year-old white female with a BMI of 20.51. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2179,0,"The patient is a 47-year-old white male with a BMI of 25.72. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2180,0,"The patient is a 46-year-old white female with a BMI of 32.84. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2181,0,"The patient is a 68-year-old white male with a BMI of 28.55. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has developed thrombosis as an adverse effect."
2182,1,"This patient is a 62-year-old female with a BMI of 25.68 who is receiving treatment with the FOLFOX regimen. She has a primary tumor diagnosis of rectal cancer and has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
2183,1,The patient is a 67-year-old white male with a BMI of 28.06. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
2184,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She only used narcotics for 1 day post-surgery. Despite having symptoms, she is able to walk around. The pathology report indicates malignancy."
2185,0,The patient is a 63-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows well-differentiated cells. The patient is experiencing adverse effects of low neutrophils/granulocytes and low leukocytes.
2186,0,"The patient is a 76-year-old white female with a BMI of 24.48. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during her treatment."
2187,0,"The patient is a 50-year-old white female with a BMI of 38.83. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2188,1,The patient is a 60-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2189,1,The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 4 days and is experiencing symptoms but is still able to walk around.
2190,0,"The patient is a 60-year-old female of a race categorized as ""other"" with a BMI of 31.85. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2191,1,"The patient is a 71-year-old white female with a BMI of 31.07. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects of thrombosis and diarrhea."
2192,0,The patient is a 49-year-old Black or African American male with a BMI of 22.72. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has the wild-type gene. He is currently undergoing treatment with the FOLFOX regimen.
2193,1,"The patient is a 61-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also reported experiencing nausea as an adverse effect of the treatment."
2194,0,The patient is a 51-year-old Black male participating in the ECF + Radiation treatment arm. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low neutrophils/granulocytes and leukocytes.
2195,1,"The patient is a 54-year-old white male with a BMI of 32.93 who is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. He has a mutant KRAS biomarker and is experiencing a rash as an adverse effect of the treatment. Despite having symptoms, he is still able to ambulate."
2196,0,The patient is a 62-year-old white male with a BMI of 26.82. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a mutant KRAS biomarker.
2197,0,"The patient is a 55-year-old white female with a BMI of 29.34. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
2198,1,The patient is a 36-year-old white male with a BMI of 31.07 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing acne as an adverse effect of the treatment.
2199,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. She is experiencing symptoms but is still able to move around. The pathology results showed that the cause of her symptoms is due to malignancy.
2200,0,"The patient is a 56-year-old white male with a BMI of 32.33. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2201,0,The patient is a 45-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of low neutrophils/granulocytes and low leukocytes.
2202,0,The patient is a 77-year-old female of other race with a BMI of 28.04. She is fully active in terms of performance status. She has been diagnosed with a primary tumor in the rectum and has a mutant KRAS biomarker. The patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
2203,0,The patient is a 55-year-old white male with a BMI of 28.94. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active. The KRAS biomarker shows that he has a wild-type status.
2204,0,"This patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 2 days. Her histology indicates that she is in bed less than 50% of the time, and her pathology results show that she has a malignant condition."
2205,0,"The patient is a 65-year-old white male with a BMI of 35.08. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
2206,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the cause of his symptoms is malignant.
2207,0,"The patient is a 76-year-old white female with a BMI of 22.58. She is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2208,0,"The patient is a 58-year-old Black male with a BMI of 26.42. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of treatment."
2209,1,"The patient is a 58-year-old white male with a BMI of 24.81. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
2210,0,The patient is a 36-year-old white female with a BMI of 34.81. She is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer. She has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
2211,1,"This patient is a 42-year-old white male with a BMI of 27.35. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing a serious adverse effect, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has developed thrombosis as an adverse effect."
2212,1,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2213,0,"The patient is a 52-year-old female of a race categorized as ""other"" with a BMI of 20.61. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. Additionally, the KRAS biomarker testing revealed a mutation in the patient."
2214,0,"The patient is a 63-year-old white male with a BMI of 34.54. He is receiving the FOLFOX treatment arm for his cancer. Unfortunately, he has experienced a serious adverse effect during his treatment. He has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has a mutant KRAS status."
2215,0,The patient is a 45-year-old Black female with a BMI of 26.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2216,0,"The patient is a 51-year-old white female with a BMI of 37.23. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles. Her cancer histology is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2217,0,"The patient is a 58-year-old white male with a BMI of 29.56. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
2218,0,"The patient is a 52-year-old Black male with a BMI of 28.88. He is receiving the FOLFOX treatment arm and has experienced a bowel perforation. He has undergone 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
2219,0,The patient is a 69-year-old white male with a BMI of 29.59. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2220,0,"The patient is a 41-year-old white female with a BMI of 26.71. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2221,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has used narcotic medication for 2 days. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
2222,0,"The patient is a 75-year-old white male with a BMI of 37.18. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
2223,0,"The patient is a 44-year-old white female with a BMI of 29.07. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also experienced adverse effects in the form of diarrhea and infection."
2224,1,"The patient is a 56-year-old female of a race other than Caucasian, with a BMI of 25.24. She is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for her rectal cancer. The KRAS biomarker analysis revealed a mutant status."
2225,1,"The patient is a 70-year-old white male with a BMI of 30.93. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2226,0,"The patient is a 53-year-old white female with a BMI of 32.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2227,0,The patient is a 64-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2228,1,The patient is a 55-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around. She is experiencing nausea as an adverse effect of the treatment.
2229,1,"This patient is a 71-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. She is also experiencing a common adverse effect known as granulocytes/bands. This means that her body may be experiencing a decrease in a type of white blood cells called granulocytes, which are important for fighting infections."
2230,0,"The patient is a 42-year-old white female with a BMI of 22.79. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2231,1,The patient is a 55-year-old Black male with a BMI of 26.11. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
2232,1,"The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has only used narcotics for 1 day. Despite experiencing symptoms, she is still able to be ambulatory. The pathology results indicate malignancy."
2233,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. She spends less than 50% of her time in bed. The pathology report indicates a malignant condition.
2234,0,"The patient is a 61-year-old Black male with a BMI of 34.61. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
2235,1,"The patient is a 65-year-old white male with a BMI of 19.08 who is receiving treatment with the FOLFOX regimen. He has a performance status indicating that he is in bed less than 50% of the time. His primary tumor diagnosis is colon cancer, and he has a mutant KRAS biomarker."
2236,1,The patient is a 32-year-old white female with a BMI of 27.59 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that she has a wild-type status.
2237,1,The patient is a 61-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her granulocytes/bands and white blood cells.
2238,0,"The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 31.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker shows that it is wild-type."
2239,0,The patient is a male who is part of the conventional surgery treatment arm. He has not used any narcotics for pain relief. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2240,0,The patient is a 49-year-old white female with a BMI of 27.96. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2241,1,The patient is a 63-year-old white male with a performance status indicating symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
2242,1,"The patient is a 66-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
2243,1,The patient is a 67-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing fatigue as an adverse effect.
2244,0,The patient is a 41-year-old white male with a very low BMI of 15.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. His KRAS biomarker status is wild-type.
2245,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 19.4. She is fully active in terms of performance status. She has been diagnosed with a primary tumor in the colon and her KRAS biomarker status is wild-type. The patient is currently receiving treatment in the FOLFOX + Panitumumab treatment arm."
2246,0,"The patient is a 59-year-old white male with a BMI of 24.3 who is receiving treatment with the FOLFIRI regimen. He has been adherent to the treatment. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation after completing 9 cycles of chemotherapy. The histology of his cancer is well differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has been experiencing diarrhea as an adverse effect of the treatment."
2247,0,"The patient is a 62-year-old white male with a BMI of 29.62. He is receiving treatment with FOLFIRI due to having a KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. It is important to note that his KRAS biomarker is wild-type."
2248,1,"The patient is a 69-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2249,1,"The patient is a 72-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2250,0,The patient is a 49-year-old Black female with a performance status of experiencing symptoms but still able to walk around. She is enrolled in the treatment arm involving 5FU/LV + Radiation. The histology shows poorly differentiated characteristics.
2251,1,"The patient is a 34-year-old white male with a BMI of 28.32. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2252,0,"The patient is a 54-year-old white male with a BMI of 42.01. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2253,1,The patient is a 57-year-old white male with a BMI of 24.34 who is receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a mutant KRAS gene.
2254,0,"The patient is a 54-year-old white male with a BMI of 29.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type."
2255,1,The patient is a 48-year-old white male with a BMI of 26.83. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type.
2256,1,"The patient is a 72-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, which indicates an abnormality in certain types of white blood cells."
2257,0,"The patient is a female who is undergoing conventional surgery for a malignant condition. She has been using narcotics for 4 days to manage her symptoms, but is still able to walk around and be ambulatory."
2258,0,"This patient is a 60-year-old white male with a BMI of 25.21. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well differentiated. Despite the treatment, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type mutation."
2259,0,"The patient is a 43-year-old white female with a BMI of 19.95. She is receiving the FOLFIRI treatment regimen for her well-differentiated cancer with a KRAS mutation. She has completed 12 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2260,0,"The patient is a 73-year-old white male with a BMI of 25.78. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2261,0,The patient is a 56-year-old white male with a BMI of 28.52 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis shows that he has a wild-type KRAS status.
2262,0,"The patient is a 48-year-old white male with a BMI of 18.71. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
2263,1,"The patient is a 50-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). Additionally, the patient has developed a decrease in lymphocytes as an adverse effect of treatment."
2264,0,"The patient is a 44-year-old white female with a BMI of 33.41. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2265,0,"The patient is a 51-year-old white female with a BMI of 28.93. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2266,0,"The patient is a 57-year-old white male with a BMI of 27.06. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
2267,0,"The patient is a 62-year-old white male with a BMI of 22.31. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He experienced a bowel perforation during the course of treatment. He completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2268,0,"The patient is a 54-year-old white male with a BMI of 31.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
2269,1,"The patient is a 63-year-old white male with a BMI of 33.9. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that he has a mutant KRAS status."
2270,0,"The patient is a 58-year-old white female with a BMI of 22.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2271,1,"The patient is a 72-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. The patient has also developed adverse effects including low levels of granulocytes/bands and lymphocytes."
2272,0,"The patient is a 54-year-old Black male with a BMI of 25.98. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory. The KRAS biomarker indicates that he is wild-type. The patient has experienced hypersensitivity as an adverse effect."
2273,0,The patient is a 61-year-old white male with a BMI of 28.28. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant result.
2274,1,The patient is a 46-year-old white male who is currently receiving treatment in the ECF + Radiation arm. He has a performance status of symptoms but is still able to ambulate. The histology shows that he has poorly differentiated cancer cells.
2275,0,"The patient is a 75-year-old male of a race categorized as ""other"" with a BMI of 25.27. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. The patient experienced a serious adverse effect during the treatment. He completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, the patient has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
2276,0,"The patient is a 47-year-old white male with a BMI of 27.05. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2277,1,"The patient is a 59-year-old male of other race with a BMI of 18.4. He is currently receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. Despite experiencing symptoms, he is still ambulatory. The patient has a mutant KRAS biomarker and is experiencing adverse effects in the form of a rash and dermatitis acneiform."
2278,0,The patient is a 55-year-old white male with a BMI of 27.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2279,1,The patient is a 72-year-old white male participating in the FOLFOX treatment arm. He has a BMI of 23.6 and is fully active with no limitations in his performance status. The primary tumor diagnosis is colon cancer.
2280,0,The patient is a 51-year-old white male with a BMI of 27.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2281,0,"This patient is a 56-year-old male of a race categorized as ""other."" He is currently receiving treatment in the 5FU/LV + Radiation arm. He has previously undergone both chemotherapy and radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory. The histology of his condition is classified as poorly differentiated."
2282,1,"The patient is a 69-year-old white male with a BMI of 21.1 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to ambulate. The primary tumor diagnosis is rectal, and the KRAS biomarker shows that it is wild-type."
2283,0,"The patient is a 46-year-old white male with a BMI of 31.2. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. Additionally, he has experienced an infarction as an adverse effect."
2284,0,The patient is a 51-year-old Black male with a BMI of 30.32. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2285,0,"The patient is a 63-year-old Black female with a BMI of 18.91. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
2286,1,The patient is a 46-year-old white female with a BMI of 39.33. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2287,1,The patient is a 63-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
2288,0,The patient is a 64-year-old male of other race with a BMI of 28.82. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. The patient is receiving treatment with FOLFOX chemotherapy combined with Panitumumab.
2289,0,The patient is a 47-year-old white female with a BMI of 20.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2290,1,"The patient is a 73-year-old white male with a BMI of 26.06. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, he has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis has shown a mutant status."
2291,0,"The patient is a 34-year-old white female with a BMI of 23.03. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
2292,1,"The patient is a 65-year-old white male with a BMI of 23.89. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2293,0,The patient is a 63-year-old white male with a BMI of 37.98. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2294,1,"The patient is a 51-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing adverse effects such as low granulocytes/bands and nausea."
2295,0,The patient is a 66-year-old white female with a BMI of 25.78. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
2296,0,The patient is a 49-year-old white male who is fully active. He is currently receiving treatment with Sunitinib.
2297,1,This patient is a 64-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation therapy. The histology of the cancer is well differentiated. The patient is experiencing an adverse effect of decreased neutrophils/granulocytes.
2298,1,"The patient is a 77-year-old white male with a BMI of 20.27. He is currently receiving treatment with the FOLFOX regimen for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a mutant KRAS status."
2299,1,"The patient is a 63-year-old white female with a BMI of 30.43. She is receiving the FOLFOX treatment regimen and has experienced serious adverse effects during her 6 chemotherapy cycles. Her cancer histology is poorly differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a wild-type result. She has also experienced adverse effects in the form of thrombosis and infection."
2300,0,The patient is a 55-year-old white female with a BMI of 33.07. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
2301,1,The patient is a 64-year-old white male with a BMI of 27.36. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
2302,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. There have been complications during the treatment. He used narcotics for 6 days post-surgery. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
2303,0,"The patient is a 49-year-old white female with a BMI of 45.14. She is receiving treatment with FOLFOX and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates a mutant status."
2304,1,"The patient is a 76-year-old white male with a BMI of 27.48. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
2305,0,"The patient is a 67-year-old white female with a BMI of 18.76. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2306,0,"The patient is a 60-year-old white male with a BMI of 32.7. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2307,0,"The patient is a 46-year-old white female with a BMI of 25.06 who is receiving treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2308,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She used narcotics for 6 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates a malignant condition."
2309,0,"The patient is a 67-year-old white female with a BMI of 33.76. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. Additionally, the patient experienced an infarction as an adverse effect."
2310,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results showed well-differentiated cells, and the pathology report indicated that the condition was benign."
2311,1,The patient is a 45-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of her condition is poorly differentiated.
2312,0,The patient is a 51-year-old Black female with a BMI of 36.78. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2313,0,"The patient is a 58-year-old white male with a BMI of 24.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2314,0,"The patient is a 63-year-old white female with a BMI of 25.15. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2315,0,"The patient is a 35-year-old white male with a BMI of 24.02. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2316,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 2 days following the procedure. Their histology indicates that they were in bed less than 50% of the time, and the pathology results showed that the condition is malignant."
2317,1,"The patient is a 62-year-old white male participating in the treatment arm involving 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. Additionally, the patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
2318,0,The patient is a 46-year-old white male with a BMI of 36.42. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status.
2319,1,"The patient is a 72-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2320,1,The patient is a 52-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
2321,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
2322,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates a malignant condition."
2323,0,"The patient is a 43-year-old white male with a BMI of 29.05. He is receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2324,0,"The patient is a 64-year-old white male with a BMI of 31.87. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2325,1,The patient is a 63-year-old white female with a BMI of 23.04. She is fully active with a primary tumor diagnosis of rectal cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. The KRAS biomarker analysis shows a mutant status.
2326,1,"The patient is a 59-year-old male of a race categorized as ""other"" who is currently receiving treatment in the ECF + Radiation arm. He has a performance status of experiencing symptoms but is still able to walk around. The histology of the patient's condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
2327,0,"The patient is a 58-year-old white male with a BMI of 31.94. He is enrolled in the FOLFOX treatment arm and is adherent to the treatment. He has not yet started any chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2328,0,The patient is a 43-year-old white female with a BMI of 30.89. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
2329,0,"This patient is a 71-year-old white female receiving treatment with 5FU/LV + Radiation. She has a well-differentiated histology and spends less than 50% of her time in bed due to her performance status. She is experiencing anorexia as an adverse effect, which may be causing a loss of appetite or a decreased desire to eat."
2330,0,"The patient is a male who underwent conventional surgery and has bowel adhesions. He experienced complications post-surgery and required narcotic pain medication for 3 days. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
2331,0,"The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 32.8. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker status is wild-type."
2332,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. He is typically out of bed more than 50% of the time. The pathology report indicates a malignant condition.
2333,0,The patient is a 47-year-old black male with a performance status of having symptoms but still able to walk around. He is receiving treatment in the ECF + Radiation arm. The histology shows poorly differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
2334,1,"The patient is a 74-year-old white male with a BMI of 27.28. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2335,0,"The patient is a 59-year-old white female with a BMI of 30.19. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a mutant KRAS status."
2336,0,"The patient is a 59-year-old white male with a BMI of 25.8. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the serious adverse effect, the patient's performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
2337,1,The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed.
2338,0,"The patient is a 59-year-old white female with a BMI of 31.2. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2339,1,"The patient is a 68-year-old white male with a BMI of 25.54. He is in the FOLFIRI treatment arm for his KRAS mutant status. He has not started any chemotherapy cycles yet. His histology shows well-differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type."
2340,1,This patient is a 64-year-old white male with a BMI of 27.76. He is fully active and is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
2341,0,"The patient is a 68-year-old white female with a well-differentiated histology. She is part of the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, she is still able to walk and move around, indicating an ambulatory performance status."
2342,1,"The patient is a 44-year-old white female with a BMI of 22.58 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) despite her condition. She has been diagnosed with colon cancer, and her KRAS biomarker status is wild-type."
2343,0,"The patient is a 34-year-old white female with a BMI of 36.23. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
2344,0,"The patient is a 60-year-old white female with a BMI of 22.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker indicates that it is wild-type."
2345,1,"The patient is a 59-year-old white male with a BMI of 25.59. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with a primary colon tumor, and his KRAS biomarker status is wild-type."
2346,1,"The patient is a 74-year-old white male with a BMI of 29.06. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab, and the KRAS biomarker indicates a mutant status."
2347,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the patient has a malignant condition.
2348,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the cause of her symptoms is malignant.
2349,0,The patient is a 59-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
2350,0,The patient is a 63-year-old white male with a BMI of 29.21. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2351,1,"The patient is a 67-year-old white male with a BMI of 19.81. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2352,1,The patient is a 66-year-old white female with a BMI of 20.03. She is fully active and is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis revealed a mutant status.
2353,1,The patient is a 69-year-old white male with a BMI of 24.0. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status is wild-type.
2354,0,"The patient is a 27-year-old white female with a BMI of 18.2. She is fully active and is receiving treatment with the FOLFOX regimen. The primary tumor diagnosis is rectal cancer, and the KRAS biomarker indicates that it is wild-type."
2355,0,"The patient is a 36-year-old white female with a BMI of 23.78. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2356,0,"The patient is a 73-year-old white female with a BMI of 33.17. She is undergoing treatment with FOLFOX chemotherapy and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2357,0,"The patient is a 61-year-old white male with a BMI of 25.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2358,1,The patient is a 73-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy and radiation. The histology of his cancer is well-differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2359,0,"The patient is a 67-year-old white female with a BMI of 23.1. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status."
2360,1,"The patient is a 73-year-old white female with a BMI of 20.61 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. She has a mutant KRAS biomarker and is experiencing symptoms but is still able to be ambulatory. Additionally, she is experiencing dermatitis acneiform as an adverse effect of her treatment. This condition presents as acne-like skin rash or inflammation."
2361,1,"The patient is a 37-year-old white female with a BMI of 25.12. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2362,0,The patient is a 44-year-old white male with a BMI of 29.68. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2363,1,The patient is a 71-year-old white male with a BMI of 25.58. He is fully active and is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that the tumor is wild-type.
2364,0,"The patient is a male who underwent laparoscopic-assisted colectomy and experienced complications. He used narcotics for 3 days post-surgery. Despite having symptoms, he is able to walk around. The pathology report revealed a malignant condition."
2365,1,The patient is a 73-year-old white male with a BMI of 26.42 who is currently undergoing treatment with the FOLFOX regimen. He has a fully active performance status and has been diagnosed with a primary tumor in the colon.
2366,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 7 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate malignancy.
2367,0,"The patient is a 62-year-old white male with a BMI of 28.82. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
2368,0,"The patient is a 46-year-old white male with a BMI of 44.79. He is receiving the FOLFOX treatment regimen for his poorly differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker status is mutant."
2369,1,The patient is a 68-year-old female of other race with a BMI of 39.64. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker indicates it is mutant. The patient is experiencing acne as an adverse effect of the treatment with FOLFOX and Panitumumab.
2370,0,The patient is a 43-year-old white female with a BMI of 29.87. She is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker status is wild-type.
2371,0,"The patient is a 45-year-old white male with a BMI of 25.81. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles so far. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
2372,0,"The patient is a 72-year-old white male with a BMI of 22.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2373,1,"The patient is a 58-year-old white male with a BMI of 21.22. He is fully active and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal, and his KRAS biomarker status is wild-type."
2374,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
2375,1,"The patient is a 70-year-old white male who is part of the treatment arm receiving Cisplatin + Etoposide. He has not started any chemotherapy cycles yet. Despite experiencing symptoms, he is still able to walk around."
2376,0,"The patient is a 47-year-old white male with a BMI of 37.1. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
2377,1,"The patient is a 37-year-old white male with a BMI of 24.99. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infection as an adverse effect during his treatment."
2378,0,"The patient is a 60-year-old Black male with a BMI of 25.72. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2379,1,The patient is a 61-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
2380,0,"The patient is a 67-year-old white female with a BMI of 19.51 who is undergoing treatment with FOLFOX chemotherapy. She has experienced a serious adverse effect in the form of a bowel obstruction. Despite this, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect."
2381,0,"The patient is a 59-year-old white female with a BMI of 33.08. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2382,0,"The patient is a 74-year-old white female with a BMI of 20.8. She is receiving treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker status is indeterminate."
2383,0,The patient is a 62-year-old white male with a BMI of 26.13. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2384,0,The patient is a female who is part of the conventional surgery treatment arm. She has only used narcotics for 1 day. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2385,1,"The patient is a 55-year-old white female who is currently receiving treatment with Sunitinib. She has symptoms but is still able to walk around and be active, indicating that her performance status is relatively good despite experiencing some symptoms."
2386,1,"The patient is a 71-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has shown adverse effects on his granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
2387,1,"The patient is a 68-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has shown adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
2388,0,"The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications post-surgery. They used narcotics for 2 days following the procedure. The histology results showed that the tissue was well-differentiated, and the pathology results indicated that the condition was benign."
2389,0,"The patient is a 54-year-old white male with a BMI of 23.79. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate."
2390,1,The patient is a 59-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around.
2391,1,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. Despite experiencing symptoms, he is still able to be ambulatory. The pathology results indicate malignancy."
2392,0,"The patient is a 44-year-old white male with a BMI of 36.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2393,0,"The patient is a 64-year-old white female with a BMI of 28.29. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
2394,0,The patient is a male undergoing conventional surgery for a malignant condition. He has experienced symptoms but is still able to walk around. He has used narcotics for 2 days as part of his treatment.
2395,0,The patient is a 61-year-old white male participating in the treatment arm involving 5FU/LV and radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2396,1,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 4 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
2397,1,The patient is a 39-year-old white female with a BMI of 21.48 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker indicates that the patient has a mutant form of the gene.
2398,0,The patient is a 37-year-old white female with a BMI of 26.99. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
2399,0,"The patient is a 70-year-old white male with a history of prior cancer. He is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to move around independently. His histology shows well-differentiated cells."
2400,0,"The patient is a 50-year-old white female with a BMI of 35.78. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her diagnosis, she has a fully active performance status."
2401,0,"The patient is a 42-year-old white male with a BMI of 25.94. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2402,0,"The patient is a 51-year-old white male with a BMI of 28.68. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2403,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is able to move around. The pathology report indicates that the cause of her symptoms is malignant.
2404,0,"The patient is a 71-year-old white male with a BMI of 21.8. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2405,0,"The patient is a 65-year-old white male with a BMI of 23.77. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
2406,1,"The patient is a 46-year-old black female with a performance status of symptoms but still able to walk around. She is receiving treatment with ECF and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing anorexia as an adverse effect, which means she has a decreased appetite or loss of interest in food."
2407,0,"The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 28.91. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her diagnosis, she maintains a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2408,0,"The patient is a 42-year-old white female with a BMI of 18.94. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2409,0,"The patient is a 37-year-old white male with a BMI of 24.01. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel perforation and has completed 2 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2410,1,"The patient is a 78-year-old white female with a BMI of 22.28 who is currently receiving treatment with the FOLFOX regimen. She has symptoms related to her condition but is still able to walk around. Her primary tumor diagnosis is colon cancer, and her KRAS biomarker status is wild-type."
2411,0,"The patient is a 49-year-old Black female with a BMI of 45.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced adverse effects of diarrhea and infection during her treatment."
2412,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 1 day. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
2413,1,"The patient is a 60-year-old white male with a BMI of 22.65. He is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm for this patient is FOLFOX and Panitumumab, and his KRAS biomarker status is mutant."
2414,0,"The patient is a 53-year-old Black female with a BMI of 25.58. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2415,0,"The patient is a 45-year-old white female with a BMI of 21.21. She is receiving the FOLFIRI treatment regimen for KRAS mutant status and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker for this patient is wild-type."
2416,0,"The patient is a 76-year-old Black male with a BMI of 27.12. He is currently receiving treatment with the FOLFOX regimen for his cancer. He has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2417,1,The patient is a 59-year-old white female with a BMI of 22.86. She is fully active and is receiving treatment with FOLFOX and Panitumumab for her colon cancer. Her KRAS biomarker status is wild-type.
2418,1,"The patient is a 56-year-old white male with a BMI of 24.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a serious adverse effect in the form of thrombosis after completing 5 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a performance status of experiencing symptoms but still being able to ambulate. The KRAS biomarker testing showed that he has a wild-type KRAS status."
2419,0,"The patient is a 75-year-old white male with a BMI of 24.49. He is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm for this patient is FOLFOX and Panitumumab, and the KRAS biomarker indicates a mutant status."
2420,1,"The patient is a 51-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate."
2421,1,"The patient is a 52-year-old white female with a BMI of 19.63 who is currently receiving treatment with the FOLFOX regimen. She has symptoms related to her condition but is still able to walk around (ambulatory). Her primary tumor diagnosis is colon cancer, and her KRAS biomarker status is wild-type."
2422,0,"The patient is a 40-year-old Black male with a BMI of 21.61. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Despite this, his performance status is fully active. The patient has a mutant KRAS biomarker and has also experienced thrombosis as an adverse effect."
2423,1,"The patient is a 39-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating that his performance status is relatively good."
2424,1,"The patient is a 73-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. He has experienced weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has also developed adverse effects related to his granulocytes/bands and white blood cells."
2425,0,"The patient is a 52-year-old white female with a BMI of 26.68. She is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea and infection as adverse effects, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
2426,0,The patient is a 40-year-old white male with a BMI of 39.41. He is receiving FOLFIRI treatment for his well-differentiated cancer with a KRAS mutation. He has completed 10 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced thrombosis as an adverse effect.
2427,0,"The patient is a 72-year-old white male with a well-differentiated histology who is currently receiving treatment with ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, the patient is still able to ambulate. Additionally, the patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
2428,1,"The patient is a 62-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
2429,0,"The patient is a 54-year-old white female with a BMI of 40.83. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not yet started chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2430,1,"The patient is a 69-year-old male of a race categorized as ""other"" who is currently undergoing treatment in the ECF + Radiation arm. He has a performance status indicating that he is experiencing symptoms but is still able to walk around. The histology of the patient's condition is classified as poorly differentiated."
2431,0,"This patient is a 45-year-old white female with a BMI of 30.62. She is receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2432,1,"The patient is a 45-year-old Black or African American male with a BMI of 22.44. He is currently receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2433,0,"The patient is a 59-year-old white female with a BMI of 25.07 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2434,0,"The patient is a 46-year-old white male with a BMI of 38.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2435,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2436,1,"The patient is a 51-year-old white male with a BMI of 27.14 who is currently receiving treatment with the FOLFOX regimen. He has symptoms related to his condition but is still able to be ambulatory. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
2437,1,"The patient is a 49-year-old white male with a BMI of 31.44. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
2438,0,"The patient is a 55-year-old white female with a BMI of 22.54. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2439,1,"The patient is a 40-year-old white male with a BMI of 26.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
2440,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is able to walk around. The pathology report indicates that the condition is malignant.
2441,1,"The patient is a 43-year-old white male with a BMI of 36.1 who is receiving the FOLFOX treatment regimen for 12 chemotherapy cycles. His cancer histology is well differentiated, and he has symptoms but is still ambulatory. The KRAS biomarker shows that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2442,0,"The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has been using narcotics for 5 days. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
2443,1,The patient is a 65-year-old white female with a BMI of 24.2. She is fully active with a primary tumor diagnosis of rectal cancer. She is enrolled in the FOLFOX + Panitumumab treatment arm. Her KRAS biomarker status is wild-type.
2444,0,"The patient is a 54-year-old white male with a BMI of 30.65. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
2445,0,The patient is a 54-year-old white male with a BMI of 29.24. He is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2446,1,"The patient is a 57-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
2447,1,The patient is a 56-year-old Black male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. He is experiencing an adverse effect of low neutrophils/granulocytes.
2448,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. She is experiencing symptoms but is still able to be ambulatory. The pathology report indicated that the cause of her symptoms is malignant.
2449,0,The patient is a 55-year-old white male with a BMI of 29.59. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2450,1,This patient is a 62-year-old white male with a BMI of 27.73. He is fully active and is receiving treatment with FOLFOX for colon cancer. His KRAS biomarker status is wild-type.
2451,0,"The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 16.88. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker testing has revealed a mutant status."
2452,1,"The patient is a 74-year-old white male with a BMI of 29.45. He is currently receiving the FOLFIRI treatment regimen and has completed 3 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a mutant KRAS status."
2453,0,"The patient is a 50-year-old white female with a BMI of 32.78 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect during her 11 chemotherapy cycles. The histology of her cancer is well differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2454,0,"The patient is a 73-year-old white male with a BMI of 25.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant."
2455,0,The patient is a 64-year-old white male with a BMI of 20.55. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. The KRAS biomarker analysis revealed a mutant status.
2456,1,"The patient is a 57-year-old white male with a BMI of 23.03. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
2457,0,"The patient is a 73-year-old white female with a BMI of 34.84. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
2458,0,"The patient is a 57-year-old Black female with a BMI of 37.02. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2459,1,The patient is a 56-year-old white male with a BMI of 25.06. He is fully active and his primary tumor diagnosis is colon cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
2460,1,The patient is a 72-year-old white male with a BMI of 24.77. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is mutant. He is receiving treatment in the FOLFOX treatment arm.
2461,0,The patient is a 70-year-old white female with a BMI of 18.07. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
2462,0,"The patient is a 60-year-old white female with a BMI of 20.68. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
2463,0,The patient is a 68-year-old white female with a BMI of 25.39. She is fully active and is receiving treatment with FOLFOX and Panitumumab for her colon cancer. The KRAS biomarker indicates that she has a wild-type status.
2464,1,"This patient is a 61-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated. Additionally, he is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
2465,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology report indicates that the condition is malignant.
2466,0,The patient is a 38-year-old white male with a BMI of 34.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2467,0,"The patient is a 54-year-old white male with a BMI of 32.05. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 4 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker analysis indicates a wild-type result."
2468,0,"The patient is a 46-year-old white male with a BMI of 25.97. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2469,0,The patient is a 52-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated.
2470,1,"The patient is a 61-year-old Black male who is currently receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around."
2471,0,"The patient is a 53-year-old white female with a BMI of 29.55. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2472,0,"The patient is a 62-year-old white male with a BMI of 21.87. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2473,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 5 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
2474,0,The patient is a 56-year-old white female with a BMI of 25.47 who is fully active. She is receiving treatment with the FOLFOX regimen for colon cancer. The KRAS biomarker analysis revealed a mutant status.
2475,0,"The patient is a 45-year-old white male with a BMI of 28.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
2476,0,"The patient is a 67-year-old white female with a BMI of 25.89. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
2477,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the procedure. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2478,0,"The patient is a 57-year-old white female with a BMI of 24.33. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that she has a mutant form."
2479,1,This patient is a 70-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
2480,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. She spent less than 50% of her time in bed. The pathology report indicated a malignant condition.
2481,0,"The patient is a 48-year-old white male with a BMI of 25.73. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2482,0,The patient is a 63-year-old white male with a BMI of 24.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2483,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He experienced complications and used narcotics for 7 days post-surgery. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
2484,0,"The patient is a 45-year-old white male with a BMI of 27.74. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker status is mutant."
2485,1,The patient is a 65-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
2486,1,"The patient is a 68-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
2487,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
2488,1,The patient is a 71-year-old white male with a BMI of 31.2. He is fully active and is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis showed a mutant status.
2489,1,"The patient is a 60-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient has developed low white blood cell count and is also experiencing nausea as adverse effects of the treatment."
2490,0,The patient is a 56-year-old white male with a BMI of 25.91 who is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced a hypersensitivity reaction as an adverse effect.
2491,1,"The patient is a 54-year-old white female with a BMI of 20.31. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2492,1,"The patient is a 77-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
2493,1,The patient is a 66-year-old white male with a BMI of 23.81. He is fully active and is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS gene.
2494,0,"The patient is a 38-year-old Black female with a BMI of 23.67. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2495,1,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows well-differentiated cells.
2496,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, along with some complications post-surgery. He used narcotics for 3 days following the procedure. Despite experiencing symptoms, he is able to move around and be ambulatory. The pathology report indicates malignancy."
2497,0,The patient is a male undergoing conventional surgery for a malignant condition. He has experienced symptoms but is still able to move around. He has only used narcotics for 1 day.
2498,0,The patient is a 71-year-old white male with a BMI of 36.98. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2499,1,"The patient is a 52-year-old white male with a BMI of 22.98. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. His performance status is fully active. The KRAS biomarker shows that he has a wild-type mutation."
2500,0,"The patient is a 52-year-old female of a race categorized as ""other"" with a BMI of 26.76. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutation in the patient."
2501,0,The patient is a 72-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and Radiation therapy. The histology of her condition is poorly differentiated. She is experiencing an adverse effect related to her neutrophils/granulocytes.
2502,1,The patient is a female undergoing conventional surgery as part of her treatment. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2503,0,"The patient is a 60-year-old Black male with a BMI of 35.17. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. Histologically, the tumor is well-differentiated. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
2504,0,"The patient is a 62-year-old white female with a BMI of 27.55. She is receiving treatment with the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2505,0,The patient is a 51-year-old white male with a BMI of 48.85. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type result.
2506,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required narcotic pain medication for 3 days. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
2507,1,The patient is a 50-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
2508,1,The patient is a 53-year-old male of other race with a BMI of 24.8. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the rectum. His KRAS biomarker status is wild-type. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab.
2509,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2510,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2511,0,"The patient is a 37-year-old white male with a BMI of 29.1. He is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
2512,0,The patient is a 60-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV and radiation. She has a histology of poorly differentiated cancer and is experiencing fatigue as an adverse effect.
2513,0,"This patient is a 76-year-old white male with a BMI of 27.22. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel perforation, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2514,0,The patient is a 66-year-old white male with a BMI of 21.88 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
2515,1,The patient is a 66-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows that the cancer cells are well-differentiated.
2516,1,The patient is a 67-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects related to neutrophils/granulocytes and leukocytes.
2517,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions, as well as experienced complications post-surgery. She used narcotics for 2 days. Histology shows that she spent less than 50% of her time in bed. The pathology report indicates malignancy."
2518,1,"The patient is a 59-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
2519,0,"The patient is a 55-year-old white female with a BMI of 20.46. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2520,0,"The patient is a 39-year-old white female with a BMI of 27.55. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
2521,0,"The patient is a 64-year-old white female with a BMI of 27.82. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2522,0,"The patient is a 41-year-old white male with a BMI of 26.57. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has reported experiencing hypersensitivity as an adverse effect."
2523,1,"The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 3 days post-surgery. The histology showed symptoms, but the patient was still able to walk around. The pathology results indicated a malignant condition."
2524,0,"The patient is a 75-year-old white female with a BMI of 31.88. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2525,0,The patient is a 67-year-old white female with a BMI of 23.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
2526,0,"The patient is a 44-year-old Black male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite this, he is still able to ambulate, although he is experiencing symptoms related to his treatment."
2527,1,The patient is a 48-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects of low neutrophil/granulocyte levels and is also dealing with nausea.
2528,0,"The patient is a 45-year-old white male with a BMI of 32.03 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2529,0,The patient is a 57-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
2530,0,"The patient is a 70-year-old white male with a BMI of 25.54. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2531,0,"The patient is a 42-year-old white male with a BMI of 28.47. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient's performance status is fully active, and the KRAS biomarker indicates that he has a wild-type status."
2532,0,"The patient is a 48-year-old white male with a BMI of 39.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has symptoms but is still able to be ambulatory. The KRAS biomarker shows that he is wild-type. Additionally, the patient has experienced a thrombosis as an adverse effect."
2533,0,"The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 22.5. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab. The patient has been adherent to the treatment. He has experienced a bowel perforation. However, he has not undergone any chemotherapy cycles yet. The histology shows well-differentiated cells. The patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
2534,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to move around. The pathology report indicates that the condition is malignant.
2535,0,"The patient is a 45-year-old white male with a BMI of 27.87. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is well-differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2536,0,"The patient is a 59-year-old white female with a BMI of 28.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a mutant status."
2537,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 6 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
2538,0,The patient is a 40-year-old white male with a BMI of 28.33. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
2539,1,The patient is a 60-year-old white female with a BMI of 23.26. She is fully active with a performance status. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor diagnosis.
2540,0,"The patient is a 57-year-old white female with a BMI of 22.39. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
2541,0,"The patient is a 63-year-old white male with a BMI of 24.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
2542,0,"The patient is a 46-year-old white male with a BMI of 32.71 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect during treatment. He has completed 7 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. Additionally, the patient has developed thrombosis as an adverse effect."
2543,1,The patient is a 51-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory). She is experiencing a common adverse effect known as granulocytes/bands.
2544,1,"This patient is a 67-year-old white female with a BMI of 33.8 who is undergoing treatment with FOLFOX + Cetuximab for well-differentiated histology. She has completed 12 cycles of chemotherapy and has been adherent to her treatment. However, she experienced a serious adverse effect in the form of bowel perforation. Additionally, she has a mutant KRAS biomarker and has also developed thrombosis as an adverse effect. Despite experiencing symptoms, she is still ambulatory and has a performance status that allows her to carry out daily activities."
2545,0,"This patient is a 71-year-old female of a race categorized as ""other"" with a BMI of 21.6. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. Unfortunately, she has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
2546,1,"This patient is a 49-year-old white female who has not yet started chemotherapy treatment. She is assigned to the treatment arm that includes Cisplatin, Etoposide, and Paclitaxel. Despite not having undergone any chemotherapy cycles yet, her performance status is fully active, indicating that she is in good physical condition."
2547,0,"The patient is a 34-year-old white female with a BMI of 24.97. She is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2548,1,"The patient is a 45-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low granulocytes/bands and low white blood cell counts, as well as experiencing nausea."
2549,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 4 days. Histology results indicate that she spent less than 50% of her time in bed, and the pathology report revealed a malignant condition."
2550,0,"The patient is a 74-year-old white male with a BMI of 28.77. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2551,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
2552,0,"The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 22.31. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and she has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2553,0,"The patient is a 65-year-old white female with a BMI of 35.97. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles so far. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2554,1,"The patient is a 75-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she has developed a decrease in granulocytes/bands as an adverse effect of the treatment."
2555,0,"The patient is a 76-year-old white male with a BMI of 23.35. He is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His cancer histology is well-differentiated, and he has a performance status of fully active. The KRAS biomarker status is indeterminate for this patient."
2556,0,"The patient is a 70-year-old white male with a BMI of 28.76. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2557,1,"The patient is a 73-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 5 cycles of chemotherapy and has a fully active performance status. The patient is experiencing a common adverse effect known as granulocytes/bands, which refers to a decrease in a type of white blood cell called granulocytes, specifically bands."
2558,0,"The patient is a 39-year-old Black male with a BMI of 30.99. He is receiving the FOLFOX treatment arm for his colorectal cancer. He has experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
2559,1,"The patient is a 38-year-old white female receiving treatment with a combination of Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around and carry out daily activities, indicating an ambulatory performance status."
2560,1,"The patient is a 56-year-old white male with a BMI of 30.04. He is receiving treatment with the FOLFIRI regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
2561,0,The patient is a 69-year-old Black male with a BMI of 26.71. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2562,0,"The patient is a 72-year-old Black female with a BMI of 27.51. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
2563,0,"The patient is a 41-year-old white female with a BMI of 27.23 who is receiving the FOLFOX treatment regimen. She experienced a serious adverse effect during treatment. She completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active. The KRAS biomarker analysis showed that she has a wild-type KRAS status. Additionally, she experienced an adverse effect of thrombosis during her treatment."
2564,1,"The patient is a 71-year-old white male with a BMI of 20.52. He is currently receiving treatment with FOLFOX for rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
2565,0,"The patient is a 68-year-old white female with a BMI of 23.59. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2566,0,The patient is a 43-year-old white male with a BMI of 26.91. He is currently receiving treatment in the FOLFIRI treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2567,1,"The patient is a 68-year-old white male with a history of prior cancer. He is currently receiving treatment in the ECF + Radiation arm. Despite his age, he has a fully active performance status. The histology of his cancer is poorly differentiated."
2568,1,The patient is a 45-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
2569,0,"The patient is a 69-year-old white male with a BMI of 36.76. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2570,0,"The patient is a 39-year-old white female with a BMI of 32.3. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
2571,0,"The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 22.03. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated, and his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2572,1,"The patient is a 48-year-old female of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is described as fully active. The patient has also developed an adverse effect related to her granulocytes/bands."
2573,0,"The patient is a 56-year-old male of a race categorized as ""other"" with a BMI of 26.57. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status, and his KRAS biomarker is wild-type."
2574,0,"The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 24.68. He is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. The histology indicates that the cancer cells are well-differentiated. The patient has a fully active performance status and the KRAS biomarker shows that it is wild-type."
2575,1,The patient is a 57-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. His histology shows poorly differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
2576,1,The patient is a 58-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
2577,0,The patient is a 65-year-old white female with a performance status of symptoms but still able to walk around (ambulatory). She is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
2578,0,"The patient is a 68-year-old white male with a BMI of 26.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2579,0,"The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 22.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2580,0,"The patient is a 57-year-old white male with a BMI of 28.89. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient's KRAS biomarker is mutant."
2581,1,"The patient is a 46-year-old white male with a BMI of 31.15. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2582,1,"The patient is a 59-year-old female of a race other than specified, receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 8 chemotherapy cycles. Her performance status indicates that she is spending less than 50% of her time in bed. She is experiencing an adverse effect on her white blood cells."
2583,1,"The patient is a 62-year-old white female with a BMI of 20.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a serious adverse effect during her treatment. So far, she has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
2584,1,"The patient is a 46-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, which indicates an abnormality in the white blood cell count."
2585,0,The patient is a 51-year-old white female with a BMI of 45.58 who is currently receiving treatment with the FOLFOX regimen. She has a fully active performance status and has been diagnosed with a primary tumor in the colon.
2586,0,"The patient is a 75-year-old white male with a BMI of 25.28. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2587,0,"The patient is a 70-year-old male of a race other than specified, who is currently receiving treatment with 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology of the patient's condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
2588,0,"The patient is a 47-year-old male of ""other"" race with a BMI of 21.71. He is currently receiving treatment in the FOLFOX chemotherapy arm and has completed one cycle of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active, indicating that he is able to carry out his daily activities without limitations. Additionally, his KRAS biomarker status is wild-type."
2589,0,"The patient is a 75-year-old white male with a BMI of 31.14. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2590,0,"The patient is a 50-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment arm for his cancer and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his cancer treatment, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2591,0,"The patient is a 50-year-old white female with a BMI of 40.1. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
2592,1,"The patient is a 74-year-old white female with a BMI of 27.58. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2593,1,"The patient is a 56-year-old black female undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite this, she is still able to ambulate with symptoms. The patient has also developed a decrease in granulocytes/bands as an adverse effect of the treatment."
2594,0,"The patient is a 49-year-old white male with a BMI of 27.21. He is receiving treatment with FOLFOX + Cetuximab. He has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his condition is well differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that it is mutant."
2595,0,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2596,0,"This patient is a 61-year-old white female with a BMI of 34.52. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has also experienced adverse effects such as diarrhea and infection."
2597,0,"This patient is a 49-year-old white female with a BMI of 20.17. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2598,1,The patient is a 60-year-old white male with a BMI of 26.51. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
2599,0,The patient is a 46-year-old white male with a BMI of 24.69. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2600,0,"The patient is a 67-year-old white male with a BMI of 42.05. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type gene."
2601,1,The patient is a 67-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects with low neutrophils/granulocytes and leukocytes.
2602,0,"The patient is a 63-year-old white male with a BMI of 55.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his high BMI, his performance status is fully active, indicating that he is able to carry out daily activities without limitations. Additionally, the KRAS biomarker analysis revealed that he has a wild-type KRAS status."
2603,0,"The patient is a 58-year-old female of a race other than specified, with a BMI of 36.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced serious adverse effects after one chemotherapy cycle. The histology shows that the cancer is well-differentiated. Despite the serious adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type. Additionally, the patient has experienced adverse effects of thrombosis and infarction."
2604,1,"The patient is a 57-year-old white female with a BMI of 28.55. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker testing revealed that she has a mutant KRAS gene."
2605,0,"The patient is a 67-year-old white male with a BMI of 27.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite being fully active, he has tested positive for a mutant KRAS biomarker. Additionally, he has experienced an infection as an adverse effect of his treatment."
2606,0,The patient is a 75-year-old white male with a BMI of 28.52. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2607,1,The patient is a 63-year-old white female participating in the placebo treatment arm of the study. She is experiencing symptoms but is still able to move around independently.
2608,1,"This patient is a 75-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. She has experienced significant weight loss of more than 5-10%. Despite this, she maintains a fully active performance status. However, she has developed adverse effects related to her blood counts, specifically a decrease in granulocytes/bands and white blood cells."
2609,1,The patient is a 63-year-old white male with a BMI of 29.09. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type. He is receiving treatment with the FOLFOX regimen.
2610,0,"The patient is a 58-year-old white male with a BMI of 26.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
2611,1,"This patient is a 73-year-old white female with a BMI of 36.51. She is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker in her tumor is wild-type."
2612,1,"The patient is a 71-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects including low granulocytes/bands, low white blood cells, and nausea."
2613,0,"The patient is a 71-year-old white male with a BMI of 27.96. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
2614,0,"The patient is a 56-year-old white male with a BMI of 27.22. He is receiving the FOLFOX treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2615,0,"The patient is a 69-year-old white female with a BMI of 19.81. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active, indicating that she is able to carry out her daily activities without limitations. Additionally, her KRAS biomarker status is wild-type."
2616,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the complications, he was able to remain ambulatory with symptoms. The pathology report revealed malignant findings."
2617,0,The patient is a 59-year-old black male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
2618,0,"The patient is a 54-year-old white male with a BMI of 36.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2619,0,"The patient is a 70-year-old white male with a BMI of 35.25. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has the wild-type variant."
2620,1,"The patient is a 65-year-old white female with a BMI of 26.45. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2621,1,The patient is a 45-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
2622,1,"The patient is a 75-year-old white male with a BMI of 26.33. He is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to walk around. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
2623,0,"The patient is a 59-year-old white female with a BMI of 27.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
2624,1,"The patient is a 64-year-old white male with a BMI of 22.07. He is currently receiving treatment with FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows that it is wild-type."
2625,0,The patient is a 67-year-old white male with a BMI of 29.0. He is fully active and is receiving treatment with FOLFOX for colon cancer. His KRAS biomarker status is wild-type.
2626,0,The patient is a 44-year-old white male with a BMI of 22.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2627,1,The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to move around. The pathology report indicates malignancy.
2628,0,The patient is a male who is undergoing conventional surgery for a malignant condition. He has experienced symptoms but is still able to be ambulatory. He has used narcotics for 2 days as part of his treatment.
2629,0,"The patient is a 74-year-old white female with a BMI of 26.52. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
2630,0,"The patient is a 53-year-old male of other race with a BMI of 27.22. He is fully active in terms of performance status. The primary tumor diagnosis is colon, and the KRAS biomarker status is wild-type. The patient is receiving treatment in the FOLFOX + Panitumumab treatment arm."
2631,1,"The patient is a 51-year-old white male with a BMI of 48.35. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2632,1,"The patient is a 68-year-old white female with a BMI of 25.89. She is fully active and her primary tumor diagnosis is colon cancer. She is receiving treatment with FOLFOX and Panitumumab, and her KRAS biomarker status is mutant."
2633,0,The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery. He used narcotics for 2 days. The histology report indicates that he was in bed less than 50% of the time. The pathology report shows that the condition was malignant.
2634,1,"The patient is a 62-year-old white male with a BMI of 22.16. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the patient has a mutant KRAS biomarker."
2635,1,The patient is a 62-year-old white male with a BMI of 26.14. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
2636,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications post-surgery. They used narcotics for 6 days following the procedure. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated that the condition was malignant.
2637,0,"The patient is a 52-year-old white male with a BMI of 35.95 who is receiving the FOLFOX treatment regimen. He has experienced serious adverse effects during his 11 chemotherapy cycles, including thrombosis and hypersensitivity reactions. His cancer histology is poorly differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a wild-type result."
2638,1,"The patient is a 55-year-old white female with a BMI of 22.22. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is mutant."
2639,0,The patient is a 53-year-old white female with a BMI of 26.57. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment.
2640,0,"The patient is a 38-year-old white female with a BMI of 30.98 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has experienced a serious adverse effect in the form of diarrhea during her treatment."
2641,0,"The patient is a 67-year-old white female with a BMI of 37.01. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
2642,1,"The patient is a 72-year-old white male with a BMI of 32.89. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
2643,1,"The patient is a 61-year-old white female with a BMI of 34.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2644,0,The patient is a 67-year-old white female with a fully active performance status who is receiving treatment with a placebo.
2645,0,The patient is a 50-year-old white female with a BMI of 25.35. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows a mutant result.
2646,1,"The patient is a 69-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. He is currently experiencing adverse effects such as low levels of granulocytes/bands and nausea."
2647,0,The patient is a 47-year-old white female with a BMI of 32.87. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. Her KRAS biomarker status is wild-type.
2648,0,"The patient is a 53-year-old white male with a BMI of 25.18. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
2649,0,"The patient is a 76-year-old white female with a BMI of 40.87. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2650,1,"The patient is a 74-year-old Black male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to ambulate."
2651,1,"The patient is a 45-year-old female of a race categorized as ""other"" who is undergoing treatment with Cisplatin + Etoposide. She has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she has shown adverse effects including low levels of granulocytes/bands and nausea."
2652,0,"The patient is a 57-year-old white female with a BMI of 21.22. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker analysis showed a mutant result."
2653,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2654,1,"The patient is a 66-year-old white male with a BMI of 23.53. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
2655,0,"The patient is a 59-year-old white male with a BMI of 28.88. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 8 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
2656,0,"The patient is a 41-year-old white male with a BMI of 23.91. He is currently receiving treatment with the FOLFOX regimen. He has experienced a bowel perforation and has completed one cycle of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
2657,1,"The patient is a 64-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to ambulate."
2658,0,"The patient is a 60-year-old white male with a BMI of 26.36. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2659,0,"The patient is a 74-year-old white male with a BMI of 26.92 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. His KRAS biomarker indicates that it is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
2660,0,"The patient is a 65-year-old white male with a BMI of 31.94. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2661,0,"The patient is a 42-year-old male of a race categorized as ""other"" with a BMI of 23.31. He is undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2662,0,This patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
2663,0,The patient is a 72-year-old white male with a BMI of 22.85. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2664,0,The patient is a 47-year-old white female with a BMI of 29.74 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. Her KRAS biomarker status is wild-type.
2665,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the patient has a malignant condition.
2666,0,"The patient is a 50-year-old white male with a BMI of 30.43. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2667,0,The patient is a 53-year-old white male with a BMI of 34.43. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2668,0,"The patient is a 72-year-old white female with a BMI of 19.99. She is receiving treatment with FOLFOX and Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
2669,0,"The patient is a 61-year-old white female with a BMI of 43.41. She is undergoing treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
2670,0,"The patient is a 64-year-old white male with a BMI of 32.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type status."
2671,1,"The patient is a 50-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a performance status of fully active."
2672,0,"The patient is a 68-year-old female of a race categorized as ""other"" with a BMI of 19.42. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
2673,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
2674,0,The patient is a 53-year-old white male with a BMI of 36.73. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment.
2675,0,"The patient is a 51-year-old white female with a BMI of 27.35. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2676,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. He spends less than 50% of his time in bed. The pathology report indicates a malignant condition.
2677,0,"The patient is a 49-year-old white female with a BMI of 25.68. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2678,1,"The patient is a 51-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has developed adverse effects including low granulocytes/bands and low white blood cell count."
2679,0,"The patient is a 73-year-old white female with a BMI of 24.56. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 11 chemotherapy cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
2680,0,"The patient is a 51-year-old white female with a BMI of 25.01. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2681,0,The patient is a 64-year-old white male with a BMI of 21.21. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2682,0,"The patient is a 63-year-old white female with a BMI of 25.66. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
2683,0,"The patient is a 53-year-old white female with a BMI of 28.69. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
2684,1,"The patient is a 67-year-old white female with a BMI of 23.43. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Additionally, the KRAS biomarker analysis indicates that she has a mutant KRAS status."
2685,0,"This patient is a 57-year-old white female with a BMI of 32.88. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her 12 chemotherapy cycles. The histology of her cancer is well-differentiated, and her performance status is fully active."
2686,0,"The patient is a 72-year-old white male with a BMI of 23.27. He is currently undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2687,0,"The patient is a 76-year-old male of a race categorized as ""other"" with a BMI of 22.44. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed chemotherapy regimen for 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker status is wild-type."
2688,0,"The patient is a 65-year-old white female with a BMI of 18.75. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2689,0,"The patient is a 53-year-old Black male with a BMI of 33.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
2690,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has experienced complications. She used narcotics for 6 days post-surgery. The histology shows that she is in bed less than 50% of the time, and the pathology report indicates malignancy."
2691,1,"The patient is a 72-year-old white male with a BMI of 28.39 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
2692,1,"The patient is a 74-year-old white male with a BMI of 26.26 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker shows that he has a wild-type status. Additionally, the patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which is a skin condition characterized by acne-like eruptions."
2693,1,"The patient is a 53-year-old white male with a BMI of 30.22. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed chemotherapy cycles, completing all 12 cycles. His tumor histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he has experienced an infection as an adverse effect during his treatment."
2694,1,"The patient is a 57-year-old white male with a BMI of 24.24. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
2695,0,"The patient is a 46-year-old female of a race categorized as ""other"" with a BMI of 29.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2696,1,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotics for 2 days as part of her treatment.
2697,0,"The patient is a 34-year-old white male with a BMI of 22.81. He is receiving treatment with the FOLFOX regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2698,0,The patient is a 42-year-old white male with a BMI of 22.46. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2699,1,"The patient is a 66-year-old white female with a BMI of 19.36. She is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker indicates that she has a wild-type status. Additionally, she is experiencing acne as an adverse effect of the treatment."
2700,0,"The patient is a 60-year-old white female with a BMI of 22.03. She is receiving the FOLFOX treatment regimen for her cancer, with a planned total of 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite undergoing treatment, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2701,0,"The patient is a 47-year-old white female with a BMI of 22.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2702,0,"The patient is a 60-year-old white male with a BMI of 28.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
2703,0,"The patient is a 40-year-old white male with a BMI of 22.9. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2704,1,"The patient is a 70-year-old white female with a BMI of 26.19 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect, which presents as a skin rash resembling acne."
2705,1,"The patient is a 78-year-old white male with a BMI of 22.79 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker testing revealed that the patient has a mutant KRAS status."
2706,0,"The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 22.75. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his condition is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, his KRAS biomarker status is wild-type."
2707,0,"The patient is a 74-year-old white male with a BMI of 28.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2708,1,"The patient is a 46-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around, indicating that his performance status is relatively good."
2709,0,"The patient is a 72-year-old female of a race other than Caucasian. She has a BMI of 31.87 and is undergoing treatment with the FOLFOX regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has been adherent to her treatment. However, she has experienced a serious adverse effect. Despite this, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
2710,1,"The patient is a 66-year-old white male who is currently receiving treatment in the ECF + Radiation arm. He has a history of prior cancer, prior chemotherapy, and prior radiation therapy. Despite experiencing symptoms, he is still ambulatory. The histology of his cancer is poorly differentiated."
2711,0,"The patient is a 62-year-old white female with a BMI of 34.87. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2712,0,"The patient is a 64-year-old white female with a BMI of 19.61 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and she has a mutant KRAS biomarker."
2713,1,"The patient is a 38-year-old white male with a BMI of 23.08. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker for this patient is mutant."
2714,1,"The patient is a 58-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 6 chemotherapy cycles. She has a fully active performance status. The patient is experiencing adverse effects related to her blood counts, specifically a decrease in granulocytes/bands and white blood cells."
2715,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 25.96. She is currently undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2716,0,"The patient is a 65-year-old white male with a BMI of 32.15. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status."
2717,1,The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. His performance status indicates that he is in bed less than 50% of the time.
2718,0,"This patient is a 67-year-old Black female with a BMI of 31.47. She is receiving the FOLFIRI chemotherapy regimen for her KRAS mutant status. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2719,1,"The patient is a 59-year-old white male with a BMI of 31.0 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a wild-type KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
2720,0,"The patient is a 56-year-old Black female with a BMI of 27.03. She is receiving the FOLFIRI treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite undergoing treatment, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type status."
2721,0,"The patient is a 46-year-old white male with a BMI of 23.56. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2722,0,"The patient is a 48-year-old white male with a BMI of 22.72. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
2723,0,"The patient is a 76-year-old white male with a BMI of 32.14. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2724,0,"The patient is a 71-year-old male of a race categorized as ""other"" with a BMI of 24.69. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced diarrhea as an adverse effect of the treatment."
2725,1,The patient is a 69-year-old white male with a BMI of 30.78. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type.
2726,1,"The patient is a 70-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. Despite experiencing symptoms, he is still able to ambulate, indicating a moderate performance status."
2727,1,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to move around. She has used narcotics for 2 days.
2728,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 2 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
2729,0,"The patient is a 57-year-old white female with a BMI of 19.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has undergone 12 chemotherapy cycles and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
2730,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 7 days. The histology shows that she is in bed less than 50% of the time, and the pathology report indicates malignancy."
2731,0,"The patient is a 68-year-old male of a race other than specified, who is fully active with a poorly differentiated histology. He is receiving treatment in the ECF + Radiation arm. The patient is experiencing an adverse effect related to neutrophils/granulocytes."
2732,0,The patient is a 41-year-old white male with a BMI of 26.71. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2733,1,The patient is a 54-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells.
2734,1,"The patient is a 79-year-old white male with a BMI of 27.82 who is currently receiving treatment with FOLFOX and Panitumumab. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment."
2735,0,"The patient is a 63-year-old white male with a BMI of 28.32. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2736,1,"The patient is a 70-year-old white female with a BMI of 20.07. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to ambulate. The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows that it is wild-type."
2737,0,The patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology indicates that the condition is malignant.
2738,1,"The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 3 days. His histology shows that he is in bed less than 50% of the time, and his pathology indicates a malignant condition."
2739,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He experienced complications post-surgery and used narcotics for 8 days. Despite having symptoms, he is able to walk around. The pathology report indicated malignancy."
2740,0,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2741,0,"The patient is a 41-year-old white male with a BMI of 32.47. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2742,1,This patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 6 days following the procedure. The histology report indicates symptoms but the patient is still able to walk around. The pathology report shows that the cause of the symptoms is malignant.
2743,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
2744,0,"The patient is a 53-year-old white male with a well-differentiated histology. He is in the treatment arm receiving ECF chemotherapy along with radiation. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects related to his neutrophils/granulocytes and leukocytes."
2745,1,The patient is a 47-year-old white female enrolled in the ECF + Radiation treatment arm. She has a performance status of symptoms but is still able to walk around (ambulatory). Her histology shows poorly differentiated cells. The patient is experiencing nausea as an adverse effect of the treatment.
2746,1,The patient is a 44-year-old white male with a BMI of 28.77. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker indicates that it is wild-type.
2747,0,"The patient is a 46-year-old white male with a BMI of 26.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2748,1,The patient is a 74-year-old white male with a BMI of 23.38 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
2749,0,"The patient is a 50-year-old white female with a BMI of 26.9. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2750,0,"The patient is a 39-year-old white male with a BMI of 22.6. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2751,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to move around independently. The pathology report indicates malignancy."
2752,1,"The patient is a 58-year-old male of a race categorized as ""other."" He is currently undergoing treatment in the ECF + Radiation treatment arm. Despite his age, he has a fully active performance status. The histology of his condition is classified as poorly differentiated."
2753,0,"This patient is a 59-year-old white female with a BMI of 31.0. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2754,1,"The patient is a 52-year-old white male with a BMI of 35.95. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient has experienced an adverse effect in the form of an infection."
2755,0,"The patient is a 53-year-old white female with a BMI of 19.72. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
2756,1,"The patient is a 45-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing adverse effects related to his white blood cells, specifically granulocytes/bands."
2757,0,The patient is a 73-year-old white male with a BMI of 25.4. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2758,0,The patient is a 53-year-old white male enrolled in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing nausea as an adverse effect of the treatment.
2759,0,The patient is a female who is part of the conventional surgery treatment arm. She has bowel adhesions and has been using narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2760,1,The patient is a 72-year-old white female who is fully active and is receiving treatment with Sunitinib.
2761,0,"The patient is a 36-year-old white male with a BMI of 24.36. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2762,1,"The patient is a 59-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating a relatively good performance status."
2763,0,"The patient is a 63-year-old white female with a BMI of 34.95. She is receiving treatment in the FOLFOX + Cetuximab treatment arm for her condition. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her condition is well differentiated. Despite her bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a mutant status."
2764,0,This patient is a 49-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy in combination with radiation therapy. The histology of her cancer is poorly differentiated.
2765,1,The patient is a 66-year-old white male with a BMI of 23.83. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
2766,0,"The patient is a 46-year-old Black male with a BMI of 26.32. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
2767,0,The patient is a 69-year-old white male with a BMI of 29.14. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
2768,1,This patient is a 67-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects of low neutrophil/granulocyte levels and fatigue.
2769,0,"The patient is a 70-year-old white female with a BMI of 19.61. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2770,1,"The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
2771,0,"The patient is a 60-year-old black male with a BMI of 30.16. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2772,0,The patient is a 43-year-old white male with a BMI of 32.41. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2773,1,"The patient is a 53-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
2774,0,"The patient is a female who is undergoing conventional surgery for a malignant condition. She has been using narcotics for 2 days to manage her symptoms, but is still able to walk around."
2775,0,The patient is a 64-year-old white male with a BMI of 29.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker analysis showed a mutant result.
2776,0,The patient is a 55-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. He has a histology of poorly differentiated cancer. He is experiencing nausea and anorexia as adverse effects of the treatment.
2777,0,"The patient is a 56-year-old white male with a BMI of 32.15. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect."
2778,0,"The patient is a 66-year-old white male with a BMI of 31.05. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2779,0,The patient is a 51-year-old Black male with a BMI of 27.55. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
2780,0,"The patient is a 41-year-old white male with a BMI of 27.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
2781,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate malignancy.
2782,1,"The patient is a 60-year-old white female with a BMI of 20.08. She is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the FOLFOX treatment arm, and her KRAS biomarker status is wild-type."
2783,0,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has been using narcotics for 5 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2784,1,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 2 days following the surgery. Her histology indicates that she is in bed less than 50% of the time, and her pathology report shows that the condition is malignant."
2785,1,"The patient is a 51-year-old white male with a BMI of 37.06. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
2786,1,The patient is a 48-year-old white male who is fully active. He is currently receiving treatment with Sunitinib.
2787,0,The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 6 days and is experiencing symptoms but is still able to walk around. The pathology report indicates malignancy.
2788,1,The patient is a 67-year-old white male with a BMI of 22.86. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene.
2789,0,The patient is a 54-year-old white male with a BMI of 27.58. He is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2790,1,"The patient is a 70-year-old white male with a BMI of 28.38. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
2791,0,"The patient is a 37-year-old white male with a BMI of 32.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and the patient has a fully active performance status. His KRAS biomarker is wild-type."
2792,1,The patient is a 67-year-old white male with a BMI of 24.16 who is currently receiving treatment with the FOLFOX regimen. He has a fully active performance status and has been diagnosed with a primary tumor in the colon.
2793,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 4 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
2794,0,"The patient is a 67-year-old white male with a BMI of 27.44. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
2795,0,"The patient is a 59-year-old Black female with a BMI of 28.05. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
2796,0,"The patient is a 68-year-old white male with a BMI of 23.04. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2797,1,The patient is a 55-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy and has symptoms but is still able to walk around.
2798,0,"The patient is a 48-year-old white female with a BMI of 22.19. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
2799,0,The patient is a 63-year-old white female with a BMI of 22.35. She is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. Her KRAS biomarker status is wild-type.
2800,0,"This patient is a 52-year-old white female who is currently receiving treatment with ECF chemotherapy and radiation therapy. She has a history of prior cancer. Despite experiencing nausea as an adverse effect of her treatment, her performance status remains fully active. The histology of her current cancer is poorly differentiated."
2801,0,The patient is a 72-year-old white male with a BMI of 27.27 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker status is wild-type. The patient is experiencing acne as an adverse effect of the treatment.
2802,1,The patient is a 62-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. She is experiencing a decrease in white blood cells as an adverse effect of the treatment.
2803,0,"The patient is a 69-year-old white male with a BMI of 21.99. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
2804,0,"The patient is a 57-year-old white male with a BMI of 25.68. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
2805,0,"The patient is a 45-year-old white female with a BMI of 21.72. She is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
2806,1,The patient is a 70-year-old white male with a BMI of 25.71. He is fully active and is receiving treatment with FOLFOX chemotherapy combined with Panitumumab for his colon cancer. The KRAS biomarker in his tumor is identified as mutant.
2807,1,"The patient is a male who underwent laparoscopic-assisted colectomy and experienced complications. He used narcotics for 9 days post-surgery. Despite having symptoms, he is able to walk around. The pathology report revealed that the underlying cause was malignant."
2808,0,"The patient is a 37-year-old white female with a BMI of 23.28 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
2809,0,"The patient is a 38-year-old white male with a BMI of 30.87. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
2810,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
2811,0,"The patient is a 62-year-old white male with a BMI of 39.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2812,1,"The patient is a 54-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing a side effect known as granulocytes/bands."
2813,0,"The patient is a 66-year-old white male with a fully active performance status. He is receiving treatment with ECF and radiation therapy. The histology shows well-differentiated characteristics. The patient is experiencing adverse effects including low neutrophil/granulocyte levels, nausea, anorexia, and fatigue."
2814,0,"The patient is a 66-year-old white female with a BMI of 27.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
2815,1,"The patient is a 51-year-old white male with a BMI of 27.76. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2816,0,"The patient is a 42-year-old white male with a BMI of 29.92. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. The patient has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. His KRAS biomarker is wild-type."
2817,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions present. He used narcotics for 2 days post-surgery. The histology results show that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
2818,1,"The patient is a 57-year-old white female with a BMI of 24.62. She is currently receiving FOLFIRI chemotherapy treatment for KRAS mutant cancer. She has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
2819,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 3 days following the procedure. Despite having symptoms, he is ambulatory. The pathology report indicates malignancy."
2820,1,"The patient is a 57-year-old white male with a BMI of 23.06. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2821,1,"In this patient profile, the individual is a 61-year-old white female who is undergoing treatment with Cisplatin + Etoposide chemotherapy regimen. She has completed 4 cycles of chemotherapy and has a performance status of fully active. The patient has experienced an adverse effect related to her granulocytes/bands, indicating a potential issue with her white blood cell count."
2822,0,"The patient is a 65-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). Additionally, she is experiencing an adverse effect related to her neutrophils/granulocytes."
2823,0,"The patient is a 46-year-old white female with a BMI of 44.45. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2824,0,"The patient is a 41-year-old white female with a BMI of 31.12. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her fully active performance status, she carries a mutant KRAS biomarker. The patient is experiencing diarrhea as an adverse effect of the treatment."
2825,0,The patient is a 67-year-old white male with a BMI of 25.6 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
2826,0,"The patient is a 54-year-old white male with a BMI of 30.56. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has the wild-type KRAS gene."
2827,0,"The patient is a 66-year-old white male with a BMI of 43.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2828,1,The patient is a 49-year-old white female who is currently receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy and has a performance status of fully active.
2829,0,"The patient is a 71-year-old white female with a BMI of 23.98. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2830,0,"The patient is a 56-year-old white female with a BMI of 32.49. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2831,0,"The patient is a 38-year-old white male with a BMI of 28.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he experienced an adverse effect in the form of an infarction."
2832,1,The patient is a 77-year-old white female with a BMI of 34.52. She is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker indicates that she has a wild-type status.
2833,1,"This patient is a 62-year-old white female with a well-differentiated histology who is fully active. She is currently undergoing treatment with ECF and radiation. One of the adverse effects she is experiencing is anorexia, which is a loss of appetite leading to decreased food intake. Anorexia can result in weight loss and nutritional deficiencies if not managed properly."
2834,0,"The patient is a 55-year-old white female with a BMI of 26.35. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
2835,0,The patient is a 66-year-old white female with a BMI of 26.37 who is fully active. She is receiving treatment with FOLFOX for colon cancer. The KRAS biomarker indicates that her tumor is wild-type.
2836,1,"The patient is a 58-year-old Black female with a BMI of 27.39. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant result."
2837,0,"The patient is a 48-year-old white female with a BMI of 25.41. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
2838,0,The patient is a 75-year-old white male with a performance status indicating symptoms but still able to walk around (ambulatory). He is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of the cancer is poorly differentiated.
2839,0,"The patient is a 40-year-old white female with a BMI of 42.6. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has experienced a serious adverse effect during her treatment. The patient has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active."
2840,0,The patient is a 61-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has a histology of poorly differentiated. The patient is experiencing fatigue as an adverse effect.
2841,0,"The patient is a 56-year-old white male with a BMI of 29.89. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
2842,1,The patient is a 47-year-old white female who is receiving treatment with Sunitinib. Her performance status indicates that she is spending less than 50% of her time in bed.
2843,0,The patient is a 55-year-old white male with a BMI of 38.44. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and carries a mutant KRAS biomarker.
2844,0,"The patient is a 35-year-old white male with a BMI of 35.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker indicates that it is wild-type."
2845,0,"The patient is a 57-year-old white female with a BMI of 23.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
2846,0,"The patient is a 72-year-old white male with a BMI of 29.9. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
2847,0,"The patient is a 55-year-old white female with a BMI of 19.14. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
2848,1,"The patient is a 58-year-old white male who is undergoing treatment with Cisplatin + Etoposide chemotherapy regimen. He has completed 6 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. He has developed adverse effects including low levels of granulocytes/bands and white blood cells."
2849,0,"The patient is a 53-year-old white female with a BMI of 25.94. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects in the form of bowel obstruction and perforation. Despite these challenges, she has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2850,1,"The patient is a 60-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. She has experienced significant weight loss of more than 5-10%. Her performance status indicates that she is spending less than 50% of her time in bed. The patient has also experienced adverse effects including low levels of granulocytes/bands and white blood cells, as well as symptoms of nausea."
2851,1,"This patient is a 70-year-old white male with a BMI of 31.05. He is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
2852,1,"The patient is a 57-year-old white male with a BMI of 21.53. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
2853,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 12 days. Despite the symptoms, he was still able to be ambulatory. The pathology report revealed malignant findings."
2854,1,"This patient is a 60-year-old white male who is part of the ECF + Radiation treatment arm. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
2855,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
2856,0,"The patient is a 67-year-old white female with a BMI of 17.26. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of her treatment. She has completed 10 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker status is indeterminate."
2857,1,The patient is a 68-year-old white male with a BMI of 25.91 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS gene.
2858,0,The patient is a 66-year-old white male with a BMI of 29.32 who has symptomps but remains ambulatory. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
2859,0,The patient is a 67-year-old white male with a BMI of 30.77. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2860,1,"The patient is a 41-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
2861,1,"The patient is a 62-year-old white female who is fully active and is receiving treatment with Sunitinib. She is experiencing an adverse effect related to her neutrophils/granulocytes. This may indicate a decrease in the levels of these important white blood cells, which are crucial for fighting infections."
2862,0,"The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 22.86. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel obstruction and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
2863,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have been using narcotics for 5 days. Their histology shows symptoms but they are still able to walk around. The pathology report indicates that the condition is malignant.
2864,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology showed symptoms but she was still able to be ambulatory. The pathology report indicated that the cause of her symptoms was malignant.
2865,0,"The patient is a 71-year-old white female with a BMI of 26.7. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker status is wild-type."
2866,1,"The patient is a 51-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood counts, specifically a decrease in granulocytes/bands and white blood cells."
2867,1,The patient is a female who underwent laparoscopic-assisted colectomy. She did not require any narcotic pain medication post-surgery. Her histology indicates symptoms but she is still able to be ambulatory. The pathology report revealed that the cause of her symptoms was malignant.
2868,0,"The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 4 days to manage his symptoms, but is still able to walk around."
2869,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is still able to move around. The pathology report indicates that the condition is malignant.
2870,0,"The patient is a 56-year-old white female with a BMI of 30.34 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 9 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The patient's KRAS biomarker is mutant, and she has also experienced thrombosis as an adverse effect."
2871,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 3 days following the surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
2872,0,"The patient is a 49-year-old white female with a BMI of 33.87 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The patient's KRAS biomarker is mutant. She has also experienced adverse effects including hypersensitivity and diarrhea."
2873,0,"The patient is a 44-year-old white female with a BMI of 20.58. She is currently receiving treatment in the FOLFOX treatment arm. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2874,0,"The patient is a 41-year-old white female with a BMI of 25.22. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2875,0,"The patient is a 42-year-old white female with a BMI of 28.23. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
2876,1,"The patient is a 47-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
2877,0,The patient is a 60-year-old Black male with a BMI of 22.99. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2878,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery. She used narcotics for 5 days following the procedure. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated malignancy."
2879,0,"The patient is a 63-year-old white male with a BMI of 32.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an adverse effect of thrombosis."
2880,0,"The patient is a 58-year-old white male with a BMI of 22.69. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2881,1,"The patient is a 59-year-old white female with a BMI of 21.57. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant result."
2882,0,"The patient is a 50-year-old white female with a BMI of 25.35. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
2883,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is ambulatory. The pathology results indicate a malignant condition.
2884,0,"The patient is a female who underwent conventional surgery and has bowel adhesions. She experienced complications post-surgery and required narcotic pain medication for 3 days. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
2885,0,"The patient is a 43-year-old Black male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. The patient's KRAS biomarker status is mutant."
2886,1,"The patient is a 70-year-old white female with a BMI of 26.85. She is currently receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite this, her performance status is fully active. The KRAS biomarker shows that she is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
2887,1,"The patient is a 36-year-old female of other race with a BMI of 16.2. She is currently receiving treatment with FOLFOX for a rectal tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a mutant KRAS status."
2888,0,"The patient is a 51-year-old white female with a BMI of 25.81. She is receiving treatment with FOLFOX chemotherapy and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
2889,1,"The patient is a 72-year-old white male with a BMI of 27.68. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
2890,0,"The patient is a 54-year-old white female with a BMI of 25.5. She is receiving treatment with FOLFOX and has been adherent to the chemotherapy regimen for 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2891,0,"The patient is a 62-year-old white female with a BMI of 23.96. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2892,1,"The patient is a 68-year-old white female with a BMI of 37.11 who is receiving treatment with the FOLFOX regimen for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
2893,0,"The patient is a 65-year-old white female with a BMI of 32.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant result."
2894,0,The patient is a 49-year-old white male with a BMI of 20.95. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2895,0,"The patient is a 46-year-old female of a race other than specified, with a BMI of 18.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 6 cycles of chemotherapy. Histologically, her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type."
2896,0,"The patient is a 71-year-old white female with a BMI of 43.28. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2897,0,"The patient is a 48-year-old white female with a BMI of 22.32. She is undergoing treatment with FOLFOX chemotherapy and has completed 11 cycles so far. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2898,0,"The patient is a 49-year-old female of other race with a BMI of 23.67. She is fully active in terms of performance status. The primary tumor diagnosis is rectal, and the KRAS biomarker status is wild-type. The patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab."
2899,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 5 days following the procedure. The histology shows symptoms but the patient is still ambulatory. The pathology report indicates that the condition is malignant.
2900,0,"This patient is a 76-year-old white female with a BMI of 27.02 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 5 chemotherapy cycles. Her histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has developed diarrhea as an adverse effect of her treatment."
2901,1,The patient is a male who underwent laparoscopic-assisted colectomy. He did not require any narcotics for pain relief post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is due to a malignant condition.
2902,1,The patient is a 37-year-old white female with a BMI of 20.63 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker for this patient is mutant.
2903,1,"The patient is a 44-year-old white male with a BMI of 22.75. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
2904,1,"The patient is a 72-year-old white male with a BMI of 24.54 who is currently receiving treatment with the FOLFOX regimen. He has symptoms but is still able to walk around (ambulatory) despite his condition. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
2905,0,"The patient is a 43-year-old white female with a BMI of 30.41. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. The patient has experienced a hypersensitivity adverse effect."
2906,0,"The patient is a 38-year-old white male with a BMI of 27.65. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
2907,0,The patient is a 58-year-old white male with a performance status indicating symptoms but still able to walk around. He is enrolled in the treatment arm involving 5FU/LV chemotherapy along with radiation therapy. The histology shows poorly differentiated cells.
2908,0,"The patient is a 60-year-old white male with a BMI of 27.04. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
2909,1,"The patient is a 72-year-old white female with a BMI of 22.27. She is fully active with a primary tumor diagnosis of colon cancer. The treatment arm she is in involves receiving FOLFOX chemotherapy in combination with Panitumumab. Additionally, the patient has a mutant KRAS biomarker status."
2910,1,The patient is a 66-year-old white male with a BMI of 25.65 who is receiving treatment with FOLFOX for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker analysis shows a mutant status.
2911,0,"The patient is a 70-year-old white female with a BMI of 21.91. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
2912,0,"The patient is a 66-year-old white male with a BMI of 38.68 who is receiving the FOLFIRI treatment regimen for KRAS mutant colorectal cancer. He has a history of bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite experiencing diarrhea as an adverse effect of treatment, his performance status remains fully active."
2913,0,"The patient is a 55-year-old white female with a BMI of 25.96. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
2914,0,"The patient is a 55-year-old black male with a well-differentiated histology who is fully active. He is currently undergoing treatment with 5FU/LV and radiation therapy. The patient is experiencing anorexia, which is a condition characterized by a loss of appetite or a decreased desire to eat. This adverse effect may impact the patient's nutritional intake and overall well-being during treatment."
2915,1,"The patient is a 54-year-old female of other race with a BMI of 21.96. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
2916,0,"The patient is a 60-year-old white female with a BMI of 26.37. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
2917,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology indicates that the condition is malignant.
2918,1,The patient is a 66-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated characteristics.
2919,1,"The patient is a 51-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status."
2920,0,"The patient is a 70-year-old white male with a BMI of 35.14 who is currently receiving treatment with FOLFIRI + Cetuximab. He is adherent to his treatment regimen and has experienced a bowel obstruction. He has completed 2 cycles of chemotherapy and has well-differentiated histology. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infarction as an adverse effect."
2921,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and experienced symptoms but is still able to move around. Pathology results indicate malignancy. He only used narcotics for 1 day.
2922,0,"The patient is a 60-year-old white male who is in the treatment arm receiving Cisplatin + Etoposide. He has not started any chemotherapy cycles yet. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
2923,1,The patient is a 70-year-old white male with a BMI of 29.07. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS status.
2924,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
2925,0,The patient is a 42-year-old white male with a BMI of 37.22. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He is experiencing diarrhea as an adverse effect of the treatment.
2926,1,"The patient is a 67-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. The patient has also experienced adverse effects on her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2927,0,The patient is a 37-year-old white male with a BMI of 21.32. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2928,0,The patient is a male who is part of the conventional surgery treatment arm. He has been using narcotics for 7 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
2929,1,The patient is a 56-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active.
2930,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. They experienced complications post-surgery and required narcotic use for 4 days. Despite having symptoms, the patient is ambulatory. The pathology report indicates malignancy."
2931,0,The patient is a 71-year-old white male with a BMI of 25.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
2932,1,"The patient is a 63-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around (ambulatory). She is also experiencing adverse effects related to her white blood cell counts, specifically low levels of neutrophils/granulocytes, platelets and leukocytes, indicating a significant impact on her immune system and overall blood cell health."
2933,0,"The patient is a 51-year-old white female with a BMI of 25.72. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed regimen. She has completed one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2934,0,"This patient is a 52-year-old white female with a BMI of 20.08. She is receiving treatment with the FOLFIRI chemotherapy regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy and her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
2935,0,"The patient is a 71-year-old white male with a BMI of 27.8. He is currently receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2936,0,The patient is a female undergoing conventional surgery for a malignant condition. She has been using narcotics for 4 days to manage her symptoms but is still able to walk around.
2937,0,"The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 23.56. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
2938,0,"The patient is a 46-year-old white male with a BMI of 20.2 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 chemotherapy cycles. The histology shows well-differentiated cancer cells, and the patient's performance status is characterized by experiencing symptoms but still being ambulatory. The KRAS biomarker indicates a wild-type status. The patient has experienced a serious adverse effect in the form of thrombosis."
2939,0,The patient is a 34-year-old white male with a BMI of 28.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2940,0,"The patient is a 58-year-old male of a race classified as ""other"" with a BMI of 26.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
2941,0,"The patient is a 38-year-old white male with a BMI of 22.46. He is enrolled in the FOLFOX + Cetuximab treatment arm and has not started any chemotherapy cycles yet. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
2942,1,This patient is a 72-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. She is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
2943,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
2944,0,"The patient is a 70-year-old white male with a BMI of 30.06. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his age, he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene."
2945,1,The patient is a 71-year-old white female with a BMI of 19.2 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker shows a mutant status.
2946,0,The patient is a 34-year-old white male with a BMI of 26.52. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
2947,1,"The patient is a 62-year-old female of other race with a BMI of 19.04. She is currently receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. Despite experiencing symptoms, she is still able to walk and move around (ambulatory). Additionally, the KRAS biomarker indicates that she has a mutant KRAS status."
2948,0,"The patient is a 43-year-old male of a race categorized as ""other"" with a BMI of 22.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a wild-type result."
2949,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 2 days following the surgery. The histology results showed that the tumor was well-differentiated, and the pathology results indicated that the tumor was benign."
2950,0,"This patient is a 82-year-old white female with a BMI of 20.84. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2951,1,"The patient is a 55-year-old white male with a BMI of 27.7. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker status is wild-type."
2952,0,"The patient is a 57-year-old white female with a BMI of 22.55. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
2953,0,"The patient is a 46-year-old male of a race categorized as ""other."" He is fully active with a performance status indicating good overall health and ability to carry out daily activities. The treatment arm for this patient includes a combination of 5-fluorouracil (5FU) and leucovorin (LV) along with radiation therapy. The histology of the patient's condition is described as poorly differentiated."
2954,1,"The patient is a 46-year-old white male with a BMI of 18.71. He is receiving treatment in the FOLFOX + Panitumumab arm. His performance status indicates that he is in bed less than 50% of the time. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
2955,1,"The patient is a 66-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around and be ambulatory."
2956,1,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
2957,0,"The patient is a 47-year-old white male with a BMI of 29.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
2958,0,The patient is a 60-year-old white male with a BMI of 32.72. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
2959,0,The patient is a 51-year-old black male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
2960,0,"The patient is a 49-year-old white male with a BMI of 22.76. He is currently receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
2961,1,The patient is a female who underwent laparoscopic-assisted colectomy. She only used narcotics for 1 day following the procedure. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate that the cause of her symptoms is malignant.
2962,0,"The patient is a 45-year-old white male with a BMI of 29.57. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a performance status of being in bed less than 50% of the time. His KRAS biomarker status is wild-type."
2963,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
2964,1,"The patient is a 68-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects related to his blood cell counts, specifically having low levels of granulocytes/bands, white blood cells, and lymphocytes."
2965,1,The patient is a 62-year-old white male who is undergoing treatment with Cisplatin + Etoposide. He has completed 6 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his white blood cells and granulocytes/bands.
2966,0,"The patient is a 37-year-old white male with a BMI of 22.28. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
2967,0,"The patient is a 53-year-old white female with a BMI of 28.28. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology indicates poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
2968,1,The patient is a 49-year-old white female receiving treatment with Sunitinib. She is fully active but is experiencing fatigue as an adverse effect of the treatment.
2969,0,"The patient is a 49-year-old white male with a BMI of 28.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
2970,1,The patient is a 68-year-old white female with a BMI of 21.26. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker analysis shows that she has a mutant KRAS status.
2971,0,"In this patient profile, the individual is a 50-year-old female of a race categorized as ""other."" She is currently undergoing treatment in the ECF + Radiation treatment arm. Her performance status is fully active, indicating that she is able to carry out daily activities without limitations. The histology of her condition is poorly differentiated. Additionally, she is experiencing an adverse effect related to neutrophils/granulocytes."
2972,1,"The patient is a 75-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing a side effect known as granulocytes/bands."
2973,0,"The patient is a 54-year-old white male with a BMI of 38.86. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2974,0,The patient is a 63-year-old white female with a BMI of 28.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
2975,0,"The patient is a 43-year-old female of a race categorized as ""other"" with a BMI of 18.24. She is receiving treatment in the FOLFOX regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
2976,0,"The patient is a 59-year-old Black male with a low BMI of 16.91. He is receiving treatment with FOLFOX + Cetuximab for his condition. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite his health challenges, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type mutation."
2977,0,"The patient is a 56-year-old white male with a BMI of 23.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
2978,0,"The patient is a 56-year-old white male with a BMI of 21.54. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. He is also experiencing diarrhea as an adverse effect of the treatment."
2979,1,"In this patient profile, the individual is a 53-year-old white female who is fully active. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. An adverse effect noted in this patient is leukopenia, which is a decrease in the number of white blood cells."
2980,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is able to walk around. Pathology results indicate a malignant condition.
2981,0,"The patient is a 61-year-old white male with a BMI of 41.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
2982,1,The patient is a 42-year-old white female with a BMI of 19.84. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
2983,0,"The patient is a 72-year-old female of a race other than specified, with a BMI of 28.79. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
2984,1,"The patient is a 62-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. The patient has also developed adverse effects related to his white blood cells and granulocytes/bands."
2985,1,The patient is a 48-year-old white male participating in the treatment arm involving 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology indicates that the cancer is poorly differentiated.
2986,1,"The patient is a 53-year-old white male receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient has developed low white blood cell count as an adverse effect of the treatment."
2987,0,"The patient is a 48-year-old white male with a BMI of 30.13. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker is identified as mutant in this patient."
2988,0,"The patient is a 58-year-old white male with a BMI of 24.13. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
2989,0,"The patient is a 38-year-old white male with a BMI of 24.34. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. His KRAS biomarker is wild-type. He has experienced a hypersensitivity adverse effect."
2990,1,"The patient is a 56-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. His performance status indicates that he is in bed less than 50% of the time."
2991,0,"The patient is a 44-year-old white male with a BMI of 40.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
2992,0,"The patient is a 53-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing a side effect known as granulocytes/bands, which refers to a decrease in the number of certain types of white blood cells called granulocytes."
2993,0,"The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 19.59. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
2994,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. Pathology results indicate a malignant condition.
2995,0,"The patient is a 64-year-old white male with a BMI of 27.82. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of hypersensitivity and diarrhea during treatment."
2996,1,The patient is a 56-year-old white male with a BMI of 21.26. He is fully active with a primary tumor diagnosis of colon. He is enrolled in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
2997,1,The patient is a 77-year-old white male with a BMI of 27.1. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status for this patient is mutant.
2998,0,The patient is a 59-year-old white female with a BMI of 23.46. She is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. The KRAS biomarker indicates a mutant status. The patient is experiencing acne as an adverse effect of the treatment.
2999,0,"The patient is a 35-year-old white male with a BMI of 31.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed a mutation. The patient has experienced thrombosis as an adverse effect."
3000,0,"In this patient profile, the individual is a 63-year-old female of a race categorized as ""other."" She is part of the treatment arm receiving ECF chemotherapy along with radiation. Her performance status is fully active, indicating that she is able to carry out daily activities without limitations. The histology of her condition is classified as poorly differentiated. Additionally, she is experiencing an adverse effect related to leukocytes, which suggests a decrease in white blood cell count."
3001,1,"The patient is a 60-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient has shown adverse effects on her blood counts, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
3002,0,"This patient is a 55-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. The patient is experiencing adverse effects including low neutrophils/granulocytes, low leukocytes, nausea, anorexia, and fatigue."
3003,0,The patient is a 33-year-old white female with a BMI of 17.36 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis showed a mutant status.
3004,0,"The patient is a 76-year-old white female with a BMI of 33.01. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker is wild-type."
3005,0,"The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 19.49. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status. The patient has experienced an adverse effect in the form of an infection."
3006,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to move around. The pathology results indicate malignancy.
3007,0,"The patient is a 56-year-old white female with a BMI of 19.76. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. It is important to note that her KRAS biomarker is wild-type."
3008,1,The patient is a 45-year-old white male receiving treatment with 5FU/LV and radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing adverse effects of nausea and fatigue.
3009,0,"The patient is a 58-year-old white female with a BMI of 37.94. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
3010,1,"The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 30.3. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
3011,0,"The patient is a 44-year-old white female with a BMI of 39.12. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type."
3012,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
3013,1,"The patient is a 69-year-old white male with a BMI of 20.3. He is currently receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
3014,0,The patient is a 61-year-old white female with a BMI of 34.45. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. Her KRAS biomarker status is wild-type.
3015,0,"The patient is a 47-year-old white male with a BMI of 35.76. He is receiving the FOLFOX treatment arm for his bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite his bowel perforation, his performance status is fully active. His KRAS biomarker is wild-type."
3016,0,"The patient is a 50-year-old white male with a BMI of 28.15. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status."
3017,0,"The patient is a 56-year-old white female with a BMI of 35.0. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
3018,0,"The patient is a 66-year-old white male with a high BMI of 56.4. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite this, his performance status is fully active. The patient's KRAS biomarker is mutant. He has also experienced adverse effects such as diarrhea and infection."
3019,1,This patient is a 72-year-old white female with a BMI of 29.76. She is fully active with a primary tumor diagnosis of colon. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
3020,1,"The patient is a 67-year-old male of a race classified as ""other"" who is currently receiving treatment in the ECF + Radiation arm. He has a performance status of experiencing symptoms but is still able to walk around. The histology of the patient's condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
3021,1,The patient is a 56-year-old white female with a BMI of 28.64 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker for this patient is mutant.
3022,0,"The patient is a 63-year-old white male with a BMI of 23.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
3023,1,The patient is a 76-year-old white male with a BMI of 23.66. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. His KRAS biomarker status is wild-type.
3024,1,The patient is a 55-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated.
3025,1,"The patient is a 61-year-old white male with a BMI of 27.14. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
3026,0,The patient is a 56-year-old white female with a BMI of 28.4. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
3027,0,The patient is a 49-year-old white female with a BMI of 21.97. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
3028,0,"The patient is a 46-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced an infection as an adverse effect during treatment."
3029,1,The patient is a 55-year-old white male with a BMI of 21.23. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
3030,1,"In this patient profile, the individual is a 54-year-old white female who is fully active. She is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated. An adverse effect noted is leukocytes, indicating a decrease in white blood cells."
3031,1,"The patient is a 47-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. He has also developed an adverse effect related to his granulocytes/bands."
3032,0,"The patient is a 58-year-old Black male with a BMI of 25.24. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3033,1,The patient is a 57-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of her cancer is poorly differentiated. She is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
3034,1,This patient is a 65-year-old white female with a BMI of 20.5. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that she has a wild-type status. She is currently undergoing treatment with the FOLFOX regimen.
3035,0,"The patient is a 74-year-old Black female with a BMI of 34.84. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3036,0,"The patient is a 71-year-old white female with a BMI of 29.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3037,0,The patient is a 58-year-old white female with a BMI of 36.06 who is undergoing treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has completed 6 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of her treatment.
3038,1,"The patient is a 59-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is showing adverse effects related to her blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
3039,1,"The patient is a 40-year-old white male with a BMI of 22.49. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
3040,1,The patient is a 76-year-old white female with a BMI of 27.55. She is receiving treatment with FOLFOX for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker shows that she has a wild-type status.
3041,1,"The patient is a 49-year-old female of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV + Radiation. She has a performance status of experiencing symptoms but is still able to walk around. The histology of her condition is poorly differentiated. Additionally, she is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
3042,0,"The patient is a 56-year-old white male with a BMI of 34.02. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
3043,0,"The patient is a 70-year-old white male with a BMI of 31.14. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
3044,0,"The patient is a 56-year-old white male with a BMI of 37.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
3045,0,"The patient is a 42-year-old white female with a BMI of 26.49. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3046,0,"The patient is a 47-year-old white male with a BMI of 27.59. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type KRAS gene."
3047,1,"The patient is a 44-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects related to his granulocytes/bands and white blood cells."
3048,1,"The patient is a 56-year-old female of a race categorized as ""other."" She is currently receiving treatment with 5FU/LV + Radiation therapy. Despite experiencing symptoms, she is able to move around independently (ambulatory). The histology of the patient's condition is well-differentiated."
3049,1,"The patient is a 61-year-old white male with a BMI of 25.52. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to ambulate."
3050,1,The patient is a 53-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. He has a histology of poorly differentiated cancer. He is experiencing adverse effects of anorexia and fatigue.
3051,1,"This patient is a 56-year-old white female with a BMI of 21.29. She is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
3052,1,"The patient is a 72-year-old white male with a BMI of 22.86 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3053,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3054,0,The patient is a 40-year-old white male with a BMI of 27.05. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type.
3055,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications during the treatment. She did not require any days of narcotic use post-surgery. The histology results showed that the tissue was well-differentiated, and the pathology report indicated that the condition was benign."
3056,1,"The patient is a 65-year-old white male with a BMI of 24.0. He is fully active and has been diagnosed with a primary colon tumor. The treatment arm for this patient is FOLFOX and Panitumumab. Additionally, the KRAS biomarker for this patient is mutant."
3057,0,"The patient is a 70-year-old white male with a BMI of 28.49. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy with good adherence. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3058,1,"The patient is a 36-year-old white male with a BMI of 34.95. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
3059,0,"The patient is a 71-year-old white male with a BMI of 28.8. He is currently undergoing treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has experienced both bowel obstruction and bowel perforation. So far, he has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3060,0,"The patient is a 67-year-old white male with a BMI of 31.42. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction and perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3061,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3062,1,"The patient is a 62-year-old black female receiving treatment with Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around. She is also experiencing nausea as an adverse effect of the treatment."
3063,0,"This patient is a 77-year-old white female with a BMI of 28.51. She is fully active with a primary tumor diagnosis of rectal cancer. The patient is enrolled in the FOLFOX treatment arm. Additionally, the KRAS biomarker testing revealed a mutant status."
3064,1,"The patient is a 65-year-old white male with a BMI of 20.05. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing showed that he has a wild-type KRAS gene."
3065,1,"The patient is a female who underwent laparoscopic-assisted colectomy and experienced complications. She used narcotics for 1 day post-surgery. Despite having symptoms, she was able to move around. The pathology report indicated malignant findings."
3066,0,"The patient is a 59-year-old female of a race other than Caucasian. She has a BMI of 20.78 and is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her treatment. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite her treatment, she maintains a fully active performance status. Her KRAS biomarker is wild-type."
3067,0,"This patient is a 52-year-old white female with a BMI of 30.12. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite the adverse effect of thrombosis, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
3068,1,The patient is a 48-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
3069,1,"This patient is a 68-year-old white male with a BMI of 23.25. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
3070,1,"The patient is a 59-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands, which refers to a decrease in a type of white blood cell that helps fight infection."
3071,1,The patient is a 53-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing adverse effects related to her granulocytes/bands and white blood cells.
3072,0,This patient is a 61-year-old white female with a BMI of 27.7 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker test results show that she has a wild-type KRAS gene.
3073,0,"The patient is a 46-year-old white male with a BMI of 24.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3074,1,"The patient is a 64-year-old white male with a BMI of 22.94. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
3075,1,"The patient is a 75-year-old white female with a BMI of 27.28. She is currently receiving the FOLFIRI treatment regimen and has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3076,0,"The patient is a 75-year-old white male with a BMI of 28.17. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3077,1,The patient is a 64-year-old white female with a BMI of 31.4 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis shows a mutant status.
3078,1,"The patient is a 47-year-old white male enrolled in the ECF + Radiation treatment arm. He has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
3079,1,The patient is a 60-year-old white male with a BMI of 33.14. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 7 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
3080,0,The patient is a 51-year-old white female with a fully active performance status. She is receiving treatment with ECF and radiation therapy. The histology shows well-differentiated cancer cells. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3081,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3082,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is still able to walk around. The pathology report indicates the presence of malignancy.
3083,1,The patient is a 50-year-old white female with a BMI of 24.91. She is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker status is wild-type in this patient.
3084,0,"The patient is a 66-year-old male of a race classified as ""other."" He is fully active with a performance status indicating good overall health. The treatment arm for this patient includes 5FU/LV chemotherapy combined with radiation therapy. The histology of the patient's condition is described as poorly differentiated."
3085,0,"The patient is a 50-year-old white male with a BMI of 29.57. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
3086,1,"The patient is a 61-year-old white male who is receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced weight loss of more than 5-10%. Despite this, he has a fully active performance status. The patient has reported adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
3087,0,"The patient is a 69-year-old white male with a BMI of 28.96 who is undergoing treatment with the FOLFIRI chemotherapy regimen. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
3088,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is ambulatory. The pathology report indicates malignancy.
3089,0,The patient is a 45-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of his cancer is poorly differentiated. He is experiencing an adverse effect related to his neutrophils/granulocytes.
3090,0,The patient is a 47-year-old white female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to her neutrophils/granulocytes and leukocytes.
3091,1,"The patient is a 69-year-old black female with a well-differentiated histology. She is part of the treatment arm receiving ECF chemotherapy along with radiation. Despite experiencing symptoms, she is still able to move around independently."
3092,1,The patient is a 65-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated.
3093,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, and has experienced complications post-surgery. He used narcotics for 2 days following the procedure. Despite having symptoms, he is ambulatory. The pathology report indicates malignancy."
3094,1,The patient is a 59-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3095,0,"The patient is a 41-year-old white female with a BMI of 31.9. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3096,0,"The patient is a 39-year-old white male with a BMI of 23.41. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
3097,1,"The patient is a 47-year-old white female with a BMI of 25.2. She is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker indicates a mutant status."
3098,1,"The patient is a 58-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects including low levels of granulocytes/bands and lymphocytes, as well as nausea."
3099,0,"The patient is a 69-year-old white male with a BMI of 25.64. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
3100,0,"The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 31.87. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed that the patient has a wild-type KRAS status."
3101,1,"The patient is a 68-year-old male of other race with a BMI of 24.19. He is fully active in terms of performance status. The primary tumor diagnosis is rectal, and the KRAS biomarker is mutant. The patient is receiving treatment with FOLFOX and Panitumumab."
3102,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. The histology shows that he is in bed less than 50% of the time, and the pathology report indicates malignancy."
3103,1,"The patient is a 53-year-old white male with a BMI of 26.75. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
3104,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3105,0,"The patient is a 55-year-old white female with a BMI of 37.02. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite the bowel issues, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
3106,0,The patient is a 61-year-old white male with a BMI of 29.4. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
3107,0,"The patient is a 51-year-old white female with a BMI of 19.65. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
3108,0,"The patient is a 60-year-old white female with a BMI of 29.73. She is currently undergoing treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
3109,1,"The patient is a 44-year-old white female with a BMI of 31.06. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3110,0,"The patient is a 64-year-old white female with a BMI of 18.1. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3111,1,The patient is a 48-year-old white male with a BMI of 28.34. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. His KRAS biomarker status is wild-type.
3112,0,"The patient is a 72-year-old white female with a BMI of 35.44. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
3113,0,The patient is a 59-year-old white female with a BMI of 25.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
3114,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates a malignant condition.
3115,0,"The patient is a 49-year-old white male with a BMI of 23.26. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing diarrhea and infection as adverse effects, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
3116,0,The patient is a male undergoing conventional surgery for a malignant condition. He has experienced symptoms but is still able to move around. He has used narcotics for 2 days.
3117,0,"The patient is a 37-year-old white male with a BMI of 31.53. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. Additionally, he has developed thrombosis as an adverse effect of the treatment."
3118,0,"The patient is a 46-year-old white male with a BMI of 27.34. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3119,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology report indicates that the tumor is well differentiated, and the pathology report confirms that it is malignant."
3120,0,"The patient is a 47-year-old white male with a BMI of 32.4. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
3121,0,"This patient is a 68-year-old white female with a BMI of 34.64 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a serious adverse effect during treatment. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
3122,0,The patient is a 58-year-old white male with a BMI of 19.08. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
3123,0,"The patient is a 53-year-old white female with a BMI of 23.53. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant form of the KRAS gene."
3124,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. Her histology indicates that she spends less than 50% of her time in bed, and her pathology report shows that the tumor is malignant."
3125,0,The patient is a 42-year-old Black male with a BMI of 27.17. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
3126,1,The patient is a 63-year-old white female with a BMI of 20.2. She is fully active and is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker in her tumor is mutant.
3127,1,"The patient is a 41-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects related to her white blood cells and granulocytes/bands."
3128,1,"The patient is a 51-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he is experiencing nausea as an adverse effect of the treatment."
3129,0,"The patient is a 56-year-old black male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to ambulate, indicating a relatively good performance status."
3130,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 2 days following the procedure. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
3131,1,"The patient is a 41-year-old white male with a BMI of 26.71. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
3132,0,The patient is a 66-year-old white female with a BMI of 26.16. She is receiving treatment with the FOLFIRI chemotherapy regimen and has completed one cycle so far. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
3133,0,"The patient is a 58-year-old white male with a BMI of 39.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
3134,1,The patient is a 54-year-old white female with a BMI of 20.17. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is wild-type.
3135,1,"The patient is a 55-year-old white male with a BMI of 25.97. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
3136,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery. He used narcotics for 3 days. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
3137,1,"The patient is a 61-year-old white male with a BMI of 23.51 who is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. He has a mutant KRAS biomarker and is experiencing acne as an adverse effect of the treatment. Despite having symptoms, he is still able to ambulate."
3138,0,"The patient is a 52-year-old white male with a BMI of 27.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
3139,0,"The patient is a 62-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
3140,0,The patient is a 52-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology shows well-differentiated cells.
3141,1,"The patient is a 45-year-old white female with a BMI of 26.73. She is enrolled in the treatment arm receiving FOLFIRI + Cetuximab. She has a bowel obstruction and has not started any chemotherapy cycles yet. The histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
3142,1,"The patient is a 40-year-old male of a race other than specified, with a BMI of 20.23. He is currently receiving treatment in the FOLFOX arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal, and the KRAS biomarker shows that it is wild-type."
3143,1,The patient is a 66-year-old white male with a BMI of 30.46 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
3144,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 7 days. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
3145,0,"The patient is a 70-year-old white male with a BMI of 31.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, the patient has a fully active performance status. The KRAS biomarker indicates that the patient has a mutant status."
3146,0,"The patient is a 41-year-old white female with a BMI of 34.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3147,1,"The patient is a 60-year-old white female with a BMI of 22.77. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk and move around (ambulatory). The KRAS biomarker analysis shows that she has a mutant KRAS gene."
3148,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the patient has a malignant condition.
3149,1,"The patient is a 66-year-old Black male with a BMI of 31.42. He is receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. The patient has experienced a hypersensitivity adverse effect during treatment."
3150,1,"The patient is a 60-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory)."
3151,0,"The patient is a 75-year-old white female with a BMI of 31.88. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
3152,0,"The patient is a 53-year-old Black female with a BMI of 26.53. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates a mutant status."
3153,0,"The patient is a 59-year-old white male with a BMI of 33.35 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to the treatment regimen and has completed 12 cycles of chemotherapy. The patient's histology shows well-differentiated cancer, and he has a mutant KRAS biomarker. Despite experiencing serious adverse effects, the patient is still ambulatory with symptoms. He has also developed hypersensitivity as an adverse effect to the treatment."
3154,0,"This patient is a 60-year-old white male with a BMI of 26.78. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his treatment, he maintains a fully active performance status. His KRAS biomarker status is wild-type."
3155,1,"The patient is a 71-year-old white male with a BMI of 26.32. He is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows a mutation."
3156,0,"The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 23.67. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
3157,0,"The patient is a 49-year-old white male with a BMI of 32.55 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has developed an infection as an adverse effect of the treatment."
3158,0,"The patient is a 46-year-old white female with a BMI of 38.32. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
3159,1,"The patient is a 58-year-old white male with a BMI of 21.02. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab, and his KRAS biomarker status is mutant."
3160,0,"The patient is a 58-year-old white male with a BMI of 26.3. He is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
3161,1,"The patient is a 64-year-old Black male with a BMI of 31.87. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type status."
3162,0,The patient is a male who underwent laparoscopic-assisted colectomy. He only used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the cause of his symptoms is malignant.
3163,1,"The patient is a 70-year-old white male with a BMI of 22.53. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker for this patient is mutant."
3164,1,"This patient is a 60-year-old black female receiving treatment with 5FU/LV and radiation. She has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. She is also experiencing adverse effects such as low neutrophils/granulocytes, low leukocytes, and fatigue."
3165,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology showed symptoms but she was still able to be ambulatory. The pathology report indicated that the cause was malignant.
3166,0,"The patient is a 44-year-old white male with a BMI of 32.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
3167,0,"The patient is a 56-year-old white female with a BMI of 23.31. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
3168,1,"The patient is a 52-year-old white female with a BMI of 19.61. She is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
3169,1,"The patient is a 67-year-old white male with a BMI of 21.54 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a good performance status, experiencing symptoms but still able to walk around. The KRAS biomarker shows that he has a wild-type mutation. The patient is experiencing a rash as an adverse effect of the treatment."
3170,1,The patient is a 75-year-old white male with a BMI of 26.64. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is mutant. He is currently receiving treatment with the FOLFOX regimen.
3171,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the surgery. The histology indicates that she is in bed less than 50% of the time, and the pathology results show that the condition is malignant."
3172,1,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. The histology report indicates that the tumor cells are well-differentiated, and the pathology report shows that the tumor is benign."
3173,0,"The patient is a 66-year-old white male with a BMI of 25.12. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3174,0,The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery. He used narcotics for 1 day. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates a malignant condition.
3175,0,"The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 19.46. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis has revealed a mutant status."
3176,0,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3177,1,The patient is a male who is receiving treatment through conventional surgery. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3178,0,The patient is a 59-year-old white male enrolled in the ECF + Radiation treatment arm. He has a performance status of experiencing symptoms but is still able to walk around. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3179,0,"The patient is a 46-year-old white female with a BMI of 25.8. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed a mutant result. She has experienced adverse effects of hypersensitivity and diarrhea during her treatment."
3180,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He only used narcotics for 1 day. Despite having symptoms, he is able to walk around. The pathology results showed malignancy."
3181,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 4 days post-surgery. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the cause of the symptoms is malignant.
3182,0,The patient is a 51-year-old white male with a BMI of 26.79. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
3183,0,The patient is a 69-year-old white male with a BMI of 28.89 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a fully active performance status and has been identified as having a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
3184,0,"The patient is a male undergoing conventional surgery as part of their treatment. They have used narcotics for 6 days. The histology indicates that they are in bed less than 50% of the time, and the pathology report shows that the condition is malignant."
3185,1,"The patient is a 74-year-old white male with a BMI of 47.85. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
3186,1,The patient is a 45-year-old female of other race with a BMI of 18.29. She is experiencing symptoms but is still able to walk around (ambulatory). She has been diagnosed with a primary tumor in the colon and has a mutant KRAS biomarker. The patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
3187,0,"The patient is a 48-year-old white male with a BMI of 23.52. He is undergoing treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
3188,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 7 days post-surgery. The histology showed symptoms but the patient remained ambulatory. The pathology report indicated a malignant condition.
3189,1,"The patient is a 66-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
3190,0,"The patient is a 68-year-old white male with a BMI of 28.42. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3191,1,"The patient is a 52-year-old white male with a BMI of 28.39. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
3192,0,The patient is a 36-year-old Black female with a BMI of 25.47. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
3193,1,The patient is a 66-year-old white male with a BMI of 25.1 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status.
3194,0,"The patient is a 44-year-old white male with a BMI of 29.25. He is currently receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3195,1,The patient is a 64-year-old female of other race with a BMI of 27.56. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker indicates that it is mutant. The patient is receiving treatment with FOLFOX and Panitumumab.
3196,0,"The patient, a 51-year-old white male with a BMI of 28.17, is receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a fully active performance status. The patient has developed a rash as an adverse effect of the treatment. The rash is a skin reaction characterized by redness, itching, and possibly the formation of small bumps or blisters on the skin."
3197,0,The patient is a 66-year-old white female with a BMI of 29.1. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
3198,0,"The patient is a 57-year-old white male with a BMI of 26.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type mutation."
3199,0,The patient is a 58-year-old white male with a BMI of 20.96 who is currently receiving treatment with FOLFOX for a colon tumor. He has symptoms but is still able to walk around. The KRAS biomarker testing revealed a mutation in the KRAS gene.
3200,0,The patient is a 73-year-old white male with a BMI of 30.8. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type.
3201,1,"The patient is a 79-year-old white female with a BMI of 20.17. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a mutant KRAS status."
3202,1,"The patient is a 60-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around. His histology shows poorly differentiated cells. The patient is experiencing anorexia as an adverse effect, which means he has a decreased appetite or loss of interest in food."
3203,1,"The patient is a 66-year-old white female with a BMI of 21.12. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
3204,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days following the procedure. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
3205,0,"The patient is a 40-year-old white male with a BMI of 24.91. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
3206,1,"The patient is a 58-year-old white male with a BMI of 22.5. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around and perform daily activities."
3207,0,"The patient is a 75-year-old white male with a BMI of 26.09. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker indicates that the cancer is wild-type."
3208,0,The patient is a 56-year-old white male with a BMI of 34.42 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). His KRAS biomarker status is wild-type.
3209,0,"The patient is a male who underwent conventional surgery and has bowel adhesions. He experienced complications post-surgery and required 6 days of narcotic pain medication. Despite having symptoms, he is able to move around and be ambulatory. The pathology report indicates a malignant condition."
3210,1,"The patient is a 72-year-old white female with a BMI of 22.94. She is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
3211,1,"The patient is a 62-year-old black male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
3212,1,"The patient is a 61-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
3213,0,"The patient is a 48-year-old white male with a BMI of 32.25. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
3214,0,"The patient is a 68-year-old white female with a BMI of 31.89. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
3215,1,The patient is a 62-year-old white male participating in the treatment arm receiving ECF chemotherapy along with radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3216,1,"The patient is a 57-year-old white female with a BMI of 24.97. She is currently receiving treatment with FOLFOX and Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a mutant KRAS status."
3217,0,"The patient is a 57-year-old white female with a BMI of 33.91. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
3218,1,"The patient is a 64-year-old white female with a BMI of 25.4. She is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker test showed a mutation. The patient has developed a rash as an adverse effect of the treatment."
3219,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to be ambulatory. The pathology report indicates malignancy."
3220,1,"The patient is a 71-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and white blood cells."
3221,1,The patient is a 53-year-old black female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated.
3222,0,"The patient is a 48-year-old white male with a BMI of 47.18. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced serious adverse effects, including thrombosis and hypersensitivity reactions. The patient has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and his KRAS biomarker is wild-type. Despite experiencing symptoms, the patient is still ambulatory."
3223,0,"The patient is a 37-year-old white female with a BMI of 25.87. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
3224,0,"The patient is a 73-year-old white female with a BMI of 33.16. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3225,1,"The patient is a 69-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. Additionally, the patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
3226,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 28.76. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker status is indeterminate."
3227,0,"The patient is a 52-year-old white female with a BMI of 25.72. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
3228,1,The patient is a 54-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3229,0,"The patient is a 70-year-old white female with a BMI of 25.5. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3230,1,"The patient is a 54-year-old white male with a BMI of 23.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3231,1,This patient is a 61-year-old white male with a BMI of 28.08. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. His KRAS biomarker status is wild-type.
3232,0,"The patient is a 69-year-old white male with a BMI of 32.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
3233,0,"The patient is a 40-year-old white male with a BMI of 33.56. He is receiving treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 9 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the adverse effect of hypersensitivity, the patient's performance status remains fully active. The KRAS biomarker indicates that he has a wild-type mutation."
3234,1,"The patient is a 62-year-old white female with a BMI of 31.83. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3235,0,"The patient is a 55-year-old white female with a BMI of 26.25. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3236,0,The patient is a 40-year-old white female with a BMI of 31.62. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Her performance status is fully active. The KRAS biomarker status is indeterminate.
3237,0,The patient is a 60-year-old white female with a BMI of 37.11. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
3238,0,"The patient is a 74-year-old female of a race categorized as ""other"" with a BMI of 21.91. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the KRAS biomarker testing revealed a mutant status."
3239,0,The patient is a 64-year-old white female with a BMI of 25.79. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
3240,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results showed well-differentiated cells, and the pathology report indicated that the tissue was benign."
3241,1,The patient is a 57-year-old white female with a BMI of 28.65 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis revealed a mutant status.
3242,0,"The patient is a 60-year-old female of a race other than Caucasian. She has a BMI of 26.27 and is receiving treatment with FOLFOX + Cetuximab. She is scheduled for 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3243,0,The patient is a 61-year-old white female with a BMI of 28.57. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
3244,1,"The patient is a 49-year-old white male with a BMI of 30.94. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
3245,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
3246,0,"The patient is a 53-year-old white female with a BMI of 28.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a wild-type result. The patient is currently experiencing diarrhea as an adverse effect of the treatment."
3247,0,"The patient is a 67-year-old white female with a BMI of 33.61. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3248,1,The patient is a 49-year-old black male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. The histology of the cancer is poorly differentiated.
3249,1,"The patient is a 70-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
3250,0,The patient is a 47-year-old white female with a BMI of 20.51. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and carries a mutant KRAS biomarker.
3251,1,The patient is a 69-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
3252,0,"The patient is a 70-year-old white female with a BMI of 25.03. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates she has a wild-type status. She is experiencing diarrhea as an adverse effect of the treatment."
3253,0,"The patient is a 43-year-old white female with a BMI of 25.54. She is receiving treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
3254,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He used narcotics for 5 days post-surgery. Despite experiencing symptoms, he is able to move around independently. The pathology report indicates a malignant condition."
3255,1,"The patient is a 70-year-old white male with a BMI of 21.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
3256,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days post-surgery. Their histology shows that they are in bed less than 50% of the time, and their pathology indicates a malignant condition."
3257,0,The patient is a 43-year-old white female with a BMI of 31.56. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
3258,1,"This patient is a 65-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
3259,1,"The patient is a 48-year-old white male with a BMI of 26.1. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3260,0,"This patient is a 65-year-old white female with a BMI of 30.11 who is receiving treatment with FOLFOX for a rectal tumor. She has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
3261,0,"The patient is a 52-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing an adverse effect of leukocytes, indicating a decrease in white blood cells."
3262,0,This patient is a 46-year-old white female who is part of the placebo treatment arm. She has a performance status indicating that she spends less than 50% of her time in bed.
3263,0,"The patient is a 62-year-old white female with a BMI of 26.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
3264,0,The patient is a 35-year-old white female with a BMI of 28.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
3265,1,"The patient is a 70-year-old white male with a BMI of 26.12 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and he has a mutant KRAS biomarker."
3266,0,"The patient is a 36-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a bowel perforation and has completed 3 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
3267,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 4 days. She spends less than 50% of her time in bed. The histology indicates a malignant condition.
3268,1,The patient is a 50-year-old white male with a BMI of 23.79 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. The KRAS biomarker indicates that he has a wild-type mutation. The patient is experiencing a rash as an adverse effect of the treatment.
3269,0,The patient is a 44-year-old white female with a BMI of 34.62. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
3270,1,"The patient is a 68-year-old white female with a BMI of 29.36. She is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that the patient has a mutant KRAS gene."
3271,1,"The patient is a 46-year-old white male with a BMI of 26.12. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to the prescribed regimen. He has experienced both a bowel obstruction and a bowel perforation. So far, he has completed 3 cycles of chemotherapy. The histology of his condition is well-differentiated, and his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
3272,1,"The patient is a 35-year-old Black female with a BMI of 47.06. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite having a fully active performance status, she has experienced hypersensitivity as an adverse effect. Her KRAS biomarker is wild-type."
3273,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to walk around (ambulatory). The pathology report indicates that the tumor is malignant.
3274,0,"The patient is a 62-year-old white female with a BMI of 29.77. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
3275,1,"The patient is a 61-year-old white female with a BMI of 34.48. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
3276,0,"The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 29.27. He is undergoing treatment with the FOLFIRI regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active despite the adverse effect."
3277,0,"The patient is a 56-year-old white male with a BMI of 31.57. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his treatment, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3278,0,"The patient is a 49-year-old white female with a BMI of 18.03 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a wild-type KRAS biomarker. Despite experiencing symptoms, she is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
3279,1,"The patient is a 70-year-old white male with a BMI of 29.17. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
3280,1,The patient is a 64-year-old white male with a BMI of 23.38 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a mutant status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
3281,1,"The patient is a 72-year-old black male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated. Additionally, he is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
3282,0,"The patient is a 58-year-old white male with a well-differentiated histology. He is currently enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to move around independently."
3283,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3284,0,"The patient is a 53-year-old white male with a BMI of 28.85 who is undergoing treatment with FOLFOX + Cetuximab for colorectal cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
3285,0,"The patient is a 54-year-old white female with a BMI of 31.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
3286,0,"The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 29.4. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
3287,0,The patient is a 51-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology of the cancer is poorly differentiated.
3288,1,The patient is a 63-year-old white female with a fully active performance status. She is currently enrolled in the treatment arm receiving a placebo in the clinical trial.
3289,0,"The patient is a 65-year-old white male with a BMI of 35.34. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3290,0,The patient is a 62-year-old white female with a BMI of 30.29. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
3291,0,"The patient is a 45-year-old white female with a BMI of 27.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
3292,1,"The patient is a 48-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low neutrophil/granulocyte levels, nausea, and loss of appetite."
3293,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. They experienced complications and used narcotics for 4 days post-surgery. Despite having symptoms, they are able to walk around. The pathology report indicated malignancy."
3294,1,"The patient is a 74-year-old white male with a BMI of 22.16. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker is mutant. The patient has also experienced diarrhea as an adverse effect of the treatment."
3295,1,This patient is a 59-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3296,1,"The patient is a male undergoing laparoscopic-assisted colectomy. He has bowel adhesions present. He has been using narcotics for 4 days. Histologically, he is experiencing symptoms but is still able to be ambulatory. Pathologically, the condition is malignant."
3297,1,The patient is a 76-year-old white male with a BMI of 29.03. He is receiving treatment with FOLFOX for colon cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
3298,0,"The patient is a 46-year-old white female with a BMI of 26.8. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3299,0,The patient is a 41-year-old white female with a BMI of 41.84 who is undergoing treatment with FOLFOX + Cetuximab for well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
3300,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3301,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery. She used narcotics for 7 days following the procedure. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated malignancy."
3302,0,"The patient is a 60-year-old white male with a BMI of 36.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker shows that he is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
3303,1,"The patient is a 59-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects related to his blood cells, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
3304,0,The patient is a male undergoing treatment with laparoscopic-assisted colectomy. He has only used narcotics for 1 day. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3305,0,"The patient is a 54-year-old white male with a BMI of 33.34. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3306,1,The patient is a 63-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has a fully active performance status.
3307,1,The patient is a 68-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3308,0,"The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 25.96. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status and her KRAS biomarker is wild-type."
3309,0,"The patient is a 57-year-old female of a race categorized as ""other"" with a BMI of 20.97. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3310,1,"In this patient profile, the individual is a 71-year-old white female receiving treatment with Cisplatin and Etoposide. She has undergone 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. An adverse effect noted in this case is the presence of lymphocytes."
3311,0,"The patient is a 41-year-old white male with a BMI of 24.33. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3312,0,"The patient is a 71-year-old white male with a BMI of 31.88 who is undergoing treatment with FOLFIRI + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. Additionally, he has developed an infection as an adverse effect of the treatment."
3313,0,The patient is a 53-year-old white female with a BMI of 24.97. She is receiving the FOLFOX treatment regimen and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
3314,1,"The patient is a 48-year-old Black male with a BMI of 25.18. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status remains fully active. The KRAS biomarker analysis showed that he has a wild-type KRAS status."
3315,1,"The patient is a 53-year-old white female with a BMI of 20.31. She is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
3316,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and experienced complications post-surgery. He only used narcotics for 1 day. His histology shows symptoms but he is ambulatory, and the pathology report indicates malignancy."
3317,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results showed well-differentiated cells, and the pathology report indicated a benign condition."
3318,1,"The patient is a 67-year-old white female with a BMI of 25.24 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to be ambulatory. The patient has developed a rash as an adverse effect of the treatment."
3319,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall and bowel adhesions present. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates a malignant condition.
3320,0,"The patient is a 63-year-old white male with a BMI of 32.19. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates he is wild-type. The patient has experienced a hypersensitivity adverse effect."
3321,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications during his treatment. He used narcotics for 5 days post-surgery. Despite having symptoms, he was able to remain ambulatory. The pathology report revealed a malignant condition."
3322,0,"The patient is a 48-year-old Black female with a BMI of 26.45. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, she has a mutant KRAS biomarker."
3323,0,"The patient is a 72-year-old Black female with a BMI of 28.76. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
3324,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 4 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3325,0,"The patient is a 66-year-old white male with a BMI of 32.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker indicates that he has a wild-type gene."
3326,1,"The patient is a 72-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
3327,1,"The patient is a 57-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
3328,0,"The patient is a 68-year-old Black male with a BMI of 33.36. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker is mutant, and the patient has also experienced thrombosis as an adverse effect."
3329,1,"This patient is a 50-year-old white female with a BMI of 18.26. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis revealed that she has a mutant KRAS status."
3330,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
3331,0,"The patient is a 52-year-old male of a race categorized as ""other"" with a BMI of 36.23. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
3332,1,"The patient is a 66-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient has developed a decrease in white blood cells as an adverse effect of the treatment."
3333,0,The patient is a 58-year-old Black male with a BMI of 20.0. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3334,0,The patient is a 66-year-old white male with a BMI of 34.38. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
3335,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3336,0,"This patient is a 40-year-old white male with a BMI of 29.9. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
3337,1,"The patient is a 52-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to ambulate. The histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and fatigue."
3338,1,"The patient is a 49-year-old white male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory, indicating a relatively good performance status."
3339,1,The patient is a 61-year-old white male with a BMI of 26.99 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
3340,1,"The patient is a 46-year-old black female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. The patient has experienced an adverse effect related to her granulocytes/bands, which suggests a potential issue with her white blood cell count."
3341,0,"This patient is a 63-year-old white female with a BMI of 38.21. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
3342,1,The patient is a male who is undergoing conventional surgery as part of their treatment. They have been using narcotics for 9 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
3343,1,"The patient is a 63-year-old white female with a BMI of 32.67. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3344,0,"The patient is a 52-year-old white male with a BMI of 27.75. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is mutant, and he has also experienced an adverse effect of thrombosis."
3345,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She has been using narcotics for 5 days. Despite experiencing symptoms, she is still able to move around. The pathology report indicates that the condition is malignant."
3346,1,"The patient is a 65-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite this, she is able to move around and perform daily activities, although she is experiencing symptoms. Additionally, she is showing adverse effects related to low levels of granulocytes/bands."
3347,0,"The patient is a 72-year-old white female with a BMI of 24.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced adverse effects including hypersensitivity and diarrhea."
3348,1,"The patient is a 74-year-old white male with a BMI of 33.11. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the cancer is wild-type."
3349,0,"The patient is a 52-year-old white female with a BMI of 29.44. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
3350,0,This patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has not used any narcotics for pain relief. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates a malignant condition.
3351,0,"The patient is a 55-year-old white male with a BMI of 41.95. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
3352,1,"The patient is a 75-year-old white male with a BMI of 33.75. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
3353,0,The patient is a 48-year-old white female with a fully active performance status. She is currently enrolled in the treatment arm receiving a placebo.
3354,1,The patient is a 73-year-old black female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
3355,1,"The patient is a 51-year-old Black or African American female with a BMI of 23.44. She is currently receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3356,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
3357,0,"The patient is a 46-year-old white female with a BMI of 24.14. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
3358,0,"The patient is a 65-year-old white female with a BMI of 22.86. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 12 cycles. Her histology shows poorly differentiated cancer cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
3359,0,"The patient is a 46-year-old white male with a BMI of 44.02. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3360,0,The patient is a 54-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
3361,0,"The patient is a 35-year-old white male with a BMI of 25.82. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3362,0,"The patient is a 45-year-old white female with a BMI of 19.85. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
3363,0,"The patient is a 47-year-old white male with a BMI of 26.56. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. Despite this, his performance status remains fully active. The patient has a mutant KRAS biomarker and has also experienced thrombosis as an adverse effect."
3364,0,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotic medication for 3 days.
3365,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the cause of her symptoms is malignant.
3366,0,"The patient is a 60-year-old white female with a BMI of 25.95. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
3367,0,The patient is a 42-year-old white male with a BMI of 28.74. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type gene.
3368,1,"The patient is a 58-year-old white male with a BMI of 19.0. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
3369,0,The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 4 days and is experiencing symptoms but is still able to walk around. The pathology report indicates that the condition is malignant.
3370,0,"The patient is a 64-year-old white female with a BMI of 40.74. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during treatment."
3371,1,"In this patient profile, the individual is a 63-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
3372,0,"The patient is a 59-year-old white male with a BMI of 29.48. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
3373,0,"The patient is a 48-year-old white female with a BMI of 27.49. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3374,0,"The patient is a 46-year-old Black male with a BMI of 23.36. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
3375,0,The patient is a 51-year-old white male with a BMI of 24.41. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
3376,1,"The patient is a 59-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She is currently on her 6th cycle of chemotherapy. Despite experiencing symptoms, she is still able to walk around and perform daily activities."
3377,0,"The patient is a 41-year-old white female with a BMI of 27.4. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type."
3378,1,"The patient is a 68-year-old white male with a BMI of 25.8. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
3379,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
3380,1,The patient is a 41-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
3381,0,"The patient is a 73-year-old white female with a BMI of 23.21. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3382,0,"The patient is a 53-year-old white female with a BMI of 27.73. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is mutant. Additionally, she has experienced thrombosis as an adverse effect."
3383,0,"The patient is a 57-year-old white female with a BMI of 29.16. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3384,0,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3385,0,"The patient is a male who underwent conventional surgery and was found to have bowel adhesions. He experienced complications post-surgery and required narcotic pain medication for 5 days. The histology results showed that the tissue was well-differentiated, and the pathology report indicated that the condition was benign."
3386,1,"The patient is a 45-year-old Black male with a BMI of 20.99. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3387,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days following the procedure. The histology results showed that the tumor was well-differentiated, and the pathology report confirmed that it was malignant."
3388,0,"The patient is a 39-year-old white male with a BMI of 36.08. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3389,0,"The patient is a 74-year-old white male with a BMI of 29.87. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3390,0,"The patient is a 40-year-old white female with a BMI of 23.64. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
3391,0,"The patient is a 65-year-old white male with a BMI of 26.25 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect in the form of a bowel obstruction after completing one cycle of chemotherapy. The histology of his cancer is well-differentiated, and he has symptoms but is still able to be ambulatory. His KRAS biomarker status is wild-type. Additionally, he has also experienced an infarction as an adverse effect."
3392,0,"The patient is a 42-year-old white male with a BMI of 27.64. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3393,0,The patient is a 70-year-old Black male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated.
3394,0,"The patient is a 70-year-old white female with a BMI of 47.72. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 chemotherapy cycles. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate."
3395,1,The patient is a 51-year-old white female with a fully active performance status. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3396,0,"The patient is a 35-year-old white male with a BMI of 22.68. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3397,1,The patient is a 71-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the clinical trial. The histology of his condition is well differentiated.
3398,0,"The patient is a 72-year-old white male with a BMI of 31.14. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. Unfortunately, he has experienced an adverse effect in the form of thrombosis."
3399,0,"The patient is a 45-year-old white female with a BMI of 30.24. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3400,1,The patient is a 50-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low neutrophil/granulocyte levels and fatigue.
3401,0,The patient is a 52-year-old white male with a BMI of 27.47 who is receiving the FOLFOX treatment regimen for his well-differentiated cancer. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
3402,0,The patient is a 66-year-old white male with a BMI of 33.43. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
3403,0,"The patient is a 62-year-old white male with a BMI of 29.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
3404,1,The patient is a 54-year-old white female with a BMI of 21.51. She is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS status.
3405,1,"In this patient profile, the individual is a 62-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is the presence of granulocytes/bands. This indicates that there is an abnormal level of immature white blood cells in the bloodstream, which may be a result of the chemotherapy treatment."
3406,0,The patient is a 40-year-old Black male with a BMI of 23.84. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3407,0,The patient is a male who underwent conventional surgery as part of their treatment plan. They experienced complications following the surgery. They used narcotics for 6 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology report indicated a malignant condition.
3408,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
3409,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has been using narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
3410,0,"The patient is a 49-year-old white male with a BMI of 27.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
3411,0,"The patient is a 55-year-old white female with a BMI of 38.95. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3412,1,The patient is a 64-year-old black male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
3413,0,The patient is a 73-year-old white male with a BMI of 32.18 who is currently receiving treatment with FOLFOX for colon cancer. He has a fully active performance status and has been identified as having a wild-type KRAS biomarker.
3414,1,"The patient is a 34-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of the treatment."
3415,0,"The patient is a 69-year-old white male with a BMI of 29.79. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3416,1,"The patient is a 66-year-old white male with a BMI of 28.63 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker is mutant. The patient is experiencing dermatitis acneiform as an adverse effect, which presents as a skin condition characterized by acne-like eruptions."
3417,1,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
3418,1,"The patient is a 62-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
3419,1,The patient is a 66-year-old white male with a BMI of 25.71. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker status is wild-type.
3420,0,The patient is a 63-year-old white female with a BMI of 20.27 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
3421,1,The patient is a 59-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his granulocytes/bands and white blood cells.
3422,0,"The patient is a 65-year-old white male with a BMI of 26.04. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
3423,1,"The patient is a 71-year-old white male with a BMI of 23.25. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around. His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
3424,1,The patient is a 58-year-old white male with a fully active performance status who is receiving treatment with a placebo.
3425,0,"This patient is a 73-year-old white male with a BMI of 26.53. He is receiving treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
3426,1,"The patient is a 61-year-old white male with a BMI of 28.73. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite this, his performance status is fully active. The patient's KRAS biomarker status is mutant."
3427,0,The patient is a 48-year-old Black male with a BMI of 33.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3428,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the cause of the symptoms is malignant.
3429,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days following the procedure. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
3430,0,The patient is a 73-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with ECF and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
3431,1,"The patient is a 72-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. Additionally, he is experiencing a decrease in lymphocytes as an adverse effect of the treatment."
3432,1,The patient is a 67-year-old white female with a BMI of 25.0 who has symptomps but remains ambulatory. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
3433,0,"The patient is a 74-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and perform daily activities."
3434,1,"The patient is a 74-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
3435,0,The patient is a male undergoing treatment with laparoscopic-assisted colectomy. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3436,1,"The patient is a 59-year-old white male with a BMI of 30.48. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 8 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3437,0,"The patient is a 49-year-old white female with a BMI of 30.61. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
3438,1,"The patient is a 50-year-old white male with a BMI of 22.59 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has mutant KRAS biomarker status. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a rash as an adverse effect of the treatment."
3439,0,"The patient is a 70-year-old white male with a BMI of 31.91. He is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
3440,1,The patient is a 54-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3441,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still able to move around. The pathology report indicates malignancy.
3442,0,"The patient is a 36-year-old white male with a BMI of 18.37. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
3443,1,The patient is a 72-year-old white male with a BMI of 24.72 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type. The patient is experiencing acne as an adverse effect of the treatment.
3444,1,"In this patient profile, the individual is a 52-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is the presence of granulocytes/bands. This indicates that the patient may be experiencing a decrease in certain types of white blood cells, which are important for fighting infections."
3445,1,The patient is a 56-year-old white male with a BMI of 21.56. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
3446,0,"The patient is a 66-year-old white female with a BMI of 25.51. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3447,1,This patient is a 45-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated.
3448,1,The patient is a 62-year-old white female with a BMI of 34.95. She is fully active with a primary tumor diagnosis of colon cancer. The patient is receiving treatment with the FOLFOX regimen. The KRAS biomarker analysis shows a mutant status.
3449,0,The patient is a female who is part of the conventional surgery treatment arm. She has bowel adhesions and has been using narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate malignancy.
3450,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 8 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3451,1,"The patient is a 67-year-old white female with a BMI of 24.58. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3452,1,The patient is a 73-year-old white male with a BMI of 22.04. He is fully active and is receiving treatment with the FOLFOX regimen for his colon cancer. His KRAS biomarker status is wild-type.
3453,1,The patient is a 54-year-old white female with a BMI of 21.37 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker indicates that she has a mutant status.
3454,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required 10 days of narcotic medication for pain management. Despite the symptoms, he was still able to be ambulatory. The pathology report revealed a malignant condition."
3455,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate malignancy.
3456,0,The patient is a 48-year-old white female with a BMI of 27.99. She is receiving treatment with FOLFOX and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
3457,1,The patient is a 53-year-old white female with a BMI of 29.69. She is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
3458,0,"The patient is a 71-year-old white female with a BMI of 18.48. She is currently receiving treatment with FOLFOX and Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3459,0,"The patient is a 61-year-old white male with a BMI of 22.14. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is mutant in this patient. He has experienced hypersensitivity as an adverse effect."
3460,0,"The patient is a 75-year-old male of a race categorized as ""other"" with a BMI of 17.86. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker shows that he has a wild-type status. Additionally, the patient has developed an infection as an adverse effect of the treatment."
3461,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 6 days post-surgery. Their histology indicates that they are in bed less than 50% of the time, and their pathology report shows that the condition is malignant."
3462,1,"The patient is a 72-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. She is experiencing adverse effects of low granulocytes/bands and nausea."
3463,1,The patient is a 75-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated.
3464,0,"The patient is a 52-year-old white male with a high BMI of 46.11. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
3465,0,The patient is a 74-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3466,0,"The patient is a 50-year-old white male with a BMI of 35.66. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant. The patient is experiencing diarrhea as an adverse effect of the treatment."
3467,1,"The patient is a 73-year-old white female with a BMI of 20.0. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
3468,0,The patient is a 41-year-old white female with a BMI of 21.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
3469,0,"The patient is a 70-year-old white male with a BMI of 31.39. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he is wild-type. The patient has experienced an adverse effect in the form of an infection."
3470,0,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotic medication for 2 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
3471,0,"The patient is a 46-year-old white male with a BMI of 33.98. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
3472,1,"The patient is a 66-year-old white female with a BMI of 16.75. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She experienced a serious adverse effect in the form of a bowel obstruction after completing one cycle of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she developed a hypersensitivity adverse effect during treatment."
3473,1,"The patient is a 56-year-old white male with a BMI of 28.68. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. His primary tumor diagnosis is rectal cancer, and he has a mutant KRAS biomarker."
3474,0,"This patient is a female who is in the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows that she is in bed less than 50% of the time, and her pathology indicates that she has a malignant condition."
3475,0,The patient is a male who is receiving conventional surgery as part of their treatment. They have used narcotics for 2 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
3476,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. There have been complications during the treatment. He used narcotics for 5 days post-surgery. Despite experiencing symptoms, he is able to walk around. The pathology report indicates malignancy."
3477,0,"The patient is a 44-year-old female of a race categorized as ""other"" with a BMI of 23.37. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
3478,1,"The patient is a 46-year-old white female with a BMI of 20.89. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker status is indeterminate."
3479,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days following the surgery. The histology results indicate that she is in bed less than 50% of the time, and the pathology report shows that the tumor is malignant."
3480,0,"The patient is a 61-year-old white female with a BMI of 26.06. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3481,0,This patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 6 days and spends less than 50% of his time in bed. The pathology report indicates a malignant condition.
3482,0,"The patient is a 34-year-old white female with a BMI of 28.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. She has experienced a hypersensitivity adverse effect."
3483,0,"The patient is a 68-year-old female of a race categorized as ""other"" with a BMI of 21.06. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3484,1,The patient is a 58-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around (ambulatory). She is also reporting fatigue as an adverse effect of the treatment.
3485,0,"The patient is a 46-year-old Black male with a BMI of 27.25. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3486,0,"The patient is a 41-year-old white male with a BMI of 29.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3487,0,The patient is a 59-year-old white male with a BMI of 25.23. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3488,0,"This patient is a 65-year-old white female with a BMI of 21.51. She is currently receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She is experiencing a bowel obstruction and has completed 7 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
3489,0,The patient is a 58-year-old white female with a BMI of 33.98. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate for this patient.
3490,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 1 day post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
3491,0,"The patient is a 61-year-old Black male with a BMI of 23.22. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology with a KRAS mutant status. He has experienced a serious adverse effect during the treatment, specifically diarrhea. Despite this, he has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type."
3492,0,This patient is a 59-year-old white male participating in the placebo treatment arm of the study. He has symptoms but is still able to move around and be ambulatory.
3493,1,"The patient is a 63-year-old white male with a BMI of 23.2. He is receiving treatment with FOLFOX for a primary rectal tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, his KRAS biomarker status is wild-type."
3494,0,"The patient is a 62-year-old white male with a BMI of 28.69 who is receiving treatment with FOLFOX + Cetuximab for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. He has experienced an adverse effect in the form of an infection."
3495,0,The patient is a 42-year-old white male with a BMI of 27.96. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is mutant. He has experienced adverse effects of diarrhea and infection.
3496,0,The patient is a 58-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. The histology shows well-differentiated characteristics.
3497,1,"The patient is a 64-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed low white blood cell count as an adverse effect of the treatment."
3498,0,"The patient is a 48-year-old white male with a BMI of 35.63. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
3499,0,"The patient is a 65-year-old white female with a BMI of 22.76. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
3500,0,This patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 2 days and her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
3501,1,"The patient is a 45-year-old black female with a well-differentiated histology. She is in the treatment arm receiving ECF chemotherapy along with radiation. Despite her cancer treatment, she has a fully active performance status."
3502,0,"The patient is a 68-year-old female of a race classified as ""other"" with a BMI of 21.79. She is part of the FOLFOX treatment arm but has not undergone any chemotherapy cycles yet. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker indicates that it is wild-type."
3503,1,The patient is a 64-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
3504,1,"The patient is a 79-year-old white female who is undergoing treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around. The patient has developed adverse effects related to her blood counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
3505,0,"The patient is a 41-year-old white male with a BMI of 36.12. He is currently receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is mutant. Additionally, he has developed thrombosis as an adverse effect."
3506,0,"The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications following the procedure. They used narcotics for 9 days post-surgery. Despite having symptoms, the patient was still able to be ambulatory. The pathology results indicated malignancy."
3507,0,"The patient is a 65-year-old white male with a BMI of 26.37. He is receiving treatment with FOLFOX chemotherapy. He has experienced both a bowel obstruction and perforation. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
3508,0,"The patient is a 76-year-old Black male with a BMI of 30.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
3509,1,"The patient is a 71-year-old white male with a BMI of 26.61. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3510,0,"This patient is a 44-year-old white male with a BMI of 27.72. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
3511,0,"The patient is a 69-year-old white male with a BMI of 20.28. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3512,0,"The patient is a 63-year-old white male with a BMI of 33.71 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
3513,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3514,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesion as well as bowel adhesion. She experienced complications post-surgery and used narcotics for 4 days. Despite having symptoms, she is able to walk around. The pathology report indicates malignancy."
3515,0,"The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 38.52. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her diagnosis, she maintains a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
3516,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 4 days post-surgery. The histology showed symptoms but the patient was still able to be ambulatory. The pathology results indicated malignancy.
3517,1,"The patient is a 51-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, indicating an abnormality in his white blood cell count."
3518,0,"The patient is a 53-year-old white female with a BMI of 19.69 who is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has been adherent to her treatment. However, she experienced a serious adverse effect after completing one cycle of chemotherapy, which was diarrhea. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
3519,0,"The patient is a 52-year-old white male with a BMI of 27.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3520,1,"The patient is a 67-year-old white male with a BMI of 21.45. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
3521,0,"The patient is a 67-year-old white female with a BMI of 23.48. She is currently receiving the FOLFIRI treatment regimen and has completed 11 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3522,1,The patient is a 46-year-old white male with a BMI of 26.49 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory) and has been diagnosed with a primary tumor in the rectum.
3523,0,"The patient is a 43-year-old white female with a BMI of 37.6 who is receiving the FOLFIRI treatment regimen. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Her cancer histology is poorly differentiated, and her performance status indicates that she has symptoms but is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
3524,1,"The patient is a 43-year-old Black male with a BMI of 27.76. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his condition, he has a fully active performance status."
3525,0,"The patient is a 56-year-old white female with a BMI of 30.72. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect in the form of a bowel perforation. She has completed 11 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced adverse effects in the form of hypersensitivity and diarrhea."
3526,0,"The patient is a 40-year-old white male with a BMI of 38.58. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status. Additionally, the patient has developed thrombosis as an adverse effect."
3527,0,"This patient is a 64-year-old white male with a BMI of 31.87. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
3528,0,"The patient is a 41-year-old white female with a BMI of 33.39. She is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3529,0,"The patient is a 62-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is currently experiencing adverse effects related to his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
3530,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 5 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the condition is malignant.
3531,1,"The patient is a 32-year-old white male with a BMI of 23.45. He is currently receiving treatment with FOLFOX + Planitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS gene. Additionally, he is experiencing dermatitis acneiform as adverse effect."
3532,0,This patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
3533,0,"The patient is a 56-year-old white male with a BMI of 31.06. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3534,0,"This patient is a 72-year-old white male with a BMI of 33.32. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
3535,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3536,1,"The patient is a 49-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low neutrophil/granulocyte levels, low leukocyte levels, and anorexia."
3537,0,"The patient is a 50-year-old white female with a BMI of 33.19. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced a hypersensitivity adverse effect."
3538,1,The patient is a 67-year-old male of other race with a BMI of 21.89. He is experiencing symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer. The KRAS biomarker shows that he has a wild-type status. The patient is currently on the FOLFOX chemotherapy regimen combined with Panitumumab for treatment.
3539,1,"The patient is a 68-year-old white male who is currently receiving treatment with Sunitinib. He has symptoms but is still able to walk around, indicating that his performance status is relatively good despite experiencing some health issues."
3540,0,"The patient is a 52-year-old white male with a BMI of 32.95. He is currently undergoing treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to move around independently. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
3541,0,"The patient is a 49-year-old male of a race other than specified, with a BMI of 23.58. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
3542,0,"This patient is a 55-year-old Black female with a BMI of 40.88 who is receiving treatment with FOLFOX + Cetuximab for her well-differentiated cancer. She has undergone 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced the adverse effect of thrombosis."
3543,1,The patient is a 57-year-old white male with a BMI of 33.15. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is mutant.
3544,0,The patient is a 62-year-old white female with a BMI of 23.83. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type.
3545,0,"The patient is a 46-year-old white female with a BMI of 20.43. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3546,0,The patient is a 39-year-old white male with a BMI of 22.64. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
3547,1,The patient is a 63-year-old white male with a BMI of 31.83 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
3548,0,"The patient is a 40-year-old male of a race categorized as ""other"" with a BMI of 26.82. He is undergoing treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3549,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery. She used narcotics for 3 days following the procedure. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated a malignant condition."
3550,0,The patient is a female undergoing conventional surgery for a malignant condition. She has experienced symptoms but is still able to walk around. She has used narcotics for 2 days.
3551,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3552,0,"The patient is a 59-year-old white female with a BMI of 27.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
3553,1,This patient is a 65-year-old white male with a BMI of 30.85 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis shows that he has a mutant KRAS status.
3554,0,"The patient is a 40-year-old white female with a BMI of 22.13. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She experienced serious adverse effects during the 12 chemotherapy cycles, including diarrhea and infection. The histology of her condition is poorly differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type."
3555,1,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 3 days post-surgery. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
3556,1,"The patient is a 72-year-old Black male with a BMI of 19.14. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
3557,1,The patient is a 69-year-old white male with a BMI of 28.52. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type.
3558,0,"The patient is an 81-year-old white male with a BMI of 29.07. He is currently receiving treatment in the FOLFOX + Panitumumab treatment arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
3559,1,"The patient is a 48-year-old white male with a BMI of 30.25. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
3560,0,The patient is a male who is receiving conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3561,0,"The patient is a 76-year-old white male with a BMI of 19.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of his 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3562,1,This patient is a 62-year-old white female with a BMI of 17.12. She is fully active with a primary tumor diagnosis of colon. She is in the treatment arm receiving FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
3563,1,"The patient is a 73-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood counts, specifically a decrease in granulocytes/bands and white blood cells."
3564,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the surgery. The histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
3565,1,"The patient is a 69-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. He has shown adverse effects on his blood counts, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
3566,1,"The patient is a 65-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient has developed lymphocytopenia as an adverse effect, meaning his lymphocyte count is low."
3567,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required 12 days of narcotic use for pain management. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
3568,1,"This patient is a 77-year-old white male with a BMI of 25.86. He is currently receiving treatment with the FOLFOX regimen for a primary colon tumor. Despite experiencing symptoms, he is still able to walk and be active (performance status: symptoms but ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene."
3569,0,The patient is a 53-year-old white male with a BMI of 37.06. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3570,1,"The patient is an 80-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes."
3571,1,"The patient is a 56-year-old white male receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. The patient is showing adverse effects with low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
3572,0,"The patient is a 52-year-old white male with a BMI of 27.02. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3573,0,"The patient is a 62-year-old white female with a BMI of 22.98. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
3574,0,"The patient is a male who underwent conventional surgery and has bowel adhesions. He experienced complications post-surgery and used narcotics for 4 days. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
3575,0,"The patient is a 73-year-old white male with a BMI of 33.41. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
3576,0,"The patient is a 56-year-old white male with a BMI of 25.17. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has experienced serious adverse effects, including diarrhea and infection, during the 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
3577,0,"The patient is a 47-year-old white male with a BMI of 35.76. He is receiving FOLFIRI treatment for his KRAS mutant status and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status."
3578,0,"The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 18.92. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
3579,0,"The patient is a 62-year-old white male with a BMI of 21.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
3580,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
3581,0,"The patient is a 62-year-old white male with a BMI of 25.95 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 8 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect of his treatment."
3582,0,"The patient is a 45-year-old white male with a BMI of 26.89. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates a wild-type result."
3583,0,"The patient is a 41-year-old white male with a BMI of 37.12. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3584,1,The patient is a 46-year-old white male with a BMI of 26.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is wild-type.
3585,1,"The patient is a 67-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed adverse effects related to her white blood cells and granulocytes/bands."
3586,0,"The patient is a 44-year-old white female with a BMI of 24.04. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3587,1,"The patient is a 77-year-old white male with a BMI of 23.24. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that the patient has a mutant KRAS status."
3588,1,"The patient is a 75-year-old white male with a fully active performance status. He is receiving treatment with ECF and radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
3589,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 1 day. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
3590,0,"The patient is a 34-year-old white male with a BMI of 31.12. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3591,1,"This patient is a 59-year-old white female with a BMI of 20.08. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk around."
3592,0,"The patient is a 56-year-old white female with a BMI of 37.11. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
3593,1,"The patient is a 69-year-old white male with a BMI of 27.28. He is currently receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with colon cancer, and his KRAS biomarker status is wild-type."
3594,1,"The patient is a 62-year-old Black female who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. She has not started any chemotherapy cycles yet. Despite experiencing symptoms, she is still able to move around independently."
3595,1,"The patient is a 60-year-old white male with a BMI of 27.68. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that the patient has a mutant KRAS status."
3596,1,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 3 days post-surgery. The histology shows that he spent less than 50% of his time in bed, and the pathology report indicates a malignant condition."
3597,0,"The patient is a 53-year-old white female with a BMI of 32.28. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has symptoms but is still ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced a hypersensitivity adverse effect."
3598,1,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology indicates symptoms but the patient is still ambulatory. The pathology report shows that the condition is malignant.
3599,1,"The patient is a 50-year-old white female with a BMI of 23.5. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. It is worth noting that her KRAS biomarker is wild-type."
3600,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 3 days post-surgery. The histology shows symptoms but the patient is ambulatory. Pathology results indicate malignancy.
3601,1,"The patient is a 27-year-old white male with a BMI of 20.53 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows a mutation."
3602,0,"The patient is a 64-year-old white male with a BMI of 36.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
3603,1,"The patient is a 57-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory. The histology of his cancer is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and anorexia."
3604,0,The patient is a 61-year-old white male with a BMI of 23.56. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
3605,0,The patient is a 55-year-old white male with a BMI of 28.54. He is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
3606,0,"The patient is a 66-year-old female of a race categorized as ""other."" She is receiving treatment with 5FU/LV + Radiation. Despite experiencing symptoms, she is still able to move around (ambulatory). The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
3607,0,"The patient is a 75-year-old white male with a BMI of 29.56. He is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3608,0,The patient is a female undergoing treatment with laparoscopic-assisted colectomy. She has used narcotics for 1 day. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the condition is malignant.
3609,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications. He used narcotics for 2 days post-surgery. Despite having symptoms, he is able to walk around. The pathology report indicates a malignant condition."
3610,1,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days following the procedure. The histology indicates that she is in bed less than 50% of the time, and the pathology results show that the condition is malignant."
3611,0,"The patient is a 46-year-old white female with a BMI of 22.77. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker indicates that it is mutant. She has also experienced diarrhea as an adverse effect of the treatment."
3612,0,"The patient is a 67-year-old white male with a BMI of 34.19. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his cancer diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
3613,0,"The patient is a 42-year-old white female with a BMI of 34.18. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including thrombosis and diarrhea."
3614,0,The patient is a 59-year-old white male with a BMI of 23.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3615,1,The patient is a 57-year-old white male with a BMI of 28.56 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor. His KRAS biomarker status is wild-type.
3616,1,"The patient is a 71-year-old white male with a BMI of 32.72. He is fully active with a primary colon tumor diagnosis. The treatment arm for this patient is FOLFOX and Panitumumab, and the KRAS biomarker indicates a mutant status."
3617,1,The patient is a 56-year-old white female with a BMI of 23.42 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
3618,0,The patient is a 65-year-old white male with a BMI of 27.16. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3619,1,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3620,0,"The patient is a 76-year-old white male with a BMI of 27.5. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3621,1,"The patient is a 53-year-old white female undergoing treatment with Cisplatin + Etoposide. She has completed 5 cycles of chemotherapy and has symptoms but is still able to walk around (ambulatory). She is experiencing a side effect known as granulocytes/bands. This side effect involves changes in certain types of white blood cells called granulocytes, which can indicate an immune response to the treatment."
3622,0,"The patient is a 51-year-old white female with a BMI of 28.91. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker analysis shows that she has a mutant KRAS status."
3623,0,"The patient is a 61-year-old white female with a BMI of 29.1. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type KRAS gene."
3624,1,"The patient, a 50-year-old white male with a BMI of 31.71, is receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
3625,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the condition is malignant.
3626,1,"The patient is a 55-year-old white female with a BMI of 40.01. She is receiving the FOLFIRI treatment regimen for her well-differentiated cancer with a KRAS wild-type biomarker. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. She has completed 12 cycles of chemotherapy."
3627,0,The patient is a 55-year-old Black female with a BMI of 31.88. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is mutant.
3628,1,"The patient is a 34-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing an adverse effect known as granulocytes/bands. This side effect involves a decrease in the number of certain types of white blood cells, which are important for fighting infections."
3629,0,"The patient is a 43-year-old white female with a BMI of 22.77. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker shows that she is wild-type."
3630,0,"The patient is a 66-year-old white female with a BMI of 29.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced adverse effects including hypersensitivity and diarrhea."
3631,1,The patient is a 49-year-old white male with a BMI of 43.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
3632,0,"The patient is a 53-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3633,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He experienced complications post-surgery and used narcotics for 4 days. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
3634,1,"The patient is a 69-year-old white male with a BMI of 33.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3635,0,"The patient is a 65-year-old white female with a BMI of 29.02. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing indicates that she has a wild-type KRAS status."
3636,0,"The patient is a 59-year-old white female with a BMI of 20.87. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
3637,0,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3638,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and used narcotics for 3 days. Histologically, she is in bed less than 50% of the time, and the pathology report indicates malignancy."
3639,0,"The patient is a 50-year-old white male with a BMI of 30.99. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3640,1,"The patient is a 63-year-old white male with a BMI of 22.88. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is mutant."
3641,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. There have been complications post-surgery. He has used narcotics for 5 days. Despite experiencing symptoms, he is able to walk around. The pathology report indicates malignancy."
3642,1,"The patient is a 65-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
3643,1,"The patient is a 65-year-old white male with a BMI of 24.15. He is currently receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
3644,1,"The patient is a 57-year-old white female receiving treatment with Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy and is experiencing symptoms but is still able to walk around. She is also experiencing nausea as an adverse effect of the treatment."
3645,1,The patient is a 68-year-old white male with a BMI of 22.27. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
3646,0,"The patient is a 60-year-old white female with a BMI of 35.03. She is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
3647,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology results indicate that the cause of her symptoms is malignant.
3648,0,"The patient is a 55-year-old white female with a BMI of 29.98. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, she experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
3649,1,The patient is a 71-year-old white female who is receiving treatment with Sunitinib. Her performance status indicates that she spends less than 50% of her time in bed.
3650,0,"The patient is a 60-year-old white male with a BMI of 27.18. He is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3651,0,"The patient is a 64-year-old white female with a BMI of 33.19. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
3652,1,"The patient is a 54-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy and has a fully active performance status. He is experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
3653,0,"This patient is a 58-year-old Black male with a BMI of 35.8. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab. He has been adherent to the treatment plan. So far, he has not started any chemotherapy cycles. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
3654,0,"This patient is a 68-year-old white female with a BMI of 23.44. She is receiving treatment with FOLFOX + Cetuximab for her cancer. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is mutant."
3655,1,"The patient is a 64-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 31 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
3656,1,"The patient is a 60-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
3657,1,"The patient is a 67-year-old white female with a BMI of 23.94. She is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. She has completed one cycle of chemotherapy. The histology of her cancer is well differentiated. Despite her diagnosis, she has a fully active performance status."
3658,1,"The patient is a 65-year-old white female with a BMI of 36.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows poorly differentiated cancer, and her performance status is fully active. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
3659,0,"The patient is a 70-year-old white female with a BMI of 19.48. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to move around independently. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
3660,0,"The patient is a 44-year-old white female with a BMI of 31.64. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates a mutant status."
3661,0,"The patient is a 54-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
3662,1,"This patient is a 55-year-old female of a race categorized as ""other."" She is receiving treatment with ECF chemotherapy in combination with radiation therapy. Her performance status indicates that she is in bed less than 50% of the time. The histology of her condition is poorly differentiated. Additionally, she is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
3663,0,"The patient is a 43-year-old white female with a BMI of 21.16. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced both a bowel obstruction and a bowel perforation. So far, she has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3664,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the cause of her symptoms is malignant.
3665,1,"The patient is a 68-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
3666,0,The patient is a 41-year-old white male with a BMI of 31.35. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3667,0,"This patient is a 55-year-old female of a race other than specified, with a BMI of 30.22. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, she has reported experiencing diarrhea as an adverse effect of her treatment."
3668,0,"The patient is a 59-year-old white male with a BMI of 41.7. He is receiving the FOLFOX treatment regimen and has experienced serious adverse effects during the 12 chemotherapy cycles. The histology shows well-differentiated cells, and the patient has a fully active performance status. The KRAS biomarker is wild-type. Additionally, the patient has experienced adverse effects including thrombosis and infarction."
3669,0,"The patient is a 41-year-old Black female with a BMI of 27.0. She is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
3670,0,"The patient is a 61-year-old white female with a BMI of 26.43. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3671,1,"The patient is a 72-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects on his blood cells, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
3672,0,"The patient is a 39-year-old white female with a BMI of 31.72. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3673,0,"The patient is a 65-year-old white female with a BMI of 38.96. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type status."
3674,0,"The patient is a 47-year-old white female with a BMI of 22.34. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3675,1,The patient is a 47-year-old black female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated.
3676,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesion and bowel adhesion. She used narcotics for 5 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
3677,0,"The patient is a 49-year-old white male with a BMI of 40.17. He is receiving treatment with the FOLFOX regimen and has been adherent to the chemotherapy. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he is fully active in terms of performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3678,0,The patient is a 74-year-old white male with a BMI of 26.04 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
3679,1,"This patient is a 76-year-old white male with a BMI of 30.3. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite his medical challenges, his performance status is fully active. His KRAS biomarker is wild-type."
3680,1,"The patient is a 77-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is showing adverse effects with low levels of granulocytes/bands and white blood cells."
3681,1,"This patient is a 75-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed one cycle of chemotherapy. Despite experiencing symptoms, she is still able to move around. She is currently experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
3682,0,"The patient is a 49-year-old white female with a BMI of 23.35. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3683,1,"The patient is a 66-year-old white male with a BMI of 26.81. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has been diagnosed with poorly differentiated histology. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type. Additionally, he has developed an infection as an adverse effect of his treatment."
3684,0,"The patient is a 49-year-old white male with a BMI of 26.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
3685,0,"The patient is a 46-year-old white male with a BMI of 31.12. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 6 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
3686,0,"The patient is a 56-year-old female of a race other than specified, with a BMI of 20.95. She is currently undergoing treatment with the FOLFOX regimen for her bowel obstruction. She has completed one cycle of chemotherapy. The histology of her condition is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3687,0,"The patient is a 57-year-old white female with a BMI of 31.0. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
3688,0,"The patient is a 53-year-old white female with a BMI of 25.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
3689,0,"The patient is a 62-year-old white female with a BMI of 29.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a wild-type KRAS status."
3690,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
3691,1,"This patient is a 79-year-old white female with a BMI of 28.15. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
3692,0,"The patient is a 50-year-old male of a race categorized as ""other"" with a BMI of 23.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is wild-type."
3693,1,The patient is a 62-year-old white female with a BMI of 32.02. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
3694,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 5 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
3695,0,The patient is a 70-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low neutrophils/granulocytes and leukocytes.
3696,0,"This patient is a 69-year-old white male with a BMI of 28.03. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
3697,0,The patient is a 50-year-old white male with a BMI of 30.34. He is undergoing treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
3698,1,"The patient is a 76-year-old white male with a BMI of 25.39. He is receiving treatment with FOLFOX and Panitumumab for a colon tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker analysis shows a mutant status."
3699,1,The patient is a 75-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low neutrophils/granulocytes and leukocytes.
3700,0,"This patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 5 days following the procedure. Their histology indicates that they were in bed less than 50% of the time, and their pathology results showed malignancy."
3701,0,The patient is a 45-year-old white female with a BMI of 43.97. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that she has the wild-type KRAS gene.
3702,0,The patient is a 54-year-old Black male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing an adverse effect of low white blood cell count (leukocytes).
3703,0,The patient is a 46-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated.
3704,0,"The patient is a 55-year-old white male with a BMI of 26.66. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3705,1,The patient is a 65-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects of low granulocytes/bands and nausea.
3706,0,"The patient is a 74-year-old white female with a BMI of 38.01. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
3707,1,The patient is a 51-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has undergone 8 cycles of chemotherapy and has symptoms but is still able to walk around.
3708,0,"The patient is a 67-year-old Black male with a BMI of 34.08. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
3709,1,"The patient is a 61-year-old white male who is receiving treatment with Cisplatin + Etoposide. He has completed 2 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
3710,1,"This patient is a 69-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to move around. She has also developed adverse effects related to her blood counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
3711,0,The patient is a 51-year-old Black female with a BMI of 24.49. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows a mutant status.
3712,0,"The patient is a 69-year-old white male with a BMI of 29.48. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
3713,0,"The patient is a 71-year-old white male with a BMI of 24.95. He is receiving treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect after completing one cycle of chemotherapy. His histology shows well-differentiated cells, and his performance status indicates that he has symptoms but is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3714,0,The patient is a female with malignant pathology who underwent conventional surgery. She experienced symptoms but was still able to be ambulatory. She used narcotics for 5 days following the surgery.
3715,1,"The patient is a 58-year-old white male with a BMI of 42.07. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3716,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during the treatment. She used narcotics for 4 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
3717,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 4 days and has symptoms but is still able to walk around. The pathology report indicates malignancy.
3718,1,"The patient is a 67-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has developed adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands and lymphocytes."
3719,0,"The patient is a 65-year-old white male with a BMI of 27.76. He is fully active and is receiving treatment with the FOLFOX regimen for his colon cancer. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
3720,1,"The patient is a 62-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is showing adverse effects related to low levels of granulocytes/bands and white blood cells."
3721,0,The patient is a 59-year-old white female with a fully active performance status who is receiving treatment with ECF and radiation therapy. She has well-differentiated histology and is experiencing adverse effects of nausea and fatigue.
3722,0,"The patient is a 69-year-old white female with a BMI of 40.2. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She has experienced an adverse effect of thrombosis."
3723,1,"This patient is a 78-year-old white male with a BMI of 22.51. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker status is wild-type."
3724,0,"The patient is a 54-year-old white male with a BMI of 28.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
3725,0,"This patient is a 51-year-old white male with a BMI of 28.09. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
3726,1,The patient is a 62-year-old white male with a BMI of 20.52. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
3727,0,"The patient is a 60-year-old white male with a BMI of 28.78. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker analysis indicates a wild-type status."
3728,0,"The patient is a 42-year-old white female with a BMI of 43.49. She is receiving the FOLFOX treatment arm and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
3729,1,"The patient is a 75-year-old white male with a BMI of 35.41. He is currently undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 2 cycles so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3730,0,The patient is a 43-year-old white male with a BMI of 47.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3731,0,The patient is a 57-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has a histology of poorly differentiated cancer. An adverse effect noted is a decrease in neutrophils/granulocytes.
3732,1,"The patient is a 64-year-old white male with a BMI of 24.64. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3733,0,"The patient is a 66-year-old male of a race categorized as ""other"" with a BMI of 25.37. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
3734,0,The patient is a 55-year-old white female with a BMI of 44.89. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
3735,1,"The patient is a 55-year-old white male with a BMI of 24.91. He is currently receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
3736,0,"The patient is a 59-year-old white female with a BMI of 22.9. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
3737,1,"The patient is a 59-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing an adverse effect known as granulocytes/bands, which refers to a decrease in the levels of a type of white blood cell called granulocytes, specifically bands."
3738,0,"The patient is a 40-year-old female of a race categorized as ""other"" with a BMI of 20.02. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She is scheduled for 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
3739,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is still able to move around. The pathology report indicates malignancy.
3740,0,"The patient is a 58-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
3741,1,"The patient is a 67-year-old white female enrolled in the ECF + Radiation treatment arm. She has a performance status of symptoms but is still ambulatory. The histology shows poorly differentiated cancer. The patient is experiencing adverse effects including low neutrophil/granulocyte levels, nausea, and anorexia."
3742,0,"The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 31.32. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3743,1,The patient is a 44-year-old white male with a BMI of 30.41. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
3744,0,This patient is a 70-year-old white female with a high BMI of 40.44. She is receiving treatment with FOLFOX + Cetuximab for her poorly differentiated cancer. She has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is mutant. She is experiencing diarrhea as an adverse effect of her treatment.
3745,0,"The patient is a 55-year-old white female with a BMI of 27.34. She is in the FOLFOX treatment arm and has not undergone any chemotherapy cycles yet. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
3746,0,"The patient is a 58-year-old white male with a BMI of 20.18. He is receiving the FOLFOX treatment regimen and has been adherent to the prescribed chemotherapy cycles, completing 12 cycles so far. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3747,0,The patient is a 59-year-old white female with a BMI of 36.05 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 4 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
3748,0,"The patient is a 68-year-old white male with a BMI of 30.02. He is undergoing treatment with FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The patient's KRAS biomarker status is mutant."
3749,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during her treatment. She used narcotics for 4 days post-surgery. Despite experiencing symptoms, she is able to move around and is ambulatory. The pathology report indicates malignancy."
3750,0,"The patient is a 66-year-old white male with a BMI of 36.56. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, he has developed hypersensitivity as an adverse effect."
3751,0,"The patient is a 53-year-old white female with a BMI of 22.72. She is currently enrolled in the treatment arm receiving FOLFOX + Cetuximab. She is adherent to her treatment regimen. The patient has a history of bowel obstruction. She has not yet started any chemotherapy cycles. Histologically, her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
3752,0,"The patient is a 37-year-old white male with a BMI of 24.7. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He is currently experiencing a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
3753,0,"The patient is a 59-year-old white female with a BMI of 32.59. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, her cancer is poorly differentiated. Despite these challenges, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
3754,0,The patient is a 66-year-old white female with a BMI of 21.73. She is enrolled in the FOLFOX treatment arm but has not started chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
3755,0,"The patient is a 75-year-old white male with a BMI of 23.06. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced adverse effects of diarrhea and infarction."
3756,0,"The patient is a 51-year-old white male with a BMI of 28.99. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3757,1,The patient is a 53-year-old white male with a BMI of 33.42 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). The KRAS biomarker shows a mutation.
3758,0,"The patient is a 54-year-old white female with a BMI of 24.88. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3759,0,"The patient is a 64-year-old white male with a BMI of 34.63. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3760,0,The patient is a 41-year-old Black male with a BMI of 24.65. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
3761,1,"This patient is a 43-year-old white male with a BMI of 28.38. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker status is wild-type."
3762,1,The patient is a 52-year-old white male with a BMI of 29.41. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
3763,1,"The patient is a 46-year-old white female with a BMI of 22.39. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a mutant status."
3764,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 6 days post-surgery. She is experiencing symptoms but is able to move around independently. The pathology report indicates that the cause of her symptoms is malignant.
3765,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He experienced complications post-surgery and used narcotics for 5 days. Despite histological symptoms, he is ambulatory. The pathology report indicates malignancy."
3766,0,"The patient is a 42-year-old white female with a BMI of 25.98. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3767,1,"The patient is a 57-year-old white male with a BMI of 22.53 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, the patient is still able to move around. The KRAS biomarker indicates that the patient has a wild-type status. Additionally, the patient is experiencing a rash as an adverse effect of the treatment."
3768,1,"The patient is a 59-year-old white male with a BMI of 34.78. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis indicates that the patient has a mutant KRAS gene."
3769,0,"The patient is a 55-year-old white male with a BMI of 27.55. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
3770,0,"The patient is a 73-year-old white male with a BMI of 23.03. He is currently receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
3771,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. Pathology results indicate malignancy.
3772,0,"The patient is a 63-year-old Black female with a BMI of 27.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3773,1,"The patient is a 51-year-old female of a race categorized as ""other"" who is currently receiving treatment in the ECF + Radiation arm. She has a fully active performance status and has been diagnosed with poorly differentiated histology. Additionally, she is experiencing an adverse effect related to leukocytes."
3774,0,The patient is an 85-year-old white male with a BMI of 29.27. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for a primary colon tumor diagnosis. The KRAS biomarker status is wild-type.
3775,0,"The patient is a 72-year-old white female with a BMI of 23.54. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
3776,0,"The patient is a 44-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation during the course of treatment. He completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel perforation, his performance status is fully active. His KRAS biomarker status is wild-type."
3777,0,"The patient is a 52-year-old white male with a well-differentiated histology. He is currently receiving treatment with 5FU/LV + Radiation in a clinical trial. Despite experiencing symptoms, he is still able to move around independently."
3778,0,The patient is a 47-year-old white female with a BMI of 35.18. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She is fully active with a mutant KRAS biomarker. She is scheduled to undergo 12 cycles of chemotherapy.
3779,1,"The patient is a 52-year-old white male receiving treatment with 5FU/LV + Radiation. He has a performance status of symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects such as low neutrophil and granulocyte counts, low leukocyte count, nausea, and loss of appetite."
3780,0,The patient is a 53-year-old white male with a BMI of 21.94 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
3781,1,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the surgery. The histology results showed that the tumor was well differentiated, and the pathology report indicated that it was benign."
3782,0,The patient is a 51-year-old white male with a BMI of 23.41 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis showed a mutant status.
3783,0,"The patient is a 54-year-old white female with a BMI of 24.02. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
3784,0,"The patient is a 47-year-old white male with a BMI of 32.83. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that it is wild-type."
3785,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 4 days following the procedure. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
3786,0,"The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 18.5. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type."
3787,0,"The patient is a 72-year-old white male with a BMI of 39.0. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3788,0,"The patient is a 40-year-old white male with a BMI of 27.9. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3789,0,"The patient is a 70-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
3790,0,"The patient is a 67-year-old white male with a BMI of 23.86. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
3791,1,"The patient is a 69-year-old white female with a BMI of 37.72. She is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer. Additionally, the KRAS biomarker testing revealed a mutant status."
3792,1,The patient is a 58-year-old white male with a BMI of 26.78 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment.
3793,0,"The patient is a 67-year-old white female with a BMI of 31.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient experienced a hypersensitivity reaction as an adverse effect during treatment."
3794,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has experienced complications. She used narcotics for 28 days post-surgery. The histology shows that she is in bed less than 50% of the time, and the pathology report indicates malignancy."
3795,1,"The patient is a 61-year-old white male with a BMI of 26.15. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates a mutant status."
3796,0,"The patient is a 40-year-old white female with a BMI of 27.28. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
3797,1,The patient is a 48-year-old white female with a BMI of 32.66. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 6 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene.
3798,1,"The patient is a 72-year-old white male with a BMI of 23.57. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
3799,0,The patient is a 52-year-old white male with a BMI of 25.8 who is receiving the FOLFOX treatment regimen for his well-differentiated cancer. He has completed 6 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced hypersensitivity as an adverse effect during the treatment.
3800,0,"The patient is a 55-year-old white male with a BMI of 26.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel perforation. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced adverse effects of thrombosis and infection."
3801,1,"The patient is a female who underwent conventional surgery and has abdominal wall and bowel adhesions. She has used narcotics for 5 days. Histologically, she has been in bed less than 50% of the time, and pathologically, the condition is malignant."
3802,1,"The patient is a 42-year-old white male with a BMI of 26.31. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
3803,0,The patient is a 38-year-old white male with a BMI of 27.04 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a fully active performance status and has been identified as having a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
3804,0,"The patient is a 65-year-old white male with a BMI of 39.12. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
3805,0,"The patient is a 64-year-old white female with a BMI of 27.8. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
3806,0,The patient is a 70-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3807,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has been using narcotics for 5 days. The histology shows symptoms but he is still able to move around. The pathology report indicates malignancy.
3808,1,"The patient is a 49-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
3809,0,"The patient is a 70-year-old Black female with a BMI of 31.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3810,0,"The patient is a 63-year-old white female with a BMI of 37.85. She is receiving the FOLFOX treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that it is wild-type."
3811,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
3812,1,"The patient is a 72-year-old white male with a BMI of 32.27. He is fully active and is receiving treatment in the FOLFOX + Panitumumab treatment arm. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
3813,0,"The patient is a 73-year-old white male with a BMI of 37.86. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the treatment. He is currently experiencing a bowel obstruction. The patient has completed 11 cycles of chemotherapy and has a histology of well-differentiated cancer. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
3814,0,"This patient is a 44-year-old white female with a BMI of 21.09. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
3815,1,"The patient is a 61-year-old white male with a BMI of 29.67. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to walk and move around (ambulatory). The KRAS biomarker testing revealed a mutation in the KRAS gene."
3816,0,"The patient is a 48-year-old white female with a BMI of 37.87. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 4 cycles of chemotherapy. Her performance status is fully active, and her KRAS biomarker status is indeterminate."
3817,0,"The patient is a 55-year-old white male with a BMI of 29.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
3818,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
3819,1,The patient is a 59-year-old Black or African American female with a BMI of 32.86. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows a mutant status. The patient is receiving treatment with the FOLFOX regimen.
3820,0,"The patient is a 76-year-old white male with a BMI of 22.26. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 9 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3821,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 6 days. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
3822,1,"The patient is a 65-year-old white male with a BMI of 31.83 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to be ambulatory. The patient has developed a rash as an adverse effect of the treatment regimen."
3823,0,"The patient is a 45-year-old white male with a BMI of 30.16. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
3824,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotic medication for 3 days following the procedure. Their histology indicates that they were in bed less than 50% of the time, and the pathology results showed that the condition is malignant."
3825,1,"The patient is a 72-year-old white female with a BMI of 25.51. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her KRAS biomarker status is wild-type."
3826,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She has been using narcotics for 4 days. The histology shows symptoms but she is still able to walk around. The pathology report indicates a malignant condition.
3827,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to move around. The pathology report indicates that the condition is malignant.
3828,1,The patient is a 53-year-old white male with a BMI of 18.81. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
3829,1,The patient is a 57-year-old black female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
3830,1,"The patient is a 40-year-old white female with a BMI of 20.39. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a mutant status."
3831,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall and bowel adhesions. He has not used any narcotics. His histology shows symptoms but he is still able to walk around. The pathology results indicate malignancy.
3832,0,The patient is a 57-year-old white female with a BMI of 28.56. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a mutant form of the gene.
3833,0,The patient is a female who is part of the conventional surgery treatment arm. She has bowel adhesions and has used narcotics for 2 days. Her histology shows symptoms but she is still able to move around. The pathology results indicate malignancy.
3834,0,The patient is a 57-year-old white male with a BMI of 25.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3835,0,"The patient is a 45-year-old white female with a BMI of 26.53. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
3836,0,The patient is a 59-year-old white male with a BMI of 39.34. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles so far. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type.
3837,1,"The patient is a 59-year-old white male with a BMI of 22.6. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
3838,0,"The patient is a 64-year-old white female with a BMI of 23.44. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. The KRAS biomarker status is indeterminate."
3839,0,The patient is a 43-year-old white male with a BMI of 26.06. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3840,1,"In this patient profile, the individual is a 56-year-old white female who is undergoing treatment with a combination of Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy and has a performance status of fully active. The patient has experienced an adverse effect related to her granulocytes/bands, indicating a potential impact on her white blood cell count."
3841,0,"The patient is a 66-year-old white female with a BMI of 40.57. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 9 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker is mutant."
3842,1,"The patient is a 76-year-old white female with a BMI of 25.3. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
3843,1,"The patient is a 68-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. The patient is experiencing adverse effects including low granulocytes/bands and low white blood cells, as well as nausea."
3844,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. She spends less than 50% of her time in bed. The pathology report indicated that the condition was malignant.
3845,0,"The patient is a 47-year-old white female with a BMI of 30.01. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
3846,0,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
3847,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications post-surgery. They used narcotics for 3 days to manage pain. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated a malignant condition.
3848,0,"The patient is a 66-year-old white male with a BMI of 26.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
3849,0,"The patient is a 45-year-old white female with a BMI of 36.42. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
3850,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
3851,0,The patient is a 64-year-old white female with a BMI of 21.3 who is fully active. She is receiving treatment with the FOLFOX regimen for colon cancer. The KRAS biomarker testing revealed a mutant status.
3852,0,The patient is a female who is undergoing treatment with conventional surgery. She has used narcotics for 11 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
3853,1,"The patient is a 75-year-old white male who is currently receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed one cycle of chemotherapy and has a performance status of fully active."
3854,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates that the condition is malignant.
3855,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotic medication for 4 days post-surgery. The histology showed symptoms but the patient remained ambulatory. Pathology results indicated a malignant condition.
3856,1,The patient is a 67-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. He is experiencing fatigue as an adverse effect of the treatment.
3857,1,The patient is a 61-year-old white male participating in the placebo treatment arm. He is experiencing symptoms but is still able to move around. He has reported feeling fatigued as an adverse effect of the treatment.
3858,0,"The patient is a 54-year-old white male with a BMI of 24.66. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
3859,1,"This patient is a 41-year-old white female with a BMI of 43.1 who is receiving the FOLFOX treatment regimen. She has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced the adverse effect of thrombosis."
3860,1,"The patient is a 46-year-old white female with a BMI of 28.73. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
3861,0,The patient is a 50-year-old white male with a BMI of 29.2. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
3862,0,"The patient is a 67-year-old white male with a BMI of 22.69. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3863,1,"The patient is a 52-year-old white male with a BMI of 26.47. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a mutant KRAS status."
3864,0,"The patient is a 49-year-old female of a race other than Caucasian. She has a high BMI of 46.71 and is currently undergoing treatment with FOLFOX + Cetuximab. She has been adherent to her treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS gene. Unfortunately, she has experienced an infection as an adverse effect during her treatment."
3865,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has used narcotics for 2 days. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
3866,1,"The patient is a 48-year-old white male with a BMI of 20.96 who is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker shows that he has a wild-type status."
3867,0,The patient is a 70-year-old white male with a BMI of 23.34 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
3868,0,"The patient is a 72-year-old white male with a BMI of 24.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has experienced a hypersensitivity adverse effect during treatment."
3869,0,"The patient is a 72-year-old male of a race categorized as ""other"" with a BMI of 22.19. He is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
3870,1,The patient is a 63-year-old Black male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
3871,0,"The patient is a 39-year-old white female with a BMI of 19.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3872,0,"The patient is a 74-year-old white male with a BMI of 23.72. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
3873,0,"The patient is a 64-year-old white female with a BMI of 32.61. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
3874,0,"This patient is a 56-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around (ambulatory). She is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
3875,1,The patient is a 53-year-old white female with a fully active performance status who is receiving treatment with ECF and radiation. She has a histology of poorly differentiated. The patient is experiencing nausea and anorexia as adverse effects.
3876,1,"The patient is a 36-year-old white male with a BMI of 19.59. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to the treatment. He is currently experiencing a bowel obstruction and has completed 10 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates that the cancer is wild-type."
3877,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
3878,0,"The patient is a 63-year-old Black female with a BMI of 36.23. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type KRAS status. She experienced a hypersensitivity adverse effect during treatment."
3879,1,"The patient is a 72-year-old white male with a BMI of 23.72. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
3880,0,"The patient is a 36-year-old white male with a BMI of 23.96. He is receiving treatment in the FOLFOX arm and has been adherent to the prescribed chemotherapy. He has completed one cycle of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker analysis indicates a mutant status."
3881,0,"The patient is a 40-year-old white male with a BMI of 23.99. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
3882,1,"The patient is a 55-year-old white female with a BMI of 23.44. She is fully active with a primary tumor diagnosis of colon cancer. The patient is receiving treatment with the FOLFOX regimen. Additionally, the KRAS biomarker testing revealed a mutant status."
3883,1,"The patient is a 71-year-old white male with a BMI of 23.34. He is undergoing treatment with the FOLFIRI regimen for his well-differentiated histology and mutant KRAS biomarker. He has experienced a serious adverse effect during the treatment, specifically an infection. Despite experiencing symptoms, he is still able to be ambulatory. He has completed 12 cycles of chemotherapy."
3884,0,"The patient is a 71-year-old white female with a BMI of 17.72. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
3885,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 4 days. Her histology indicates symptoms but she is still able to walk around. The pathology report shows that the condition is malignant.
3886,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications following the procedure. She required narcotic pain medication for 2 days post-surgery. Despite experiencing symptoms, she was able to remain ambulatory. The pathology report indicated a malignant condition."
3887,0,"The patient is a 76-year-old white male with a BMI of 28.22. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
3888,1,This patient is a 71-year-old white female who is part of the placebo treatment arm. Her performance status indicates that she spends less than 50% of her time in bed.
3889,0,"The patient is a 67-year-old white male with a BMI of 32.42. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
3890,0,"The patient is a 55-year-old white male with a BMI of 22.5. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
3891,1,"The patient is a 51-year-old white male undergoing treatment with Cisplatin + Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. The patient has also developed adverse effects including low granulocytes/bands and low lymphocytes."
3892,0,"The patient is a 63-year-old white male with a BMI of 24.83. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
3893,0,"This patient is a 49-year-old white female with a BMI of 18.78. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3894,0,"The patient is a 39-year-old male of a race categorized as ""other"" with a BMI of 26.56. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. He has a fully active performance status and his KRAS biomarker status is wild-type."
3895,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 5 days. Her histology shows symptoms but she is still able to move around. The pathology report indicates malignancy.
3896,1,The patient is a 63-year-old white male with a BMI of 28.41. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
3897,0,"The patient is a 63-year-old Black male with a BMI of 29.38. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
3898,1,"The patient is a 72-year-old white female with a BMI of 21.12. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3899,1,"The patient is a 41-year-old white female with a BMI of 33.11. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
3900,1,The patient is a 48-year-old white male with a BMI of 33.64. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis showed a mutant status.
3901,0,"This patient is a 51-year-old white female with a BMI of 27.78. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel perforation. Despite having not started any chemotherapy cycles yet, her histology shows poorly differentiated cancer. She has symptoms but is still able to be ambulatory. Her KRAS biomarker status is wild-type."
3902,0,"The patient is a 63-year-old white male with a BMI of 25.91. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
3903,0,"The patient is a 63-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is currently experiencing adverse effects related to low levels of granulocytes/bands and white blood cells."
3904,0,"The patient is a 48-year-old female of a race other than specified, with a BMI of 24.97. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. The histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still ambulatory. The KRAS biomarker analysis reveals a wild-type result."
3905,1,"The patient is a 70-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
3906,1,This patient is a 66-year-old white female with a BMI of 29.97. She is fully active and is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. Her KRAS biomarker status is wild-type.
3907,1,"The patient is a 44-year-old white male with a BMI of 22.88. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is in the rectum, and his KRAS biomarker status is wild-type."
3908,1,"The patient is a 59-year-old white male with a BMI of 27.59. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
3909,0,"The patient is a 35-year-old male of a race categorized as ""other"" with a BMI of 36.67. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient is experiencing a bowel obstruction and has completed one cycle of chemotherapy. Histology results indicate that the cancer is well-differentiated. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker testing revealed a wild-type result."
3910,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has experienced complications. She used narcotics for 3 days post-surgery. The histology shows that she is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
3911,1,"In this patient profile, the individual is a 56-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, indicating an abnormality in her white blood cell count."
3912,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the surgery. Her histology indicates that she is in bed less than 50% of the time, and the pathology report shows that the condition is malignant."
3913,0,"The patient is a 51-year-old white male with a BMI of 25.57. He is receiving treatment with FOLFOX + Cetuximab. He experienced a serious adverse effect during the treatment. He has completed 11 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, he has a fully active performance status. His KRAS biomarker is wild-type."
3914,0,"The patient is a 69-year-old Black male with a BMI of 23.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type status."
3915,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions and experienced complications post-surgery. She used narcotics for 2 days. Despite having symptoms, she is ambulatory. The pathology report indicates malignancy."
3916,0,The patient is a 36-year-old Black male with a BMI of 28.34. He is receiving the FOLFOX treatment arm and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3917,1,"The patient is a 65-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. Additionally, he is experiencing an adverse effect related to neutrophils/granulocytes."
3918,0,"The patient is a 75-year-old white female with a BMI of 28.68. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
3919,1,The patient is a 66-year-old white female with a BMI of 34.29 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around. The KRAS biomarker testing showed a mutation in the KRAS gene.
3920,0,"The patient is a 50-year-old white male with a BMI of 27.41. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
3921,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He used narcotics for 6 days post-surgery. The histology results show well-differentiated cells, and the pathology report indicates that the condition is benign."
3922,0,"The patient is a 63-year-old white male with a BMI of 34.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3923,1,The patient is a 37-year-old Black male with a BMI of 20.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
3924,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 5 days. Histologically, she has been spending less than 50% of her time in bed. The pathology report indicates malignancy."
3925,0,"The patient is a 40-year-old white female with a BMI of 25.62. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
3926,0,"The patient is a 37-year-old white female with a BMI of 37.54. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
3927,0,The patient is a 54-year-old white female with a BMI of 32.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status and her KRAS biomarker is wild-type.
3928,0,"The patient is a 46-year-old white male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to ambulate, indicating a relatively good performance status."
3929,0,"The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 21.84. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
3930,0,"The patient is a 49-year-old white female with a BMI of 22.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction and perforation. She has completed 12 chemotherapy cycles and her histology shows well-differentiated cells. Despite the bowel issues, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced diarrhea as an adverse effect of the treatment."
3931,1,"The patient is a 53-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as experiencing nausea."
3932,1,The patient is a 72-year-old white male with a BMI of 31.02. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon tumor. The KRAS biomarker indicates that the tumor has a mutant KRAS gene.
3933,0,"The patient is a 69-year-old white male with a BMI of 25.57. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. Additionally, he has experienced thrombosis as an adverse effect."
3934,0,"The patient is a 76-year-old male of a race categorized as ""other"" with a BMI of 21.87. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to ambulate, indicating a reasonable performance status. Additionally, his KRAS biomarker status is wild-type."
3935,0,The patient is a 58-year-old Black female with a BMI of 24.77. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
3936,1,"The patient is a 43-year-old white female who is currently undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands. This side effect may indicate a decrease in certain types of white blood cells, which are important for fighting infections."
3937,0,"The patient is a 58-year-old white female with a BMI of 31.62. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
3938,1,"The patient is a 63-year-old white male who is fully active and is receiving treatment with 5FU/LV + Radiation. He has a histology of poorly differentiated. He is experiencing anorexia as an adverse effect, which is a loss of appetite or decreased desire to eat. This can lead to weight loss and nutritional deficiencies if not managed properly."
3939,0,"The patient is a 67-year-old white male with a BMI of 29.98. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3940,0,"The patient is a 45-year-old Black female with a BMI of 55.22. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, the patient has experienced thrombosis as an adverse effect."
3941,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required narcotic use for 7 days. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
3942,0,"This patient is a 58-year-old white female with a BMI of 30.52. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her bowel issues, her performance status is fully active. Her KRAS biomarker status is wild-type."
3943,0,This patient is a 46-year-old black female participating in the ECF + Radiation treatment arm. She has a performance status of symptoms but is still able to walk around (ambulatory). Her histology shows poorly differentiated cells. She is experiencing nausea as an adverse effect of the treatment.
3944,1,"The patient is a 63-year-old white female with a fully active performance status. She is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of her cancer is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
3945,1,"The patient is a 68-year-old white female with a BMI of 32.3. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm, and her KRAS biomarker status is wild-type."
3946,0,"The patient is a 63-year-old white female who is part of the treatment arm receiving Cisplatin + Etoposide. She has not started any chemotherapy cycles yet. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
3947,0,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They have been using narcotics for 4 days post-surgery. The histology shows symptoms but the patient is still able to move around. The pathology report indicates that the cause of the surgery was due to malignancy.
3948,0,"The patient is a 75-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation. Despite experiencing symptoms, he is still able to ambulate. The histology of his cancer is well-differentiated. He is experiencing adverse effects including low neutrophil and leukocyte counts, as well as anorexia."
3949,1,The patient is a 56-year-old white male with a BMI of 27.47. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
3950,0,"The patient is a 73-year-old white female with a BMI of 26.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
3951,1,The patient is a 74-year-old white female who is fully active. She is currently receiving treatment in the placebo arm of the study.
3952,0,The patient is a 41-year-old white female with a BMI of 31.7. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker shows a mutation.
3953,0,"The patient is a 55-year-old white female with a BMI of 32.18. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, the KRAS biomarker analysis indicates a mutant status."
3954,0,This patient is a 61-year-old white female with a BMI of 30.86 who is currently receiving treatment with FOLFOX for a rectal tumor. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a mutant KRAS status.
3955,0,The patient is a 56-year-old white male with a fully active performance status. He is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of his cancer is poorly differentiated.
3956,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 2 days. Despite experiencing symptoms, he is still able to move around independently. The pathology report indicates the presence of malignancy."
3957,1,The patient is a 63-year-old white male with a BMI of 25.59. He is fully active with a primary tumor diagnosis of colon. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
3958,0,"The patient is a 51-year-old Black female with a BMI of 21.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
3959,0,"The patient is a 51-year-old Black female with a BMI of 27.73. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
3960,0,"This 75-year-old white female patient with a BMI of 28.45 is undergoing treatment with FOLFOX + Cetuximab for her poorly differentiated cancer. She has experienced a serious adverse effect during her 12 chemotherapy cycles. Despite this, she maintains a fully active performance status. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of her treatment."
3961,0,"The patient is a 74-year-old white female with a BMI of 31.31. She is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
3962,1,"In this patient profile, the individual is a 73-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy and has a performance status of fully active. An adverse effect noted is the presence of granulocytes/bands."
3963,0,"The patient is a 65-year-old white female with a BMI of 35.86. She is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. Her histology shows poorly differentiated cancer cells. Despite this, she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type gene."
3964,0,"The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 33.4. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. She has experienced a hypersensitivity adverse effect during her treatment."
3965,0,"This patient is a 61-year-old white female with a BMI of 23.53. She is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
3966,1,The patient is a 47-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active.
3967,0,"The patient is a 52-year-old white female with a BMI of 23.5. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
3968,0,"The patient is a 48-year-old white male with a BMI of 31.56. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
3969,0,The patient is a 36-year-old white female with a BMI of 21.64. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
3970,1,"The patient is a 67-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 3 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to walk around. The patient has developed adverse effects related to his white blood cells and granulocytes/bands."
3971,0,"The patient is a 53-year-old male of a race categorized as ""other"" with a BMI of 31.6. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
3972,1,"The patient is a 77-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has shown adverse effects on his blood cells, specifically on his granulocytes/bands, white blood cells, and lymphocytes."
3973,0,"The patient is a 43-year-old white male with a BMI of 24.26. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
3974,1,The patient is a 59-year-old white female with a fully active performance status. She is currently in the treatment arm receiving a placebo.
3975,0,"The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 20.17. He is currently undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 7 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. Additionally, the KRAS biomarker testing indicates that he has a wild-type KRAS status."
3976,1,"The patient is a 66-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is showing adverse effects related to her granulocytes/bands and white blood cells."
3977,0,"The patient is a 56-year-old white female with a BMI of 22.65. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
3978,0,"The patient is a 45-year-old male of a race categorized as ""other"" with a BMI of 35.09. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced a hypersensitivity adverse effect."
3979,0,"This patient is a 51-year-old white female with a BMI of 37.04. She is receiving the FOLFOX treatment regimen for her cancer. She has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced the adverse effect of thrombosis."
3980,1,"This patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has used narcotics for 6 days. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
3981,0,"The patient is a 51-year-old white female with a BMI of 29.06. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is mutant."
3982,1,"The patient is a 65-year-old white male with a BMI of 25.56 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a wild-type KRAS biomarker and is experiencing symptoms but is still able to be ambulatory. Additionally, he is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
3983,1,"This patient is a 67-year-old white female who is undergoing treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Her performance status indicates that she is spending less than 50% of her time in bed. Additionally, she has experienced adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
3984,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 7 days. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
3985,0,"The patient is a 54-year-old white male with a BMI of 25.21. He is receiving the FOLFIRI + Cetuximab treatment regimen and has experienced a serious adverse effect. He has completed 8 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status. Additionally, he is experiencing diarrhea as an adverse effect of the treatment."
3986,0,"The patient is a 73-year-old white female with a BMI of 37.26. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of treatment."
3987,1,"The patient is a 70-year-old white male with a BMI of 31.22. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
3988,0,"The patient is a 52-year-old Black male with a BMI of 22.5. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
3989,1,The patient is a 47-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands.
3990,0,The patient is a 40-year-old white male with a BMI of 36.58 who is receiving the FOLFOX treatment arm for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect.
3991,1,The patient is a female who underwent laparoscopic-assisted colectomy. She only used narcotics for 1 day following the procedure. She is typically out of bed more than 50% of the time. The pathology report indicated that the cause of the surgery was malignant.
3992,0,The patient is a 41-year-old white male with a BMI of 30.67. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
3993,0,"The patient is a 40-year-old white female with a BMI of 31.8. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
3994,0,"The patient is a 62-year-old white female with a BMI of 26.19. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her histology shows well-differentiated cancer cells. Despite her diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker indicates that she has a wild-type gene."
3995,0,"The patient is a 57-year-old white male with a BMI of 27.95. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 3 cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
3996,0,The patient is a 72-year-old Black male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
3997,1,"The patient is a 60-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
3998,0,"The patient is a 44-year-old white male with a BMI of 24.86. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
3999,0,"The patient is a 50-year-old white male with a BMI of 26.58. He is receiving treatment with FOLFOX + Cetuximab and is adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
4000,0,"The patient is a 67-year-old white female with a BMI of 36.11. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age and BMI, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
4001,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and experienced complications post-surgery. She only used narcotics for 1 day. Histologically, she spent less than 50% of her time in bed. The pathology report indicates malignancy."
4002,1,"The patient is a 52-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has developed a decrease in granulocytes/bands as an adverse effect of the treatment."
4003,1,The patient is a 53-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of the cancer is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4004,0,"The patient is a 52-year-old white female with a BMI of 29.1. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4005,0,The patient is a 46-year-old white male with a BMI of 27.32. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4006,0,The patient is a 50-year-old white male with a BMI of 28.33. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
4007,1,"The patient is a 65-year-old white male with a BMI of 30.56. He is receiving treatment in the FOLFOX treatment arm and has experienced a bowel obstruction. He has completed 4 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
4008,0,"The patient is a 69-year-old white female with a BMI of 22.02. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4009,0,"The patient is a 66-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis revealed a mutant status."
4010,0,"The patient is a 44-year-old white male with a BMI of 22.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
4011,1,"The patient is a 64-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing adverse effects such as low neutrophil/granulocyte levels and anorexia, his performance status remains fully active. The histology of his cancer is poorly differentiated."
4012,0,The patient is a 57-year-old white male with a BMI of 30.07 who is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
4013,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
4014,0,"The patient is a 69-year-old white male with a BMI of 24.72 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect during his 4 chemotherapy cycles. The histology shows that the cancer is well-differentiated. Despite the adverse effects, the patient's performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
4015,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
4016,1,"The patient is a 64-year-old white male with a BMI of 28.31. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4017,0,This patient is a 55-year-old white male with a BMI of 26.93. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. His KRAS biomarker status is wild-type.
4018,1,The patient is a 35-year-old white male with a BMI of 22.22. He is receiving the FOLFIRI treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4019,1,"The patient is a 58-year-old white male with a BMI of 23.67 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect, which is a skin condition characterized by acne-like eruptions on the skin."
4020,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. Despite experiencing symptoms, he is still able to be ambulatory. The pathology report indicates that the patient has malignant cells."
4021,1,The patient is a 59-year-old white female with a BMI of 20.62 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She is experiencing symptoms but is still able to walk around. The patient has developed a rash as an adverse effect of the treatment.
4022,1,"The patient is an 81-year-old white male with a BMI of 18.19. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
4023,0,"The patient is a 62-year-old white male with a BMI of 27.67. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
4024,0,"The patient is a 63-year-old white female with a BMI of 20.81. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
4025,1,The patient is a 68-year-old white female with a BMI of 22.52. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that she has a wild-type status. She is currently receiving treatment in the FOLFOX treatment arm.
4026,1,The patient is a 53-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology treatment arm.
4027,0,The patient is a male undergoing conventional surgery with complications. He has used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
4028,0,"The patient is a 58-year-old white female with a BMI of 32.41. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced an infection as an adverse effect during her treatment."
4029,0,"The patient is a 55-year-old white male with a BMI of 29.96 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect, which presents as a skin rash resembling acne."
4030,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
4031,1,"The patient is a 58-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite this, her performance status is fully active. The patient has also experienced adverse effects related to her granulocytes/bands and white blood cells."
4032,0,The patient is a 41-year-old white male with a BMI of 32.07. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4033,0,"The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 22.5. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
4034,0,This patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the cause of her symptoms was malignant.
4035,0,"The patient is a 49-year-old white female with a BMI of 26.54. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
4036,0,"The patient is a 76-year-old white female with a BMI of 23.36. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4037,1,"The patient is a 52-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated characteristics. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
4038,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She has used narcotics for 4 days. The histology indicates that she is in bed less than 50% of the time. The pathology report shows that the condition is malignant.
4039,1,The patient is a 69-year-old white male participating in the placebo treatment arm. He has symptoms but is still able to move around independently.
4040,1,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
4041,0,The patient is a 56-year-old white male with a BMI of 27.95. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
4042,0,"The patient is a 56-year-old white female with a BMI of 22.41. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4043,0,"The patient is a 65-year-old white male with a BMI of 28.87. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4044,1,"The patient is a 68-year-old white male with a BMI of 38.97. He is fully active and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
4045,0,The patient is a 62-year-old white male with a BMI of 27.89. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4046,1,"The patient is a 68-year-old white female with a BMI of 24.39. She is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
4047,1,"The patient is a 70-year-old white male with a BMI of 23.62. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
4048,1,"This patient is an 82-year-old male of other race with a BMI of 27.04. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. Additionally, the KRAS biomarker testing revealed a mutant status."
4049,0,"The patient is a 55-year-old white male with a BMI of 28.58 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is symptomatic but still able to walk around. His KRAS biomarker is wild-type. The patient has experienced adverse effects including thrombosis and infection."
4050,0,"The patient is a 56-year-old white female with a BMI of 27.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker analysis revealed a mutant status."
4051,0,"The patient is a 47-year-old white male with a BMI of 24.71. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4052,0,"The patient is a 52-year-old white female with a BMI of 23.39. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate."
4053,1,The patient is a 59-year-old white female with a BMI of 28.4. She is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. The KRAS biomarker analysis shows that she has a mutant KRAS status.
4054,0,"The patient is a 63-year-old white female with a BMI of 34.65. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced an infection as an adverse effect."
4055,1,The patient is a 58-year-old white female with a BMI of 23.01. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker indicates that she has a wild-type status. The patient is experiencing a rash as an adverse effect of the FOLFOX + Panitumumab treatment.
4056,0,The patient is a 57-year-old white female with a BMI of 24.97 who is currently receiving treatment with FOLFOX. She has a fully active performance status and has been diagnosed with a primary tumor in the colon. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
4057,1,"The patient is a 64-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to be ambulatory. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
4058,0,The patient is a 50-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around. The histology shows well-differentiated cells. The patient is experiencing an adverse effect of leukocytes.
4059,0,The patient is a 50-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4060,0,The patient is a 61-year-old white male with a BMI of 26.46. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4061,0,The patient is a 37-year-old Black male with a BMI of 25.68. He is receiving treatment with FOLFOX + Cetuximab for bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4062,1,"The patient is a 70-year-old white male with a BMI of 24.8. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab, and the KRAS biomarker shows that it is mutant."
4063,1,The patient is a 47-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has a histology of poorly differentiated. The patient is experiencing nausea as an adverse effect of the treatment.
4064,0,The patient is a 58-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects related to low neutrophils/granulocytes and leukocytes.
4065,1,"The patient is a 51-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
4066,1,"The patient is a 70-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and lymphocytes."
4067,0,"The patient is a 39-year-old white male with a BMI of 28.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type gene."
4068,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions present. He used narcotics for 4 days post-surgery. The histology results show that the tumor is well-differentiated, and the pathology report indicates that it is benign."
4069,1,"The patient is a 50-year-old white male with a BMI of 24.26 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect after one cycle of chemotherapy, with well-differentiated histology. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant. He has also experienced adverse effects of diarrhea and infection."
4070,0,"The patient is a 57-year-old white female with a BMI of 29.19. She is receiving treatment with FOLFOX + Cetuximab and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker testing showed that she has a wild-type result. She is experiencing diarrhea as an adverse effect of the treatment."
4071,1,"The patient is a 68-year-old white female with a BMI of 24.75. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker testing revealed a mutant status."
4072,0,The patient is a 59-year-old white female who is part of the Sunitinib treatment arm. She is experiencing symptoms but is still able to walk around.
4073,1,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They only used narcotics for 1 day following the procedure. The histology shows symptoms but the patient is still able to be ambulatory. Pathology results indicate the presence of malignancy.
4074,0,"The patient is a 68-year-old white male with a BMI of 23.86. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4075,1,"The patient is a 45-year-old white male enrolled in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low neutrophils/granulocytes and leukocytes, as well as symptoms of nausea, anorexia, and fatigue."
4076,0,"The patient is a 43-year-old white female with a BMI of 22.84. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. Additionally, she has experienced diarrhea as an adverse effect."
4077,0,The patient is a 72-year-old white female with a BMI of 15.82 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
4078,0,"The patient is a 74-year-old white male with a BMI of 26.37. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient's performance status indicates that he is in bed less than 50% of the time. Additionally, his KRAS biomarker status is wild-type."
4079,1,The patient is a 61-year-old white male with a BMI of 23.49. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker is wild-type. He is currently receiving treatment with the FOLFOX regimen.
4080,0,The patient is a 55-year-old white male with a BMI of 25.42. He is receiving the FOLFOX treatment regimen and has adhered to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker analysis shows that he has a wild-type KRAS gene.
4081,1,The patient is a male who is receiving conventional surgery as part of their treatment. They have been using narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
4082,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days following the procedure. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
4083,0,The patient is a 59-year-old white female with a BMI of 23.08 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. Her KRAS biomarker status is wild-type. She is experiencing a rash as an adverse effect of the treatment.
4084,1,"The patient is a 46-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also developed a decrease in lymphocytes as an adverse effect of the treatment."
4085,1,"The patient is a 63-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He will undergo a total of 6 cycles of chemotherapy. Despite his age, he has a fully active performance status, indicating that he is able to carry out his daily activities without any limitations."
4086,0,"The patient is a 45-year-old Black male with a BMI of 27.74. He is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. The KRAS biomarker testing revealed a wild-type result. Additionally, he has experienced diarrhea as an adverse effect."
4087,0,"The patient is a 68-year-old white male with a BMI of 44.42. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4088,0,"The patient is a 44-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
4089,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 6 days. Despite experiencing symptoms, she is still able to be ambulatory. The pathology report indicates malignancy."
4090,0,"The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 24.06. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started any chemotherapy cycles yet. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4091,0,"The patient is a 38-year-old white female with a BMI of 21.19. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4092,1,"The patient is a 54-year-old white male with a BMI of 30.45. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker status is wild-type."
4093,1,The patient is a 56-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy combined with radiation. The histology of his cancer is well-differentiated. He is experiencing adverse effects related to his neutrophils/granulocytes and leukocytes.
4094,1,"The patient is a 58-year-old white male with a BMI of 30.52. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active."
4095,0,"The patient is a 71-year-old white male with a BMI of 32.35. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 8 cycles. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4096,0,"The patient is a 68-year-old white male with a BMI of 32.81. He is receiving treatment with the FOLFOX regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4097,1,"The patient is a 65-year-old white male with a BMI of 19.49. He is currently receiving treatment with FOLFOX for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
4098,1,"The patient is a 62-year-old white male with a BMI of 24.79 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
4099,1,The patient is a 72-year-old white male with a BMI of 32.21. He is fully active and is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker status is wild-type.
4100,0,"The patient is a 56-year-old white female with a BMI of 33.99. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
4101,0,"The patient is a female who received conventional surgery as treatment. She only used narcotics for 1 day. Her histology shows well-differentiated cells, and the pathology results indicate a benign condition."
4102,0,"The patient is a 60-year-old Black female with a BMI of 47.58 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing adverse effects such as diarrhea and infection, her performance status remains fully active. Additionally, her KRAS biomarker is mutant."
4103,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 2 days following the surgery. The histology results showed that the tumor was well-differentiated, and the pathology results indicated that it was benign."
4104,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 4 days. The histology shows that she is in bed less than 50% of the time, and the pathology indicates malignancy."
4105,0,"The patient is a 54-year-old white male with a BMI of 30.24. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and his KRAS biomarker status is wild-type."
4106,1,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 7 days post-surgery. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates malignancy."
4107,1,"The patient is a 52-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory)."
4108,0,"The patient is a 71-year-old white female with a BMI of 25.13. She is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite undergoing treatment, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type."
4109,1,"The patient is a 55-year-old black male who is currently undergoing treatment with Cisplatin and Etoposide. He has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to walk around and carry out his daily activities, indicating that his performance status is relatively good."
4110,0,"The patient is a 46-year-old white female with a BMI of 19.26 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory). Her primary tumor diagnosis is colon cancer, and she has a mutant KRAS biomarker."
4111,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. She is typically in bed less than 50% of the time. The pathology report indicated malignancy.
4112,0,"The patient is a 57-year-old male of a race other than specified, with a BMI of 24.42. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to ambulate. The KRAS biomarker shows a mutation in this patient."
4113,1,"The patient is a 63-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed a side effect known as granulocytes/bands."
4114,1,"The patient is a 61-year-old white male with a BMI of 30.44. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed a mutant status."
4115,0,The patient is a 55-year-old Black male with a BMI of 32.83. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
4116,0,"The patient is a 59-year-old white male with a BMI of 30.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis revealed a mutant status."
4117,0,"The patient is a 55-year-old white male with a BMI of 28.46. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
4118,1,The patient is a 74-year-old white female with a BMI of 39.97 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that the tumor is wild-type.
4119,1,This patient is a 48-year-old white female with a BMI of 23.44 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of colon cancer.
4120,1,"The patient is a 53-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and lymphocytes."
4121,0,"The patient is a 51-year-old white female with a BMI of 20.87. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of her treatment. She completed 6 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
4122,0,"The patient is a 57-year-old white female with a BMI of 24.43. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. Unfortunately, she experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the adverse effect, her performance status remains fully active. The KRAS biomarker analysis revealed that she has a wild-type KRAS status. Additionally, she has also experienced diarrhea as an adverse effect of the treatment."
4123,1,The patient is a 56-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated characteristics.
4124,0,"The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 29.24. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that it is wild-type. Additionally, the patient has also developed an infection as an adverse effect."
4125,1,The patient is a 54-year-old white male with a BMI of 20.83. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that he has a wild-type status. He is currently receiving treatment in the FOLFOX treatment arm.
4126,1,The patient is a 53-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
4127,1,The patient is a 60-year-old white male with a BMI of 32.63. He is fully active and is receiving treatment with FOLFOX and Panitumumab for colon cancer. The KRAS biomarker indicates that the patient has a mutant KRAS gene.
4128,1,The patient is a female who underwent conventional surgery as part of their treatment. They used narcotics for 3 days post-surgery. The histology results showed symptoms but the patient is still able to walk around. The pathology report indicated that the tumor is malignant.
4129,0,"The patient is a 63-year-old white male with a BMI of 29.41. He is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4130,1,The patient is a 68-year-old white female with a fully active performance status. She is currently in the treatment arm receiving a placebo in the clinical trial.
4131,0,"The patient is a 60-year-old white male with a BMI of 23.34. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite experiencing adverse effects such as diarrhea and infection, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4132,0,"The patient is a 56-year-old white male with a BMI of 26.97 who is undergoing treatment with FOLFOX + Cetuximab. He has been adherent to the treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
4133,0,"The patient is a 51-year-old white male with a BMI of 36.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
4134,1,"The patient is a 58-year-old black male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy along with radiation. The histology of his cancer is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
4135,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the challenges, she was able to maintain her ambulatory status. The pathology report revealed malignant findings."
4136,1,"The patient is a 68-year-old white male with a BMI of 31.44. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
4137,0,"The patient is a 48-year-old white female with a BMI of 30.75. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 10 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has the wild-type variant."
4138,0,"The patient is a 73-year-old white female with a BMI of 18.06. She is currently receiving treatment in the FOLFOX treatment arm. She has a bowel obstruction and has completed 11 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
4139,0,"The patient is a 36-year-old white male with a BMI of 28.97. He is undergoing treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4140,0,The patient is a 42-year-old white male with a BMI of 31.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4141,0,The patient is a 58-year-old white male with a BMI of 30.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4142,0,"The patient is a 55-year-old white female with a BMI of 25.9 who is undergoing treatment with FOLFIRI + Cetuximab. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
4143,1,The patient is a 50-year-old white male with a BMI of 32.72. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
4144,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has been using narcotics for 6 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
4145,1,"The patient is a 62-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy and is experiencing symptoms but is still able to walk around (ambulatory). He is also experiencing adverse effects including low levels of granulocytes/bands and white blood cells, as well as nausea."
4146,0,"The patient is a 37-year-old white female with a BMI of 25.4. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
4147,0,"The patient is a 62-year-old white female with a BMI of 26.12. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4148,0,"The patient is a 74-year-old white male with a BMI of 31.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4149,1,"This patient is a 41-year-old white female with a BMI of 26.9. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab, a targeted therapy. Her KRAS biomarker status is wild-type, indicating that she may benefit from the targeted therapy Panitumumab."
4150,1,"The patient is a 77-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. The patient has developed adverse effects related to his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
4151,0,"The patient is a 62-year-old female of a race categorized as ""other"" who is currently receiving treatment with ECF chemotherapy in combination with radiation therapy. She has a fully active performance status. The histology of her condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
4152,0,"The patient is a 40-year-old white male with a BMI of 28.31. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect. He has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active."
4153,0,"The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 22.68. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is well differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
4154,1,The patient is a 59-year-old white male with a BMI of 33.2. He is fully active and is receiving treatment with FOLFOX and Panitumumab for his colon cancer. His KRAS biomarker status is wild-type.
4155,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 4 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
4156,0,"The patient is a 56-year-old Black male with a BMI of 16.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 9 chemotherapy cycles. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
4157,0,"The patient is a 60-year-old white female with a BMI of 35.67. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
4158,0,"The patient is a 52-year-old female of a race other than specified, with a BMI of 20.82. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker testing revealed a mutant status. Additionally, she has also experienced a hypersensitivity adverse effect."
4159,1,"The patient is a 59-year-old white male with a BMI of 27.77 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a rectal tumor with a mutant KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect, which is a skin condition characterized by acne-like eruptions."
4160,0,"The patient is a 62-year-old female of a race categorized as ""other"" with a BMI of 33.13. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
4161,1,"The patient is a 70-year-old white female with a BMI of 29.83. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect after one cycle of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to ambulate. Additionally, her KRAS biomarker is mutant."
4162,0,The patient is a 40-year-old Black female with a BMI of 34.77. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
4163,1,"The patient is a 62-year-old white male with a BMI of 29.76 who is receiving treatment with the FOLFOX regimen. He has a performance status indicating that he is in bed less than 50% of the time. His primary tumor diagnosis is rectal, and his KRAS biomarker status is wild-type."
4164,0,"The patient is a 44-year-old white male with a BMI of 27.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
4165,0,"The patient is a 76-year-old white female with a BMI of 20.36. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4166,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
4167,0,"The patient is a 46-year-old white male with a BMI of 42.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker is mutant in this patient. He has developed an infection as an adverse effect of the treatment."
4168,1,The patient is a 53-year-old female of other race with a BMI of 21.68. She is fully active in terms of performance status. She has been diagnosed with a primary colon tumor and has a wild-type KRAS biomarker. She is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
4169,1,The patient is a 70-year-old white female with a fully active performance status. She is currently in the placebo treatment arm of the study.
4170,1,The patient is a 55-year-old white male with a performance status indicating symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4171,1,The patient is a 52-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed.
4172,1,"The patient is a 64-year-old white male with a BMI of 23.02 who is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to ambulate. His primary tumor diagnosis is colon cancer."
4173,0,"The patient is a 50-year-old white female with a BMI of 20.68. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She experienced a serious adverse effect during the treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Her performance status is fully active. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she experienced diarrhea as an adverse effect during the treatment."
4174,1,"The patient is a 73-year-old Black female with a BMI of 32.94. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 11 chemotherapy cycles. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type. The patient has reported experiencing diarrhea and infection as adverse effects of the treatment."
4175,1,The patient is a 60-year-old white male with a BMI of 33.3 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor.
4176,1,"The patient is a 55-year-old white male with a BMI of 34.42. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment regimen. He has completed 7 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4177,0,"The patient is a 59-year-old male of a race categorized as ""other"" with a BMI of 23.95. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
4178,1,"The patient is a 56-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
4179,0,"The patient is a 63-year-old female of a race other than specified, with a BMI of 32.55. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker is mutant in this patient. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
4180,1,"The patient is a 70-year-old white male with a BMI of 23.51. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, he is still able to walk around. He has been diagnosed with colon cancer, and his KRAS biomarker status is wild-type."
4181,0,"This patient is a 68-year-old white male with a BMI of 19.05. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
4182,0,"The patient is a 41-year-old white male with a BMI of 21.11. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
4183,1,The patient is a 55-year-old white male participating in the placebo treatment arm. His performance status indicates that he is in bed less than 50% of the time.
4184,0,"The patient is a 44-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
4185,1,"The patient is a 29-year-old white male with a BMI of 18.51 who is receiving treatment with the FOLFOX regimen for a colon cancer diagnosis. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed that he has a wild-type KRAS status."
4186,1,The patient is a 71-year-old white female with a BMI of 24.39. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
4187,0,"The patient is a 41-year-old white female with a BMI of 30.55. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4188,0,"This patient is a 53-year-old white female with a BMI of 28.73. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. Her KRAS biomarker status is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
4189,0,"The patient is a 66-year-old white male with a BMI of 31.94. He is currently undergoing treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4190,0,The patient is a 55-year-old white male with a BMI of 25.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4191,0,"The patient is a 37-year-old white male with a BMI of 29.8. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite the bowel perforation, the patient's performance status is fully active. The KRAS biomarker indicates that it is wild-type."
4192,0,"The patient is a 51-year-old white female with a BMI of 37.91. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4193,0,"The patient is a 60-year-old male of a race categorized as ""other"" who is undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
4194,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
4195,0,The patient is a 41-year-old white female with a BMI of 26.32. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4196,0,"The patient is a 70-year-old white male with a BMI of 27.66. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
4197,0,"The patient is a 37-year-old white male with a BMI of 26.04 who is receiving the FOLFOX treatment regimen. He has been adherent to his treatment and has completed 9 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The patient's KRAS biomarker is mutant. He has experienced adverse effects including hypersensitivity, diarrhea, and infection. Additionally, he has developed a bowel obstruction."
4198,0,The patient is a 37-year-old white male with a BMI of 38.03. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4199,0,"The patient is a 68-year-old white male with a BMI of 41.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect of thrombosis."
4200,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology indicates symptoms but she is still able to walk around. The pathology report shows that the patient has a malignant condition.
4201,1,The patient is a 70-year-old white male with a BMI of 27.28 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary diagnosis of rectal cancer. The KRAS biomarker analysis indicates that he has a wild-type KRAS status.
4202,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 2 days. The histology shows symptoms but the patient is still able to walk around. The pathology indicates that the condition is malignant.
4203,0,"The patient is a 70-year-old white female with a BMI of 43.23. She is receiving the FOLFOX treatment arm for her poorly differentiated histology. She has undergone 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. Her KRAS biomarker status is indeterminate."
4204,0,The patient is a 62-year-old white male participating in the placebo treatment arm. He is experiencing symptoms but is still able to move around independently.
4205,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicated malignancy."
4206,0,"The patient is a 42-year-old white male with a BMI of 30.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
4207,0,"The patient is a 73-year-old white female with a BMI of 32.52. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing shows that she has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infection during her treatment."
4208,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
4209,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications following the procedure. She required narcotic pain medication for 3 days post-surgery. Despite experiencing symptoms, she was able to remain ambulatory. The pathology report revealed malignant findings."
4210,1,"This patient is a 64-year-old white female with a BMI of 24.17. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Additionally, her KRAS biomarker status is mutant."
4211,0,"The patient is a 76-year-old white female with a BMI of 24.06 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects, including bowel obstruction and perforation. Despite these challenges, she has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type. She has also experienced the adverse effect of thrombosis."
4212,1,"The patient is a 53-year-old Black female with a well-differentiated histology. She is currently receiving treatment with 5FU/LV + Radiation. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing adverse effects including low levels of neutrophils/granulocytes and a decreased appetite (anorexia)."
4213,0,"The patient is a 75-year-old white male with a BMI of 30.28. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite his age, the patient has a fully active performance status. The KRAS biomarker indicates that he has a mutant status."
4214,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 4 days post-surgery. Despite having symptoms, she is able to move around independently. The pathology report indicates malignancy."
4215,1,The patient is a 45-year-old Black or African American female with a BMI of 27.99. She is fully active with a primary tumor diagnosis of colon. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
4216,1,"The patient is a 74-year-old white female with a BMI of 31.85. She is undergoing treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker is wild-type."
4217,1,"This patient is a 50-year-old white male with a BMI of 20.97. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is mutant."
4218,1,"The patient is a 54-year-old black female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing a common adverse effect known as granulocytes/bands, which indicates a decrease in a type of white blood cell."
4219,0,"The patient is a 68-year-old Black male with a BMI of 23.55. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
4220,1,"The patient is a 57-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is also experiencing a side effect known as granulocytes/bands. This side effect refers to an abnormal increase in a type of white blood cell called bands, which are immature forms of neutrophils."
4221,1,"The patient is a 54-year-old white male with a BMI of 24.22. He is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm for this patient is FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
4222,1,"The patient is a 56-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy and radiation therapy. His histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects of nausea, anorexia, and fatigue."
4223,0,"The patient is a 64-year-old white female with a BMI of 32.18. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates a mutant status."
4224,1,The patient is a 64-year-old white female with a BMI of 27.14 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory) and her primary tumor diagnosis is colon cancer. The KRAS biomarker indicates that she has a wild-type mutation.
4225,1,"The patient is a 62-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
4226,1,"The patient is a 60-year-old white female with a BMI of 20.2. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4227,1,This patient is a 64-year-old white male with a BMI of 23.18. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker status.
4228,0,"The patient is a 40-year-old white male with a BMI of 24.56 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a serious adverse effect during the treatment. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the serious adverse effect, his performance status is fully active. The KRAS biomarker shows that he has a wild-type status. Additionally, he has experienced diarrhea as an adverse effect during his treatment."
4229,0,"The patient is a 58-year-old white male with a BMI of 28.72. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4230,0,The patient is a 46-year-old white female with a BMI of 21.01. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker indicates that it is mutant.
4231,0,"The patient is a 54-year-old white male with a BMI of 26.3. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 1 cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infarction."
4232,1,The patient is a 47-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated.
4233,1,"The patient is a 60-year-old white female who has not started chemotherapy yet. She is part of the treatment arm receiving Cisplatin + Etoposide. Despite experiencing symptoms, she is still able to walk around."
4234,1,The patient is a 70-year-old white male participating in the placebo treatment arm of the study. He has symptoms but is still able to walk around and be active.
4235,0,The patient is a 72-year-old white male with a BMI of 22.68. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
4236,0,"The patient is a 70-year-old white female with a BMI of 31.92. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4237,1,"The patient is a 65-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
4238,0,"The patient is a 69-year-old white female with a BMI of 26.56. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker is wild-type."
4239,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
4240,0,"The patient is a 43-year-old white male with a BMI of 26.71. He is receiving treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the serious adverse effect, his performance status is fully active. The KRAS biomarker status is indeterminate."
4241,1,"The patient is a 69-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects with low levels of granulocytes/bands and lymphocytes."
4242,1,"The patient is a 64-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has developed adverse effects related to his granulocytes/bands and white blood cells."
4243,0,The patient is a 33-year-old white female with a BMI of 23.56 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer. She is experiencing a rash as an adverse effect of the treatment.
4244,0,"The patient is a 56-year-old white male with a BMI of 25.56 who is currently receiving treatment with the FOLFOX regimen. He has symptoms related to his condition but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation in this patient."
4245,0,"The patient is a 65-year-old white female with a BMI of 32.3. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status."
4246,0,"The patient is a 50-year-old white male with a BMI of 34.23. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4247,1,The patient is a 72-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4248,0,"The patient is a 50-year-old white male with a BMI of 29.38. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
4249,1,"The patient is a 56-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands."
4250,0,"The patient is a 74-year-old white male with a BMI of 22.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
4251,1,"The patient is a 44-year-old white female with a BMI of 30.02. She is receiving the FOLFIRI treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
4252,0,"The patient is a 48-year-old white female with a BMI of 27.03. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4253,0,"The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 4 days to manage his symptoms, but is still able to walk around."
4254,1,"The patient is a 47-year-old male of a race categorized as ""other."" He is fully active and is receiving treatment with 5FU/LV plus radiation therapy. The histology of the patient's condition is described as poorly differentiated."
4255,0,The patient is a 72-year-old white male with a BMI of 26.37. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status.
4256,1,"The patient is a 65-year-old white male with a BMI of 24.61 who is currently receiving treatment with FOLFOX and Panitumumab. He has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutant status."
4257,1,"The patient is a 44-year-old white female with a BMI of 21.45. She is receiving treatment with FOLFOX + Cetuximab and is adherent to her treatment. She has experienced a bowel obstruction and perforation. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
4258,0,"The patient is a 66-year-old white female with a BMI of 26.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type gene. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
4259,0,"The patient is a 68-year-old Black female with a BMI of 21.59. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
4260,1,The patient is a 69-year-old white male with well-differentiated histology who is part of the ECF + Radiation treatment arm. He has symptoms but is still able to walk around (ambulatory). The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4261,1,"The patient is a 45-year-old white male with a BMI of 42.84. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
4262,1,"The patient is a 65-year-old Black female with a BMI of 25.22. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 6 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
4263,0,"The patient is a 62-year-old white female with a BMI of 34.49. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
4264,1,This patient is a 49-year-old white female who is part of the placebo treatment arm. She has a performance status indicating that she spends less than 50% of her time in bed.
4265,1,This patient is a 56-year-old white female with a BMI of 24.22. She is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer.
4266,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 2 days. Despite the symptoms, she was able to remain ambulatory. The pathology report revealed a malignant condition."
4267,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 4 days following the procedure. Her histology shows symptoms but she is still able to move around, indicating that she is ambulatory. The pathology results indicate that the condition is malignant."
4268,0,The patient is a 65-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4269,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. He is typically in bed less than 50% of the time. The pathology report indicated that the underlying condition was malignant.
4270,0,"The patient is a 58-year-old white male with a BMI of 23.43. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a mutant KRAS status."
4271,0,"The patient is a 57-year-old white female with a BMI of 27.06. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type. Additionally, she has experienced an infection as an adverse effect during her treatment."
4272,1,"The patient is a 70-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy and has symptoms but is still able to walk around."
4273,0,"The patient is a 53-year-old white male with a BMI of 29.24. He is undergoing treatment with FOLFOX + Cetuximab. Unfortunately, he has experienced a serious adverse effect and is currently dealing with a bowel obstruction. He has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite these challenges, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
4274,0,"The patient is a 70-year-old Black male with a well-differentiated histology. He is currently receiving treatment with 5FU/LV + Radiation in the clinical trial. Despite experiencing symptoms, he is still able to move around independently."
4275,0,The patient is a 49-year-old white male with a BMI of 22.12. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
4276,0,"The patient is a 72-year-old white male with a BMI of 35.96. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the serious adverse effect, the patient's performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, the patient has experienced diarrhea as an adverse effect of the treatment."
4277,1,"The patient is a 61-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
4278,0,"The patient is a 70-year-old white male with a BMI of 23.81. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
4279,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has only used narcotics for 1 day. His histology shows symptoms but he is still ambulatory. The pathology results indicate a malignant condition.
4280,0,"The patient is a 63-year-old white male with a BMI of 27.17. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
4281,1,This patient is a 60-year-old white female with a BMI of 28.44 who is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. She has symptoms but is still able to move around (ambulatory). The KRAS biomarker indicates that she has a wild-type gene.
4282,0,"The patient is a 66-year-old female of a race categorized as ""other"" with a BMI of 26.91. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
4283,0,"The patient is a 62-year-old white male with a BMI of 32.66 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment and has completed 10 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
4284,0,"The patient is a 62-year-old white female with a BMI of 30.97. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. Additionally, she has experienced a hypersensitivity adverse effect during treatment."
4285,0,"The patient is a 63-year-old white male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4286,1,"The patient is a 57-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). The patient has also developed a decrease in lymphocytes as an adverse effect of the treatment."
4287,1,"The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications post-surgery and required narcotic pain medication for 5 days. Despite having symptoms, the patient was still able to be ambulatory. The pathology report indicated that the underlying cause was malignant."
4288,0,The patient is a 75-year-old male of other race with a BMI of 29.06. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment regimen FOLFOX and Panitumumab.
4289,0,"The patient is a 71-year-old white female with a BMI of 28.91. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4290,0,"The patient is a 64-year-old white female with a BMI of 31.99. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4291,0,"The patient is a 75-year-old white male with a BMI of 25.96. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. The histology of his cancer is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
4292,0,"The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 29.12. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she maintains a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4293,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around on his own, indicating that his performance status is relatively good."
4294,1,"The patient is a 65-year-old Black male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed lymphocytopenia (low lymphocyte count) as an adverse effect of the treatment."
4295,1,"The patient is a 40-year-old white female with a BMI of 40.09. She is receiving the FOLFOX treatment regimen for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
4296,0,"The patient is a 49-year-old female of a race categorized as ""other"" with a BMI of 19.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis has shown that she has a mutant KRAS status."
4297,0,"The patient is a 56-year-old white female with a BMI of 21.22. She is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that her tumor is wild-type."
4298,1,The patient is a 68-year-old white female with a BMI of 21.91 who is currently undergoing treatment with the FOLFOX regimen for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status.
4299,0,The patient is a 47-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
4300,1,"The patient is a 64-year-old white female with a BMI of 24.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
4301,1,"The patient is a 59-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around and be active (ambulatory)."
4302,1,"The patient is a 68-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. She is experiencing symptoms but is still able to walk around. Additionally, she is showing a decrease in lymphocytes, which is considered an adverse effect of the treatment."
4303,1,The patient is a male undergoing laparoscopic-assisted colectomy. He has bowel adhesions present. He has not used any narcotics for pain relief. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates a malignant condition.
4304,0,"The patient is a 55-year-old white female with a BMI of 34.31. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
4305,1,"The patient is a 53-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around and be ambulatory."
4306,0,"The patient is a 66-year-old white female with a BMI of 25.09. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology indicates that the cancer is well-differentiated. Despite the diagnosis, the patient has a fully active performance status. Additionally, the KRAS biomarker testing revealed that the patient has a wild-type KRAS status."
4307,1,"The patient is a 51-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. The patient is showing a side effect of low levels of granulocytes/bands."
4308,1,"The patient is a 51-year-old white male with a BMI of 32.35. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
4309,1,The patient is a 70-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. His histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
4310,0,The patient is a 57-year-old white male with a BMI of 26.66. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4311,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotic medication for 3 days following the surgery. The histology of the tissue sample showed that it was well-differentiated, and the pathology report indicated that the condition was benign."
4312,0,The patient is a 69-year-old white female with a BMI of 23.7. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
4313,0,"This patient is a 48-year-old white male with a BMI of 30.14. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect in the form of a bowel obstruction after completing 2 cycles of chemotherapy. The histology of his cancer is well differentiated, and his performance status is fully active. His KRAS biomarker status is wild-type."
4314,0,"The patient is a 65-year-old white female with a BMI of 24.42. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
4315,0,The patient is a 65-year-old white female with a BMI of 24.54. She is receiving the FOLFOX treatment regimen and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
4316,0,"The patient is a 46-year-old white female with a BMI of 33.95. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker indicates a mutant status."
4317,0,"The patient is a 71-year-old white female with a BMI of 27.74. She is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4318,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology results indicate that the condition is malignant.
4319,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects related to his blood counts, specifically low levels of granulocytes/bands and lymphocytes."
4320,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He experienced complications post-surgery and required narcotic pain medication for 7 days. The histology results showed that the tissue was well-differentiated, and the pathology report indicated that the condition was benign."
4321,1,The patient is a 48-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around (ambulatory). His histology shows well-differentiated characteristics.
4322,1,"The patient is a 56-year-old Black male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has developed adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands and lymphocytes."
4323,1,"This patient is a 70-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is experiencing adverse effects such as low granulocytes/bands and low white blood cell counts, as well as nausea."
4324,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the condition was malignant.
4325,0,The patient is a 45-year-old white male with a BMI of 30.42. He is enrolled in the FOLFOX treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4326,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 4 days post-surgery. The histology showed symptoms but the patient remained ambulatory. Pathology results indicated a malignant condition.
4327,1,The patient is a 50-year-old white male who is fully active and is currently receiving treatment with Sunitinib.
4328,0,"The patient is a 65-year-old Black male with a BMI of 36.64. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He experienced a serious adverse effect during the treatment. He completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
4329,1,"The patient is a 75-year-old Black male receiving treatment with Cisplatin and Etoposide. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around. The patient has developed adverse effects including low granulocytes/bands and low white blood cell count."
4330,0,The patient is a 45-year-old Black female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
4331,1,"This patient is a 63-year-old white female receiving treatment with 5FU/LV + Radiation. She has a performance status of being in bed less than 50% of the time. Her histology shows well-differentiated cells. Additionally, she is experiencing an adverse effect related to neutrophils/granulocytes."
4332,1,The patient is a male undergoing conventional surgery. He has abdominal wall adhesion and bowel adhesion. He has used narcotics for 4 days. He spends less than 50% of his time in bed. The pathology report indicates malignancy.
4333,1,The patient is a 67-year-old Black female with a BMI of 20.57. She is fully active and is receiving treatment with FOLFOX chemotherapy combined with Panitumumab for a primary tumor diagnosis of rectal cancer.
4334,1,"The patient is a 55-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as lymphocytopenia, which is a decrease in the number of lymphocytes in the blood."
4335,1,The patient is a 56-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
4336,0,"The patient is a 62-year-old male of a race categorized as ""other"" with a BMI of 25.46. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. The histology shows well-differentiated characteristics. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type result."
4337,0,"The patient is a 54-year-old white male with a BMI of 33.66. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene."
4338,0,"The patient is a 48-year-old white male with a BMI of 26.58. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
4339,1,"The patient is a 41-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
4340,0,"The patient is a 57-year-old white female with a BMI of 21.71. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4341,0,The patient is a 76-year-old white female with a BMI of 32.05. She is fully active with a primary tumor diagnosis of colon cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker indicates that her tumor has a mutant KRAS gene.
4342,0,The patient is a female who is receiving conventional surgery as part of her treatment. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
4343,0,"The patient is a 54-year-old white male with a BMI of 30.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a performance status of fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
4344,1,"This patient is a 78-year-old white male with a BMI of 23.28. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
4345,0,"The patient is a 53-year-old white male with a BMI of 26.38. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
4346,1,"This patient is a 75-year-old white female with a BMI of 28.93. She is receiving treatment with FOLFOX for a primary diagnosis of rectal cancer. Her performance status indicates that she is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed that she has a wild-type KRAS status."
4347,0,"The patient is a 43-year-old white male with a BMI of 30.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
4348,1,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 5 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
4349,1,The patient is a 67-year-old white male with a BMI of 26.46 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis revealed a mutant status.
4350,0,"The patient is a 71-year-old white male with a BMI of 30.78. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
4351,0,"This patient is a 60-year-old white male with a BMI of 18.68. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker for this patient is mutant."
4352,1,"The patient is a 66-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around."
4353,0,"The patient is a 42-year-old white male with a BMI of 24.69. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4354,1,"The patient is a 54-year-old white female with a BMI of 27.92. She is currently receiving treatment with FOLFOX and Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to walk around. Additionally, her KRAS biomarker status indicates that she has a mutant KRAS gene."
4355,0,The patient is a 56-year-old black female with a performance status of symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
4356,1,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
4357,0,The patient is a 75-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy in combination with radiation therapy. The histology of her condition is poorly differentiated.
4358,1,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 6 days following the procedure. Her histology indicates that she is in bed less than 50% of the time, and her pathology results show that the condition is malignant."
4359,0,The patient is a 58-year-old white male with a BMI of 20.99. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker is wild-type. He is currently receiving treatment in the FOLFOX treatment arm.
4360,1,"The patient is a 55-year-old male of other race, with a BMI of 21.05. He is currently receiving treatment in the FOLFOX + Panitumumab arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is in the rectal area."
4361,0,"The patient is a 71-year-old white female with a BMI of 26.27. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
4362,0,"The patient is a 49-year-old white male with a BMI of 31.07. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
4363,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. She is experiencing symptoms but is still able to move around. The pathology report indicates that the condition is malignant.
4364,0,"The patient is a 60-year-old white female with a BMI of 26.13. She is receiving treatment with FOLFOX and has adhered to the treatment plan. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced a hypersensitivity adverse effect."
4365,0,"The patient is a 47-year-old white female with a BMI of 41.26. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
4366,0,"The patient is a 69-year-old Black female with a BMI of 28.03. She is receiving the FOLFIRI chemotherapy regimen for 12 cycles as part of her treatment plan. Her cancer histology is well differentiated, and she has a KRAS mutation. Despite experiencing symptoms, she is still able to be ambulatory."
4367,0,"The patient is a 74-year-old white male with a BMI of 32.09. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells, and he has a fully active performance status. The KRAS biomarker analysis revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
4368,0,"This patient is a 76-year-old white female with a BMI of 25.54. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
4369,0,"The patient is a 57-year-old white female with a BMI of 19.11. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4370,0,"The patient is a 64-year-old white female with a BMI of 50.44. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
4371,0,The patient is a 37-year-old white female with a BMI of 43.43. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
4372,0,"The patient is a 36-year-old white male with a BMI of 17.47. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 6 cycles so far. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4373,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. The histology shows symptoms but the patient is still able to be ambulatory. The pathology report indicates that the condition is malignant.
4374,1,"The patient is a 53-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has reported experiencing nausea as an adverse effect of the treatment."
4375,1,"The patient is a 53-year-old white male with a BMI of 24.54. He is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
4376,0,"The patient is a 75-year-old Black female with a BMI of 29.62 who is receiving the FOLFOX treatment. She has experienced a serious adverse effect during her 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4377,1,"The patient is a 74-year-old white male with a BMI of 25.95 who is receiving treatment with FOLFOX + Cetuximab. He has a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
4378,0,"The patient is a 61-year-old white male with a BMI of 28.88. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker status is indeterminate."
4379,0,"This patient is a 49-year-old white male with a BMI of 28.78. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 4 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
4380,0,The patient is a 59-year-old white female who is part of the Sunitinib treatment arm. She has a fully active performance status but is experiencing fatigue as an adverse effect. This means that she is feeling tired or lacking energy as a result of the treatment.
4381,1,"The patient is a 61-year-old white male receiving treatment with Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed lymphocytopenia (low lymphocyte count) as an adverse effect of the treatment."
4382,1,"The patient is a 60-year-old white male with a BMI of 27.44. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
4383,1,"The patient is a 56-year-old white male with a BMI of 23.6 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a performance status of symptoms but is still ambulatory. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin rash or inflammation."
4384,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions and has used narcotics for 6 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
4385,1,"The patient is a 73-year-old white male with a BMI of 24.23. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4386,0,"The patient is a 45-year-old white male with a BMI of 34.16. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and thrombosis as adverse effects during his 12 chemotherapy cycles. Despite these challenges, his performance status remains fully active. Additionally, his KRAS biomarker is mutant."
4387,0,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4388,1,"The patient is a 61-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
4389,1,"This patient is a 64-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes, nausea, and anorexia."
4390,1,The patient is a 47-year-old white male participating in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to ambulate. The histology shows poorly differentiated characteristics.
4391,1,"The patient is a 68-year-old male of a race categorized as ""other."" He is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The histology of his condition is classified as poorly differentiated. Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4392,0,The patient is a 69-year-old white male with a BMI of 26.1. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4393,1,"The patient is a 38-year-old white male with a BMI of 24.25 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
4394,0,"The patient is a 63-year-old white male with a BMI of 18.93. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still ambulatory. His KRAS biomarker is wild-type. He has experienced adverse effects including hypersensitivity and diarrhea."
4395,0,"The patient is a 55-year-old white male with a BMI of 25.53. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
4396,1,The patient is a 76-year-old white male with a BMI of 35.07. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
4397,1,The patient is a 50-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
4398,0,"This patient is a 67-year-old white female with a BMI of 18.66. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
4399,0,"The patient is a 71-year-old white female with a fully active performance status. She is receiving treatment with ECF and radiation therapy. Her histology shows poorly differentiated cancer. She is experiencing adverse effects of nausea, anorexia, and fatigue."
4400,0,The patient is a 55-year-old white male with a BMI of 29.24. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4401,1,"The patient is a 64-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 3 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around on his own, indicating that his performance status is relatively good."
4402,1,"The patient is a 53-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is showing adverse effects related to her blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
4403,0,The patient is a 58-year-old white female with a BMI of 25.1. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
4404,0,"The patient is a 35-year-old white female with a BMI of 20.08. She is in the FOLFOX treatment arm and has experienced a bowel perforation. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
4405,0,"The patient is a 57-year-old white female with a BMI of 25.61. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4406,0,"The patient is a 35-year-old white female with a BMI of 34.21. She is receiving treatment with FOLFOX chemotherapy and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
4407,0,"The patient is a 53-year-old white female with a BMI of 22.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing indicates she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
4408,1,"The patient is a 60-year-old white male with a BMI of 24.49. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker testing revealed that he has a mutant KRAS gene."
4409,0,"The patient is a 55-year-old white female with a BMI of 29.76. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4410,1,"The patient is a 62-year-old white female with a BMI of 29.96. She is receiving the FOLFOX treatment regimen and has been adherent to her treatment. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
4411,1,"The patient is a 37-year-old white female with a BMI of 20.57. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates a mutant status."
4412,1,"The patient is a 62-year-old male of other race with a BMI of 21.28. He is experiencing symptoms but is still able to walk around (ambulatory). He has been diagnosed with colon cancer, and his KRAS biomarker status is wild-type. The patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab."
4413,0,"The patient is a 51-year-old white male with a BMI of 31.85. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker status is mutant."
4414,1,The patient is a 55-year-old white male with a fully active performance status. He is enrolled in the treatment arm receiving ECF chemotherapy in combination with radiation therapy. The histology of his condition is poorly differentiated.
4415,1,The patient is a 71-year-old white male with a BMI of 27.43. He is fully active with a primary tumor diagnosis of colon. The KRAS biomarker shows that he has a wild-type status. He is currently receiving treatment with the FOLFOX regimen.
4416,0,"The patient is a 76-year-old white male with a BMI of 21.72. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status. He is also experiencing diarrhea as an adverse effect of the treatment."
4417,0,"The patient is a male who is receiving treatment through conventional surgery. He has used narcotics for 3 days. The histology results show that the tumor is well-differentiated, and the pathology report indicates that the tumor is benign."
4418,0,"The patient is a 45-year-old white male with a BMI of 26.71. He is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. The histology indicates poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4419,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days following the procedure. The histology results show that the tumor is well-differentiated, and the pathology report indicates that it is benign."
4420,1,"This patient is a 68-year-old white female with a BMI of 24.25. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is well differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
4421,1,The patient is a 67-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her granulocytes/bands and white blood cells.
4422,0,"The patient is a 56-year-old white male with a BMI of 27.82. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced both a bowel obstruction and a bowel perforation. He is undergoing 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his bowel issues, his performance status is fully active. His KRAS biomarker status is wild-type."
4423,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 4 days. The histology shows that she is in bed less than 50% of the time, and the pathology report indicates malignancy."
4424,0,"The patient is a 52-year-old Black male with a BMI of 54.85. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he has a wild-type status."
4425,1,"The patient is a 65-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
4426,1,"The patient is a 65-year-old white male who has previously undergone chemotherapy and radiation treatment. He is currently enrolled in the treatment arm involving 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to move around independently. The histology of the patient's condition is poorly differentiated."
4427,0,"This patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 20.23. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel perforation, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
4428,0,"The patient is a 45-year-old white male with a BMI of 29.79. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
4429,0,"The patient is a 68-year-old male of a race categorized as ""other"" with a BMI of 29.62. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer cells are well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type KRAS gene."
4430,1,"The patient is a 62-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Her performance status indicates that she is spending less than 50% of her time in bed. Additionally, she is experiencing a decrease in lymphocytes as an adverse effect of the treatment."
4431,0,The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 3 days and is experiencing symptoms but is still able to walk around.
4432,0,"The patient is a 44-year-old white female with a BMI of 26.56. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced adverse effects during treatment, including thrombosis and diarrhea."
4433,1,"The patient is a 47-year-old white female with a BMI of 30.35. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
4434,0,"The patient is a 62-year-old white male with a BMI of 25.24. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4435,0,"The patient is a 51-year-old white male with a BMI of 25.28 who is undergoing treatment with the FOLFIRI regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker is mutant, and he has also developed thrombosis as an adverse effect of treatment."
4436,1,"The patient is a 51-year-old black female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with ECF + Radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as fatigue."
4437,0,"The patient is a 68-year-old white female with a BMI of 24.96. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4438,0,"The patient is a 65-year-old white female with a BMI of 27.44. She is currently receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
4439,0,"The patient is a 70-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type. The patient has developed an infection as an adverse effect of the treatment."
4440,1,"The patient is a 65-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 4 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around (ambulatory)."
4441,0,"The patient is a female who underwent a laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that the tumor was benign."
4442,0,The patient is a 65-year-old white female with a BMI of 24.45. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
4443,1,"The patient is a 65-year-old male of a race other than specified, with a BMI of 26.09. He is undergoing treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4444,1,"The patient is a 59-year-old female of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation therapy. She has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
4445,0,"The patient is a 66-year-old white male with a BMI of 28.41. He is currently receiving treatment with FOLFOX for rectal cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
4446,1,"The patient is a 67-year-old white male with a BMI of 29.1. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
4447,1,"The patient is a 66-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around independently."
4448,1,"The patient is a 70-year-old Black female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is also experiencing a white blood cell adverse effect."
4449,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 4 days post-surgery. Histologically, she spends less than 50% of her time in bed. Pathologically, the condition is malignant."
4450,1,"The patient is a 57-year-old white female with a BMI of 36.96. She is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 3 cycles. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker shows that it is wild-type."
4451,1,The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She has used narcotics for 4 days. She is in bed less than 50% of the time. The pathology report indicates malignancy.
4452,0,"The patient is a 52-year-old white male with a BMI of 26.14. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite these challenges, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4453,0,"The patient is a 49-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV + Radiation therapy. Despite being fully active, he is experiencing nausea as an adverse effect of the treatment. The histology of his cancer is well-differentiated."
4454,0,"The patient is a 42-year-old white female with a BMI of 23.58. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4455,1,The patient is a 68-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
4456,0,"The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 21.12. He is undergoing treatment with FOLFIRI + Cetuximab and has been adherent to the treatment. The patient has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the patient has a mutant KRAS biomarker."
4457,1,"The patient is a 36-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She has developed a white blood cell adverse effect."
4458,0,"The patient is a 48-year-old white female with a BMI of 29.67. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4459,0,The patient is a 67-year-old white female with a BMI of 29.26. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis.
4460,1,"The patient is a 71-year-old white male with a BMI of 22.91 who is currently receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
4461,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology indicates symptoms but she is still able to move around. The pathology report shows that the cause of her symptoms is malignant.
4462,0,"The patient is a 73-year-old white female with a BMI of 34.69 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 10 chemotherapy cycles. Her histology shows well-differentiated cells, and her performance status indicates that she has symptoms but is still able to be ambulatory. The patient's KRAS biomarker is wild-type. She has also experienced adverse effects such as hypersensitivity and diarrhea."
4463,0,The patient is a 34-year-old white male with a BMI of 25.52. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
4464,0,"The patient is a 34-year-old white female with a BMI of 22.98. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
4465,0,"The patient is a 57-year-old male of a race categorized as ""other"" with a BMI of 22.32. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has a bowel obstruction and has completed 2 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite these challenges, the patient has a fully active performance status. The KRAS biomarker shows that it is wild-type."
4466,1,The patient is a 53-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation therapy for poorly differentiated histology.
4467,1,The patient is a 48-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects of low neutrophil/granulocyte levels and nausea.
4468,0,The patient is a male who is receiving conventional surgery. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 10 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate malignancy.
4469,0,The patient is a 74-year-old white female with a BMI of 19.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status.
4470,0,"The patient is a 52-year-old white female with a BMI of 23.36. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated, and her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
4471,1,"The patient is a 62-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). The patient has developed adverse effects related to his white blood cells and granulocytes/bands."
4472,0,"The patient is a 53-year-old black male with a well-differentiated histology. He is currently in the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite experiencing symptoms, he is still able to walk around (ambulatory) indicating a relatively good performance status."
4473,1,"The patient is a 77-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her blood cells, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
4474,0,"The patient is a 40-year-old white male with a BMI of 20.71. He is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4475,0,"The patient is a 56-year-old white male with a BMI of 27.9. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4476,0,"The patient is a 63-year-old white male with a BMI of 31.35. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4477,0,"The patient is a 69-year-old white female with a BMI of 30.47. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 4 chemotherapy cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene. The patient has experienced diarrhea as an adverse effect of the treatment."
4478,1,The patient is a 45-year-old white male with a BMI of 26.86 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing an adverse effect in the form of a rash.
4479,0,"The patient is a 34-year-old white male with a BMI of 27.39. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates a mutant status."
4480,1,The patient is a 67-year-old white male with a BMI of 28.65 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer.
4481,1,The patient is a 64-year-old white male with a BMI of 32.24 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to ambulate. The primary tumor diagnosis is rectal cancer.
4482,0,The patient is a 56-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
4483,1,The patient is a 66-year-old white male with a BMI of 25.62 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type.
4484,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 2 days and her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
4485,0,"This patient is a 49-year-old white male who is currently undergoing treatment with 5FU/LV and radiation therapy. He has symptoms but is still able to be ambulatory, indicating a relatively good performance status. The histology shows that the cancer is well differentiated."
4486,1,"The patient is a 51-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
4487,0,The patient is a male who is part of the conventional surgery treatment group. He has used narcotics for 3 days. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
4488,1,The patient is a female who is undergoing treatment with conventional surgery. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
4489,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days following the surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
4490,0,"The patient is a 49-year-old Black female with a BMI of 21.71 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has also experienced diarrhea as an adverse effect of the treatment."
4491,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
4492,1,"The patient is a 69-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has developed adverse effects including low granulocytes/bands and low white blood cell count."
4493,0,"The patient is a 39-year-old Black female with a BMI of 24.91 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated, and her performance status is characterized by symptoms but she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has experienced an adverse effect of thrombosis."
4494,0,The patient is a 55-year-old white male with a BMI of 25.25 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient is experiencing acne as an adverse effect of the treatment.
4495,0,"The patient is a 65-year-old white female with a BMI of 40.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
4496,1,"This patient is a 71-year-old white female with a BMI of 25.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
4497,0,"The patient is a 39-year-old female of other race, with a BMI of 14.6. She is currently undergoing treatment with the FOLFOX regimen for colon cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis showed that she has a wild-type KRAS gene."
4498,1,"The patient is a 55-year-old white male with a BMI of 22.3. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer. The KRAS biomarker status is wild-type in this case."
4499,0,"This patient is a 50-year-old white female with a BMI of 36.47. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
4500,1,"The patient is a 60-year-old white male with a BMI of 32.45 who is currently undergoing treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is mutant."
4501,1,"The patient is a 60-year-old female of a race categorized as ""other."" She is currently receiving treatment in the 5FU/LV + Radiation arm. Despite experiencing symptoms, she is still able to move around independently. The histology indicates that the cancer is poorly differentiated."
4502,0,The patient is a 63-year-old white female with a BMI of 23.17. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
4503,0,"The patient is a 64-year-old white male with a BMI of 34.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker testing indicates a wild-type result. The patient is experiencing diarrhea as an adverse effect of the treatment."
4504,0,"The patient is a 65-year-old white male with a BMI of 26.06. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing showed that he has a wild-type KRAS status."
4505,0,The patient is a 53-year-old white male with a BMI of 34.1. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4506,0,The patient is a 47-year-old Black male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
4507,0,"The patient is a 62-year-old white female with a BMI of 31.39. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
4508,1,"The patient is a 62-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). Additionally, he has developed low white blood cell counts as an adverse effect of the treatment."
4509,1,"The patient is a 49-year-old white female with a BMI of 22.46. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Her performance status indicates that she is in bed less than 50% of the time. Additionally, her KRAS biomarker status is wild-type."
4510,1,The patient is a 55-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects on her neutrophils/granulocytes.
4511,1,"The patient is a 46-year-old black male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing an adverse effect known as granulocytes/bands."
4512,1,This patient is a 51-year-old white female with a performance status indicating she is in bed less than 50% of the time. She is receiving treatment with 5FU/LV + Radiation. The histology of her condition is poorly differentiated. She is experiencing an adverse effect related to neutrophils/granulocytes.
4513,0,The patient is a male who is undergoing conventional surgery for a malignant condition. He has been using narcotics for 5 days and is experiencing symptoms but is still able to walk around.
4514,1,"The patient is a 53-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects related to her white blood cells and granulocytes/bands."
4515,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 3 days following the surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
4516,1,"The patient is a 45-year-old white female with a BMI of 20.23. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
4517,1,"The patient is a 60-year-old male of a race categorized as ""other."" He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to move around independently. The histology of his condition is classified as poorly differentiated."
4518,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 6 days. Despite experiencing symptoms, she is still able to move around. The pathology report indicates malignancy."
4519,1,"The patient is a 56-year-old white male with a BMI of 20.77 who is currently receiving treatment with FOLFOX. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is rectal cancer."
4520,0,"The patient is a 40-year-old white male with a BMI of 20.76. He is receiving treatment with FOLFOX for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the adverse effect of hypersensitivity, his performance status remains fully active. Additionally, his KRAS biomarker is wild-type."
4521,0,"The patient is a 52-year-old white male with a BMI of 29.45. He is receiving the FOLFOX treatment arm for his condition. He has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite these challenges, the patient has a fully active performance status. Additionally, the KRAS biomarker indicates that he has a wild-type status."
4522,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required 6 days of narcotic use for pain management. Despite having symptoms, she is able to walk around. The pathology report indicates a malignant condition."
4523,0,The patient is a 64-year-old white female with a BMI of 25.3. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status and her KRAS biomarker is wild-type.
4524,0,The patient is a 39-year-old white male with a BMI of 37.09. He is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a wild-type status.
4525,0,"The patient is a 56-year-old white male with a BMI of 36.01. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
4526,0,"This patient is a 52-year-old white female with a BMI of 39.04. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is indeterminate."
4527,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He used narcotics for 3 days post-surgery. Despite having symptoms, he is able to walk around. The pathology report indicates malignancy."
4528,1,The patient is a 74-year-old white female with a BMI of 28.19. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
4529,0,"This patient is a 55-year-old male of a race other than specified, with a BMI of 19.33. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker status is wild-type."
4530,0,The patient is a 65-year-old white female with a BMI of 28.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
4531,1,The patient is a female who underwent conventional surgery as part of her treatment. She has been using narcotics for 7 days. The histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
4532,0,"The patient is a 36-year-old Black male with a BMI of 39.02. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
4533,1,"The patient is a 51-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving ECF chemotherapy along with radiation therapy. Despite his cancer diagnosis, he has a fully active performance status. The histology of his cancer is well-differentiated."
4534,1,"The patient is a 55-year-old white female with a BMI of 39.92. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab, and her KRAS biomarker status is wild-type."
4535,1,The patient is a 56-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active.
4536,1,"The patient is a 53-year-old white male with a BMI of 31.14 who is receiving treatment with FOLFIRI + Cetuximab. He has been adherent to the treatment regimen. After one cycle of chemotherapy, he experienced a serious adverse effect in the form of an infarction. The histology of his condition is well differentiated, and his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
4537,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 4 days post-surgery. The histology results show that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
4538,0,"The patient is a 68-year-old white male with a BMI of 26.72. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
4539,0,"The patient is a 55-year-old white male with a BMI of 24.33. He is undergoing treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4540,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She experienced complications post-surgery and required narcotic pain medication for 4 days. Despite having symptoms, she is able to move around and is ambulatory. The pathology report indicates malignant findings."
4541,0,The patient is a 49-year-old white male participating in the treatment arm involving 5FU/LV and radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated characteristics.
4542,0,"The patient is a 44-year-old white male with a BMI of 25.47. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker analysis shows that he has a wild-type KRAS status."
4543,1,"This patient is a 51-year-old white female with a BMI of 21.54 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4544,0,"The patient is a 60-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status."
4545,0,"The patient is a 50-year-old white male with a BMI of 28.01 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
4546,0,"The patient is a 62-year-old white female with a BMI of 32.87. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4547,1,"The patient is a 60-year-old white male with a BMI of 27.74. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4548,0,"The patient is a 59-year-old Black female with a BMI of 21.7. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. Despite these challenges, her performance status is fully active. She has completed 12 cycles of chemotherapy. The KRAS biomarker shows that she has a wild-type status."
4549,1,"The patient is an 81-year-old white male with a BMI of 25.11. He is currently receiving treatment with the FOLFOX regimen for his colon cancer. His performance status is fully active, indicating that he is able to carry out all normal activities without any restrictions. The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
4550,1,"The patient is a 37-year-old female of a race categorized as ""other"" with a BMI of 21.38. She is undergoing treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. She is expected to complete a total of 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the challenges with her bowel, her performance status is noted as fully active. Additionally, the KRAS biomarker analysis has revealed a mutation in this patient."
4551,1,"The patient is a 70-year-old white female with a BMI of 32.52 who is undergoing treatment with FOLFOX + Cetuximab for 10 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker test revealed a mutant result. Additionally, the patient has experienced an infection as an adverse effect of treatment."
4552,0,"The patient is a 39-year-old white male with a BMI of 38.92. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker is wild-type."
4553,0,"The patient is a 49-year-old white female participating in the treatment arm involving 5FU/LV + Radiation. She has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and anorexia."
4554,0,This patient is a 58-year-old white female with a BMI of 24.45. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker status.
4555,1,"The patient is a 56-year-old white female with a BMI of 24.69 who is currently receiving treatment with FOLFOX. She has a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
4556,0,The patient is a 48-year-old white male with a BMI of 22.35. He is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4557,1,"The patient is a 67-year-old white female with a BMI of 38.94. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. It is important to note that her KRAS biomarker is wild-type."
4558,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology indicates that the condition is malignant.
4559,0,"The patient is a 53-year-old white female with a BMI of 34.3. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still ambulatory. Her KRAS biomarker is wild-type. She is experiencing adverse effects of diarrhea and infection."
4560,1,The patient is a 74-year-old white female with a BMI of 30.43 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker analysis shows that she has a mutant KRAS gene.
4561,0,The patient is a 42-year-old white male with a BMI of 33.45. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4562,1,The patient is a 74-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation therapy. The histology shows well-differentiated characteristics.
4563,0,"The patient is a 68-year-old white female with a BMI of 29.07. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She is currently experiencing a bowel obstruction. The patient has completed 6 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite the bowel obstruction, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
4564,0,"The patient is a 49-year-old white female with a BMI of 27.22. She is receiving the FOLFIRI treatment regimen and has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4565,0,"The patient is a 65-year-old male of a race categorized as ""other"" with a BMI of 27.26. He is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. The histology of the cancer is well-differentiated, and the patient's performance status is fully active. The KRAS biomarker status is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
4566,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions and has experienced complications. She did not require any days of narcotic use post-surgery. Histology indicates symptoms but she is still able to be ambulatory. Pathology results show malignancy.
4567,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology indicates symptoms but he is still able to move around. The pathology report shows that the cause of his symptoms is malignant.
4568,1,"The patient is a 66-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 3 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to ambulate."
4569,0,"The patient is a 39-year-old white female with a BMI of 20.28. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type gene."
4570,1,The patient is a 67-year-old white female with a BMI of 18.36 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker for this patient is mutant.
4571,0,"The patient is a 56-year-old white male with a BMI of 34.6. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
4572,0,"The patient is a 53-year-old white female with a BMI of 23.69. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
4573,1,The patient is a 52-year-old white female with a BMI of 28.62 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker indicates that she has a wild-type status.
4574,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 4 days post-surgery. His histology indicates that he is in bed less than 50% of the time, and the pathology report shows that the condition is malignant."
4575,0,This patient is a 71-year-old white male with a BMI of 22.28. He is fully active and is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. His primary tumor diagnosis is rectal cancer. The KRAS biomarker testing revealed a mutant status.
4576,0,The patient is a 74-year-old white female with a BMI of 27.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis revealed a mutant status.
4577,1,"The patient is a 79-year-old white male who is undergoing treatment with Cisplatin + Etoposide. He has completed 4 cycles of chemotherapy. He has experienced weight loss greater than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory). The patient has also developed a decrease in granulocytes/bands, which is an adverse effect of the treatment."
4578,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. She is experiencing symptoms but is still able to walk around. The pathology report indicates a malignant condition.
4579,0,"The patient is a 59-year-old white female with a BMI of 31.6. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4580,0,"The patient is a 54-year-old white male with a BMI of 30.15. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology cancer. Despite being fully active, he experienced a serious adverse effect in the form of thrombosis during his 12 cycles of chemotherapy. His KRAS biomarker status is wild-type."
4581,0,"The patient is a 63-year-old white female with a BMI of 22.87. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
4582,0,"The patient is a 70-year-old white female with a BMI of 32.9 who is receiving treatment with FOLFIRI + Cetuximab. She is experiencing a bowel obstruction and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The KRAS biomarker indicates that she is wild-type. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
4583,0,"The patient is a 52-year-old white female with a BMI of 27.53. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
4584,0,"The patient is a 66-year-old white male with a BMI of 29.67. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4585,1,"The patient is a 68-year-old white male with a BMI of 40.23. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type."
4586,0,"The patient is a 49-year-old white female with a BMI of 20.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4587,1,The patient is a 48-year-old white female with a BMI of 18.75 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a performance status of symptoms but is still ambulatory. The KRAS biomarker indicates that she has a wild-type gene. The patient is experiencing a rash as an adverse effect of the treatment.
4588,0,"The patient is a 55-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for a total of 6 chemotherapy cycles. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is also experiencing nausea as an adverse effect of the treatment."
4589,0,The patient is a 47-year-old white male with a BMI of 30.07. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
4590,0,The patient is a 54-year-old white male with a BMI of 25.83. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
4591,1,"The patient is a 58-year-old white male with a BMI of 23.35. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
4592,0,"The patient is a 60-year-old white male with a BMI of 24.45. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
4593,0,"The patient is a 46-year-old white male with a BMI of 24.49. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
4594,1,The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 10 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
4595,0,"The patient is a 76-year-old white male with a BMI of 31.82. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4596,0,"The patient is a 71-year-old Black female with a BMI of 38.3 who is receiving the FOLFOX treatment regimen for chemotherapy. She has completed 4 cycles of chemotherapy and her histology shows well-differentiated cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
4597,1,The patient is a 66-year-old white male participating in the placebo treatment arm. He has symptoms but is still able to move around independently.
4598,0,"The patient is a 59-year-old white female with a BMI of 39.56. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The patient's KRAS biomarker is mutant."
4599,1,"The patient is a 42-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects including low white blood cell count and nausea."
4600,0,The patient is a 59-year-old white male with a BMI of 28.06. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4601,0,The patient is a 73-year-old white male with a BMI of 22.91. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a rectal tumor. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status.
4602,1,"The patient is a 43-year-old white male with a BMI of 33.24. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4603,0,"The patient is a 49-year-old white male with a BMI of 23.4. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type gene."
4604,1,The patient is a 63-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around.
4605,1,The patient is a 66-year-old white female with a BMI of 19.23 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker analysis showed a mutant status.
4606,0,"The patient is a 51-year-old white female with a BMI of 42.94. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
4607,0,The patient is a 64-year-old white male with a BMI of 28.08. He is fully active with a primary tumor diagnosis of colon cancer. The KRAS biomarker indicates that he has a wild-type status. He is currently receiving treatment with the FOLFOX regimen.
4608,0,"The patient is a 70-year-old white female with a BMI of 23.61. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab, and her KRAS biomarker status is wild-type."
4609,1,"The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 2 days post-surgery. The histology indicates that he spent less than 50% of his time in bed, and the pathology report shows that the condition is malignant."
4610,0,"The patient is a 48-year-old white female with a BMI of 39.54. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
4611,0,The patient is a 46-year-old white male with a BMI of 26.29. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4612,1,The patient is a 65-year-old white male with a BMI of 17.86. He is receiving treatment with FOLFOX for a colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows a mutant status.
4613,0,The patient is a 53-year-old Black male with a BMI of 27.62. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He experienced a serious adverse effect during the treatment. The patient completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. He has a fully active performance status. The KRAS biomarker analysis revealed a wild-type result.
4614,1,"The patient is a 68-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 6 chemotherapy cycles. She has a fully active performance status. The patient has experienced an adverse effect related to her lymphocytes."
4615,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. Pathology results indicate malignancy.
4616,0,"The patient is a 40-year-old white male with a BMI of 25.33. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
4617,1,"The patient is a 59-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects on her white blood cells and lymphocytes."
4618,0,"The patient is a 40-year-old white male with a BMI of 35.88. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status."
4619,0,"This patient is a 66-year-old white male with a BMI of 30.17. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4620,0,"The patient is a 38-year-old white male with a BMI of 27.93 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment and has completed 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS gene. The patient has experienced diarrhea as an adverse effect of the treatment."
4621,0,"The patient is a 75-year-old white male with a BMI of 28.03. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4622,1,"The patient is a 56-year-old white male with a BMI of 28.54 who is receiving the FOLFOX treatment regimen. He has experienced a serious adverse effect in the form of a bowel obstruction after completing 4 cycles of chemotherapy. The histology of his cancer is poorly differentiated, but his performance status is fully active. His KRAS biomarker status is wild-type. Additionally, he has also experienced diarrhea as an adverse effect of the treatment."
4623,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
4624,1,"The patient is a 58-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects including low granulocytes/bands and low white blood cells, as well as nausea."
4625,0,"The patient is a 43-year-old white male with a BMI of 25.6. He is undergoing treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his cancer diagnosis, he has a fully active performance status."
4626,0,"The patient is a 65-year-old white female with a BMI of 24.24. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
4627,0,The patient is a 59-year-old white male with a BMI of 27.4 who has symptomps but is ambulatory. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
4628,1,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days post-surgery. Her histology indicates that she is in bed less than 50% of the time, and her pathology report shows that the tumor is malignant."
4629,0,The patient is a 62-year-old Black male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation. The histology shows poorly differentiated cells. The patient is experiencing adverse effects with low levels of neutrophils/granulocytes and leukocytes.
4630,1,"The patient is a 57-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing an adverse effect known as granulocytes/bands. This adverse effect refers to a decrease in the number of a type of white blood cell called granulocytes, which can lead to an increased risk of infection."
4631,0,"The patient is a 38-year-old white female with a BMI of 33.3. She is currently receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has completed one cycle of chemotherapy. The histology of her condition is well differentiated. Despite the bowel obstruction, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
4632,0,"This patient is a 54-year-old white female with a BMI of 25.33. She is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
4633,1,"The patient is a 77-year-old white male with a BMI of 22.13. He is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that the patient has a mutant KRAS status."
4634,1,The patient is a 59-year-old white male with a BMI of 30.97. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
4635,1,The patient is a 72-year-old white male with well-differentiated histology who is receiving treatment with 5FU/LV and radiation therapy. He has symptoms but is still able to walk around. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4636,0,The patient is a 56-year-old white male with a BMI of 24.89 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker analysis indicates a mutant status.
4637,0,"The patient is a male who is part of the conventional surgery treatment group. He has bowel adhesions present and has used narcotics for 3 days. The histology shows that the tissue is well-differentiated, and the pathology indicates that it is benign."
4638,1,"The patient is a 59-year-old female of a race other than Caucasian, who has not yet started chemotherapy treatment with Cisplatin and Etoposide. She has experienced significant weight loss of more than 5-10% and has symptoms but is still able to walk around (ambulatory)."
4639,1,"The patient is a 71-year-old white male with a BMI of 28.93. He is currently receiving treatment with FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows a mutation."
4640,1,"The patient is a 51-year-old white female with a BMI of 29.07. She is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4641,0,"The patient is a 67-year-old white female with a BMI of 30.66. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type gene. She is experiencing diarrhea as an adverse effect of the treatment."
4642,0,"The patient is a 51-year-old white female with a BMI of 30.22. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and is adherent to her treatment. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. The histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
4643,0,"The patient is a 45-year-old white female with a BMI of 20.23. She is currently receiving treatment with FOLFOX for a rectal tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
4644,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 5 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
4645,1,"This patient is a 63-year-old white male who is currently receiving treatment with 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4646,1,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days post-surgery. The histology indicates that she spends less than 50% of her time in bed, and the pathology report shows that the condition is malignant."
4647,0,"The patient is a 73-year-old male of a race categorized as ""other"" who is currently undergoing treatment with 5FU/LV and radiation therapy. He has a history of prior cancer. His performance status indicates that he is in bed less than 50% of the time. The histology of his current condition is well-differentiated. Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4648,0,The patient is a 35-year-old white female with a BMI of 22.41. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
4649,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 2 days post-surgery. Her histology indicates that she is in bed less than 50% of the time, and her pathology report shows that the condition is malignant."
4650,1,The patient is a 49-year-old white female with a BMI of 20.96 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker indicates that the patient has a mutant KRAS gene.
4651,0,"This patient is a 63-year-old white female with a BMI of 25.3. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab, a targeted therapy. The KRAS biomarker status in her tumor is wild-type, which suggests that she may benefit from the targeted therapy Panitumumab."
4652,0,"The patient is a 64-year-old white female with a BMI of 22.81. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She experienced a bowel perforation during the course of treatment. She completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
4653,1,"The patient is a 40-year-old Black female with a BMI of 22.04. She is receiving the FOLFOX treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4654,1,"The patient is a 68-year-old white male who is currently undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and is considered ambulatory."
4655,0,"The patient is a 49-year-old white female with a BMI of 36.34. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
4656,0,"This patient is a 76-year-old white female with a BMI of 24.75. She is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4657,1,The patient is a 55-year-old white female with a BMI of 28.28. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4658,0,The patient is a 42-year-old white male with a BMI of 31.66. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4659,0,"The patient is a 45-year-old Black female with a BMI of 15.58. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
4660,1,The patient is a 42-year-old female of other race with a BMI of 31.5. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab.
4661,0,"The patient is a 34-year-old white male with a BMI of 37.39. He is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4662,1,The patient is a 76-year-old white male with a BMI of 23.8. He is fully active with a performance status. He is receiving treatment with FOLFOX and Panitumumab for colon cancer.
4663,0,"The patient is a 50-year-old Caucasian woman with a BMI of 19.18. She is undergoing treatment with FOLFOX and Cetuximab. Unfortunately, she has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker is wild-type."
4664,0,"The patient is a 46-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving ECF chemotherapy along with radiation therapy. His performance status is fully active, indicating that he is able to carry out daily activities without limitations. The histology of his condition is poorly differentiated, suggesting that the cancer cells appear abnormal and are growing rapidly."
4665,1,The patient is a 62-year-old white female with a BMI of 24.6. She is fully active and her primary tumor diagnosis is rectal. She is in the treatment arm receiving FOLFOX chemotherapy along with Panitumumab. Her KRAS biomarker status is wild-type.
4666,0,"The patient is a 59-year-old white female with a BMI of 49.73. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
4667,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during her treatment. She used narcotics for 2 days post-surgery. Despite having symptoms, she is ambulatory. The pathology report indicates malignancy."
4668,0,"The patient is a 44-year-old white male with a BMI of 38.33. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4669,1,The patient is a 47-year-old black female with a performance status of symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy along with radiation. The histology of her cancer is poorly differentiated. She is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4670,0,The patient is a 42-year-old white male with a BMI of 30.37. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
4671,1,"The patient is a 73-year-old male of a race categorized as ""other."" He is currently receiving treatment in the 5FU/LV + Radiation arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The histology results indicate that the cancer is poorly differentiated."
4672,1,"The patient is a 70-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is showing adverse effects on his blood cells, specifically with low levels of granulocytes/bands, white blood cells, and lymphocytes."
4673,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She experienced complications post-surgery and used narcotics for 3 days. Despite having symptoms, she is able to walk around. The pathology report indicates malignancy."
4674,1,"The patient is a 65-year-old white male who is undergoing treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is also experiencing a common adverse effect known as granulocytes/bands."
4675,0,"The patient is a 45-year-old white female with a BMI of 24.17. She is receiving treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
4676,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 4 days post-surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the tumor was malignant.
4677,1,The patient is a 60-year-old white male with a BMI of 28.64. He is receiving the FOLFOX treatment regimen and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
4678,0,"The patient is a 57-year-old white female with a BMI of 20.72. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has been adherent to her treatment. The patient has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
4679,0,The patient is a 54-year-old white male with a BMI of 31.15. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4680,0,"The patient is a 70-year-old white female with a BMI of 32.17. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
4681,0,"The patient is a 42-year-old white male with a BMI of 28.22. He is receiving treatment in the FOLFOX arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4682,0,"The patient is a 63-year-old white male with a BMI of 41.52. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
4683,0,The patient is a 66-year-old white male with a BMI of 27.35. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a mutant KRAS biomarker.
4684,0,"The patient is a 56-year-old white male with a BMI of 26.16. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has symptoms but is still ambulatory. The KRAS biomarker indicates that he is wild-type. He has experienced a hypersensitivity adverse effect."
4685,1,"This patient is a 67-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a performance status of fully active."
4686,0,The patient is a 41-year-old white female with a BMI of 26.29. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. She has a fully active performance status. The KRAS biomarker status is indeterminate.
4687,1,"This patient is a 68-year-old white female with a BMI of 24.24 who is enrolled in the FOLFOX treatment arm. She has a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker status is wild-type."
4688,1,The patient is a 54-year-old female of other race with a BMI of 26.78. She is fully active in terms of performance status. She is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker analysis shows a mutant status.
4689,1,"The patient is a 69-year-old white male with a BMI of 35.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
4690,1,"The patient is a 47-year-old female of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytopenia, indicated by a decrease in the number of granulocytes/bands in her blood."
4691,0,The patient is a 60-year-old white female with a BMI of 23.82. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4692,0,The patient is a 38-year-old white male with a BMI of 30.47. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is mutant. He has experienced a hypersensitivity adverse effect.
4693,0,"The patient is a female who is undergoing conventional surgery. She has used narcotics for 2 days. Her histology shows that the tumor is well-differentiated, and the pathology report indicates that the tumor is benign."
4694,1,This patient is a 62-year-old white female with a BMI of 28.67 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory) and her KRAS biomarker status is wild-type.
4695,1,The patient is a 50-year-old black male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
4696,0,"This patient is a 62-year-old white male with a BMI of 37.53. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his health challenges, his performance status is fully active. His KRAS biomarker status is wild-type."
4697,0,"The patient is a 75-year-old white male with a BMI of 32.15. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 11 cycles so far. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
4698,0,"The patient is a 55-year-old white male with a BMI of 40.46. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing revealed that he has a wild-type KRAS status."
4699,1,The patient is a 45-year-old female of other race with a BMI of 17.72. She is fully active in terms of performance status. She has been diagnosed with a primary tumor in the colon and has a mutant KRAS biomarker. The patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
4700,0,The patient is a 53-year-old white female with a BMI of 27.27. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4701,1,"The patient is a 56-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also experienced adverse effects including low levels of granulocytes/bands and nausea."
4702,1,This patient is a 61-year-old white male with a fully active performance status. He is receiving treatment with ECF + Radiation. The histology shows well-differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
4703,0,The patient is a 58-year-old white male with a BMI of 29.54. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
4704,1,"The patient, a 60-year-old white female with a BMI of 29.26, is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a fully active performance status. The patient is experiencing a rash as an adverse effect of the treatment. The rash is a skin reaction characterized by redness, itching, and possibly the presence of small bumps or blisters on the skin."
4705,1,The patient is a 72-year-old white male with a BMI of 24.52. He is fully active with a primary tumor diagnosis of rectal cancer. He is enrolled in the FOLFOX + Panitumumab treatment arm. His KRAS biomarker status is wild-type.
4706,1,The patient is a 62-year-old white male with a BMI of 26.37. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is mutant. He is currently receiving treatment with the FOLFOX regimen.
4707,0,"The patient is a 52-year-old white female with a BMI of 48.7. She is receiving treatment in the FOLFOX arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4708,1,"The patient is a 76-year-old white female with a BMI of 25.82. She is enrolled in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has not started any chemotherapy cycles yet. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4709,1,The patient is a 66-year-old white female with a BMI of 25.53. She is fully active and is receiving treatment with FOLFOX for colon cancer. The KRAS biomarker indicates that she has a wild-type status.
4710,1,"The patient is a 65-year-old white male with a BMI of 25.49. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4711,1,"This patient is a 70-year-old white female with a BMI of 32.63. She is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and she has a mutant KRAS biomarker."
4712,1,"The patient is a 70-year-old white female with a BMI of 22.66. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status."
4713,0,"This patient is a 59-year-old white female with a BMI of 21.29. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is wild-type."
4714,1,"The patient is a 47-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and perform daily activities."
4715,1,"The patient is a 47-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4716,1,The patient is a male undergoing laparoscopic-assisted colectomy treatment. He has been using narcotics for 4 days. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
4717,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. She was in bed less than 50% of the time. The pathology report indicated malignancy.
4718,1,"The patient is a 76-year-old white male with a BMI of 31.47 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin rash."
4719,0,"This patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. The histology report shows that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
4720,1,"This patient is a female who received conventional surgery as treatment. She used narcotics for 4 days following the procedure. The histology shows that she was in bed less than 50% of the time, and the pathology indicates that the condition is malignant."
4721,1,"In this patient profile, the individual is a 67-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around and be ambulatory. One of the adverse effects noted is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
4722,1,"The patient is a 48-year-old white male with a BMI of 20.45 who is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. His primary tumor diagnosis is colon cancer."
4723,0,The patient is a 60-year-old white female with a BMI of 39.37. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation.
4724,0,"The patient is a 52-year-old white male with a BMI of 19.72. He is receiving treatment with the FOLFOX regimen and has been adherent to the chemotherapy. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
4725,0,This patient is a 48-year-old white male with a well-differentiated histology. He is fully active and is receiving treatment in the ECF + Radiation arm.
4726,0,"The patient is a 66-year-old white male participating in the treatment arm involving 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. Additionally, the patient is experiencing an adverse effect related to neutrophils/granulocytes."
4727,1,The patient is a 59-year-old white male with a BMI of 27.43 who is fully active. He is receiving treatment with FOLFOX for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
4728,0,"This patient is a 72-year-old white female with a BMI of 30.71. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. Unfortunately, she has experienced a serious adverse effect in the form of a bowel obstruction. Despite this, she has completed 12 cycles of chemotherapy and has a fully active performance status. Her KRAS biomarker status is wild-type."
4729,0,The patient is a 71-year-old white male with a BMI of 30.41. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
4730,1,"The patient is a 68-year-old white male with a BMI of 24.16. He is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4731,1,"The patient is a 67-year-old white male with a BMI of 27.34 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows that it is wild-type."
4732,1,The patient is a female who is part of the conventional surgery treatment group. She has used narcotics for 6 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
4733,1,"The patient is a 53-year-old white male with a BMI of 36.11. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
4734,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 5 days post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
4735,0,"The patient is a 62-year-old white female who has not yet started chemotherapy treatment. She is experiencing symptoms but is still able to walk around on her own. She is assigned to the treatment arm that includes Cisplatin, Etoposide, and Paclitaxel."
4736,0,"The patient is a 45-year-old female of a race categorized as ""other"" with a BMI of 25.39. She is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect."
4737,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
4738,0,The patient is a 49-year-old white female with a BMI of 21.83. She is in the FOLFOX treatment arm and is adherent to her treatment. She is currently experiencing a bowel obstruction. The patient has not yet undergone any chemotherapy cycles. Her histology shows poorly differentiated cells. She has a performance status of being in bed less than 50% of the time. The KRAS biomarker status is indeterminate.
4739,0,"The patient is a 52-year-old white male with a BMI of 26.16. He is currently receiving treatment with FOLFOX for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
4740,1,The patient is a 51-year-old white female with a BMI of 20.55 who is currently receiving treatment with the FOLFOX regimen. She has a fully active performance status and has been diagnosed with a primary tumor in the colon. The KRAS biomarker analysis has shown that she has a mutant KRAS status.
4741,1,The patient is a 51-year-old white male who is fully active and is receiving treatment with Sunitinib.
4742,0,"The patient is a 60-year-old white male with a BMI of 26.22. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4743,1,"The patient is a 59-year-old white male with a BMI of 24.54 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is mutant."
4744,0,"The patient is a 56-year-old Black male with a BMI of 36.89. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4745,0,"The patient is a 50-year-old white female with a BMI of 19.49. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4746,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He used narcotics for 2 days post-surgery. Despite experiencing symptoms, he is able to walk around. The pathology report indicates malignancy."
4747,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 7 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
4748,0,The patient is a 43-year-old white female with a BMI of 26.68. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
4749,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions present. She only used narcotics for 1 day post-surgery. The histology shows symptoms but the patient is still ambulatory. Pathology results indicate a malignant condition.
4750,1,"The patient is a female who underwent conventional surgery and experienced complications. She used narcotics for 7 days post-surgery. The histology indicates that she spent less than 50% of her time in bed, and the pathology report shows that the tumor is malignant."
4751,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She experienced complications post-surgery and required narcotic pain medication for 6 days. Despite having symptoms, she is still able to be ambulatory. The pathology report indicates malignancy."
4752,0,"The patient is a 64-year-old white female with a BMI of 21.64. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4753,1,"The patient is a 54-year-old white female with a BMI of 17.93. She is currently receiving treatment in the FOLFOX + Panitumumab arm. Despite experiencing symptoms, she is still able to walk around (ambulatory). She has been diagnosed with a primary tumor in the colon and her KRAS biomarker status is mutant."
4754,1,"The patient is a 59-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed a decrease in granulocytes/bands, which is considered an adverse effect of the treatment."
4755,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 8 days. Their histology shows symptoms but they are still able to walk around. The pathology results indicate that the condition is malignant.
4756,1,The patient is a 58-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows well-differentiated cells.
4757,1,"The patient is a 48-year-old white male with a BMI of 21.18. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker indicates that it is wild-type."
4758,0,The patient is a 57-year-old Black male with a BMI of 31.24. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
4759,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 1 day post-surgery. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
4760,1,The patient is a 73-year-old white male with a BMI of 32.8 who is undergoing treatment with FOLFIRI + Cetuximab for well-differentiated histology. He has completed 12 cycles of chemotherapy and has a fully active performance status. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
4761,0,"The patient is a 61-year-old female of other race, with a BMI of 21.32. She is fully active with a primary tumor diagnosis of colon. Her KRAS biomarker status is wild-type. She is experiencing dermatitis acneiform as an adverse effect of the FOLFOX + Panitumumab treatment. This adverse effect presents as acne-like skin rash or inflammation."
4762,0,"This patient is a 62-year-old white female with a BMI of 25.07. She is receiving treatment with the FOLFOX regimen for her cancer. She has experienced a bowel perforation and has undergone 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
4763,1,"The patient is a 52-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She is scheduled to undergo a total of 8 chemotherapy cycles. Despite her treatment, she maintains a fully active performance status."
4764,0,"The patient is a 55-year-old white male with a BMI of 32.65. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4765,0,"The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 26.67. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4766,0,"The patient is a 65-year-old white female with a BMI of 19.84. She is receiving the FOLFIRI treatment regimen for KRAS mutant cancer and has completed 9 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker for her cancer is wild-type."
4767,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 4 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
4768,1,"The patient is a 60-year-old male of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin and Etoposide. He is expected to complete a total of 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around and remain ambulatory."
4769,1,"This patient is a 66-year-old white female with a BMI of 41.06. She is receiving treatment with FOLFOX + Cetuximab for her bowel obstruction. She has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, she has a fully active performance status. Her KRAS biomarker is wild-type."
4770,0,"The patient is a 58-year-old white female with a BMI of 22.92. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she is wild-type. Additionally, she has developed an infection as an adverse effect of the treatment."
4771,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 6 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate malignancy.
4772,1,"The patient is a 69-year-old white male with a BMI of 35.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4773,0,"The patient is a 52-year-old white female with a BMI of 20.63. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4774,1,"The patient is a 72-year-old white male participating in the placebo treatment arm of the study. He has symptoms but is still able to walk around, indicating that his performance status is affected but he is still ambulatory."
4775,1,"The patient is a 52-year-old male of a race categorized as ""other."" He is fully active with a well-differentiated histology. The treatment arm for this patient includes 5FU/LV + Radiation."
4776,1,The patient is a 55-year-old white male with a BMI of 26.26. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. He is currently undergoing treatment with the FOLFOX regimen.
4777,0,"The patient is a 73-year-old white female with a BMI of 27.56. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
4778,0,"The patient is a 38-year-old Black female with a BMI of 31.87. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type KRAS gene."
4779,1,The patient is a 51-year-old white male with a fully active performance status. He is currently enrolled in the treatment arm receiving a placebo.
4780,0,"The patient is a 72-year-old white male with a BMI of 33.88. He is currently receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
4781,0,The patient is a 42-year-old white female with a BMI of 22.66. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker indicates that it is wild-type.
4782,0,The patient is a 34-year-old white female with a BMI of 25.35. She is receiving treatment with the FOLFOX chemotherapy regimen and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. The patient has a fully active performance status. Her KRAS biomarker status is wild-type.
4783,0,"The patient is a 50-year-old white female with a BMI of 26.2. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
4784,1,"The patient is a 64-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he has experienced adverse effects on his white blood cells and lymphocytes."
4785,0,The patient is a 53-year-old Black female with a BMI of 24.1 who is receiving the FOLFOX treatment regimen for her well-differentiated histology. She has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced hypersensitivity as an adverse effect during her treatment.
4786,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required 9 days of narcotic use for pain management. Despite the symptoms, he was still able to be ambulatory. The pathology report indicated that the underlying cause was malignant."
4787,0,"The patient is a 46-year-old white female with a BMI of 21.18. She is receiving treatment with the FOLFOX regimen and has experienced both a bowel obstruction and perforation. She has completed 12 cycles of chemotherapy. The histology of her condition is well differentiated. Despite the bowel issues, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4788,0,This patient is a 49-year-old white male who is currently receiving treatment with ECF chemotherapy combined with radiation therapy. He has a performance status of experiencing symptoms but is still able to be ambulatory. The histology of his cancer is poorly differentiated. He is experiencing fatigue as an adverse effect of his treatment.
4789,1,"The patient is a 74-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is experiencing adverse effects related to his granulocytes/bands and white blood cells."
4790,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and experienced complications post-surgery. She used narcotics for 5 days following the procedure. Despite having symptoms, she is able to walk around. The pathology report indicated malignancy."
4791,1,The patient is a 64-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects of nausea and fatigue.
4792,0,"The patient is a 42-year-old female of a race categorized as ""other"" with a BMI of 23.21. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite these challenges, the patient has a fully active performance status. Additionally, the KRAS biomarker is wild-type in this case."
4793,1,The patient is a 73-year-old white female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation therapy. The histology of her condition is poorly differentiated.
4794,0,"The patient is a 65-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects related to his granulocytes/bands and white blood cells."
4795,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology results showed well-differentiated cells, and the pathology report indicated that the condition was benign."
4796,1,"The patient is a 71-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. She has experienced weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around. She has experienced adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
4797,1,The patient is a 61-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology of the patient's condition is poorly differentiated. The patient is experiencing an adverse effect of leukocytes.
4798,0,The patient is a 55-year-old Black male with a BMI of 20.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. He has a bowel obstruction and has completed 6 cycles of chemotherapy. The histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker is mutant in this case.
4799,1,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
4800,1,"The patient is a 36-year-old Black male with a BMI of 17.15. He is receiving treatment in the FOLFIRI chemotherapy arm for KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
4801,0,"The patient is a 55-year-old white male with a BMI of 20.28. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment in the FOLFOX treatment arm."
4802,0,The patient is a 56-year-old white female with a BMI of 34.12. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker status is indeterminate.
4803,0,"The patient is a 41-year-old white female with a BMI of 18.24. She is currently enrolled in the FOLFOX + Cetuximab treatment arm and is adherent to her treatment. She has experienced both bowel obstruction and bowel perforation. Despite having not started any chemotherapy cycles yet, her histology shows poorly differentiated cells. The patient's performance status is fully active, and her KRAS biomarker indicates that she has a wild-type status."
4804,1,"The patient is a 69-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. The patient has also developed adverse effects including low granulocytes/bands and low white blood cell count."
4805,0,The patient is a 66-year-old white male with a BMI of 33.87. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4806,1,The patient is a 75-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
4807,0,The patient is a 51-year-old white male with a BMI of 28.41 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer. His KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment.
4808,0,The patient is a 52-year-old white male with a BMI of 26.29. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4809,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She used narcotics for 2 days post-surgery. The histology results show that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
4810,0,The patient is a 55-year-old white male with a BMI of 30.18. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
4811,0,"The patient is a 70-year-old white female with a BMI of 19.17. She is receiving treatment with the FOLFIRI regimen for her KRAS mutant status. She has a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory."
4812,0,"The patient is a 56-year-old white female with a BMI of 24.05. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
4813,0,"The patient is a 60-year-old white female with a BMI of 36.76. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
4814,0,"The patient is a 46-year-old white male with a BMI of 30.17. He is receiving the FOLFOX treatment regimen for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing showed that he has a wild-type KRAS status."
4815,0,"The patient is a 69-year-old white female with a BMI of 22.75. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. She has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to move around. Her KRAS biomarker is wild-type."
4816,0,"The patient is a 34-year-old female of a race categorized as ""other"" with a BMI of 26.38. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient is experiencing a bowel obstruction and has completed one cycle of chemotherapy. Histologically, the patient's cancer is well-differentiated. Her performance status indicates that she is in bed less than 50% of the time. The KRAS biomarker analysis shows that she has a wild-type KRAS status. Additionally, the patient is experiencing diarrhea as an adverse effect."
4817,1,"The patient is a 72-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to his blood cell counts, specifically a decrease in neutrophils/granulocytes and leukocytes."
4818,0,The patient is a female who received conventional surgery as treatment. She used narcotics for 5 days following the procedure. The histology indicates symptoms but she is still able to walk around. The pathology results show that the condition is malignant.
4819,1,"The patient is a 73-year-old white female with a BMI of 22.04. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. However, she has experienced a serious adverse effect. She has completed 4 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type."
4820,0,"The patient is a 58-year-old white male with a BMI of 28.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
4821,0,"The patient is a 71-year-old white female with a BMI of 30.12. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. The patient has experienced diarrhea as an adverse effect of the treatment."
4822,0,"The patient is a 55-year-old Black female with a BMI of 40.72. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
4823,0,"The patient is a 68-year-old white female with a BMI of 35.7. She is part of the treatment arm receiving FOLFOX + Cetuximab and has been adherent to the treatment. She experienced a bowel perforation and completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells, and her performance status is fully active. The KRAS biomarker indicates that she has a wild-type mutation."
4824,0,"The patient is a 53-year-old female of a race other than Caucasian, with a BMI of 21.2. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her treatment, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
4825,0,"The patient is a 63-year-old white female with a BMI of 30.2. She is currently receiving treatment with FOLFOX for her well-differentiated histology. She has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
4826,0,"The patient is a 52-year-old white female with a BMI of 27.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
4827,0,The patient is a 56-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a fully active performance status and has been diagnosed with poorly differentiated histology. An adverse effect noted is the presence of neutrophils/granulocytes.
4828,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
4829,0,"The patient is a 59-year-old white male with a BMI of 26.9. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
4830,1,"The patient is a 69-year-old white male with a BMI of 31.77. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker test results indicate that he has a wild-type KRAS status. Additionally, the patient has developed an infection as an adverse effect of the treatment."
4831,0,"The patient is a 71-year-old white male with a BMI of 27.91. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His cancer histology is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4832,1,The patient is a 48-year-old white female with a BMI of 21.3. She is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker for this patient is mutant.
4833,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotic medication for 4 days following the procedure. The histology results showed that the tumor was well differentiated, and the pathology report indicated that it was benign."
4834,0,"The patient is a 55-year-old white female with a BMI of 27.53. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. Unfortunately, she has experienced a thrombosis as an adverse effect during her treatment."
4835,0,"The patient is a 59-year-old male of other race, with a BMI of 25.95. He is fully active with a primary tumor diagnosis of colon. His KRAS biomarker is wild-type. The patient is experiencing acne as an adverse effect."
4836,1,"The patient is a 61-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
4837,0,"The patient is a 38-year-old Black female with a BMI of 29.68. She is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
4838,1,"The patient is a 74-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. His performance status indicates that he is in bed less than 50% of the time. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
4839,0,"The patient is a 60-year-old male of a race categorized as ""other"" with a BMI of 24.59. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles of chemotherapy. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type."
4840,1,"This patient is a 66-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm. The histology of his condition is poorly differentiated. Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4841,1,"The patient is a 43-year-old white male with a BMI of 30.12. He is fully active and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal, and his KRAS biomarker status is wild-type."
4842,0,"The patient is a 62-year-old white male with a BMI of 31.47. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4843,0,"The patient is a 68-year-old white female with a BMI of 27.85. She is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
4844,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions present. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is still able to move around. The pathology report indicates the presence of malignancy.
4845,0,The patient is a 47-year-old white male receiving treatment with Sunitinib. He is fully active but is experiencing fatigue as an adverse effect of the treatment.
4846,0,"The patient is a 50-year-old white female with a BMI of 33.91. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to move around independently. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
4847,0,"The patient is a 52-year-old white male with a BMI of 18.83. He is receiving treatment in the FOLFOX arm and has been adherent to his chemotherapy regimen for 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
4848,1,"The patient is a 61-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is also experiencing adverse effects such as low granulocytes/bands and nausea."
4849,0,The patient is a 46-year-old white female with a BMI of 23.83. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4850,0,The patient is a 59-year-old white male with a fully active performance status. He is currently in the treatment arm receiving a placebo.
4851,0,The patient is a 47-year-old white female with a BMI of 37.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker is wild-type.
4852,0,The patient is a 45-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4853,1,"The patient is a 60-year-old white female with a BMI of 34.6. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing a total of 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type status."
4854,1,The patient is a 75-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology.
4855,1,"The patient is a 41-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around. The patient is showing adverse effects related to low levels of granulocytes/bands and white blood cells."
4856,0,"The patient is a 60-year-old white female with a BMI of 25.02. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient has experienced a hypersensitivity adverse effect."
4857,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and experienced complications post-surgery. She used narcotics for 2 days. Histologically, she has symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
4858,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 5 days following the procedure. Their histology indicates that they are in bed less than 50% of the time, and their pathology report shows that the condition is malignant."
4859,1,The patient is a 48-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but still able to walk around. His histology shows well-differentiated characteristics. The patient is experiencing nausea as an adverse effect.
4860,0,"The patient is a 71-year-old white male with a BMI of 29.24. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, his performance status is fully active. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4861,0,"The patient is a 35-year-old white male with a BMI of 25.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
4862,1,The patient is a 67-year-old white male participating in the treatment arm involving 5FU/LV and radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated characteristics.
4863,1,The patient is a 55-year-old white male with a BMI of 23.95 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis shows that the patient has a mutant KRAS status.
4864,1,The patient is a 71-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
4865,0,The patient is a 65-year-old white female who has not yet started chemotherapy treatment. She is fully active and is assigned to the treatment arm that includes Cisplatin and Etoposide.
4866,0,"The patient is a 66-year-old white male with a BMI of 25.46. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
4867,1,The patient is a 57-year-old white female with a BMI of 27.88. She is fully active with a primary tumor diagnosis of rectal cancer. She is enrolled in the treatment arm receiving FOLFOX chemotherapy combined with Panitumumab. Her KRAS biomarker status is wild-type.
4868,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 2 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
4869,1,"This patient is a 43-year-old white female with a BMI of 20.23. She is fully active and is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab (a targeted therapy). Her primary tumor diagnosis is colon cancer, and her KRAS biomarker status is wild-type."
4870,0,"The patient is a 43-year-old white male with a BMI of 39.51. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker status is indeterminate for this patient."
4871,1,The patient is a 66-year-old white male with a BMI of 22.92 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis shows that he has a wild-type KRAS status.
4872,1,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she is ambulatory. Pathology results indicated a malignant condition.
4873,1,"The patient is a 61-year-old white male with a BMI of 28.04. He is fully active with a primary tumor diagnosis of colon cancer. The patient's treatment arm is FOLFOX, and he has a mutant KRAS biomarker."
4874,0,"In this patient profile, the individual is a 54-year-old black female who is receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. An adverse effect noted is a decrease in lymphocytes, which is a type of white blood cell important for the immune system."
4875,1,"The patient is a 68-year-old white female receiving treatment with 5FU/LV and radiation therapy. She has a performance status of experiencing symptoms but is still able to walk around. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and anorexia."
4876,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
4877,0,The patient is a 46-year-old white male with a BMI of 27.78. He is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker is wild-type.
4878,1,"The patient is a 35-year-old white male with a BMI of 23.63. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4879,1,"The patient is a 69-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
4880,0,"The patient is a 42-year-old white male with a BMI of 22.44. He is receiving treatment in the FOLFOX arm and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. His performance status is fully active, and his KRAS biomarker is wild-type."
4881,0,The patient is a 49-year-old white male with a BMI of 30.07. He is receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. His cancer histology is well-differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type.
4882,0,"This patient is a 72-year-old white male with a BMI of 37.46. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
4883,1,"The patient is a 50-year-old white male with a BMI of 25.08. He is receiving treatment with FOLFIRI + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
4884,1,The patient is a 61-year-old black male participating in the placebo treatment arm. He is experiencing symptoms but is still able to move around independently.
4885,0,"The patient is a 44-year-old white female with a BMI of 19.76. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite the serious adverse effect, her performance status is fully active. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect."
4886,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 4 days. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates malignancy.
4887,0,"The patient is a 36-year-old white male with a BMI of 30.85. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
4888,0,"The patient is a 66-year-old white male with a BMI of 33.8. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4889,1,"The patient is a 62-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced weight loss greater than 5-10%. Despite having symptoms, he is still able to walk around. The patient has developed low levels of granulocytes/bands and lymphocytes as adverse effects of the treatment."
4890,0,"The patient is a 52-year-old white male with a BMI of 27.81. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
4891,1,"The patient is a 64-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is also experiencing an adverse effect known as granulocytes/bands."
4892,0,"The patient is a 38-year-old white female with a BMI of 22.95. She is receiving treatment with the FOLFOX regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
4893,1,The patient is a 69-year-old white male with a fully active performance status. He is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of his condition is poorly differentiated.
4894,0,The patient is a 56-year-old white male with a BMI of 30.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4895,1,The patient is a 63-year-old white male enrolled in the Sunitinib treatment arm. He is experiencing symptoms but is still able to walk around (ambulatory).
4896,0,"The patient is a 54-year-old white female with a BMI of 19.38. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4897,1,"The patient is a 67-year-old white female with a BMI of 23.11. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker in her tumor is wild-type."
4898,0,The patient is a female who is in the conventional surgery treatment arm. She has abdominal wall adhesions and has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates malignancy.
4899,1,"The patient is a 44-year-old white female with a BMI of 49.0 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during her 11 chemotherapy cycles. Her histology shows well-differentiated cells, and she has symptoms but is still able to be ambulatory. The patient's KRAS biomarker is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
4900,0,"The patient is a 56-year-old white male with a BMI of 22.29. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
4901,1,The patient is a 70-year-old white male with a BMI of 24.49 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
4902,0,"The patient is a 68-year-old white female with a BMI of 24.8. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
4903,0,"The patient is a 73-year-old white male with a BMI of 38.62. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4904,1,"This patient is a 48-year-old white female with a BMI of 19.8. She is fully active and is receiving treatment with the FOLFOX regimen. Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
4905,1,"The patient is a 72-year-old white male with well-differentiated histology who is currently receiving treatment with ECF and radiation. Despite experiencing symptoms, the patient is still able to be ambulatory. An adverse effect that the patient is facing is anorexia, which is a loss of appetite or decreased desire to eat. This can lead to weight loss and nutritional deficiencies if not managed properly."
4906,0,"The patient is a 64-year-old white male with a BMI of 25.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
4907,1,"The patient is a 54-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He is scheduled to undergo a total of 6 cycles of chemotherapy. Despite his cancer treatment, he has a fully active performance status, indicating that he is able to carry out his daily activities without any significant limitations."
4908,0,"The patient is a 54-year-old white female with a fully active performance status who is receiving treatment with ECF and radiation. She has well-differentiated histology. The patient is experiencing adverse effects including low neutrophil and granulocyte levels, low leukocyte levels, nausea, anorexia, and fatigue."
4909,0,"The patient is a 71-year-old white female with a BMI of 27.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4910,0,"The patient is a 54-year-old white male with a BMI of 26.4. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker is wild-type. The patient has experienced an infection as an adverse effect."
4911,0,"The patient is a 59-year-old white female with a BMI of 32.0. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates she is wild-type. She has experienced a hypersensitivity adverse effect."
4912,1,"The patient is a 60-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing an adverse effect known as granulocytes/bands. This side effect involves a decrease in the number of certain types of white blood cells, which are important for fighting infections."
4913,1,"The patient is a 75-year-old white male with a BMI of 26.64. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker is wild-type. The patient has also experienced adverse effects in the form of thrombosis and diarrhea."
4914,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 3 days. Histologically, she is in bed less than 50% of the time, and the pathology report indicates malignancy."
4915,0,"The patient is a female who is undergoing conventional surgery for a malignant condition. She has been using narcotics for 4 days to manage her symptoms, but is still able to walk around and be mobile."
4916,0,"The patient is a 43-year-old white male with a BMI of 30.79. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker testing revealed a mutant status."
4917,1,"This patient is a 55-year-old white female with a BMI of 18.78. She is receiving treatment with the FOLFIRI regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
4918,0,"The patient is a 43-year-old white female with a BMI of 27.6. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing adverse effects such as diarrhea and infection, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
4919,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days post-surgery. Their histology shows that they are in bed less than 50% of the time, and their pathology indicates a malignant condition."
4920,1,This patient is a 50-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV and radiation therapy. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4921,0,This patient is a 42-year-old white female with a BMI of 22.03. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that she has a wild-type status. She is receiving treatment with the FOLFOX regimen.
4922,0,The patient is a 60-year-old white male with a BMI of 33.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4923,1,"The patient is a 46-year-old white male participating in the ECF + Radiation treatment arm. He has well-differentiated histology and is experiencing symptoms but is still able to walk around (ambulatory). Additionally, he is experiencing an adverse effect related to his neutrophils/granulocytes."
4924,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She only used narcotics for 1 day. Despite experiencing symptoms, she is able to move around. The pathology results showed malignancy."
4925,1,The patient is a 72-year-old white male with a BMI of 28.24. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
4926,0,"The patient is a 69-year-old white female with a BMI of 25.47. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker indicates that it is mutant."
4927,0,"The patient is a 45-year-old white male with a BMI of 22.59. He is receiving treatment with the FOLFOX regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
4928,0,"The patient is a 71-year-old Black female with a BMI of 27.48. She is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. She has undergone 10 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker shows that it is wild-type."
4929,1,"The patient is a 57-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 6 chemotherapy cycles. She is experiencing symptoms but is still able to walk around (ambulatory). Additionally, she is experiencing nausea as an adverse effect of the treatment."
4930,1,"This patient is a 54-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects of low granulocytes/bands and nausea."
4931,0,"The patient is a 56-year-old white male with a BMI of 26.3. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
4932,0,"The patient is a 57-year-old white male with a BMI of 23.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. Additionally, he has experienced thrombosis as an adverse effect."
4933,0,"The patient is a 65-year-old white male with a BMI of 26.44. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing an infection, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type gene."
4934,1,"The patient is a 50-year-old white male with a BMI of 43.98. He is receiving treatment with FOLFOX + Cetuximab and has experienced serious adverse effects during the treatment. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient's performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker is wild-type. Additionally, the patient has experienced adverse effects such as thrombosis and infarction."
4935,0,The patient is a 74-year-old white male with a BMI of 24.29 who is receiving treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 3 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
4936,1,"The patient is a 35-year-old white male with a BMI of 23.25. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
4937,0,The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 6 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates a malignant condition.
4938,0,The patient is a 58-year-old white male with a BMI of 24.31. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
4939,0,"The patient is a 53-year-old white female with a BMI of 26.61. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation. She is experiencing diarrhea as an adverse effect of the treatment."
4940,1,"The patient is a 59-year-old female of other race, with a BMI of 19.68. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker shows a mutant status. The patient is currently receiving treatment in the FOLFOX treatment arm."
4941,1,"This patient is a 70-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). She is experiencing adverse effects related to her blood counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes. Additionally, she is also experiencing nausea as a side effect of her treatment."
4942,0,"The patient is a 72-year-old white female with a BMI of 42.09. She is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type status."
4943,0,"The patient is a 47-year-old white female with a BMI of 23.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4944,0,"The patient is a 46-year-old male of a race classified as ""other"" with a BMI of 23.21. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of his condition is well-differentiated. Despite his treatment, he maintains a fully active performance status. Additionally, the patient's KRAS biomarker status is mutant."
4945,1,"The patient is a 75-year-old male of other race with a BMI of 28.04. He is currently receiving treatment with FOLFOX for a primary colon tumor. Despite experiencing symptoms, he is still ambulatory. The KRAS biomarker analysis shows a mutant status."
4946,1,The patient is a 47-year-old white male participating in the placebo treatment arm of the study. He has symptoms but is still able to move around independently.
4947,0,"The patient is a 63-year-old female of a race other than specified, with a BMI of 22.18. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has experienced a serious adverse effect. She has completed 7 cycles of chemotherapy. The histology of her condition is well-differentiated. Despite the adverse effect, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
4948,0,"The patient is a 45-year-old white female in the placebo treatment arm. She has a fully active performance status but is experiencing fatigue. Additionally, she is experiencing adverse effects on her neutrophils/granulocytes, platelets, and leukocytes."
4949,1,The patient is a 48-year-old white male participating in the ECF + Radiation treatment arm. He has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
4950,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the complications, she was able to maintain her ambulatory status. The pathology report revealed malignant findings."
4951,0,"The patient is a 66-year-old white male with a BMI of 24.42. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. His KRAS biomarker is wild-type."
4952,0,"The patient is a 56-year-old male of a race categorized as ""other."" He is part of the treatment arm receiving 5FU/LV + Radiation therapy. The patient has a fully active performance status and has well-differentiated histology."
4953,1,"The patient is a 38-year-old white female with a BMI of 21.45. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to ambulate. Additionally, the patient has a mutant KRAS biomarker."
4954,1,"The patient is a 73-year-old white male with a fully active performance status. He is receiving treatment with ECF and radiation. His histology shows poorly differentiated cancer cells. He is experiencing adverse effects including low levels of neutrophils/granulocytes, nausea, anorexia, and fatigue."
4955,0,"This patient is a 64-year-old white male with a BMI of 31.09. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker status is wild-type."
4956,0,"The patient is a 74-year-old white male who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. He has not started any chemotherapy cycles yet. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around on his own."
4957,0,"The patient is a 52-year-old white female with a BMI of 37.4. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
4958,0,This patient is a 71-year-old white female with a BMI of 27.76 who is currently receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) and has been diagnosed with a primary tumor in the rectum.
4959,0,"The patient is a 68-year-old white male with a BMI of 31.77. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4960,1,"The patient is a 61-year-old white male with a BMI of 30.12. He is currently receiving treatment with FOLFOX (a chemotherapy regimen) in combination with Panitumumab (a targeted therapy). Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with colon cancer, and his KRAS biomarker status is wild-type."
4961,1,The patient is a 47-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around. He is experiencing nausea as an adverse effect of the treatment.
4962,1,"The patient is a 70-year-old white female with a BMI of 23.84. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). She has been diagnosed with a primary tumor in the colon, and her KRAS biomarker status is mutant."
4963,0,"The patient is a 39-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker status is indeterminate."
4964,1,"The patient is a 72-year-old white male with well-differentiated histology who is currently receiving treatment with ECF chemotherapy and radiation. Despite experiencing symptoms, the patient is still able to move around. However, the treatment has led to adverse effects on the patient's neutrophils/granulocytes and leukocytes."
4965,0,This patient is a female who underwent laparoscopic-assisted colectomy as part of her treatment. She used narcotics for 7 days post-surgery. Her histology indicates symptoms but she is still able to move around. The pathology report revealed that the cause of her symptoms is malignant.
4966,0,"The patient is a 48-year-old white female with a BMI of 22.11. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced adverse effects in the form of thrombosis and diarrhea."
4967,1,"The patient is a 66-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 3 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his white blood cells, lymphocytes, and is also experiencing nausea."
4968,0,"The patient is a 41-year-old white female with a BMI of 38.98. She is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 10 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
4969,0,"The patient is a 43-year-old white female with a BMI of 20.49. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker indicates a mutant status."
4970,1,"The patient is a 62-year-old white female who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. She has not undergone any chemotherapy cycles yet. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing an adverse effect related to her white blood cells."
4971,1,The patient is a male who is undergoing treatment with conventional surgery. He has only used narcotics for 1 day. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
4972,1,"The patient is a 53-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status."
4973,0,"The patient is a 63-year-old white male with a BMI of 27.29. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
4974,0,The patient is a 62-year-old Black male with a BMI of 31.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
4975,1,"The patient is a 64-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy and has a fully active performance status. The patient is experiencing an adverse effect known as granulocytes/bands, which refers to a decrease in a type of white blood cell called granulocytes, specifically bands."
4976,0,"The patient is a 64-year-old Black female with a BMI of 32.08. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
4977,0,"The patient is a 53-year-old white female with a well-differentiated histology. She is currently receiving treatment with 5FU/LV + Radiation. Despite experiencing symptoms, she is still able to be ambulatory. The patient is also experiencing adverse effects related to her neutrophils/granulocytes and leukocytes."
4978,0,"The patient is a 53-year-old white male with a BMI of 28.57. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the chemotherapy regimen for 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
4979,0,"The patient is a 69-year-old white female with a BMI of 39.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
4980,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days following the procedure. The histology shows symptoms, but the patient is still able to walk around. The pathology results indicate that the condition is malignant."
4981,0,"The patient is a 74-year-old white male with a BMI of 36.73. He is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
4982,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology indicates symptoms but she is still able to walk around. The pathology report shows that the condition is malignant.
4983,0,"The patient is a 65-year-old white male with a BMI of 25.23 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for colon cancer with a mutant KRAS biomarker. The patient is experiencing acne as an adverse effect of the treatment. Acne is a common skin condition characterized by the presence of pimples, blackheads, and whiteheads on the skin, often caused by inflammation and blockage of hair."
4984,1,"This patient is a 68-year-old white male with a BMI of 26.7 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
4985,0,"The patient is a 75-year-old white female with a BMI of 21.21. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
4986,1,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotics for 2 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
4987,0,"The patient is a 65-year-old white female with a BMI of 26.25. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
4988,1,The patient is a 61-year-old white female with a BMI of 19.43. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab in the clinical trial. Her KRAS biomarker status is wild-type.
4989,0,The patient is a 55-year-old white male with a BMI of 26.05. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene.
4990,0,"The patient is a 65-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
4991,0,The patient is a 55-year-old white female with a fully active performance status. She is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of her condition is poorly differentiated.
4992,0,"This patient is a 47-year-old white female with a BMI of 31.8. She is enrolled in the FOLFOX treatment arm and is currently experiencing a bowel obstruction. She has not undergone any chemotherapy cycles yet. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
4993,0,"The patient is a 55-year-old white male with a BMI of 30.03 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced an infection as an adverse effect during his treatment."
4994,0,The patient is a 71-year-old white female with a BMI of 23.24. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
4995,0,The patient is a 62-year-old white male with a BMI of 34.48. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
4996,0,The patient is a 40-year-old white male with a BMI of 28.24. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
4997,0,The patient is a 66-year-old white male with a BMI of 28.84. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status for this patient is wild-type.
4998,1,"The patient is a 61-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
4999,0,"The patient is a 59-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed adverse effects related to her white blood cells and granulocytes/bands."
5000,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days following the surgery. The histology results indicate that she spends less than 50% of her time in bed. Additionally, the pathology results show that the condition is malignant."
5001,1,"The patient is a 72-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has developed adverse effects related to her blood counts, specifically low levels of granulocytes/bands and white blood cells."
5002,0,"The patient is a 64-year-old white male with a BMI of 31.94. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
5003,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5004,0,"The patient is a 64-year-old white female with a BMI of 23.83 who is undergoing treatment with FOLFIRI chemotherapy. She has experienced a serious adverse effect during the treatment, specifically thrombosis. She has completed 8 cycles of chemotherapy and her histology shows poorly differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
5005,1,The patient is a 57-year-old white female with a BMI of 21.16. She is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that she has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment with FOLFOX and Panitumumab.
5006,1,"The patient is a 74-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects including low white blood cell count, loss of appetite, and fatigue."
5007,1,"The patient is a 62-year-old white female with a BMI of 28.36. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. The KRAS biomarker indicates that she has a wild-type status."
5008,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
5009,0,"The patient is a 63-year-old white female with a BMI of 24.5. She is fully active and is receiving treatment with the FOLFOX regimen. Her primary tumor diagnosis is rectal cancer, and she has a mutant KRAS biomarker."
5010,0,The patient is a 49-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5011,0,"The patient is a 45-year-old white female with a BMI of 37.19. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she is fully active with a good performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
5012,0,"The patient is a 48-year-old female of a race classified as ""other"" who is part of the treatment arm receiving ECF chemotherapy along with radiation. She has a fully active performance status. The histology of her condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
5013,0,The patient is a 66-year-old white male with a BMI of 26.26 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
5014,1,The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has been using narcotics for 4 days and is experiencing symptoms but is still able to walk around. The pathology results indicate malignancy.
5015,0,"The patient is a 69-year-old white male with a BMI of 25.1. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5016,0,"The patient is a 73-year-old white male with a BMI of 28.29 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has experienced serious adverse effects during the treatment, including thrombosis, diarrhea, and infection. Despite these challenges, the patient has completed 5 cycles of chemotherapy and has a well-differentiated histology. His performance status is such that he experiences symptoms but is still able to be ambulatory. Additionally, the patient's KRAS biomarker is wild-type."
5017,1,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 7 days and is experiencing symptoms but is still able to walk around. The pathology report indicates that the condition is malignant.
5018,0,"The patient is a 58-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
5019,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to walk around. The pathology report indicates malignancy."
5020,1,"The patient is a 70-year-old white male with a BMI of 35.02. He is receiving treatment with FOLFIRI for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker is wild-type."
5021,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 2 days. Histologically, he is experiencing symptoms but is still able to be ambulatory. Pathology results indicate malignancy."
5022,0,"The patient is a 41-year-old white female with a BMI of 39.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5023,0,"The patient is a 69-year-old white male with a BMI of 29.19. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
5024,0,The patient is a 71-year-old white male with a BMI of 20.68. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing acne as an adverse effect of the treatment.
5025,1,"The patient is a 48-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. Additionally, the patient has developed a side effect known as granulocytopenia, indicated by a decrease in granulocytes/bands in the blood."
5026,0,"The patient is a 61-year-old white female with a BMI of 30.85. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
5027,0,"This patient is a 47-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her cancer is poorly differentiated. She is experiencing anorexia as an adverse effect, which means she has a decreased appetite or loss of interest in food."
5028,1,"The patient is a 53-year-old white female with a BMI of 21.04. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 6 cycles of chemotherapy. Histologically, her cancer is well-differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker is wild-type. She has experienced adverse effects of diarrhea and infection during her treatment."
5029,0,"The patient is a 61-year-old Black male with a BMI of 21.98. He is receiving the FOLFOX treatment arm for his well-differentiated histology. Unfortunately, he has experienced a serious adverse effect during his 12 chemotherapy cycles. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
5030,0,"The patient is a 37-year-old white male with a BMI of 24.31. He is receiving treatment with the FOLFOX regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
5031,1,The patient is a 42-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has symptoms but is still able to walk around. He is experiencing nausea as an adverse effect of the treatment.
5032,0,The patient is a 67-year-old white male with a BMI of 28.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
5033,1,"The patient is a 77-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to walk around. Additionally, she is dealing with nausea as an adverse effect of the treatment."
5034,0,"The patient is a 58-year-old white male with a BMI of 28.27. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
5035,1,The patient is a 49-year-old white male who is receiving treatment with Sunitinib. He is experiencing symptoms but is still able to walk around. He is also experiencing fatigue as an adverse effect of the treatment.
5036,0,"The patient is a 61-year-old white female with a BMI of 26.25. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Her performance status is fully active, and her KRAS biomarker is wild-type."
5037,0,"The patient is a 57-year-old white male with a BMI of 18.82. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5038,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates a malignant condition.
5039,0,"The patient is a 54-year-old white male with a BMI of 22.59. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
5040,0,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5041,0,"The patient is a 56-year-old female of a race classified as ""other"" with a BMI of 28.34. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5042,1,The patient is a 55-year-old white male with a fully active performance status. He is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. His histology shows poorly differentiated cells.
5043,0,"The patient is a 61-year-old white male with a BMI of 30.03. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. His KRAS biomarker is wild-type."
5044,1,The patient is a 60-year-old white male with a BMI of 24.97. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon cancer diagnosis. His KRAS biomarker status is wild-type.
5045,0,The patient is a male who is part of the conventional surgery treatment arm. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5046,0,"The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotic medication for 2 days. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that the tumor was benign."
5047,0,"The patient is a 45-year-old white female with a BMI of 29.79. She is receiving treatment with the FOLFOX regimen for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, her performance status is fully active. Her KRAS biomarker status is wild-type."
5048,0,"The patient is a 60-year-old white male with a BMI of 28.58. He is receiving the FOLFOX treatment regimen and is scheduled for 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5049,0,The patient is a male who underwent laparoscopic-assisted colectomy. He only used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to move around. The pathology results indicate that the cause of his symptoms is malignant.
5050,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
5051,0,"This patient is a 75-year-old white female with a BMI of 32.72 who is receiving treatment with FOLFOX + Cetuximab. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer, and her performance status indicates that she has symptoms but is still able to walk around. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
5052,1,"The patient is a 77-year-old white female with a BMI of 22.52. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk and be active (performance status: symptoms but ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
5053,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology results indicate that the condition is malignant.
5054,1,"The patient is a 66-year-old white female with a BMI of 37.39. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 10 cycles of chemotherapy. Despite the adverse effect of diarrhea, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
5055,0,"The patient is a 40-year-old white male with a BMI of 26.24. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). Additionally, his KRAS biomarker indicates that it is wild-type."
5056,1,The patient is a 41-year-old white female with a BMI of 33.01. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
5057,1,"The patient is a 76-year-old white male with a BMI of 21.07. He is currently receiving treatment with FOLFIRI + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type. The patient has developed an infection as an adverse effect of the treatment."
5058,0,"The patient is a 69-year-old white male with a BMI of 33.96. He is receiving treatment with FOLFOX + Cetuximab for his poorly differentiated histology. He has experienced a bowel obstruction and has completed one cycle of chemotherapy. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker is wild-type. Additionally, he has suffered from an infarction as an adverse effect."
5059,0,"The patient is a 37-year-old white female with a BMI of 22.22 who is receiving the FOLFOX treatment regimen. She has experienced a bowel perforation and has completed 5 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type. Additionally, she has developed an infection as an adverse effect of her treatment."
5060,1,"This patient is a 75-year-old white female with a BMI of 32.46. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker is wild-type."
5061,0,"The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 21.7. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
5062,0,"The patient is a 48-year-old white male with a BMI of 34.01 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. He has symptoms but is still able to walk around. His KRAS biomarker status is wild-type. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
5063,1,"The patient is a 56-year-old white female with a BMI of 37.47. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite this, her performance status is fully active. Additionally, she has a mutant KRAS biomarker."
5064,0,"The patient is a 63-year-old white female with a BMI of 33.95. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her treatment. She is experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
5065,0,"The patient is a 59-year-old white female with a BMI of 24.09. She is receiving treatment with the FOLFOX regimen and has been adherent to the treatment. She has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the bowel issues, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
5066,0,"The patient is a 75-year-old white female with a BMI of 23.2. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed one cycle of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
5067,0,"The patient is a 66-year-old white male with a BMI of 31.7. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5068,0,"The patient is a 66-year-old white male with a BMI of 29.0. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5069,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 4 days post-surgery. The histology results show that the tumor is well-differentiated, and the pathology report indicates that it is benign."
5070,0,The patient is a 62-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
5071,0,"The patient is a 55-year-old white female with a BMI of 17.79 who is receiving the FOLFOX treatment regimen. She is experiencing a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
5072,1,"The patient is a 56-year-old white male with a BMI of 24.69. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk and be active (ambulatory). The primary tumor diagnosis is in the rectal area."
5073,0,The patient is a 57-year-old white female with a BMI of 19.82 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that she has a mutant form of the gene.
5074,0,"The patient is a 50-year-old white male with a BMI of 29.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
5075,1,"The patient is a 66-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he is experiencing an adverse effect related to granulocytes/bands."
5076,0,"The patient is a 56-year-old white male with a BMI of 21.71. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis revealed that he has a mutant KRAS status."
5077,0,"The patient is a 68-year-old white male with a high BMI of 48.98. He is undergoing treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age and BMI, his performance status is fully active."
5078,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated that the condition is malignant.
5079,0,"This patient is a 45-year-old white female with a BMI of 27.55. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker is mutant."
5080,0,The patient is a 58-year-old black male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology shows poorly differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
5081,0,"The patient is a 61-year-old white male with a BMI of 23.67. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5082,1,"The patient is a 73-year-old white male with a BMI of 37.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to move around. His KRAS biomarker is wild-type. The patient has reported experiencing diarrhea and infection as adverse effects of the treatment."
5083,1,The patient is a 72-year-old white male with a performance status of symptoms but still able to walk around (ambulatory). He is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
5084,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 5 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
5085,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications following the surgery. She has used narcotics for 7 days. Despite experiencing symptoms, she is still able to be ambulatory. The pathology report indicates malignancy."
5086,0,"The patient is a 51-year-old Black female with a BMI of 22.04. She is receiving treatment with FOLFOX + Cetuximab for her condition. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the challenges, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
5087,0,"The patient is a 64-year-old male of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology of the patient's condition is poorly differentiated. Additionally, the patient is experiencing an adverse effect related to low levels of neutrophils/granulocytes."
5088,0,"The patient is a 61-year-old white male with a BMI of 33.08 who is receiving treatment with FOLFOX + Cetuximab. He has been adherent to his treatment. The patient has experienced both a bowel obstruction and a bowel perforation. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, the patient's performance status is fully active. His KRAS biomarker is wild-type."
5089,1,"The patient is a 48-year-old white male with a BMI of 24.79. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
5090,0,"The patient is a 47-year-old white female with a BMI of 24.72. She is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. The histology indicates well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows a mutant status."
5091,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
5092,0,"The patient is a 47-year-old male of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV and radiation. He has a performance status that indicates he is experiencing symptoms but is still able to walk around. The histology of his condition is well-differentiated. Additionally, he is experiencing nausea as an adverse effect of his treatment."
5093,0,"The patient is a 76-year-old white male with a BMI of 24.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5094,1,This patient is a 47-year-old white female with a BMI of 20.9 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed that she has a wild-type KRAS gene.
5095,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 3 days. His histology shows symptoms but he is still able to move around. The pathology report indicates that the condition is malignant.
5096,1,"The patient is a 70-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF and radiation therapy. The histology shows poorly differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as fatigue."
5097,0,"The patient is a 54-year-old white female with a BMI of 25.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. She is experiencing diarrhea as an adverse effect of her treatment."
5098,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
5099,0,"The patient is a 41-year-old white male with a BMI of 29.89. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has experienced both a bowel obstruction and a bowel perforation. The patient has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
5100,0,The patient is a 48-year-old white female with a BMI of 27.68 who is fully active. She is receiving treatment with FOLFOX for a colon cancer diagnosis. The KRAS biomarker indicates that the patient has a mutant KRAS gene.
5101,1,"The patient is a 64-year-old white male with a BMI of 20.71. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to move around and be ambulatory."
5102,1,"The patient is a 52-year-old white female with a BMI of 41.34. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The patient's KRAS biomarker status is mutant."
5103,0,The patient is a 52-year-old white male with a BMI of 29.86. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS gene.
5104,1,"The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 4 days. His histology shows that he is in bed less than 50% of the time, and his pathology indicates that the condition is malignant."
5105,0,The patient is a 60-year-old white male receiving treatment with the FOLFOX regimen for colon cancer. He has a BMI of 24.74 and is experiencing symptoms but is still able to walk around (ambulatory).
5106,1,The patient is a 43-year-old white female with a BMI of 28.22. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
5107,1,The patient is a 55-year-old white male with a BMI of 34.66. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
5108,0,The patient is a 65-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated.
5109,0,"The patient is a 51-year-old female of a race categorized as ""other."" She is currently undergoing treatment with ECF chemotherapy in combination with radiation therapy. Despite her cancer diagnosis, she has a fully active performance status. The histology of her cancer is classified as poorly differentiated."
5110,1,"The patient is a 47-year-old female of other race with a BMI of 17.94. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
5111,0,"The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 24.57. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the prescribed regimen. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
5112,1,"The patient is a 67-year-old white male with well-differentiated histology who is part of the ECF + Radiation treatment arm. He has symptoms but is still able to walk around (ambulatory). He is experiencing anorexia as an adverse effect, which means he has a reduced appetite or lack of interest in food."
5113,1,"The patient is a 58-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
5114,0,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesions as well as bowel adhesions. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
5115,0,"The patient is a 57-year-old white male with a BMI of 30.65. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5116,0,The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to move around. Pathology results indicate a malignant condition.
5117,1,"The patient is a 68-year-old white male with a BMI of 28.66 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows a mutation. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
5118,0,"The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 19.65. He is undergoing treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient's performance status is fully active, and the KRAS biomarker shows that it is wild-type."
5119,0,"The patient is a 55-year-old white male with a BMI of 24.54. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect during the course of 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has symptoms but is still ambulatory based on his performance status. Additionally, the KRAS biomarker indicates a mutant status."
5120,0,"The patient is a 43-year-old white female with a BMI of 20.02. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
5121,0,"The patient is a 55-year-old male of a race categorized as ""other"" who is currently undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
5122,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. They experienced complications post-surgery and required 3 days of narcotic use for pain management. Despite having symptoms, the patient is still able to walk around. The pathology report indicates the presence of malignant cells."
5123,1,The patient is a 46-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around.
5124,1,"The patient is a 52-year-old white female with a BMI of 19.88 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
5125,1,"The patient is a 63-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, indicating a decrease in certain types of white blood cells."
5126,1,"The patient is a 57-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around (ambulatory). The patient is experiencing adverse effects including low levels of granulocytes/bands and nausea."
5127,1,"The patient is a 74-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to move around. The patient is showing adverse effects including low granulocytes/bands and low white blood cells, as well as experiencing nausea."
5128,0,"The patient is a 59-year-old white male with a BMI of 44.71. He is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He has also experienced a hypersensitivity adverse effect."
5129,1,"The patient is a 72-year-old white male enrolled in the placebo treatment arm. He is experiencing symptoms but is still able to walk around, indicating that he has an ambulatory performance status."
5130,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
5131,0,"The patient is a 48-year-old white female with a BMI of 27.24. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker analysis indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
5132,1,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 3 days. Despite experiencing symptoms, she is still able to walk around. The pathology report indicates malignancy."
5133,0,"The patient is a 58-year-old white female with a BMI of 38.98. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 7 cycles so far. Her cancer histology shows that it is well-differentiated. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5134,0,"This patient is a 76-year-old white male with a BMI of 27.89. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
5135,0,"The patient is a 55-year-old white male with a BMI of 22.2. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
5136,1,"The patient is a 75-year-old white female who is undergoing treatment with Cisplatin + Etoposide. She has completed 2 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing adverse effects including low granulocytes/bands and low white blood cells, as well as nausea."
5137,0,"This patient is a 59-year-old white female with a BMI of 32.24 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect, specifically a bowel obstruction, after completing 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has experienced adverse effects such as diarrhea and infection."
5138,0,The patient is a 60-year-old female of other race with a BMI of 33.78. She is fully active with a primary tumor diagnosis of colon. The patient is experiencing acne as an adverse effect of the treatment regimen FOLFOX and Panitumumab.
5139,0,The patient is a 46-year-old white female with a BMI of 18.43. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX (a chemotherapy regimen) in combination with Panitumumab. Her KRAS biomarker status is wild-type.
5140,1,The patient is a 35-year-old Black or African American female with a BMI of 25.17. She is fully active with a primary tumor diagnosis of colon. The KRAS biomarker indicates that the patient has a mutant KRAS status. She is currently receiving treatment in the FOLFOX treatment arm.
5141,1,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 8 days post-surgery. The histology showed symptoms but she remained ambulatory. The pathology results indicated malignancy.
5142,1,"The patient is a 64-year-old white female with a BMI of 38.59. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
5143,0,"The patient is a 60-year-old white male with a BMI of 24.69. He is receiving the FOLFOX treatment regimen and has experienced both a bowel obstruction and perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel issues, his performance status is fully active. The KRAS biomarker indicates a mutant status."
5144,0,"This patient is a 54-year-old white female with a BMI of 44.96. She is receiving treatment with FOLFOX + Cetuximab for her cancer. She has experienced both a bowel obstruction and a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her medical challenges, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
5145,0,"The patient is a 45-year-old white female with a BMI of 31.52. She is receiving treatment with the FOLFIRI regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
5146,0,"This patient is a 74-year-old white female with a BMI of 29.44. She is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. Her cancer histology is poorly differentiated, and her performance status is fully active. The KRAS biomarker status is indeterminate for this patient."
5147,1,The patient is a 49-year-old white female with a performance status of symptoms but still able to walk around (ambulatory). She is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of her cancer is poorly differentiated.
5148,0,"The patient is a 50-year-old white female with a BMI of 26.68. She is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has been adherent to her chemotherapy regimen for 12 cycles. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
5149,0,"The patient is a 66-year-old Black male with a BMI of 40.72. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
5150,1,"The patient is a 73-year-old white male with a BMI of 25.33. He is undergoing treatment with FOLFIRI chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient's KRAS biomarker indicates a mutant status."
5151,0,"The patient is a 65-year-old white male with a BMI of 29.05. He is undergoing treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
5152,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
5153,0,"The patient is a 36-year-old white male with a BMI of 20.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. His histology shows well-differentiated cancer, and his performance status is fully active. The KRAS biomarker testing indicates he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
5154,1,The patient is a 73-year-old white male with a BMI of 33.17 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer.
5155,1,"The patient is a 54-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. His performance status indicates that he is spending less than 50% of his time in bed. Additionally, he has experienced adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
5156,1,"The patient is a 49-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around."
5157,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications post-surgery. They used narcotics for 1 day. The histology showed symptoms but the patient was still able to walk around. The pathology report indicated malignancy.
5158,0,The patient is a 62-year-old white female who is receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around.
5159,0,"The patient is a 54-year-old white female with a BMI of 25.31. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite her cancer diagnosis, she has a fully active performance status. Her KRAS biomarker status is wild-type."
5160,0,The patient is a 57-year-old white male with a BMI of 28.73. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. His KRAS biomarker status is wild-type.
5161,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has experienced complications post-surgery. He used narcotics for 3 days following the procedure. Histologically, he is experiencing symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
5162,1,"The patient is a 47-year-old white male with a BMI of 25.83 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around (ambulatory). His KRAS biomarker status is wild-type, indicating a better response to certain treatments."
5163,0,"The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 25.6. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
5164,0,"The patient is a 42-year-old white female with a BMI of 42.22. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5165,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
5166,0,The patient is a 55-year-old white female with a BMI of 24.29. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
5167,1,"The patient is a 58-year-old white female with a BMI of 32.17 who is currently receiving treatment with FOLFOX and Panitumumab. She has symptoms but is still able to walk around. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutant status."
5168,0,"The patient is a 72-year-old white female with a BMI of 22.04. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5169,1,"The patient is a 63-year-old white male with a BMI of 23.45. He is currently receiving treatment with FOLFOX for a rectal tumor. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis revealed a mutant status."
5170,1,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 2 days and is in bed less than 50% of the time. The histology indicates a malignant pathology.
5171,1,"The patient is a 65-year-old Black female with a BMI of 21.41. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker status is indeterminate for this patient."
5172,0,"The patient is a 55-year-old white female with a BMI of 33.99. She is receiving treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5173,0,"The patient is a 42-year-old white female with a BMI of 31.22. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has developed an infection as an adverse effect of the treatment."
5174,0,"The patient is a 71-year-old white female with a BMI of 26.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5175,1,"The patient is a 52-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the patient has developed a decrease in lymphocytes as an adverse effect of treatment."
5176,0,The patient is a 47-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows poorly differentiated characteristics.
5177,0,The patient is a 55-year-old white male with a BMI of 23.57. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon cancer diagnosis. His KRAS biomarker status is wild-type.
5178,0,"The patient is a 60-year-old white male with a BMI of 23.81. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel perforation. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
5179,0,"The patient is a 43-year-old white male with a BMI of 34.23. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
5180,1,The patient is a 60-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is well-differentiated. He is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5181,0,The patient is a 68-year-old white male with a BMI of 25.48. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status is wild-type.
5182,0,"The patient is a 57-year-old Black female with a BMI of 20.83. She is receiving the FOLFOX treatment arm for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still ambulatory. The KRAS biomarker shows that she has a wild-type status."
5183,0,"The patient is a 50-year-old white female with a BMI of 28.01. She is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and she is receiving treatment with the FOLFOX regimen."
5184,0,The patient is a male who is undergoing treatment with conventional surgery. He has been using narcotics for 7 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5185,0,"This patient is a 44-year-old white male with a BMI of 34.51. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
5186,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 3 days post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the cause of his symptoms is malignant.
5187,0,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. He has used narcotics for 4 days. His histology shows that he is in bed less than 50% of the time, and the pathology report indicates malignancy."
5188,1,The patient is a 52-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of nausea and anorexia.
5189,0,"This patient is a 62-year-old white female with a BMI of 36.92 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5190,1,The patient is a 52-year-old white male with a BMI of 28.69 who is currently receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has symptoms but is still able to walk around (ambulatory). The patient is experiencing a rash as an adverse effect of the treatment.
5191,0,"The patient is a 49-year-old white male who is currently receiving treatment with 5FU/LV and radiation. He has previously undergone chemotherapy and radiation therapy. His performance status is fully active, and his histology shows well-differentiated cells. He is experiencing adverse effects related to low neutrophil/granulocyte levels."
5192,0,"The patient is a 74-year-old white male with a BMI of 25.71. He is fully active in terms of performance status. He is receiving treatment in the FOLFOX + Panitumumab arm. His primary tumor diagnosis is colon cancer, and his KRAS biomarker status is wild-type."
5193,1,"The patient is a 61-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, she has developed a decrease in granulocytes/bands as an adverse effect of the treatment."
5194,1,The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions and has used narcotics for 2 days. The histology shows symptoms but she is still able to move around. The pathology report indicates malignancy.
5195,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has bowel adhesions and experienced complications post-surgery. She used narcotics for 9 days following the procedure. Histologically, she is experiencing symptoms but is still able to be ambulatory. Pathology results indicate malignancy."
5196,1,"The patient is a 52-year-old black female undergoing treatment with Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects related to her white blood cells, specifically a decrease in granulocytes/bands and lymphocytes."
5197,1,The patient is a 56-year-old white female undergoing treatment with Cisplatin + Etoposide chemotherapy regimen. She has completed 8 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. She is experiencing nausea as an adverse effect of the treatment.
5198,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, as well as experiencing complications post-surgery. He has been using narcotics for 9 days. Histologically, he is experiencing symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
5199,0,The patient is a female who underwent laparoscopic-assisted colectomy as part of her treatment. She used narcotics for 3 days following the procedure. Her histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
5200,1,"The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 27.36. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. The patient has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite experiencing symptoms, the patient is still ambulatory. Additionally, the KRAS biomarker testing revealed a mutant status."
5201,0,"The patient is a 57-year-old Black male with a low BMI of 17.11. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
5202,0,"The patient is a 68-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation. Despite being fully active, he is experiencing anorexia as an adverse effect of the treatment. The histology of his cancer is well-differentiated."
5203,0,"The patient is a 71-year-old white male with a BMI of 29.73. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, his performance status is fully active. His KRAS biomarker status is wild-type."
5204,1,"The patient is a 62-year-old white male with a BMI of 34.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
5205,1,"The patient is a 61-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 4 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around. The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5206,0,"The patient is a 50-year-old white male with a BMI of 27.11. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). His KRAS biomarker indicates that he has a wild-type status."
5207,0,The patient is a 46-year-old white male with a BMI of 26.35. He is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for 12 cycles. The histology indicates well-differentiated cancer. The patient has a fully active performance status. The KRAS biomarker status is wild-type.
5208,1,"The patient is a 73-year-old white female with a BMI of 25.34. She is receiving treatment with FOLFOX for a primary colon tumor. Her performance status indicates that she is in bed less than 50% of the time. Additionally, the KRAS biomarker testing revealed a mutant status."
5209,0,"The patient is a 57-year-old white male with a BMI of 25.18. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. Unfortunately, he has experienced a thrombosis as an adverse effect."
5210,1,"The patient is a 71-year-old white male with a BMI of 25.22. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker is wild-type."
5211,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. He is in bed less than 50% of the time. The pathology report indicates malignancy.
5212,0,"The patient is a 54-year-old white female with a BMI of 26.06. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
5213,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 5 days. Despite experiencing symptoms, she is still able to be ambulatory. The pathology report indicates malignancy."
5214,1,"The patient is a 47-year-old white female with a BMI of 17.34. She is currently receiving treatment with FOLFOX and Panitumumab for a colon tumor. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis showed that she has a mutant KRAS status."
5215,1,"The patient is a 60-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating a relatively good performance status."
5216,0,"The patient is a 51-year-old white male with a BMI of 34.19. He is enrolled in the FOLFOX + Cetuximab treatment arm but has not started chemotherapy cycles yet. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5217,0,"The patient is a 35-year-old white male with a BMI of 27.32. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 3 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his diagnosis, he has a fully active performance status. His KRAS biomarker status is wild-type."
5218,0,"The patient is a 61-year-old white female with a BMI of 25.05. She is currently undergoing treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel perforation and has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also had adverse effects of hypersensitivity and diarrhea."
5219,0,The patient is a 63-year-old white female with a performance status of symptoms but still able to walk around (ambulatory). She is receiving treatment with 5FU/LV + Radiation therapy. The histology of her condition is poorly differentiated.
5220,1,"The patient is a 75-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to ambulate. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
5221,1,The patient is a 73-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology of his condition is poorly differentiated.
5222,1,The patient is a 38-year-old white female with a BMI of 21.93. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX chemotherapy in combination with the targeted therapy Panitumumab. Her KRAS biomarker status is wild-type.
5223,1,"The patient is a 67-year-old white female with a BMI of 40.94. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. She is currently experiencing a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cells, and her performance status is symptomatic but still ambulatory. The KRAS biomarker is wild-type. She is also experiencing diarrhea as an adverse effect of the treatment."
5224,0,"The patient is a 63-year-old white male with a BMI of 24.75. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
5225,0,"The patient is a 63-year-old male of a race other than specified, with a BMI of 26.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
5226,1,The patient is a female who is undergoing conventional surgery. She has abdominal wall adhesions and bowel adhesions. She has been using narcotics for 4 days. Her histology shows symptoms but she is still able to be ambulatory. The pathology results indicate malignancy.
5227,1,The patient is a 45-year-old white male enrolled in the treatment arm receiving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology of his condition is poorly differentiated. He is experiencing an adverse effect related to his neutrophils/granulocytes.
5228,1,The patient is a 73-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
5229,0,"The patient is a 75-year-old white female with a BMI of 32.53. She is receiving FOLFIRI chemotherapy for 10 cycles. Her cancer histology is poorly differentiated, and she has a fully active performance status. The KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
5230,0,"The patient is a 48-year-old white female with a BMI of 19.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5231,1,The patient is a male who is in the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5232,0,The patient is a 70-year-old white male with a BMI of 31.39. He is fully active and is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type.
5233,0,"The patient is a 51-year-old white male with a BMI of 19.78. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's treatment arm is FOLFOX, and his KRAS biomarker status is wild-type."
5234,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. The histology results showed that the tumor was well-differentiated, and the pathology report indicated that it was benign."
5235,1,"In this patient profile, the individual is a 71-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite her age, she has a fully active performance status. One notable adverse effect she is experiencing is a decrease in granulocytes/bands, which are types of white blood cells that play a crucial role in the immune system."
5236,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. He is typically in bed less than 50% of the time. The pathology report indicated a malignant condition.
5237,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
5238,0,"The patient is a 70-year-old female of a race categorized as ""other"" with a BMI of 25.0. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5239,1,"The patient is a 40-year-old white male with a BMI of 27.41. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology indicates well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker testing shows that he has a wild-type KRAS status."
5240,0,"The patient is a 35-year-old white female with a BMI of 42.34. She is receiving the FOLFOX treatment regimen and has completed 6 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5241,1,"The patient is a 61-year-old white male with a BMI of 25.16. He is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5242,1,"The patient is a 56-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5243,1,"The patient is a 55-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a side effect known as granulocytes/bands, indicating an impact on his white blood cell count."
5244,0,The patient is a 34-year-old white male with a BMI of 24.79 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. His KRAS biomarker status is wild-type.
5245,0,"The patient is a 50-year-old white male with a BMI of 24.57. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
5246,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has used narcotics for 4 days. The histology shows that she is in bed less than 50% of the time, and the pathology indicates a malignant condition."
5247,0,The patient is a 57-year-old white male enrolled in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still able to walk around (ambulatory). The histology shows poorly differentiated cells.
5248,0,"The patient is a 61-year-old white female with a BMI of 24.63. She is receiving treatment in the FOLFOX treatment arm and has been adherent to her treatment. She has experienced both a bowel obstruction and a bowel perforation. She has completed 2 cycles of chemotherapy. The histology shows that the cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
5249,1,"The patient is a male who underwent conventional surgery and has abdominal wall adhesions. They only used narcotics for 1 day. The histology shows that they spend less than 50% of their time in bed, and the pathology indicates a malignant condition."
5250,0,"The patient is a 72-year-old Black female with a BMI of 22.95. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
5251,0,"The patient is a 71-year-old white female with a BMI of 34.86. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates a mutant status."
5252,0,The patient is a 66-year-old white female with a BMI of 31.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
5253,1,"The patient is a 64-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically a decrease in granulocytes/bands and white blood cells."
5254,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 5 days following the surgery. The histology indicates symptoms, but the patient is still able to walk around. The pathology results show that the condition is malignant."
5255,1,"The patient is a 73-year-old white male with a BMI of 21.31 who is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
5256,0,"The patient is a 52-year-old Black female with a BMI of 25.97. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her chemotherapy regimen, completing 5 cycles. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient experienced a hypersensitivity adverse effect during treatment."
5257,0,"The patient is a 64-year-old white female with a BMI of 44.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
5258,0,"The patient is a 51-year-old white female with a BMI of 25.43. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
5259,1,"The patient is a 65-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status."
5260,1,"The patient is a 54-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his white blood cells and lymphocytes."
5261,1,"The patient is a 39-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient has shown adverse effects such as low granulocytes/bands and low white blood cell count, as well as experiencing nausea."
5262,1,"In this patient profile, the individual is a 55-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel for 8 chemotherapy cycles. Despite undergoing treatment, the patient's performance status remains fully active. An adverse effect noted is a decrease in lymphocytes, which are a type of white blood cell important for the immune system."
5263,0,"The patient is a 61-year-old white female with a BMI of 22.37. She is enrolled in the FOLFOX treatment arm for her cancer. She is currently experiencing a bowel obstruction. She has not yet started chemotherapy cycles. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
5264,0,"The patient is a 48-year-old white male with a BMI of 33.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5265,0,"The patient is a 75-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5266,1,The patient is a 46-year-old white male with a fully active performance status. He is enrolled in the treatment arm receiving ECF chemotherapy along with radiation therapy. The histology of his cancer is poorly differentiated.
5267,1,"The patient is a 54-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, he maintains a fully active performance status. An adverse effect noted is a decrease in lymphocytes."
5268,1,"The patient is a 72-year-old white female with a BMI of 22.73. She is undergoing treatment with the FOLFIRI regimen and has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
5269,1,"The patient is a female who underwent conventional surgery and experienced complications. She used narcotics for 5 days post-surgery. Her histology indicates that she is in bed less than 50% of the time, and the pathology report shows that the condition is malignant."
5270,0,"The patient is a 67-year-old white male with a BMI of 28.2. He is part of the FOLFOX treatment arm and has a bowel obstruction. He has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
5271,0,"The patient is a 48-year-old white male with a BMI of 30.53. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5272,0,"The patient is a 63-year-old white male with a BMI of 23.35. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
5273,1,The patient is a 75-year-old white male with a BMI of 22.14. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. His KRAS biomarker status is wild-type.
5274,1,The patient is a 78-year-old white female with a BMI of 25.78 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of colon cancer.
5275,1,"The patient is a 59-year-old female of a race categorized as ""other."" She is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, she is still able to walk around (ambulatory). The histology of her condition is classified as poorly differentiated."
5276,0,"The patient is a 51-year-old white male with a BMI of 26.59. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
5277,1,"The patient is a 54-year-old Black male who is in the treatment arm receiving Cisplatin + Etoposide. He has not started any chemotherapy cycles yet. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around and be ambulatory."
5278,0,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 5 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
5279,0,"The patient is a 69-year-old white female with a BMI of 26.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). Additionally, her KRAS biomarker status is wild-type."
5280,0,"The patient is a 49-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands and lymphocytes."
5281,0,The patient is a 56-year-old white male with a BMI of 24.82. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
5282,1,"The patient is a 71-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss (>5/10%) and has symptoms but is still able to walk around (ambulatory). The patient has also experienced adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5283,0,"The patient is a 47-year-old white male with a BMI of 24.59 who is undergoing treatment with FOLFOX + Cetuximab for his well-differentiated cancer. He has completed 12 cycles of chemotherapy and has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. Unfortunately, he has experienced an infection as an adverse effect during his treatment."
5284,0,"The patient is a 59-year-old white female with a BMI of 23.05. She is receiving the FOLFOX treatment arm for her bowel obstruction. She has completed 12 chemotherapy cycles and her histology shows poorly differentiated cells. Despite her condition, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5285,0,"The patient is a 61-year-old white male with a BMI of 23.12. He is receiving the FOLFOX treatment regimen for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
5286,1,"In this patient profile, the individual is a 68-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. An adverse effect noted in this patient is a decrease in lymphocytes."
5287,1,This patient is a 52-year-old white female who is part of the placebo treatment arm. She is experiencing symptoms but is still able to move around and be ambulatory.
5288,1,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. Their histology indicates that they are in bed less than 50% of the time, and the pathology results show that the condition is malignant."
5289,0,The patient is a 63-year-old white female with a BMI of 24.76. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
5290,0,"The patient is a 60-year-old white female with a BMI of 28.36. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
5291,0,The patient is a 59-year-old white male with a BMI of 34.33. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker indicates that the tumor is wild-type. The patient is receiving treatment with the FOLFOX regimen.
5292,0,"The patient is a 49-year-old white male with a BMI of 29.95. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5293,1,The patient is a 31-year-old white female with a BMI of 21.41 who is fully active. She is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker analysis revealed a mutant status.
5294,0,"The patient is a 50-year-old white male with a BMI of 27.02. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effect, his performance status is fully active. His KRAS biomarker status is wild-type."
5295,1,This patient is a 64-year-old white male with a BMI of 27.47. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker analysis shows that he has a wild-type KRAS status.
5296,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
5297,0,"The patient is a 71-year-old white male with a BMI of 24.9. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5298,0,The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 5 days and is experiencing symptoms but is still able to walk around.
5299,1,"This patient is a 77-year-old white male with a BMI of 32.39. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, the KRAS biomarker analysis shows that he has a mutant KRAS status."
5300,0,"The patient is a 44-year-old white male with a BMI of 29.15. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
5301,0,"The patient is a 70-year-old white male with a BMI of 26.01. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
5302,0,The patient is a 51-year-old white female with a BMI of 21.94. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
5303,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the cause of her symptoms is malignant.
5304,1,"This patient is a 70-year-old white male with a BMI of 27.5. He is receiving the FOLFOX treatment regimen and has a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
5305,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has been using narcotics for 7 days. Her histology shows that she is in bed less than 50% of the time, and her pathology indicates a malignant condition."
5306,0,"The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 34.4. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 6 cycles. The histology of his cancer is well-differentiated. He has a fully active performance status. His KRAS biomarker status is wild-type."
5307,0,"The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 22.04. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed 2 cycles so far. The histology of her cancer is well-differentiated. In terms of performance status, she is fully active. Additionally, the KRAS biomarker testing revealed that she has a wild-type KRAS status."
5308,0,"The patient is a 46-year-old Black female with a BMI of 27.3. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5309,0,"The patient is a 52-year-old Black male with a BMI of 24.26. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5310,0,"The patient is a 73-year-old white male with a BMI of 23.57. He is enrolled in the FOLFIRI treatment arm for his KRAS mutant status. He has not undergone any chemotherapy cycles yet. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. It is important to note that his KRAS biomarker is wild-type."
5311,1,"This patient is a 57-year-old white female who is undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a fully active performance status. She is experiencing adverse effects related to her blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
5312,0,The patient is a 59-year-old white male with a BMI of 27.46. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5313,1,"The patient is a 62-year-old white male with a BMI of 20.95. He is currently receiving treatment with FOLFOX and Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type, indicating a potentially better response to the treatment regimen."
5314,0,"The patient is a 58-year-old female of a race other than specified, with a fully active performance status. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
5315,1,"This patient is a 67-year-old white female with a BMI of 20.31. She is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to walk around and be active, indicating a relatively good performance status."
5316,0,"The patient is a 75-year-old white male with a BMI of 27.77. He is receiving the FOLFOX treatment regimen for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5317,0,The patient is a 35-year-old white male with a BMI of 27.44. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5318,1,"The patient is a 72-year-old white female with a BMI of 18.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker test revealed a mutant result."
5319,1,"The patient is a 60-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 6 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects on her white blood cells and lymphocytes."
5320,0,The patient is a 37-year-old white female with a BMI of 24.2. She is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status and her KRAS biomarker is wild-type. She has also experienced hypersensitivity as an adverse effect.
5321,0,"This patient is a 41-year-old white female with a BMI of 32.98 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 12 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effects, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type. She has also experienced an infarction as an adverse effect."
5322,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 6 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates a malignant condition.
5323,0,"The patient is a 52-year-old white male with a BMI of 36.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5324,0,"The patient is a 50-year-old white female with a BMI of 24.1. She is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5325,1,"The patient is a 72-year-old white male with a BMI of 23.15. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is wild-type."
5326,0,"The patient is a 71-year-old male of a race categorized as ""other."" He is currently undergoing treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The histology of the patient's condition is poorly differentiated."
5327,1,"The patient is a 62-year-old white female who is receiving treatment with Cisplatin and Etoposide. She will undergo a total of 6 cycles of chemotherapy. Despite her age, she has a fully active performance status."
5328,0,The patient is a 52-year-old white male who is fully active and is receiving treatment with ECF and radiation. He has well-differentiated histology and is experiencing adverse effects of nausea and anorexia.
5329,0,"The patient is a 47-year-old white male with a BMI of 24.81. He is in the FOLFOX treatment arm and has a bowel obstruction. He has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
5330,1,The patient is a 58-year-old white male with a BMI of 30.78. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. He is currently receiving treatment with the FOLFOX regimen.
5331,0,"The patient is a 62-year-old white male with a BMI of 49.49. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5332,1,"The patient is a 52-year-old female of other race with a BMI of 20.7. She is currently receiving treatment in the FOLFOX + Panitumumab arm. Despite experiencing symptoms, she is still able to move around (ambulatory). The primary tumor diagnosis is in the colon, and the KRAS biomarker shows a mutation."
5333,0,"The patient is a 49-year-old white male with a BMI of 27.2. He is receiving the FOLFOX treatment arm and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
5334,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during treatment. She used narcotics for 4 days post-surgery. Histologically, she is experiencing symptoms but is still able to be ambulatory. Pathologically, the findings indicate malignancy."
5335,0,The patient is a 46-year-old black male with a well-differentiated histology. He is fully active and is receiving treatment with 5FU/LV + Radiation.
5336,0,"The patient is a 64-year-old white female with a BMI of 23.63. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, her performance status remains fully active. Additionally, her KRAS biomarker status is wild-type."
5337,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
5338,0,"The patient is a 35-year-old white female with a BMI of 28.54. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her treatment. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
5339,1,"The patient is a 58-year-old Black male with a BMI of 16.98 who is currently receiving treatment with FOLFOX for a rectal tumor. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker for this patient is wild-type."
5340,0,"The patient is a 37-year-old white female with a BMI of 44.6. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her high BMI, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
5341,1,"The patient is a 45-year-old white female with a BMI of 32.24. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 10 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
5342,0,"The patient is a 48-year-old white female with a BMI of 23.02. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. The histology of her condition is poorly differentiated. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates that she has a wild-type status."
5343,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. She is typically in bed less than 50% of the time. The pathology report indicated malignancy.
5344,1,The patient is a 73-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
5345,1,"The patient is a 64-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
5346,0,"The patient is a 44-year-old Black female with a BMI of 28.82. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 12 cycles so far. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5347,0,"The patient is a 52-year-old white male with a BMI of 29.69. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
5348,0,"The patient is a 65-year-old white female with a BMI of 31.15. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker indicates that it is wild-type."
5349,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days following the surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
5350,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 4 days post-surgery. The histology shows symptoms but she is ambulatory. The pathology report indicates a malignant condition.
5351,0,"The patient is a 50-year-old white male with a BMI of 26.3. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis showed that he has a wild-type KRAS gene."
5352,1,The patient is a 72-year-old white male receiving treatment with Sunitinib. He has symptoms but is still able to walk around.
5353,1,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications following the procedure. They used narcotics for 4 days post-surgery. The histology showed symptoms but the patient was still ambulatory. The pathology report indicated that the underlying cause was malignant.
5354,1,The patient is a 46-year-old white male with a fully active performance status. He is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5355,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 7 days post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
5356,0,"This patient is a 61-year-old white female with a BMI of 28.53. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is wild-type."
5357,1,"The patient is a 69-year-old white female with a BMI of 32.05. She is currently receiving treatment in the FOLFOX + Panitumumab arm. Despite experiencing symptoms, she is still able to ambulate. The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that she has a mutant KRAS status."
5358,0,"This patient is a 62-year-old white male with a BMI of 24.26. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker status is wild-type."
5359,0,The patient is a 48-year-old black male participating in the treatment arm involving 5FU/LV and Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated characteristics.
5360,0,The patient is a 40-year-old white male with a BMI of 29.03 who is receiving the FOLFOX treatment arm for his well-differentiated histology. He has completed 12 cycles of chemotherapy and has a performance status of experiencing symptoms but still able to walk around. His KRAS biomarker is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment.
5361,0,"The patient is a 44-year-old white female with a BMI of 23.75. She is currently receiving treatment with FOLFOX + Cetuximab and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis revealed a mutant status."
5362,0,"The patient is a 73-year-old white female with a BMI of 27.55. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker status is indeterminate."
5363,1,The patient is a male who underwent conventional surgery as part of their treatment. They have been using narcotics for 7 days. Their histology indicates symptoms but they are still able to walk around. The pathology results show that the condition is malignant.
5364,1,"The patient is a 67-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time."
5365,0,"The patient is a 57-year-old white male with a BMI of 39.33. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5366,1,"The patient is a 48-year-old white male with a BMI of 26.88 who is currently receiving treatment in the FOLFOX + Cetuximab treatment arm. He is adherent to his treatment regimen. The patient has experienced both bowel obstruction and bowel perforation. He has completed 2 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite his health challenges, the patient has a fully active performance status. His KRAS biomarker indicates that he has a wild-type mutation."
5367,0,"The patient is a 54-year-old white female with a BMI of 24.39. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has experienced a serious adverse effect. She has completed 12 chemotherapy cycles and has a histology of poorly differentiated cancer. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
5368,1,"The patient is a 61-year-old male of a race categorized as ""other"" who is currently undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
5369,0,"The patient is a 56-year-old white male with a BMI of 29.92. He is receiving treatment with FOLFOX + Cetuximab and has experienced serious adverse effects. He has undergone 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is mutant in this patient. He has also experienced adverse effects such as thrombosis and hypersensitivity reactions."
5370,0,The patient is a 74-year-old white female with a BMI of 32.04. She is fully active and is receiving treatment with the FOLFOX regimen for her colon cancer. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
5371,1,"The patient is a 58-year-old white male with a BMI of 30.34. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
5372,0,The patient is a 54-year-old white male with a BMI of 35.37. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows well-differentiated cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
5373,1,"The patient is a 42-year-old white male with a BMI of 27.22. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, the patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
5374,0,"The patient is a 57-year-old white female with a BMI of 24.6. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to her treatment. She has experienced both a bowel obstruction and a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her bowel issues, her performance status is fully active. Additionally, her KRAS biomarker is mutant."
5375,0,The patient is a male who underwent conventional surgery and experienced complications. He used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is still able to walk. The pathology report indicates a malignant condition.
5376,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
5377,0,"The patient is a 43-year-old white male with a BMI of 28.92. He is currently receiving the FOLFOX treatment regimen and has completed one cycle of chemotherapy. The histology of his cancer is well-differentiated. Despite undergoing treatment, his performance status is fully active. Additionally, the patient's KRAS biomarker status indicates that it is mutant."
5378,0,"The patient is a 71-year-old white male with a BMI of 26.57. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5379,1,"The patient is a 64-year-old white male with a BMI of 24.72 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
5380,0,"The patient is a 36-year-old male of a race categorized as ""other"" with a BMI of 20.76. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect in the form of an infection."
5381,1,"The patient is a 71-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient is showing adverse effects related to his blood cell counts, specifically low levels of granulocytes/bands, white blood cells, and lymphocytes."
5382,1,The patient is a 56-year-old white male with a BMI of 27.76. He is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
5383,0,"The patient is a 45-year-old white female with a BMI of 15.86. She is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment plan. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced diarrhea as an adverse effect of the treatment."
5384,0,The patient is a female who underwent conventional surgery and experienced complications. She used narcotics for 2 days following the procedure. The histology showed symptoms but she was still able to walk around. The pathology results indicated a malignant condition.
5385,1,The patient is a 76-year-old white male with a BMI of 30.85. He is fully active and is receiving treatment with the FOLFOX regimen for colon cancer. His KRAS biomarker status is wild-type.
5386,1,The patient is a 61-year-old white male with a BMI of 30.96. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer.
5387,0,"The patient is a 42-year-old white female with a BMI of 29.33. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
5388,1,The patient is a 57-year-old white male who is fully active. He is currently receiving treatment with Sunitinib.
5389,1,"The patient is a 70-year-old white female with a BMI of 23.1. She is currently receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has also reported experiencing diarrhea and infection as adverse effects of her treatment."
5390,0,"The patient is a 56-year-old white male with a BMI of 30.01. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed a mutant result. The patient experienced a hypersensitivity adverse effect during treatment."
5391,0,"The patient is a 72-year-old white female with a BMI of 29.78. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status."
5392,0,"The patient is a 49-year-old white male with a BMI of 24.69. He is receiving treatment with the FOLFIRI regimen for his KRAS mutant status. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite his cancer treatment, he maintains a fully active performance status."
5393,0,"The patient is a 66-year-old white female with a BMI of 25.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type mutation."
5394,0,"The patient is a 75-year-old white male with a BMI of 27.59 who is currently receiving treatment with FOLFOX regimen for colon cancer. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker testing revealed that the patient has a wild-type KRAS gene."
5395,0,"The patient is a 53-year-old white female with a BMI of 30.25. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
5396,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and has used narcotics for 2 days. The histology shows that he is in bed less than 50% of the time, and the pathology indicates a malignant condition."
5397,0,"The patient is a 55-year-old white male with a BMI of 18.65. He is receiving the FOLFOX treatment regimen for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
5398,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 2 days. Despite the complications, he was able to move around and perform daily activities. The pathology report revealed malignant findings."
5399,0,"The patient is a 56-year-old Black male with a BMI of 24.96. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the patient has a wild-type status."
5400,0,"The patient is a 76-year-old white female with a BMI of 29.01. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. Her cancer histology is well-differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5401,0,"The patient is a 73-year-old white female with a BMI of 20.06. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status. The patient has experienced adverse effects of diarrhea and infection during her treatment."
5402,0,"The patient is a 53-year-old white female with a BMI of 27.7. She is currently receiving treatment with FOLFOX for her poorly differentiated histology. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Despite the adverse effect of diarrhea, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5403,1,"The patient is a 77-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects on her blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5404,0,The patient is a female undergoing conventional surgery for a malignant pathology. She has experienced symptoms but is still able to be ambulatory. She has used narcotics for 3 days as part of her treatment.
5405,0,"This patient is a 65-year-old Black female with a BMI of 26.23. She is receiving the FOLFOX treatment regimen and has completed 11 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite undergoing treatment, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5406,0,"The patient is a 45-year-old white female with a BMI of 23.35. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy and her histology shows well-differentiated cells. Despite the serious adverse effect, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status. Additionally, she has also experienced an infection as an adverse effect during her treatment."
5407,0,"The patient is a 35-year-old white female with a BMI of 17.33. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 6 cycles of chemotherapy. Despite this, her performance status remains fully active. Her KRAS biomarker is wild-type. Unfortunately, she has also developed an infection as an adverse effect of her treatment."
5408,0,"The patient is a 74-year-old white male with a BMI of 23.03. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
5409,1,The patient is a 61-year-old white female who is receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active.
5410,0,"The patient is a 52-year-old female of a race categorized as ""other."" She is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, she is able to walk around (ambulatory) indicating a moderate performance status. The histology of the patient's condition is classified as poorly differentiated."
5411,1,This patient is a 70-year-old white male with a BMI of 18.07. He is fully active and is receiving treatment with the FOLFOX regimen for a primary colon tumor. His KRAS biomarker status is wild-type.
5412,0,"The patient is a 44-year-old white male with a BMI of 33.52. He is receiving the FOLFOX treatment regimen and has completed 5 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced a hypersensitivity adverse effect."
5413,0,"The patient is a 57-year-old white male with a BMI of 24.97. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5414,0,"The patient is a 54-year-old white male with a BMI of 27.16. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
5415,1,The patient is a 69-year-old white male with a BMI of 27.85 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary colon tumor diagnosis. The KRAS biomarker in this patient is wild-type.
5416,1,"The patient is a 54-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory)."
5417,1,"The patient is a 61-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
5418,0,The patient is a 52-year-old black female with a performance status of symptoms but still able to walk around (ambulatory). She is receiving treatment in the ECF + Radiation arm. The histology shows poorly differentiated cells.
5419,0,"The patient is a 59-year-old white female with a BMI of 33.72. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5420,0,"This patient is a 64-year-old white female with a BMI of 24.6. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. Her KRAS biomarker is wild-type. She has also experienced diarrhea as an adverse effect of the treatment."
5421,0,"The patient is a 73-year-old white male with a BMI of 23.3. He is undergoing treatment with the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker status is indeterminate."
5422,1,"The patient is a 55-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands. This side effect involves a decrease in the number of a type of white blood cell called granulocytes, which can lead to an increased risk of infection."
5423,1,"The patient is a 53-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
5424,1,"The patient is a 65-year-old white male with a BMI of 25.31. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab for his colon cancer. Despite experiencing symptoms, he is still able to walk around. The KRAS biomarker analysis shows that he has a wild-type KRAS gene."
5425,0,"The patient is a female who underwent conventional surgery and used narcotics for 4 days. The histology indicates that she is in bed less than 50% of the time, and the pathology report shows that the condition is malignant."
5426,1,"The patient is a 67-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status."
5427,0,The patient is a 68-year-old white male with a BMI of 26.96. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker. He is experiencing diarrhea as an adverse effect.
5428,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 1 day post-surgery. The histology results showed symptoms but the patient was still able to walk around. The pathology report indicated that the condition is malignant.
5429,1,This patient is a 61-year-old white female with a BMI of 26.4. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a wild-type KRAS biomarker.
5430,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has been using narcotics for 6 days post-surgery. The histology indicates symptoms but the patient is still ambulatory. The pathology report shows that the patient has a malignant condition.
5431,0,The patient is a 66-year-old white female with a BMI of 30.2. She is receiving the FOLFOX treatment regimen and is scheduled for 12 chemotherapy cycles. Her histology shows well-differentiated cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
5432,0,This patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 3 days. His histology shows symptoms but he is still ambulatory. The pathology report indicates malignancy.
5433,1,"The patient is a 72-year-old white female with a BMI of 28.03. She is currently receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker shows that she has a wild-type status."
5434,0,"This patient is a 53-year-old white female with a BMI of 21.23. She is currently receiving treatment with FOLFOX. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis for this patient is colon cancer."
5435,0,"The patient is a 50-year-old white male with a BMI of 25.72. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the chemotherapy regimen for 10 cycles. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
5436,0,"The patient is a 65-year-old white female with a BMI of 22.81. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5437,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
5438,0,"The patient is a 51-year-old female of a race categorized as ""other"" with a BMI of 26.2. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated. Despite her treatment, she maintains a fully active performance status. Additionally, the KRAS biomarker testing has revealed a mutant status."
5439,0,"The patient is a 75-year-old white male with a well-differentiated histology. He is currently receiving treatment in the ECF + Radiation arm. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
5440,0,"The patient is a 56-year-old white male with a BMI of 28.27. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker status is indeterminate for this patient."
5441,0,"The patient is a 67-year-old white female with a BMI of 22.07. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5442,1,The patient is a 65-year-old white male with a BMI of 18.16 who is receiving treatment with FOLFOX for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker shows that he has a wild-type status.
5443,0,"The patient is a 76-year-old white male with a BMI of 32.65. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5444,0,The patient is a 50-year-old white male with a BMI of 22.86. He is undergoing treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status.
5445,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall and bowel adhesions, as well as complications following the procedure. He has been using narcotics for 15 days. Despite experiencing symptoms, he is still able to be ambulatory. The histology report indicates malignancy."
5446,0,The patient is a 46-year-old white male with a BMI of 20.37. He is receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
5447,0,The patient is a 47-year-old white female with a BMI of 26.0. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status.
5448,0,"The patient is a 68-year-old white male with a BMI of 26.74. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
5449,1,The patient is a 50-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 4 cycles of chemotherapy and has a fully active performance status. She is experiencing an adverse effect known as granulocytes/bands.
5450,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. Her histology shows symptoms but she is still able to walk around. Pathology results indicate that the cause of her symptoms is malignant.
5451,0,"The patient is a 75-year-old white female with a BMI of 29.94. She is receiving the FOLFOX treatment regimen and has been adherent to the treatment. She has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5452,1,The patient is a female who is in the conventional surgery treatment arm. She has abdominal wall adhesions and has been using narcotics for 10 days. She spends less than 50% of her time in bed. The histology indicates a malignant condition.
5453,0,"The patient is a 40-year-old white male with a low BMI of 16.78. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5454,0,"The patient is a 49-year-old white female with a BMI of 35.42 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutation. Additionally, she is experiencing diarrhea as an adverse effect of the treatment."
5455,1,"The patient is a 70-year-old white male with a BMI of 26.99 who is receiving treatment with FOLFOX and Panitumumab. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment."
5456,0,The patient is a 55-year-old white male with a BMI of 31.27. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status.
5457,0,"The patient is a 42-year-old white male with a BMI of 35.15. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
5458,0,The patient is a 55-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing an adverse effect of low white blood cell count (leukocytes).
5459,0,"The patient is a 62-year-old white female with a BMI of 22.25. She is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is wild-type."
5460,0,"The patient is a 66-year-old white male with a BMI of 28.68. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
5461,0,The patient is a 67-year-old white male with a performance status of symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy combined with radiation. The histology of his cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5462,0,The patient is a 44-year-old white female with a BMI of 20.6 who is receiving the FOLFOX treatment regimen. She has completed 10 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
5463,1,"The patient is a 53-year-old white male with a BMI of 26.09 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker and is experiencing acne as an adverse effect of the treatment. Despite having symptoms, he is still able to be ambulatory."
5464,0,The patient is a 53-year-old white female with a BMI of 29.8. She is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. The histology of her cancer is well differentiated. She has a fully active performance status. The KRAS biomarker testing indicates that she has a wild-type KRAS status.
5465,0,"The patient is a 62-year-old Black male with a BMI of 24.95. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker is mutant."
5466,0,The patient is a male who is receiving conventional surgery as treatment. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5467,1,"The patient is a 54-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. The histology shows well-differentiated cells. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes, nausea, and fatigue."
5468,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 2 days post-surgery. Despite experiencing symptoms, she is able to move around independently. The pathology report indicates malignancy."
5469,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions as well as bowel adhesions. She used narcotics for 3 days post-surgery. Histologically, she is in bed less than 50% of the time. Pathologically, the findings indicate malignancy."
5470,1,"The patient is a 50-year-old white male with a BMI of 26.8. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker for this patient is mutant."
5471,1,"The patient is a 60-year-old white male with a BMI of 27.81. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. Additionally, the KRAS biomarker shows that it is mutant."
5472,0,"The patient is a 71-year-old white female with a BMI of 31.64. She is currently undergoing treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS gene. The patient experienced a hypersensitivity reaction as an adverse effect to the treatment."
5473,1,The patient is a 51-year-old white female who is fully active. She is currently undergoing treatment with Sunitinib.
5474,1,"The patient is a 35-year-old white male with a BMI of 25.4. He is enrolled in the FOLFOX treatment arm and has a bowel obstruction. He has not started any chemotherapy cycles yet. The histology shows poorly differentiated cancer cells. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type mutation."
5475,0,"The patient is a 70-year-old white male with a BMI of 29.86. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker is wild-type. He has experienced adverse effects of diarrhea and infection."
5476,0,"The patient is a 66-year-old white female with a BMI of 27.89. She is receiving the FOLFOX treatment arm for her cancer. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker status is indeterminate."
5477,0,"The patient is a 71-year-old white female with a BMI of 22.17. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient has experienced an adverse effect in the form of an infection."
5478,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 1 day following the procedure. The histology results show that the tumor is well-differentiated, and the pathology report indicates that it is benign."
5479,1,"The patient is a 56-year-old white male with a BMI of 27.06. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for his colon cancer. His KRAS biomarker status is wild-type, indicating a potentially better response to the treatment."
5480,0,"The patient is a 44-year-old white male with a BMI of 28.15. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
5481,1,The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and experienced complications post-surgery. He only used narcotics for 1 day. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates malignancy.
5482,0,"The patient is a 40-year-old white female with a BMI of 33.31. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS gene."
5483,1,The patient is a 73-year-old black female with a fully active performance status. She is receiving treatment with 5FU/LV + Radiation for poorly differentiated histology. The patient is experiencing adverse effects of low neutrophils/granulocytes and low leukocytes.
5484,0,"The patient is a 64-year-old white female with a BMI of 21.48. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker indicates that it is wild-type."
5485,0,"The patient is a 61-year-old male of a race categorized as ""other"" with a BMI of 25.97. He is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active, indicating that he is able to carry out his daily activities without limitations. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5486,0,"The patient is a 51-year-old white female with a BMI of 28.37. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she is wild-type. The patient is experiencing diarrhea as an adverse effect of the treatment."
5487,1,The patient is a 76-year-old white male receiving treatment with FOLFOX for rectal cancer. He has a BMI of 21.3 and is experiencing symptoms but is still able to walk around. His KRAS biomarker status is mutant.
5488,1,The patient is a 59-year-old white male with a BMI of 27.57. He is fully active and is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for a primary tumor diagnosis of rectal cancer.
5489,0,"The patient is a 55-year-old white male with a BMI of 45.16. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status. The patient has reported experiencing diarrhea as an adverse effect of the treatment."
5490,1,"The patient is a 73-year-old white female with a BMI of 25.83. She is receiving treatment with FOLFOX + Cetuximab for her cancer. Unfortunately, she has experienced a serious adverse effect from the treatment. She has completed 9 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker status is indeterminate."
5491,0,"The patient is a 54-year-old white male with a BMI of 26.21. He is receiving FOLFIRI treatment for his well-differentiated histology with a KRAS mutant biomarker. He has experienced a serious adverse effect in the form of thrombosis after completing 12 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory."
5492,0,"The patient is a 67-year-old white male with a BMI of 26.76. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
5493,1,"In this patient profile, the individual is a 49-year-old Black female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). An adverse effect noted is a decrease in lymphocytes (lymphopenia)."
5494,1,"The patient is a 62-year-old white female receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status. The patient is experiencing adverse effects related to her blood cell counts, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5495,0,The patient is a 63-year-old white female with a BMI of 30.9. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker status is indeterminate.
5496,0,"The patient is a 52-year-old Black female with a BMI of 33.32 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing showed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
5497,1,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. The histology shows symptoms but the patient is able to walk around. The pathology report indicates that the patient has a malignant condition.
5498,0,"The patient is a 44-year-old white male with a BMI of 31.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5499,0,"The patient is a 40-year-old white male with a BMI of 27.36 who is undergoing treatment with the FOLFOX chemotherapy regimen. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutant status. The patient is experiencing diarrhea as an adverse effect of the treatment."
5500,1,The patient is a 71-year-old white male with a BMI of 24.22. He is fully active with a primary tumor diagnosis of rectal cancer. He is receiving treatment with FOLFOX chemotherapy combined with Panitumumab. His KRAS biomarker status is wild-type.
5501,0,"The patient is a 63-year-old white female with a BMI of 26.06. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates a mutant status. Additionally, she has experienced a hypersensitivity adverse effect."
5502,0,"The patient is a 65-year-old female of a race categorized as ""other"" with a BMI of 35.76. She is currently undergoing treatment with FOLFOX + Cetuximab. Unfortunately, she has experienced a serious adverse effect. She has completed 5 cycles of chemotherapy. Her histology shows that the cancer is well-differentiated. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5503,0,"The patient is a 69-year-old white male with a BMI of 26.85. He is currently receiving the FOLFOX treatment regimen and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5504,1,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has been using narcotics for 4 days and has symptoms but is still able to walk around. The pathology results indicate malignancy.
5505,1,The patient is a 53-year-old white male participating in the placebo treatment arm. He is experiencing symptoms but is still able to move around independently.
5506,1,"The patient is a 49-year-old white male with a BMI of 26.3. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis revealed a mutant status."
5507,0,The patient is a 66-year-old white male with a BMI of 36.96. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5508,1,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 3 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
5509,0,The patient is a 70-year-old white male with a BMI of 24.19 who is fully active. He is receiving treatment with the FOLFOX regimen for a primary tumor diagnosis of rectal cancer. The KRAS biomarker status is wild-type.
5510,1,"The patient is a 62-year-old white male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed lymphocytopenia (reduced lymphocyte count) as an adverse effect of the treatment."
5511,1,"The patient is a 75-year-old white male with a BMI of 20.76 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a wild-type KRAS biomarker. Despite experiencing symptoms, he is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment regimen."
5512,0,The patient is a 61-year-old white male with a BMI of 31.41. He is fully active with a primary tumor diagnosis of colon. The treatment arm for this patient is FOLFOX and Panitumumab. The KRAS biomarker status is wild-type.
5513,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 6 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
5514,1,"This patient is a 45-year-old white female who is part of the placebo treatment arm. She spends less than 50% of her time in bed, indicating a moderate level of activity or mobility."
5515,0,"The patient is a 42-year-old white female with a BMI of 27.58 who is receiving treatment with FOLFOX + Cetuximab. She experienced a serious adverse effect during the treatment. She has undergone 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. Additionally, she has experienced diarrhea as an adverse effect of the treatment."
5516,0,"The patient is a 56-year-old male of a race categorized as ""other"" with a BMI of 21.45. He is receiving treatment in the FOLFOX chemotherapy arm and is scheduled for a total of 12 cycles. The histology of his condition is poorly differentiated. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5517,0,"The patient is a 59-year-old Black female with a BMI of 26.44. She is undergoing treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5518,0,"The patient is a 60-year-old white female with a BMI of 32.4 who is undergoing treatment with the FOLFIRI regimen. She has been adherent to her treatment. Unfortunately, she has experienced serious adverse effects in the form of bowel obstruction and perforation. She has completed 10 cycles of chemotherapy and her histology shows poorly differentiated cancer. Despite these challenges, her performance status remains fully active. Additionally, her KRAS biomarker indicates that she has a wild-type mutation."
5519,0,"The patient is a 74-year-old Black male with a BMI of 26.85. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). His KRAS biomarker status is wild-type."
5520,0,"The patient is a 45-year-old white male with a BMI of 25.8. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5521,1,The patient is a 45-year-old white male participating in the treatment arm receiving 5FU/LV + Radiation. He has symptoms but is still able to walk around (ambulatory). The histology shows well-differentiated cells. The patient is experiencing an adverse effect related to neutrophils/granulocytes.
5522,0,"The patient is a 73-year-old white female with a BMI of 22.07. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type status."
5523,0,The patient is a 43-year-old white female with a BMI of 18.25. She is receiving the FOLFOX treatment arm and has completed 4 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment.
5524,0,"The patient is a 68-year-old white male with a BMI of 22.79. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status indicates that he has symptoms but is still ambulatory. The KRAS biomarker is wild-type. Additionally, he has developed an infection as an adverse effect."
5525,0,"The patient is a 46-year-old white female with a BMI of 49.83. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite the adverse effect, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
5526,0,"The patient is a 55-year-old female of a race categorized as ""other"" with a BMI of 26.54. She is currently undergoing treatment with the FOLFOX + Cetuximab regimen and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5527,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She only used narcotics for 1 day post-surgery. Despite experiencing symptoms, she is able to be ambulatory. The pathology report indicates malignancy."
5528,1,The patient is a 69-year-old white male with a BMI of 24.93. He is fully active with a primary tumor diagnosis of colon. The patient is receiving treatment with FOLFOX and Panitumumab. His KRAS biomarker status is mutant.
5529,0,"The patient is a 73-year-old white male with a BMI of 29.31. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to be ambulatory. The patient's KRAS biomarker indicates a mutant status."
5530,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She used narcotics for 3 days post-surgery. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology report indicates malignancy."
5531,1,The patient is a 73-year-old white female with a fully active performance status who is receiving treatment with a placebo.
5532,0,"The patient is a 55-year-old white male with a BMI of 22.93. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
5533,1,The patient is a 58-year-old white female with a BMI of 23.88. She is fully active with a primary tumor diagnosis of colon cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
5534,1,"The patient is a 50-year-old white female with a BMI of 32.01. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab, and her KRAS biomarker status is wild-type."
5535,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days following the procedure. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
5536,0,"The patient is a 64-year-old white male with a BMI of 34.37. He is receiving the FOLFOX treatment arm and has experienced a serious adverse effect. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker status is indeterminate."
5537,1,"The patient is a 39-year-old male of a race categorized as ""other"" with a BMI of 32.49. He is receiving treatment with FOLFOX chemotherapy regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite these challenges, his performance status is fully active. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
5538,1,"The patient is a 53-year-old white male with a BMI of 21.24 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that the patient has a mutant KRAS gene."
5539,0,"The patient is a 56-year-old white male with a BMI of 32.32. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed one cycle of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
5540,1,The patient is a 68-year-old white male who is receiving treatment with 5FU/LV + Radiation. He has a well-differentiated histology and has a performance status where he is in bed less than 50% of the time.
5541,0,"The patient is a 50-year-old white male with a BMI of 23.67. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite this, his performance status is fully active. His KRAS biomarker status is wild-type."
5542,0,"The patient is a 57-year-old white female with a BMI of 24.01. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5543,1,The patient is a 63-year-old white female with a BMI of 28.31. She is fully active with a primary tumor diagnosis of colon. She is receiving treatment with FOLFOX and Panitumumab in the clinical trial. Her KRAS biomarker status is wild-type.
5544,0,"The patient is a 44-year-old white male with a BMI of 28.18. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. The KRAS biomarker indicates that he has a mutant status."
5545,0,"The patient is a 41-year-old female of a race categorized as ""other"" with a BMI of 28.76. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis has shown a mutant status."
5546,1,"The patient is a 76-year-old Black female with a BMI of 23.46. She is receiving treatment with FOLFOX and has been adherent to her chemotherapy regimen. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type mutation. Additionally, she has experienced an infection as an adverse effect of her treatment."
5547,0,"The patient is a 63-year-old white female with a BMI of 50.32. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
5548,0,"The patient is a 69-year-old white male with a BMI of 32.65 who is receiving treatment with FOLFOX and Panitumumab for rectal cancer. He has a wild-type KRAS biomarker. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a rash as an adverse effect of the treatment."
5549,0,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They used narcotics for 3 days post-surgery. The histology showed symptoms but the patient was still able to be ambulatory. The pathology report indicated that the cause of the symptoms was malignant.
5550,1,"The patient is a 70-year-old white male with a BMI of 27.19 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect during his treatment, specifically diarrhea. He has completed 5 cycles of chemotherapy and has a histology of poorly differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. His KRAS biomarker shows that he is wild-type."
5551,1,"The patient is a 56-year-old white male with a BMI of 27.47. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutation."
5552,0,The patient is a 45-year-old Black male with a BMI of 27.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 5 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
5553,1,"The patient is a 61-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. The patient has developed adverse effects related to his granulocytes/bands and white blood cells."
5554,0,"The patient is a 53-year-old white male with a BMI of 36.96. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5555,0,"The patient is a 42-year-old white female with a BMI of 38.19. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still ambulatory. Her KRAS biomarker status is wild-type."
5556,0,The patient is a 49-year-old Black female with a BMI of 22.53. She is receiving treatment with FOLFOX + Cetuximab and has completed 5 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status. Her KRAS biomarker indicates that it is wild-type.
5557,0,"The patient is a 52-year-old white male with a BMI of 27.82. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a serious adverse effect after one cycle of chemotherapy. Despite this, his performance status is fully active. His KRAS biomarker is wild-type."
5558,1,The patient is a 62-year-old white female with a BMI of 24.0 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker testing showed that she has a mutant KRAS status.
5559,1,"The patient is a 68-year-old female of a race categorized as ""other"" who is undergoing treatment with a combination of Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to ambulate. The patient has developed a side effect known as granulocytes/bands, indicating an abnormality in her white blood cell count."
5560,0,"The patient is a 64-year-old white male with a BMI of 38.57. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5561,1,"The patient is a 59-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. Despite experiencing symptoms, he is still able to be ambulatory. The patient has developed adverse effects related to his white blood cells and granulocytes/bands."
5562,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
5563,0,"The patient is a 65-year-old white male with a BMI of 26.36. He is receiving treatment with the FOLFIRI regimen for KRAS mutant cancer. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his cancer diagnosis, his performance status is fully active. The KRAS biomarker status is indeterminate."
5564,1,"The patient is a 66-year-old white male who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating a relatively good performance status."
5565,1,"The patient is a 64-year-old female of a race categorized as ""other"" with a BMI of 19.95. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. Her histology shows well-differentiated characteristics. Despite her age, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5566,0,"The patient is a 59-year-old white male with a BMI of 27.47. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. However, he experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis revealed a mutant status."
5567,0,"The patient is a 55-year-old white female with a BMI of 24.11. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cells. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5568,0,"The patient is a 58-year-old female of a race categorized as ""other"" with a BMI of 26.44. She is undergoing treatment with the FOLFOX regimen and has been adherent to the treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her cancer diagnosis, she maintains a fully active performance status. The KRAS biomarker analysis has revealed a mutant status."
5569,0,"The patient is a male undergoing laparoscopic-assisted colectomy. He has abdominal wall adhesions and bowel adhesions, as well as experiencing complications. He has used narcotics for 7 days. His histology shows symptoms but he is still ambulatory, and the pathology indicates malignancy."
5570,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She only used narcotics for 1 day post-surgery. Despite experiencing symptoms, she is able to move around independently. The pathology report indicates malignancy."
5571,0,"The patient is a 72-year-old male of a race categorized as ""other."" He is currently receiving treatment with 5FU/LV + Radiation therapy. Despite experiencing symptoms, he is still able to walk around (ambulatory). The histology of his condition is poorly differentiated. He is experiencing adverse effects such as nausea, anorexia, and fatigue."
5572,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 1 day post-surgery. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
5573,0,The patient is a 46-year-old white female with a performance status of symptoms but still able to walk around. She is receiving treatment in the ECF + Radiation arm. The histology of her condition is poorly differentiated. She is experiencing nausea as an adverse effect of her treatment.
5574,0,The patient is a 53-year-old white female with a BMI of 22.65. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 1 cycle of chemotherapy. Her histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
5575,1,"The patient is a 61-year-old white male who is currently receiving treatment with 5FU/LV and radiation. He has previously undergone radiation therapy. Despite experiencing symptoms, he is still able to move around. His cancer histology shows well-differentiated cells. He is experiencing adverse effects such as nausea, anorexia, and fatigue."
5576,0,"The patient is a 50-year-old female of a race categorized as ""other"" with a BMI of 41.44. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated characteristics. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker analysis indicates a mutant status."
5577,1,"The patient is a 56-year-old white male with a BMI of 24.66. He is receiving treatment in the FOLFIRI treatment arm and has been adherent to the treatment. The patient has experienced a bowel perforation and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The patient's KRAS biomarker is mutant."
5578,1,"The patient is a 60-year-old male of other race with a BMI of 25.78. He is currently receiving treatment in the FOLFOX + Panitumumab arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal, and the KRAS biomarker shows a mutant status."
5579,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 11 days post-surgery. The histology showed symptoms but the patient was still able to walk around. The pathology results indicated that the condition was malignant.
5580,0,"The patient is a 40-year-old white male with a BMI of 26.1. He is receiving treatment with FOLFOX + Cetuximab and is scheduled for 12 chemotherapy cycles. His cancer histology is poorly differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5581,1,The patient is a 72-year-old white female with a BMI of 24.97 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor. The KRAS biomarker analysis revealed a mutant status.
5582,0,The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They have been using narcotics for 4 days post-surgery. The histology shows symptoms but the patient is still able to move around. Pathology results indicate that the cause of the symptoms is malignant in nature.
5583,1,The patient is a female who is part of the conventional surgery treatment arm. She has abdominal wall adhesion and bowel adhesion. She has been using narcotics for 9 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate malignancy.
5584,0,"The patient is a 63-year-old male of a race categorized as ""other"" with a BMI of 28.92. He is receiving treatment with FOLFOX + Cetuximab and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the bowel obstruction, his performance status is fully active. Additionally, his KRAS biomarker status is wild-type."
5585,1,"The patient is a 61-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active (ambulatory)."
5586,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 4 days and his histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
5587,1,"This patient is a 51-year-old white male with a BMI of 31.48. He is currently receiving treatment with FOLFOX and Panitumumab for his rectal cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
5588,1,The patient is a 54-year-old white female with a BMI of 37.11. She is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
5589,1,"The patient is a 64-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands, which indicates a decrease in certain types of white blood cells."
5590,1,The patient is a 47-year-old white male who is receiving treatment with Sunitinib. His performance status indicates that he is spending less than 50% of his time in bed.
5591,1,"The patient is a 61-year-old white male with a BMI of 25.56 who is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to ambulate. His primary tumor diagnosis is colon cancer."
5592,1,The patient is a 72-year-old white male with a BMI of 33.18 who is receiving treatment with FOLFOX. He has a performance status indicating that he is in bed less than 50% of the time. The primary tumor diagnosis is colon cancer.
5593,0,"The patient is a 66-year-old white male with a BMI of 28.51. He is receiving treatment with FOLFIRI chemotherapy, and has completed 12 cycles so far. His histology shows well-differentiated cancer cells. Despite experiencing diarrhea as an adverse effect, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5594,0,The patient is a 36-year-old white female with a BMI of 31.25. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates a mutant status.
5595,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She did not require any narcotics for pain management post-surgery. Histologically, she is in bed less than 50% of the time. The pathology report indicates a malignant condition."
5596,0,The patient is a 40-year-old white female with a BMI of 22.33. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
5597,1,"The patient is a 43-year-old white female with a BMI of 20.45. She is receiving treatment with the FOLFOX regimen and has experienced a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5598,0,"The patient is a 56-year-old male of a race categorized as ""other"" who is currently undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects of nausea and anorexia."
5599,0,"The patient is a 58-year-old white female with a BMI of 43.49. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5600,0,The patient is a 51-year-old female of other race with a BMI of 27.16. She is fully active with a primary tumor diagnosis of rectal cancer. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. The KRAS biomarker analysis indicates that she has a mutant KRAS status.
5601,1,The patient is a 61-year-old white male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with ECF chemotherapy along with radiation therapy. The histology of his condition is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5602,0,"The patient is a 55-year-old white female with a BMI of 43.25. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5603,0,"The patient is a 40-year-old Black male with a BMI of 25.88. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type gene."
5604,1,"This patient is a 62-year-old white male with a BMI of 23.83. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker is wild-type, and he is receiving treatment with the FOLFOX regimen."
5605,0,"The patient is a 49-year-old white male with a BMI of 27.39. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. He has completed 3 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
5606,0,"The patient is a 51-year-old white male with a BMI of 36.38. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed a mutation."
5607,1,"The patient is a 70-year-old white male with a BMI of 22.87. He is receiving the FOLFIRI treatment regimen for his well-differentiated histology cancer with a KRAS wild-type biomarker. Despite being fully active with no performance status issues, he has experienced a serious adverse effect of diarrhea during his 8 cycles of chemotherapy."
5608,1,"The patient is a 73-year-old white male with a BMI of 26.53 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to walk around (ambulatory). The patient has developed a rash as an adverse effect of the treatment."
5609,0,"The patient is a 50-year-old Black male with a BMI of 35.42. He is undergoing treatment with FOLFOX + Cetuximab for his colorectal cancer. He has experienced a bowel obstruction and has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his condition, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5610,0,"This patient is a 47-year-old Black female with a BMI of 27.7. She is receiving the FOLFOX treatment regimen and has experienced a bowel perforation. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite her condition, her performance status is fully active. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5611,1,The patient is a 47-year-old white male with a BMI of 24.77. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is mutant. He is currently receiving treatment in the FOLFOX treatment arm.
5612,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 3 days post-surgery. The histology results indicate that the tumor is well differentiated, and the pathology report shows that it is benign."
5613,0,"The patient is a 56-year-old white male who is part of the treatment arm receiving Cisplatin, Etoposide, and Paclitaxel. He has not started any chemotherapy cycles yet. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
5614,0,The patient is a 52-year-old white male with a BMI of 28.09. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. The KRAS biomarker testing showed a mutant result.
5615,0,"The patient is a 47-year-old white female with a BMI of 35.68. She is undergoing treatment with FOLFOX chemotherapy and has completed 12 cycles. The histology shows well-differentiated cancer cells. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status."
5616,0,"The patient is a 47-year-old white male with a BMI of 27.93. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to ambulate. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5617,1,"The patient is a 51-year-old white male with a BMI of 32.08. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient has experienced an adverse effect of thrombosis."
5618,0,"The patient is a 47-year-old white female with a BMI of 24.76. She is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5619,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions present. He used narcotics for 2 days post-surgery. The histology results show that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
5620,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology report indicates that she was in bed less than 50% of the time, and the pathology report shows that the underlying cause was malignant."
5621,1,"The patient is a 64-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of anorexia and fatigue."
5622,1,The patient is a 71-year-old white male participating in the treatment arm involving 5FU/LV and radiation therapy. He has a performance status of experiencing symptoms but is still able to walk around. His histology shows poorly differentiated characteristics.
5623,0,"The patient is a 50-year-old white female with a low BMI of 17.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 11 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status."
5624,0,"The patient is a 58-year-old white male with a BMI of 33.22. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5625,0,"The patient is a 50-year-old white male with a BMI of 19.1. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment in the FOLFOX treatment arm."
5626,1,"The patient is a 56-year-old white female with a BMI of 17.12. She is currently receiving treatment with the FOLFOX regimen for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
5627,1,"This patient is a 43-year-old white male with a BMI of 23.88 who is currently receiving treatment with FOLFOX. He has symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is rectal cancer, and his KRAS biomarker shows that it is wild-type."
5628,1,"The patient is a 62-year-old white female receiving treatment with Sunitinib. She is experiencing symptoms but is still able to walk around (ambulatory). She is also experiencing fatigue, low platelet count, and low white blood cell count as adverse effects of the treatment."
5629,0,"The patient is a 69-year-old white female with a BMI of 21.99. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a mutant status. Additionally, she has also experienced the adverse effect of thrombosis."
5630,0,The patient is a 59-year-old white male with a BMI of 35.43. He is fully active with a primary tumor diagnosis of colon cancer. He is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab.
5631,0,The patient is a female who underwent conventional surgery and has abdominal wall and bowel adhesions. She used narcotics for 5 days post-surgery. She is in bed less than 50% of the time. The histology report indicates malignancy.
5632,1,"The patient is a 47-year-old Black female with a BMI of 26.23. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5633,1,"This patient is a 65-year-old white female participating in the ECF + Radiation treatment arm. She has a performance status of experiencing symptoms but is still able to walk around. Her histology shows poorly differentiated cells. She is experiencing adverse effects such as low neutrophil/granulocyte count, low leukocyte count, nausea, and fatigue."
5634,0,The patient is a 58-year-old white female with a BMI of 21.3. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. Her cancer histology is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
5635,1,The patient is a 66-year-old white female receiving treatment with Cisplatin + Etoposide. She has completed 2 cycles of chemotherapy. Her performance status indicates that she is in bed less than 50% of the time. The patient has experienced an adverse effect related to her granulocytes/bands.
5636,0,"The patient is a 76-year-old white male with a BMI of 25.49. He is receiving treatment with FOLFIRI + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
5637,0,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications post-surgery. They used narcotics for 7 days following the procedure. The histology showed symptoms but the patient was still able to be ambulatory. Pathology results indicated a malignant condition.
5638,0,The patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 3 days post-surgery. The histology showed symptoms but she was still able to move around. The pathology report indicated that the cause of her symptoms was malignant.
5639,1,The patient is a 61-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has a performance status of fully active. She is experiencing adverse effects of low granulocytes/bands and nausea.
5640,0,"The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 24.13. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology indicates poorly differentiated cancer. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker shows that the patient has a wild-type status."
5641,0,"The patient is a 64-year-old white male with a BMI of 30.28. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5642,0,"The patient is a 68-year-old white female with a BMI of 50.38. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer, and her performance status indicates that she has symptoms but is still able to walk around. Her KRAS biomarker is wild-type. She has experienced adverse effects of thrombosis and infection."
5643,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to move around. The pathology report indicates that the cause of his symptoms is malignant.
5644,1,This patient is a 72-year-old white male who has not yet started chemotherapy treatment. He is assigned to the treatment arm receiving Cisplatin + Etoposide. His performance status indicates that he is in bed less than 50% of the time.
5645,0,The patient is a 46-year-old white female with a BMI of 24.8. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the tumor is wild-type.
5646,0,The patient is a 58-year-old Black female with a fully active performance status. She is receiving treatment in the ECF + Radiation arm. Her histology shows poorly differentiated characteristics.
5647,0,"The patient is a 68-year-old white male with a BMI of 27.71. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5648,0,"The patient is a 52-year-old white female with a BMI of 42.68. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. The histology of her cancer is well differentiated. Despite her high BMI, her performance status is fully active. The KRAS biomarker testing revealed a mutant status."
5649,1,"The patient is a 64-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active. The patient has also experienced adverse effects on his blood cells, specifically a decrease in granulocytes/bands, white blood cells, and lymphocytes."
5650,0,"The patient is a 68-year-old white female with a BMI of 27.7. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect in the form of a bowel obstruction. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
5651,1,"The patient is a 66-year-old male of other race with a BMI of 20.75. He is fully active in terms of performance status. The primary tumor diagnosis is colon cancer, and the patient is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab."
5652,1,The patient is a 44-year-old white female with a BMI of 34.15 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a colon cancer diagnosis with a mutant KRAS biomarker. The patient is experiencing a rash as an adverse effect of the treatment.
5653,0,"The patient is a 61-year-old white female with a BMI of 30.2. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5654,1,The patient is a 57-year-old white female receiving treatment with Sunitinib. She is fully active but is experiencing fatigue as an adverse effect of the treatment.
5655,1,This patient is a 69-year-old white female with a performance status of having symptoms but still able to walk around. She is receiving treatment with ECF chemotherapy combined with radiation therapy. The histology of her cancer is poorly differentiated. She is experiencing an adverse effect related to her neutrophils/granulocytes.
5656,1,"The patient is a 54-year-old white male who is currently undergoing treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around and be active, indicating that his performance status is relatively good."
5657,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and has used narcotics for 3 days. Histologically, she is in bed less than 50% of the time, and the pathology results indicate malignancy."
5658,0,"The patient is a 68-year-old Black male with a BMI of 51.33. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a mutant KRAS status."
5659,1,The patient is a 52-year-old black male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing an adverse effect of low white blood cell count (leukocytes).
5660,0,"The patient is a 63-year-old male of a race other than specified, with a BMI of 34.94. He is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, the KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5661,0,"The patient is a 72-year-old white female with a BMI of 35.3 who is receiving treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite experiencing a serious adverse effect of diarrhea, her performance status remains fully active. Her KRAS biomarker status is wild-type."
5662,0,"The patient is a male who underwent laparoscopic-assisted colectomy as part of their treatment. They experienced complications post-surgery. They used narcotics for 3 days following the procedure. Despite having symptoms, the patient was still able to be ambulatory. The pathology report revealed malignancy."
5663,0,"The patient is a 41-year-old female of a race other than specified, with a BMI of 30.3. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. The histology of her condition is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, her KRAS biomarker status is wild-type."
5664,0,The patient is a 55-year-old white female with a BMI of 33.77. She is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
5665,1,The patient is a 66-year-old white female with a BMI of 22.09. She is fully active with a performance status indicating good overall health. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab for a primary colon tumor diagnosis.
5666,1,"The patient is a 54-year-old female of a race other than Caucasian, with a BMI of 22.35. She is receiving treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect and is currently dealing with a bowel obstruction. She has completed 11 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Her KRAS biomarker status is wild-type."
5667,1,"This patient is a 67-year-old white male with a BMI of 17.3. He is receiving treatment with FOLFOX for a primary colon tumor. His performance status indicates that he is in bed less than 50% of the time. Additionally, his KRAS biomarker status is wild-type."
5668,1,"This patient is a 79-year-old white female with a BMI of 27.58. She is currently receiving treatment with FOLFOX and Panitumumab for her colon cancer. Despite experiencing symptoms, she is still able to ambulate. The KRAS biomarker in her tumor is mutant."
5669,0,"The patient is a 71-year-old Black male with a BMI of 29.78. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
5670,0,"This patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 5 days following the surgery. The histology indicates that she spent less than 50% of her time in bed, and the pathology report shows that the condition is malignant."
5671,0,"The patient is a 45-year-old white male with a BMI of 22.95. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5672,0,The patient is a 55-year-old white male with a BMI of 24.11 who is receiving treatment with FOLFOX and Panitumumab for a colon tumor. His performance status indicates that he is in bed less than 50% of the time. The KRAS biomarker analysis revealed a mutant status.
5673,1,"The patient is a 65-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite this, he is still able to ambulate with symptoms. The patient has also developed a decrease in granulocytes/bands as an adverse effect of the treatment."
5674,0,"The patient is a 72-year-old white male with a BMI of 26.32. He is receiving treatment with FOLFOX + Cetuximab and has completed 3 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5675,1,The patient is a 77-year-old white male with a BMI of 26.98. He is fully active with a primary tumor diagnosis of rectal cancer. The patient is in the FOLFOX treatment arm and has a mutant KRAS biomarker.
5676,1,"The patient is a 46-year-old white male with a BMI of 27.56. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type status."
5677,0,"The patient is a 75-year-old white male with a BMI of 30.24 who is receiving the FOLFOX treatment regimen. He has been adherent to the treatment and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates that he is wild-type. The patient has experienced a hypersensitivity adverse effect."
5678,1,"The patient is a 59-year-old white female with a BMI of 26.33. She is receiving treatment with FOLFOX + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has symptoms but is still able to be ambulatory. The KRAS biomarker shows that she is wild-type. Additionally, she has experienced an adverse effect of thrombosis."
5679,0,"The patient is a 35-year-old white male with a BMI of 29.57. He is receiving treatment in the FOLFOX treatment arm and has been adherent to his treatment. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the bowel obstruction, the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5680,0,"The patient is a 43-year-old white female with a BMI of 24.87. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5681,0,"The patient is a 44-year-old white male with a BMI of 30.67. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
5682,1,"The patient is a 68-year-old white female with a BMI of 23.76 who is currently receiving treatment with FOLFOX and Panitumumab. She has symptoms but is still able to walk around (ambulatory). She has been diagnosed with a primary tumor in the colon, and her KRAS biomarker status is mutant."
5683,0,"The patient is a 45-year-old white female with a BMI of 36.21. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker analysis indicates a mutant status."
5684,0,"The patient is a 43-year-old white female with a BMI of 25.0. She is receiving treatment with FOLFOX chemotherapy regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is well differentiated. Despite the adverse effect, her performance status is fully active. Her KRAS biomarker status is wild-type."
5685,1,This patient is a 51-year-old white female with a performance status indicating that she is in bed less than 50% of the time. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated.
5686,0,"The patient is a 65-year-old white male with a BMI of 28.27 who is receiving the FOLFOX treatment regimen. He has been adherent to his treatment and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated, and his performance status is fully active. The patient has a mutant KRAS biomarker and has experienced a serious adverse effect in the form of an infarction."
5687,0,"The patient is a 72-year-old male of a race categorized as ""other"" who is currently receiving treatment with 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around (ambulatory). The histology shows that the cancer is well-differentiated. The patient is experiencing adverse effects of anorexia and fatigue."
5688,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 4 days following the procedure. Their histology indicates that they were in bed less than 50% of the time, and the pathology results showed that the condition is malignant."
5689,0,The patient is a male who is receiving conventional surgery as part of their treatment. They have used narcotics for 3 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
5690,1,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 2 days post-surgery. The histology results showed symptoms but she was still able to walk around. The pathology report indicated that the tumor was malignant.
5691,1,"The patient is a 62-year-old white female with a BMI of 26.95. She is receiving the FOLFOX treatment regimen and has been adherent to her chemotherapy cycles, completing 7 cycles so far. Her histology shows well-differentiated cancer cells. Despite her cancer diagnosis, she has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5692,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions and has been using narcotics for 5 days. The histology shows that he is in bed less than 50% of the time, and the pathology report indicates a malignant condition."
5693,0,The patient is a 63-year-old white male with a BMI of 24.44 who is receiving treatment with FOLFOX and Panitumumab for colon cancer. He has symptoms but is still able to ambulate. His KRAS biomarker status is wild-type. The patient is experiencing a rash as an adverse effect of the treatment.
5694,0,The patient is a 49-year-old white male with a BMI of 23.67. He is fully active with a primary tumor diagnosis of rectal cancer. He is enrolled in the FOLFOX + Panitumumab treatment arm. His KRAS biomarker status is wild-type.
5695,0,"The patient is a 70-year-old white female with a BMI of 22.01. She is undergoing treatment with FOLFIRI + Cetuximab and has completed 4 cycles of chemotherapy. Her cancer histology is well differentiated. Despite her age, she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5696,0,"The patient is a 76-year-old Black male with a BMI of 36.57. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates a mutant status."
5697,0,The patient is a 63-year-old male of other race with a BMI of 28.92. He is fully active with a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. He is currently receiving treatment in the FOLFOX regimen.
5698,1,The patient is a 49-year-old white male participating in the ECF + Radiation treatment arm. He has a well-differentiated histology and is experiencing symptoms but is still able to be ambulatory. The patient is experiencing adverse effects related to his neutrophils/granulocytes and leukocytes.
5699,1,"The patient is a 58-year-old white male receiving treatment with FOLFOX for colon cancer. He has a BMI of 25.94 and is experiencing symptoms but is still able to walk around (ambulatory). His primary tumor diagnosis is colon cancer, and his KRAS biomarker shows that it is wild-type. He is also experiencing a rash as an adverse effect of the treatment."
5700,0,"The patient is a 43-year-old white male with a BMI of 35.83. He is receiving the FOLFIRI treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The patient's KRAS biomarker status is mutant."
5701,0,This patient is a 53-year-old white female with a BMI of 35.69. She is receiving treatment with FOLFOX + Cetuximab for her poorly differentiated histology. She has experienced a bowel obstruction and is fully active with a wild-type KRAS biomarker. She has undergone 12 cycles of chemotherapy and is experiencing diarrhea as an adverse effect of her treatment.
5702,1,"The patient is a 68-year-old white female undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 5 cycles of chemotherapy. She has experienced significant weight loss of more than 5-10%. Despite having symptoms, she is still able to walk around (ambulatory)."
5703,0,The patient is a 52-year-old white female with a BMI of 24.78. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
5704,0,"The patient is a 60-year-old white male with a BMI of 24.11 who is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect in the form of a bowel obstruction. He has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the adverse effect, his performance status remains fully active. The KRAS biomarker testing revealed a mutant status. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
5705,1,"The patient is a 51-year-old white female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a performance status of fully active."
5706,0,"The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 3 days following the procedure. The histology shows symptoms, but the patient is still able to walk around. Pathology results indicate that the condition is malignant."
5707,1,The patient is a 57-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 2 cycles of chemotherapy and is experiencing symptoms but is still able to walk around (ambulatory). She is also experiencing adverse effects including low levels of granulocytes/bands and nausea.
5708,0,This patient is a female who underwent laparoscopic-assisted colectomy. She used narcotics for 2 days post-surgery. The histology showed symptoms but she was still able to walk around. The pathology report indicated that the cause of her symptoms was malignant.
5709,0,The patient is a male who is part of the conventional surgery treatment arm. He has bowel adhesions and has been using narcotics for 4 days. The histology shows symptoms but the patient is still able to walk around. The pathology report indicates that the condition is malignant.
5710,0,"The patient is a 67-year-old white male with a BMI of 31.47. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
5711,1,The patient is a 72-year-old white male with a BMI of 28.04 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing acne as an adverse effect of the treatment.
5712,1,"The patient is a 62-year-old white male with a BMI of 24.6. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment regimen. He has experienced a serious adverse effect, specifically an infarction, after completing 3 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a mutant KRAS biomarker. Despite experiencing symptoms, he is still able to be ambulatory."
5713,0,The patient is a 67-year-old white male with a fully active performance status. He is receiving treatment in the ECF + Radiation arm. His histology shows well-differentiated characteristics.
5714,1,"The patient is a 74-year-old white male with a BMI of 29.6. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 9 cycles so far. His cancer histology is well differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5715,0,"The patient is a 75-year-old white male with a BMI of 27.96. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells. Despite these challenges, his performance status is fully active. It is worth noting that his KRAS biomarker is wild-type."
5716,0,"The patient is a 64-year-old Black male with a BMI of 28.76. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5717,1,The patient is a 70-year-old white male with a BMI of 25.42. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary tumor diagnosis of rectal cancer.
5718,0,"The patient is a 64-year-old white male with a BMI of 28.39. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5719,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He has abdominal wall adhesions. He used narcotics for 1 day post-surgery. The histology results showed well-differentiated cells, and the pathology report indicated that the condition was benign."
5720,1,"The patient is a 56-year-old white male enrolled in the ECF + Radiation treatment arm. He has a fully active performance status and has been diagnosed with poorly differentiated histology. He is experiencing anorexia as an adverse effect, which is characterized by a loss of appetite and a decreased interest in food. This may result in weight loss and nutritional deficiencies, impacting his overall well-being and ability to tolerate treatment."
5721,0,"The patient is a 69-year-old white male with a BMI of 27.28. He is receiving the FOLFOX treatment arm for his cancer and has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
5722,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications following the procedure. She used narcotics for 3 days post-surgery. Despite having symptoms, she was able to remain ambulatory. The pathology report indicated malignancy."
5723,0,"The patient is a 70-year-old white male with a BMI of 25.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 3 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5724,0,The patient is a 66-year-old white female with a BMI of 32.24. She is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. Her histology shows well-differentiated cancer. She has a fully active performance status. The KRAS biomarker indicates that she has a mutant status.
5725,0,The patient is a 55-year-old white male with a BMI of 25.39 who is fully active. He is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. His KRAS biomarker status is wild-type.
5726,0,"The patient is a 47-year-old white male with a BMI of 38.43. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. The patient's KRAS biomarker is mutant."
5727,1,The patient is a 67-year-old white male with a BMI of 29.14. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is mutant. He is receiving treatment in the FOLFOX treatment arm.
5728,1,"The patient is a 53-year-old male of a race other than specified, with a BMI of 21.78. He is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer, and the KRAS biomarker shows a wild-type status."
5729,0,"The patient is a 68-year-old white male with a BMI of 36.51. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5730,0,"The patient is a 59-year-old white female with a BMI of 25.96. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 chemotherapy cycles. Her cancer histology is poorly differentiated. Despite experiencing diarrhea as an adverse effect, her performance status is fully active. Additionally, her KRAS biomarker status is wild-type."
5731,1,"The patient is a 56-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 6 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is experiencing adverse effects including low levels of granulocytes/bands and nausea."
5732,1,The patient is a male who is receiving conventional surgery. He has abdominal wall adhesion and bowel adhesion. He has used narcotics for 3 days. He spends less than 50% of his time in bed. The pathology report indicates a malignant condition.
5733,0,The patient is a 67-year-old white male with a BMI of 25.93. He is fully active with a primary tumor diagnosis of colon cancer. The KRAS biomarker indicates that he has a wild-type mutation. He is receiving treatment with the FOLFOX regimen.
5734,1,The patient is a 43-year-old white male with a BMI of 30.52. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 2 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. His KRAS biomarker is wild-type.
5735,1,"The patient is a 53-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has a fully active performance status. The patient has experienced an adverse effect known as granulocytes/bands, indicating a decrease in certain types of white blood cells."
5736,0,"The patient is a 60-year-old white male with a BMI of 25.68. He is receiving treatment with the FOLFOX regimen and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his cancer diagnosis, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5737,0,"The patient is a 64-year-old male of a race categorized as ""other"" with a BMI of 18.93. He is receiving treatment in the FOLFOX regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the challenges, his performance status is fully active. Additionally, the KRAS biomarker shows that he has a wild-type status."
5738,0,"The patient is a 57-year-old white male with a BMI of 28.28. He is enrolled in the treatment arm receiving FOLFOX + Cetuximab but has not started chemotherapy cycles yet. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker status is intermediate."
5739,0,The patient is a 53-year-old white female with a BMI of 30.98. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status.
5740,1,"This patient is a 66-year-old white female with a BMI of 22.87 who is receiving treatment with the FOLFOX regimen. She has a performance status indicating that she is in bed less than 50% of the time. Her primary tumor diagnosis is colon cancer, and she has a mutant KRAS biomarker."
5741,1,"The patient is a 38-year-old Black male with a BMI of 26.06. He is receiving the FOLFOX treatment arm for his bowel obstruction. He has undergone 12 cycles of chemotherapy. The histology shows poorly differentiated cells. Despite this, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type status."
5742,0,"The patient is a 64-year-old white male with a BMI of 24.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to ambulate. His KRAS biomarker status is wild-type."
5743,1,The patient is a 57-year-old white male with a BMI of 22.98 who is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. He has a fully active performance status. The patient has a mutant KRAS biomarker and is experiencing a rash as an adverse effect of the treatment.
5744,0,"The patient is a 52-year-old white female with a BMI of 23.83. She is currently receiving treatment with FOLFOX and Panitumumab for her rectal cancer. Despite experiencing symptoms, she is still able to walk around. The KRAS biomarker analysis revealed a mutant status."
5745,0,"The patient is a 56-year-old white male with a BMI of 28.54. He is undergoing treatment with the FOLFOX chemotherapy regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effect, his performance status is fully active. The patient's KRAS biomarker status is mutant."
5746,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. She only used narcotics for 1 day post-surgery. Despite experiencing symptoms, she is able to move around and be ambulatory. The pathology report indicates a malignant condition."
5747,1,"This patient is a 62-year-old white male with a BMI of 27.56. He is receiving treatment with FOLFOX + Cetuximab for his bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite his condition, his performance status is fully active. His KRAS biomarker is wild-type. He has experienced a hypersensitivity adverse effect during treatment."
5748,0,"The patient is a 67-year-old white male with a BMI of 44.1. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5749,0,"The patient is a 76-year-old white male with a BMI of 31.49. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab, a targeted therapy. His KRAS biomarker status is wild-type, indicating that he may respond well to the targeted therapy."
5750,0,"The patient is a 50-year-old white male with a BMI of 25.38. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status."
5751,0,"The patient is a male who underwent conventional surgery as part of his treatment. He used narcotics for 5 days following the surgery. His histology shows that he is in bed less than 50% of the time, and the pathology results indicate a malignant condition."
5752,0,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the symptoms, he was able to remain ambulatory. The pathology report revealed malignant findings."
5753,0,The patient is a 42-year-old white male with a BMI of 19.5. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5754,0,"The patient is an 81-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, she is still able to be ambulatory. The patient has also developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
5755,1,"The patient is a 47-year-old white female with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. She has a histology of poorly differentiated cancer. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia."
5756,0,The patient is a 50-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV and radiation therapy. He has a histology of poorly differentiated cancer. The patient is experiencing adverse effects of low neutrophil/granulocyte levels and anorexia.
5757,0,"The patient is a 60-year-old white male with a BMI of 23.23. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker indicates that he has a wild-type status."
5758,1,"The patient is a 64-year-old Black male who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 8 cycles of chemotherapy. The patient has experienced significant weight loss of more than 5-10%. Despite this, his performance status is fully active."
5759,1,The patient is a 50-year-old white male with a BMI of 30.3 who is currently receiving treatment with FOLFOX for colon cancer. He has symptoms but is still able to walk around. His KRAS biomarker shows that it is wild-type.
5760,0,"The patient is a 56-year-old white female with a BMI of 27.55 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced a serious adverse effect during treatment. She has completed 12 chemotherapy cycles and has well-differentiated histology. Her performance status is fully active. The KRAS biomarker is wild-type. She has experienced adverse effects including thrombosis, diarrhea, and infection."
5761,1,The patient is a 63-year-old white female with a BMI of 19.15 who is fully active. She is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. The KRAS biomarker testing revealed a mutant status.
5762,0,The patient is a 34-year-old white female with a BMI of 24.52. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. She has a fully active performance status. The KRAS biomarker analysis indicates that she has a wild-type KRAS gene.
5763,0,"The patient is a 45-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker status is wild-type."
5764,0,"The patient is a 74-year-old white male with a BMI of 24.84. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient is experiencing diarrhea as an adverse effect of the treatment."
5765,0,"The patient is a 45-year-old white female with a BMI of 29.74 who is undergoing treatment with FOLFOX + Cetuximab. She has experienced serious adverse effects during the treatment, including thrombosis and infection. The patient has completed 12 cycles of chemotherapy and has a well-differentiated histology. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker is mutant."
5766,0,The patient is a female who is part of the conventional surgery treatment arm. She has used narcotics for 5 days. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the condition is malignant.
5767,0,"The patient is a 49-year-old male of a race classified as ""other"" who is receiving treatment with 5FU/LV and radiation therapy. He has a fully active performance status and has been diagnosed with poorly differentiated histology. The patient is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea and anorexia."
5768,0,The patient is a 41-year-old white male with a BMI of 44.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 9 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5769,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 4 days post-surgery. The histology showed symptoms but the patient remained ambulatory. The pathology results indicated a malignant condition.
5770,1,"The patient is a 56-year-old white male with a BMI of 22.66. He is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. Despite experiencing symptoms, he is still able to walk around. His KRAS biomarker status is wild-type."
5771,1,"The patient is a 76-year-old white male with a BMI of 27.91. He is fully active with a primary tumor diagnosis of colon cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
5772,1,"The patient is a 53-year-old white female with a BMI of 28.04. She is fully active with a primary tumor diagnosis of rectal cancer. She is receiving treatment with FOLFOX (a chemotherapy regimen) along with Panitumumab. Her KRAS biomarker status is wild-type, indicating a potentially better response to the treatment."
5773,1,"This patient is a 64-year-old white female with a BMI of 20.31 who is currently receiving treatment with the FOLFOX regimen. She has a primary tumor diagnosis of colon cancer and carries a mutant KRAS biomarker. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status."
5774,1,"The patient is a 59-year-old white male who has previously undergone chemotherapy and radiation treatment. He is currently enrolled in the treatment arm involving 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory. The histology indicates that the cancer is well-differentiated."
5775,1,"The patient is a 75-year-old white male with a BMI of 31.02. He is fully active and is receiving treatment with the FOLFOX regimen. His primary tumor diagnosis is rectal cancer, and his KRAS biomarker status is wild-type."
5776,1,"The patient is a 46-year-old white female with a BMI of 28.03. She is currently receiving treatment in the FOLFIRI + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. Additionally, the patient's KRAS biomarker status indicates that it is mutant."
5777,0,"The patient is a 56-year-old white male with a BMI of 28.93. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates that the cancer is wild-type."
5778,1,The patient is a male undergoing treatment with laparoscopic-assisted colectomy. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. Pathology results indicate that the condition is malignant.
5779,1,The patient is a male who is undergoing conventional surgery as part of their treatment. They have used narcotics for 4 days. Their histology shows symptoms but they are still able to walk around. The pathology indicates that the condition is malignant.
5780,0,"The patient is a 69-year-old white male with a BMI of 26.84. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker status is indeterminate for this patient."
5781,0,"The patient is a 65-year-old white female with a BMI of 31.14. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker indicates that it is wild-type."
5782,0,"The patient is a 45-year-old Black male with a BMI of 19.91. He is currently receiving the FOLFOX treatment arm and has completed 2 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5783,0,"The patient is a male undergoing conventional surgery for a malignant condition. He has been using narcotics for 4 days to manage his symptoms, but is still able to walk around and be active."
5784,0,The patient is a 54-year-old Black female with a BMI of 36.29. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker status is indeterminate.
5785,0,The patient is a 41-year-old white male with a BMI of 22.57. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a mutant KRAS biomarker.
5786,1,"The patient is a 75-year-old white female with a BMI of 26.14. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is wild-type. She has reported experiencing diarrhea as an adverse effect of her treatment."
5787,0,"The patient is a 57-year-old white male with a BMI of 23.2. He is receiving treatment with FOLFOX + Cetuximab and has completed 10 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5788,0,"The patient is a 41-year-old white male with a BMI of 27.62. He is receiving treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cells, and he has a fully active performance status. His KRAS biomarker is wild-type. Additionally, he has experienced thrombosis as an adverse effect."
5789,1,The patient is a 57-year-old white male with a BMI of 31.64 who is currently receiving treatment with the FOLFOX regimen. He has a fully active performance status and has been diagnosed with a primary tumor in the colon. The patient's KRAS biomarker status is mutant.
5790,0,The patient is a 69-year-old white female receiving treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Her performance status indicates that she is experiencing symptoms but is still able to walk around. She has developed a side effect related to her white blood cells.
5791,1,The patient is a 53-year-old white female receiving treatment with Sunitinib. She spends less than 50% of her time in bed due to her performance status. She is experiencing fatigue as an adverse effect of the treatment.
5792,1,The patient is a 61-year-old white male with a BMI of 30.79 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor with a mutant KRAS biomarker. The patient has developed a rash as an adverse effect of the treatment.
5793,0,"This patient is a 53-year-old white female with a BMI of 43.49 who is receiving the FOLFOX treatment regimen. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated, and her performance status is fully active. Her KRAS biomarker is wild-type. She has experienced a serious adverse effect in the form of thrombosis."
5794,0,"The patient is a 67-year-old white male with a BMI of 27.96. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 10 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. Additionally, his KRAS biomarker indicates that he has a wild-type gene."
5795,0,"The patient is a 59-year-old white female with a fully active performance status. She is receiving treatment with ECF and radiation. The histology of her condition is poorly differentiated. She is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as nausea."
5796,0,"The patient is a 51-year-old Black male with a BMI of 29.41. He is currently receiving treatment with FOLFOX + Cetuximab and has completed 2 cycles of chemotherapy. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5797,0,The patient is a male who underwent conventional surgery as part of their treatment. They used narcotics for 5 days post-surgery. The histology showed symptoms but the patient is still able to walk around. The pathology report indicated that the tumor is malignant.
5798,1,The patient is a 62-year-old Black female receiving treatment with Sunitinib. She has a performance status indicating that she spends less than 50% of her time in bed.
5799,0,"The patient is a 45-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
5800,0,"The patient is a 46-year-old white male with a BMI of 29.33. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. His cancer histology is well-differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing showed that he has a wild-type KRAS status."
5801,1,"This patient is a 59-year-old female of a race other than specified, with a BMI of 29.68. She is currently receiving treatment with the FOLFOX regimen. Despite experiencing symptoms, she is still able to walk around (ambulatory). The primary tumor diagnosis is rectal cancer. Additionally, the KRAS biomarker testing has revealed a mutation in the KRAS gene."
5802,1,"The patient is a 75-year-old white male with a BMI of 25.53. He is receiving treatment with FOLFOX + Cetuximab. He has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 9 cycles of chemotherapy. The histology shows well-differentiated cells. Despite experiencing symptoms, the patient is still ambulatory. The KRAS biomarker indicates a mutant status. Additionally, the patient has also experienced diarrhea as an adverse effect."
5803,0,"The patient is a 69-year-old white male with a BMI of 31.25. He is receiving the FOLFOX treatment regimen and has completed 4 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5804,0,The patient is a 60-year-old white male with a BMI of 25.93. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status and the KRAS biomarker is wild-type.
5805,0,The patient is a 52-year-old white male with a BMI of 29.14. He is receiving treatment with FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates that the patient has a wild-type KRAS status.
5806,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the procedure. The histology shows symptoms but she is still able to walk around (ambulatory). The pathology results indicate that the condition is malignant.
5807,0,"The patient is a 48-year-old white female with a BMI of 30.16. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite her fully active performance status, she has a mutant KRAS biomarker. Additionally, she has experienced thrombosis as an adverse effect."
5808,1,"The patient is a 53-year-old female of a race categorized as ""other"" who is currently undergoing treatment with ECF chemotherapy combined with radiation therapy. She has a performance status of experiencing symptoms but is still able to walk around. The histology of her condition is classified as poorly differentiated. Additionally, she is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
5809,0,"This patient is a 36-year-old white male with a BMI of 31.73. He is receiving treatment in the FOLFOX + Cetuximab treatment arm. Unfortunately, he has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows that the cancer is well-differentiated. Despite the treatment, his performance status is fully active. Additionally, his KRAS biomarker is wild-type."
5810,0,"The patient is a 47-year-old white male with a BMI of 38.72. He is receiving treatment with FOLFOX + Cetuximab for his well-differentiated histology. He has a bowel obstruction and has completed 12 cycles of chemotherapy. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
5811,0,"The patient is a 69-year-old Black male with a BMI of 30.25. He is receiving the FOLFOX treatment regimen and has been adherent to the treatment. He has completed 2 cycles of chemotherapy. Histologically, the cancer is poorly differentiated. The patient has a fully active performance status. His KRAS biomarker status is wild-type."
5812,1,"The patient is a 46-year-old white male with a BMI of 24.51. He is currently receiving treatment with FOLFOX for colon cancer. Despite experiencing symptoms, he is still able to walk around (ambulatory). The KRAS biomarker testing revealed that he has a wild-type KRAS gene."
5813,0,"The patient is a 42-year-old white female with a BMI of 28.93. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite experiencing symptoms, she is still able to move around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5814,0,"The patient is a 35-year-old white female with a BMI of 33.67. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker testing indicates that she has a wild-type KRAS gene."
5815,0,"The patient is a 43-year-old white female with a BMI of 23.46. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 11 cycles of chemotherapy. Her histology shows well-differentiated cells, and she has a fully active performance status. The KRAS biomarker indicates that she has a wild-type mutation."
5816,0,"The patient is a 44-year-old white male with a BMI of 32.4. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. Additionally, his KRAS biomarker indicates that it is wild-type."
5817,1,The patient is a 48-year-old black male with a performance status of experiencing symptoms but still able to walk around. He is receiving treatment with 5FU/LV + Radiation therapy. The histology shows poorly differentiated cells.
5818,1,"The patient is a 49-year-old white female with a BMI of 20.2 who is currently receiving treatment with FOLFOX and Panitumumab for colon cancer. She has a wild-type KRAS biomarker. Despite experiencing symptoms, she is still able to ambulate. The patient has developed a rash as an adverse effect of the treatment."
5819,0,This patient is a 57-year-old white male with a BMI of 25.95. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor diagnosis.
5820,0,This patient is a 71-year-old white female with a performance status indicating symptoms but still able to walk around (ambulatory). She is receiving treatment in the ECF + Radiation arm and has a histology of poorly differentiated cancer.
5821,0,The patient is a 45-year-old white male with a BMI of 39.0. He is receiving treatment in the FOLFOX chemotherapy arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
5822,0,"The patient is a 67-year-old white male with a BMI of 30.76. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates a mutant status."
5823,0,"The patient is a 41-year-old female of a race classified as ""other"" with a BMI of 26.14. She is undergoing treatment with the FOLFOX + Cetuximab regimen and has completed 10 cycles of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. The KRAS biomarker testing revealed a wild-type result. The patient has experienced adverse effects during treatment, including hypersensitivity and diarrhea."
5824,0,The patient is a male who is part of the conventional surgery treatment arm. He has abdominal wall adhesions and has used narcotics for 2 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates malignancy.
5825,0,"The patient is a 64-year-old white male with a BMI of 26.04. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and he has a fully active performance status. Additionally, his KRAS biomarker is wild-type."
5826,0,"The patient is a 54-year-old white female with a BMI of 26.4. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. Additionally, her KRAS biomarker is wild-type."
5827,0,The patient is a 60-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy in combination with radiation therapy. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5828,1,"The patient is a 75-year-old male of a race other than specified, with a BMI of 15.43. He is in bed less than 50% of the time due to his performance status. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows a mutant status. The patient is undergoing treatment with FOLFOX chemotherapy in combination with Panitumumab."
5829,0,"The patient is a 66-year-old Black male with a BMI of 25.3. He is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene."
5830,0,"The patient is a 74-year-old white male with a BMI of 27.62. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing indicates that he has a wild-type KRAS status."
5831,1,"The patient is a 48-year-old white female with a BMI of 28.86. She is fully active with a primary tumor diagnosis of colon. The treatment arm she is in involves FOLFOX chemotherapy combined with Panitumumab. Additionally, the patient's KRAS biomarker status is mutant."
5832,0,"The patient is a 72-year-old white female with a BMI of 28.02 who is currently undergoing treatment with FOLFIRI + Cetuximab. She has completed 3 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to be ambulatory. Her KRAS biomarker is wild-type. She is experiencing diarrhea as an adverse effect of the treatment."
5833,1,The patient is a 46-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects of nausea and anorexia.
5834,0,The patient is a 57-year-old white male with a fully active performance status. He is receiving treatment with 5FU/LV + Radiation in the poorly differentiated histology arm.
5835,0,The patient is a 68-year-old white male with a BMI of 24.26. He is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
5836,0,"This patient is a 37-year-old white male with a BMI of 24.05. He is receiving treatment with FOLFOX + Cetuximab for his cancer. Unfortunately, he has experienced a serious adverse effect, specifically a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite the adverse effects, his performance status is fully active. His KRAS biomarker status is wild-type."
5837,0,"The patient is a 41-year-old white female with a BMI of 35.03. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. Her histology shows well-differentiated cancer, and she has symptoms but is still able to walk around (ambulatory). The KRAS biomarker indicates that she has a wild-type gene. She has experienced a hypersensitivity adverse effect."
5838,0,"The patient is a 51-year-old white male with a BMI of 26.79. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his cancer diagnosis, he has a fully active performance status. Additionally, the KRAS biomarker testing revealed a mutant status."
5839,1,"The patient is an 81-year-old white male undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 4 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to move around. The patient has developed adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes."
5840,0,The patient is a 55-year-old white male with a BMI of 26.54. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
5841,0,The patient is a 64-year-old white male with a BMI of 23.15. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status and has a wild-type KRAS biomarker.
5842,1,"The patient is a 59-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 6 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to be ambulatory. The patient has developed adverse effects including low levels of granulocytes/bands and white blood cells."
5843,0,"The patient is a 75-year-old female of a race other than Caucasian, with a BMI of 28.9. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5844,0,The patient is a 65-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5845,0,The patient is a 54-year-old white female with a BMI of 25.85. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated. She has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status.
5846,0,"The patient is a 60-year-old white female with a BMI of 33.59. She is receiving the FOLFOX treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker analysis indicates a mutant status."
5847,0,"The patient is a female who underwent laparoscopic-assisted colectomy. She experienced complications post-surgery. She required narcotic pain medication for 7 days. Despite symptoms, she was able to remain ambulatory. The pathology report revealed malignant findings."
5848,0,"The patient is a female who underwent laparoscopic-assisted colectomy and experienced complications. She used narcotics for 2 days post-surgery. Her histology indicates that she was in bed less than 50% of the time, and the pathology report showed malignant findings."
5849,0,"The patient is a 49-year-old male of a race categorized as ""other"" with a BMI of 38.01. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. His KRAS biomarker status is wild-type."
5850,1,The patient is a 60-year-old white female with a BMI of 26.99 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor diagnosis. The KRAS biomarker shows that she has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
5851,0,"The patient is a 49-year-old white female with a BMI of 32.81 who is receiving treatment with FOLFOX + Cetuximab. She has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing showed that she has a wild-type KRAS status. She is experiencing diarrhea as an adverse effect of the treatment."
5852,0,The patient is a 50-year-old white male with a BMI of 39.26. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status and has a wild-type KRAS biomarker.
5853,1,"The patient is a 49-year-old white female who is undergoing treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a fully active performance status."
5854,0,"The patient is a 38-year-old white male with a BMI of 25.09. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 7 cycles of chemotherapy. His histology shows well-differentiated cancer. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5855,0,"The patient is a 63-year-old white female with a BMI of 20.58. She is receiving the FOLFIRI treatment arm for her KRAS mutant status. She has experienced a bowel obstruction and has completed 2 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The patient has a mutant KRAS biomarker and has experienced thrombosis as an adverse effect."
5856,1,The patient is a 46-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is poorly differentiated. The patient is experiencing an adverse effect of low white blood cell count (leukocytes).
5857,0,The patient is a 59-year-old white male with a BMI of 19.67. He is currently on the FOLFOX treatment arm and has completed 1 cycle of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status. The KRAS biomarker analysis indicates a mutant status.
5858,1,"The patient is a 72-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around. The patient is experiencing adverse effects including low levels of granulocytes/bands, white blood cells, and lymphocytes, as well as nausea."
5859,1,The patient is a 58-year-old white female participating in the placebo treatment arm. She is experiencing symptoms but is still able to move around independently.
5860,1,"The patient is a 64-year-old Black female who is receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. She has completed 8 cycles of chemotherapy and has a performance status of fully active."
5861,1,"The patient is a 71-year-old white female with a BMI of 19.52. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is mutant."
5862,1,The patient is a 58-year-old Black male who is fully active and is receiving treatment with Sunitinib.
5863,1,"This patient is a 63-year-old white male with a BMI of 24.68. He is currently receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker status is wild-type."
5864,1,This patient is a 61-year-old white female with a BMI of 24.77. She is fully active and is receiving treatment with FOLFOX for a primary tumor diagnosis of rectal cancer. Her KRAS biomarker status is wild-type.
5865,1,"The patient is a 75-year-old white female with a BMI of 33.23. She is receiving treatment with FOLFOX + Cetuximab. Unfortunately, she experienced a serious adverse effect in the form of a bowel perforation after completing 4 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite these challenges, her performance status is fully active. The KRAS biomarker testing revealed that she has a wild-type KRAS status."
5866,0,"The patient is a 51-year-old white male with a BMI of 27.84. He is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5867,0,"The patient is a 38-year-old white female with a BMI of 30.8. She is undergoing treatment with the FOLFOX regimen and has been adherent to her treatment. She experienced a bowel perforation and has completed 12 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite the bowel perforation, her performance status is fully active. Her KRAS biomarker status is wild-type."
5868,0,"The patient is a 61-year-old Black female with a BMI of 23.19. She is receiving the FOLFIRI treatment regimen for her KRAS mutant status. Unfortunately, she is experiencing a serious adverse effect and has developed a bowel obstruction. She has completed 9 cycles of chemotherapy and her histology shows well-differentiated cells. Despite these challenges, her performance status is fully active. Her KRAS biomarker is wild-type."
5869,1,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 4 days post-surgery. The histology showed symptoms but the patient was still able to be ambulatory. The pathology results indicated malignancy.
5870,1,"The patient is a 68-year-old white male participating in the treatment arm involving 5FU/LV + Radiation. He has a performance status of experiencing symptoms but is still able to walk around. The histology shows poorly differentiated cells. The patient is experiencing adverse effects such as low leukocyte count, nausea, anorexia, and fatigue."
5871,0,"The patient is a 46-year-old white male with a BMI of 32.97. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing revealed a mutant status. The patient has experienced adverse effects of thrombosis and diarrhea during the course of treatment."
5872,0,"The patient is a 72-year-old white female with a BMI of 23.19. She is undergoing treatment with the FOLFOX regimen and has experienced a serious adverse effect. She has completed 12 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, the patient's performance status is fully active. The KRAS biomarker analysis indicates that the patient has a mutant KRAS status."
5873,1,The patient is a 55-year-old white male with a BMI of 33.06 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor. The KRAS biomarker shows that he has a wild-type status. The patient is experiencing a rash as an adverse effect of the treatment.
5874,0,"The patient is a 51-year-old white female with a BMI of 28.91 who is receiving treatment with the FOLFOX regimen. She has symptoms but is still able to walk around (ambulatory) despite her condition. The primary tumor diagnosis is colon cancer, and the KRAS biomarker shows that it is wild-type."
5875,0,The patient is a 60-year-old white male with a BMI of 26.79. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type KRAS gene.
5876,1,"The patient is a 73-year-old white male enrolled in the ECF + Radiation treatment arm. He has a performance status of symptoms but is still ambulatory. His histology shows poorly differentiated cancer cells. The patient is experiencing adverse effects such as low levels of neutrophils/granulocytes and leukocytes, as well as symptoms of nausea, anorexia, and fatigue."
5877,0,The patient is a 58-year-old white female receiving treatment with ECF chemotherapy and radiation. She has a performance status of experiencing symptoms but still able to walk around. The histology of her cancer is poorly differentiated. She is experiencing an adverse effect related to low levels of neutrophils/granulocytes.
5878,1,"The patient is a 77-year-old white male receiving treatment with a combination of Cisplatin, Etoposide, and Paclitaxel. He has completed 2 cycles of chemotherapy. Despite experiencing symptoms, he is still able to walk around (ambulatory)."
5879,0,"This patient is a 54-year-old white female with a BMI of 25.31. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has experienced a bowel obstruction and has completed 3 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her condition, her performance status is fully active. Her KRAS biomarker status is wild-type."
5880,0,"The patient is a 43-year-old white female with a BMI of 27.1 who is undergoing treatment with the FOLFOX chemotherapy regimen. She has completed 6 cycles of chemotherapy. Her cancer histology is poorly differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant result. The patient is experiencing diarrhea as an adverse effect of the treatment."
5881,0,"The patient is a 74-year-old white male with a BMI of 26.24. He is receiving the FOLFOX treatment arm for his well-differentiated histology. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite these challenges, his performance status is fully active. Additionally, the patient has a mutant KRAS biomarker."
5882,0,"This patient is a 70-year-old white female with a performance status of experiencing symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology of her condition is poorly differentiated. Additionally, she is experiencing an adverse effect on her neutrophils/granulocytes."
5883,0,"The patient is a 69-year-old Black female with a BMI of 44.42. She is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. She has completed 9 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite the treatment, her performance status is fully active. The KRAS biomarker analysis indicates that she has a mutant KRAS status."
5884,0,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotics for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
5885,1,The patient is a female who is undergoing conventional surgery as part of her treatment. She has used narcotic medication for 4 days. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
5886,0,The patient is a 59-year-old black male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation therapy. He has a histology of poorly differentiated cancer. The patient is experiencing nausea as an adverse effect of the treatment.
5887,1,"The patient is a 78-year-old white female with a BMI of 31.23. She is currently receiving treatment with FOLFOX and Panitumumab. Despite experiencing symptoms, she is still able to walk around (ambulatory). Her primary tumor diagnosis is colon cancer, and her KRAS biomarker status is wild-type."
5888,1,The patient is a 79-year-old white female with a BMI of 24.56. She is fully active with a primary tumor diagnosis of colon cancer. She is receiving treatment with FOLFOX chemotherapy in combination with Panitumumab. Her KRAS biomarker status is wild-type.
5889,0,The patient is a 64-year-old white male who is fully active and is receiving treatment with 5FU/LV + Radiation therapy. The histology of the patient's condition is poorly differentiated.
5890,0,The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications following the surgery. She used narcotics for 4 days post-surgery. The histology results showed symptoms but she was still able to walk around. The pathology results indicated that the condition was malignant.
5891,0,"The patient is a 57-year-old white female with a BMI of 18.48. She is receiving treatment in the FOLFOX + Cetuximab treatment arm. She has a bowel obstruction and has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, her performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5892,1,The patient is a male undergoing treatment with laparoscopic-assisted colectomy. He has bowel adhesions present. He has been using narcotics for 4 days. His histology shows symptoms but he is still ambulatory. The pathology report indicates a malignant condition.
5893,0,"The patient is a 42-year-old white male with a BMI of 35.0. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and is scheduled for 12 chemotherapy cycles. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5894,1,"The patient is a 66-year-old white male undergoing treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy and has experienced significant weight loss of more than 5-10%. Despite experiencing symptoms, he is still able to ambulate. The patient has also developed adverse effects including low granulocytes/bands and low white blood cell count."
5895,0,"The patient is a 43-year-old white male with a BMI of 24.78. He is receiving treatment in the FOLFOX treatment arm and has been adherent to the prescribed treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy. The histology of the cancer is poorly differentiated. Despite the challenges, the patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5896,1,The patient is a 60-year-old white male with a BMI of 30.27 who is currently receiving treatment with FOLFOX. He has a fully active performance status and has been diagnosed with a primary tumor in the rectum.
5897,1,"The patient is a 54-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around. The patient is also experiencing a side effect known as granulocytes/bands."
5898,0,"The patient is a 60-year-old white female with a BMI of 32.64. She is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. She has undergone 12 cycles of chemotherapy. Her histology shows poorly differentiated cells. Despite this, her performance status is fully active. Additionally, the KRAS biomarker indicates a mutant status."
5899,0,"The patient is a 51-year-old white male with a BMI of 27.55. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the adverse effect, his performance status is fully active. The KRAS biomarker analysis indicates a mutant status."
5900,1,"The patient is a 35-year-old white male with a BMI of 41.94. He is receiving the FOLFOX treatment regimen and has completed 8 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
5901,0,The patient is a 67-year-old white male with a BMI of 23.59. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well differentiated. The patient has a fully active performance status. His KRAS biomarker status is mutant.
5902,0,"The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. The histology shows that the tissue is well-differentiated, and the pathology report indicates that the condition is benign."
5903,1,"The patient is a 77-year-old white male receiving treatment with Cisplatin and Etoposide. He has completed 8 cycles of chemotherapy. He has experienced significant weight loss of more than 5-10%. Despite having symptoms, he is still able to walk around (ambulatory)."
5904,0,"The patient is a 54-year-old white female with a high BMI of 54.29. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker testing revealed a mutant status."
5905,0,"The patient is a 75-year-old female of a race categorized as ""other"" with a BMI of 21.93. She is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Additionally, the KRAS biomarker analysis has identified a mutant status."
5906,0,"The patient is a 55-year-old male of a race categorized as ""other"" with a BMI of 18.21. He is undergoing treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker indicates that he has a wild-type KRAS status."
5907,0,"The patient is a 72-year-old white female with a BMI of 28.4. She is currently receiving treatment with FOLFOX + Cetuximab and has been adherent to her medication. She has completed 3 cycles of chemotherapy. Histologically, she has poorly differentiated cancer. Despite this, her performance status is fully active. Her KRAS biomarker is wild-type. The patient has experienced diarrhea as an adverse effect of the treatment."
5908,0,"The patient is a 38-year-old white female with a BMI of 33.24. She is currently undergoing treatment with the FOLFOX chemotherapy regimen and has completed one cycle so far. Her cancer histology is well differentiated. Despite experiencing symptoms, she is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
5909,0,"The patient is a 76-year-old white male with a BMI of 23.65. He is receiving treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells, and his performance status is fully active. His KRAS biomarker is wild-type. Additionally, he has experienced diarrhea as an adverse effect of the treatment."
5910,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has bowel adhesions present. He has been using narcotics for 8 days. His histology shows symptoms but he is still able to be ambulatory. Pathology results indicate a malignant condition.
5911,0,The patient is a male who is undergoing treatment with conventional surgery. He has used narcotics for 3 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5912,1,"The patient is a 47-year-old male of a race categorized as ""other"" who is currently undergoing treatment with ECF chemotherapy combined with radiation therapy. He has a fully active performance status. The histology of his condition is poorly differentiated. He is experiencing adverse effects of nausea and anorexia."
5913,1,"The patient is a 53-year-old white male who is receiving treatment with Cisplatin and Etoposide. He has completed 2 cycles of chemotherapy and has a performance status of fully active. The patient is experiencing an adverse effect known as granulocytes/bands. This adverse effect refers to a decrease in the number of certain types of white blood cells, which are important for fighting infections."
5914,1,"The patient is a 72-year-old white male with a BMI of 27.55. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is poorly differentiated. Despite his age, he has a fully active performance status. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5915,0,"The patient is a 40-year-old white female with a BMI of 27.37. She is receiving treatment with the FOLFOX chemotherapy regimen and is scheduled for 12 cycles. Her cancer histology is well differentiated. Despite her diagnosis, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
5916,0,"The patient is a 69-year-old white male with a BMI of 33.02. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to the treatment. After completing 2 chemotherapy cycles, he experienced serious adverse effects including hypersensitivity and infarction. His histology shows well-differentiated cells, and his performance status is fully active. The KRAS biomarker analysis revealed that he has a wild-type KRAS status."
5917,0,"This patient is a 61-year-old white female with a BMI of 50.87 who is receiving treatment with FOLFOX + Cetuximab. She has experienced a bowel obstruction and has completed 7 cycles of chemotherapy. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type gene. She has also experienced a hypersensitivity adverse effect."
5918,0,"The patient is a 54-year-old white female with a BMI of 33.87. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows poorly differentiated cancer cells. Despite this, her performance status is fully active. The KRAS biomarker testing revealed a mutant status. The patient has experienced an adverse effect of thrombosis."
5919,1,The patient is a male who underwent conventional surgery as part of their treatment. They experienced complications following the surgery. They used narcotics for 9 days post-surgery. The histology showed symptoms but the patient was still able to move around. The pathology report indicated that the condition was malignant.
5920,0,"The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the surgery. The histology indicates that she is in bed less than 50% of the time, and the pathology results show that the condition is malignant."
5921,1,"The patient is a 57-year-old white male with a BMI of 33.83. He is receiving the FOLFIRI treatment regimen for his KRAS mutant status and has been adherent to the treatment. He has experienced a bowel obstruction. The patient has completed 12 cycles of chemotherapy and has well-differentiated histology. Despite the bowel obstruction, his performance status is fully active. His KRAS biomarker is wild-type."
5922,1,"The patient is a 55-year-old white female with a BMI of 28.7. She is currently receiving treatment with FOLFOX for her colon cancer. Despite experiencing symptoms, she is still able to walk around (ambulatory). The KRAS biomarker testing revealed that she has a wild-type KRAS gene."
5923,0,"The patient is a 51-year-old white female with a BMI of 25.3. She is receiving treatment in the FOLFOX chemotherapy arm and has been adherent to her treatment. She has completed 12 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
5924,0,"The patient is a 57-year-old white male with a BMI of 34.94 who is fully active. He is receiving treatment with FOLFOX and Panitumumab for a primary rectal tumor with a mutant KRAS biomarker. The patient is experiencing dermatitis acneiform as an adverse effect of the treatment, which presents as acne-like skin irritation."
5925,0,"The patient is a 66-year-old white female with a BMI of 29.04. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well-differentiated, and she has a fully active performance status. The KRAS biomarker analysis shows that she has a wild-type KRAS status."
5926,0,"The patient is a 58-year-old white male with a BMI of 26.19. He is undergoing treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology shows that the cancer is well-differentiated. The patient has a fully active performance status, and the KRAS biomarker indicates that it is wild-type."
5927,0,"The patient is a 73-year-old white female with a BMI of 32.3 who is receiving the FOLFOX treatment regimen for her well-differentiated cancer. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to move around (ambulatory). The KRAS biomarker testing showed that she has a wild-type KRAS status. She is currently experiencing diarrhea as an adverse effect of the treatment."
5928,1,"The patient is a 57-year-old white male with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. He has a histology of poorly differentiated. The patient is experiencing anorexia as an adverse effect, which is a decreased appetite or loss of interest in food."
5929,1,"This patient is a 76-year-old white male with a BMI of 29.22. He is undergoing treatment with FOLFOX + Cetuximab and has experienced a serious adverse effect. He has completed 11 cycles of chemotherapy. The histology of his cancer is well-differentiated. Despite his age, he has a fully active performance status. His KRAS biomarker status is wild-type."
5930,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has used narcotics for 2 days. His histology shows symptoms but he is still able to move around. The pathology report indicates that the condition is malignant.
5931,0,"The patient is a 70-year-old male of a race other than specified, with a BMI of 25.44. He is receiving the FOLFOX treatment regimen and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cells. Despite the adverse effect, the patient's performance status is fully active. The KRAS biomarker indicates that the patient has a wild-type gene."
5932,0,"The patient is a 63-year-old white female with a BMI of 29.76 who is currently receiving treatment with FOLFOX. She has symptoms but is still able to walk around (ambulatory). Her primary tumor diagnosis is rectal cancer, and her KRAS biomarker status is wild-type."
5933,0,"The patient is a 66-year-old white male with a BMI of 28.98. He is receiving treatment with FOLFIRI due to having a KRAS mutant status. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite his age, the patient has a fully active performance status. His KRAS biomarker is wild-type."
5934,0,The patient is a 74-year-old white male with a BMI of 31.05. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX (a chemotherapy regimen) in combination with Panitumumab. His KRAS biomarker status is wild-type.
5935,0,The patient is a male undergoing laparoscopic-assisted colectomy. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the cause of his symptoms is malignant.
5936,0,The patient is a female who underwent laparoscopic-assisted colectomy. She only used narcotics for 1 day following the procedure. The histology shows symptoms but she is still able to move around. The pathology report indicates that the cause of her symptoms is malignant.
5937,0,"The patient is a 44-year-old male of a race categorized as ""other"" with a BMI of 36.73. He is undergoing treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated characteristics. Despite experiencing symptoms, the patient is still able to be ambulatory. Additionally, his KRAS biomarker indicates a wild-type status."
5938,0,"The patient is a 76-year-old white male with a BMI of 31.73. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. He has completed 12 chemotherapy cycles. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. His KRAS biomarker is wild-type. He is experiencing diarrhea as an adverse effect of the treatment."
5939,1,"The patient is a 75-year-old female of a race categorized as ""other"" with a BMI of 28.18. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 8 cycles of chemotherapy. The histology indicates that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker testing revealed a mutant status."
5940,0,The patient is a female who underwent conventional surgery and has bowel adhesions. She has been using narcotics for 5 days and her histology shows symptoms but she is still able to be ambulatory. The pathology report indicates malignancy.
5941,0,"The patient is a 43-year-old white female with a BMI of 37.75 who is undergoing treatment with FOLFOX + Cetuximab. She has been adherent to her treatment and has completed 12 cycles of chemotherapy. The patient's histology shows well-differentiated cancer, and she has a performance status of experiencing symptoms but still able to be ambulatory. Her KRAS biomarker is wild-type. The patient has experienced a serious adverse effect in the form of an infection."
5942,0,The patient is a 48-year-old white female with a BMI of 27.38. She is receiving the FOLFOX treatment regimen and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer cells. The patient has a fully active performance status and her KRAS biomarker is wild-type.
5943,0,"This patient is a 54-year-old white male with a BMI of 23.92. He is receiving treatment with FOLFOX + Cetuximab for his cancer. He has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. The histology of his cancer is well differentiated. Despite the challenges, his performance status is fully active. Additionally, the KRAS biomarker testing revealed a mutant status."
5944,0,"The patient is a 48-year-old female of a race categorized as ""other"" with a BMI of 26.21. She is undergoing treatment with the FOLFIRI chemotherapy regimen and has completed 12 cycles. The histology of her cancer is poorly differentiated. Despite experiencing symptoms, she is still able to ambulate, indicating a relatively good performance status. Additionally, her KRAS biomarker status is wild-type."
5945,1,The patient is a 66-year-old white female with a BMI of 32.27 who is currently receiving treatment with FOLFOX for colon cancer. She has symptoms but is still able to walk around (ambulatory). The KRAS biomarker shows that she has a wild-type status.
5946,1,"The patient is a 70-year-old white male with a BMI of 28.27. He is currently receiving treatment in the FOLFOX + Panitumumab treatment arm. Despite experiencing symptoms, he is still able to walk around (ambulatory). The primary tumor diagnosis is colon cancer, and the KRAS biomarker indicates that it is wild-type."
5947,0,The patient is a male who underwent laparoscopic-assisted colectomy. He has bowel adhesions present. He used narcotics for 3 days post-surgery. The histology shows symptoms but the patient is ambulatory. The pathology report indicates a malignant condition.
5948,1,The patient is a 65-year-old white female with a fully active performance status who is receiving treatment with 5FU/LV + Radiation. She has a histology of poorly differentiated cancer. An adverse effect noted is a decrease in neutrophils/granulocytes.
5949,0,"The patient is a 59-year-old female of a race categorized as ""other"" with a BMI of 28.0. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed one cycle of chemotherapy. The histology of her condition is well-differentiated, and her performance status is fully active. Additionally, the KRAS biomarker analysis indicates that she has a wild-type KRAS status."
5950,0,"The patient is a 56-year-old Black female with a BMI of 26.82. She is receiving treatment with FOLFOX + Cetuximab for her well-differentiated histology. She has experienced a bowel obstruction and has completed 12 cycles of chemotherapy. Despite this, her performance status is fully active. Her KRAS biomarker status is wild-type."
5951,0,"The patient is a 60-year-old white male with a BMI of 31.84. He is receiving treatment with FOLFOX + Cetuximab and has completed one cycle of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker analysis shows that he has a wild-type KRAS status."
5952,0,The patient is a 60-year-old white male with a BMI of 23.56. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker testing revealed a mutant status.
5953,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She has experienced symptoms but is still able to walk around. The pathology report indicates malignancy. She has used narcotics for 3 days.
5954,0,"The patient is a 40-year-old white female with a BMI of 24.58 who is receiving the FOLFOX treatment regimen. She has experienced a serious adverse effect during her 9 chemotherapy cycles. Her histology shows well-differentiated cells, and her performance status is fully active. The KRAS biomarker indicates she has a wild-type status. She has also experienced adverse effects of diarrhea and infection."
5955,1,This patient is a 35-year-old white female receiving treatment with the FOLFOX regimen for colon cancer. She has a BMI of 18.61 and has a performance status indicating that she is in bed less than 50% of the time.
5956,0,"The patient is a 45-year-old white male with a BMI of 24.39. He is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles so far. His cancer histology is well differentiated, and he has a fully active performance status. Additionally, the KRAS biomarker testing showed that he has a wild-type KRAS status."
5957,0,"The patient is a 65-year-old white male with a BMI of 22.06. He is fully active with a primary tumor diagnosis of colon. He is receiving treatment with FOLFOX and Panitumumab, and his KRAS biomarker status is wild-type."
5958,0,"The patient is a 64-year-old white male with a BMI of 30.26. He is receiving treatment with the FOLFOX chemotherapy regimen and has been adherent to the treatment. He has completed 12 cycles of chemotherapy. The histology of his cancer is poorly differentiated. Despite experiencing symptoms, he is still able to be ambulatory. The KRAS biomarker testing revealed that he has a wild-type KRAS status."
5959,0,"The patient is a 64-year-old white female with a BMI of 24.88. She is currently receiving treatment in the FOLFOX + Cetuximab treatment arm and has been adherent to her medication. She has completed 4 cycles of chemotherapy. The histology shows that the cancer is well-differentiated. Despite experiencing symptoms, the patient is still able to be ambulatory. The KRAS biomarker indicates that she has a wild-type status."
5960,1,The patient is a 50-year-old white female with a BMI of 21.36 who is fully active. She is receiving treatment with FOLFOX for a primary colon tumor diagnosis. The KRAS biomarker indicates that she has a wild-type status.
5961,0,"This patient is a 73-year-old white female with a BMI of 23.33. She is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. Her cancer histology is well differentiated, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
5962,1,"The patient is a 61-year-old white male with a BMI of 31.72 who is undergoing treatment with the FOLFIRI chemotherapy regimen. He has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has a fully active performance status. The KRAS biomarker testing showed that he has a wild-type KRAS status. The patient is experiencing diarrhea as an adverse effect of the treatment."
5963,1,The patient is a 61-year-old white male with a BMI of 28.73 who has symptomps but remains ambulatory. He is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor. The KRAS biomarker indicates that he has a wild-type status. The patient is experiencing a dermatitis acneiform as an adverse effect of the treatment.
5964,0,"This patient is a 55-year-old white female with a BMI of 20.12. She is receiving treatment with FOLFIRI + Cetuximab for her well-differentiated cancer. She has completed 12 cycles of chemotherapy. Despite experiencing symptoms, she is still able to be ambulatory. Her KRAS biomarker is mutant. She is also experiencing diarrhea as an adverse effect of her treatment."
5965,0,The patient is a 51-year-old white male with a BMI of 29.31. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cells. The patient has a fully active performance status and his KRAS biomarker is wild-type.
5966,0,The patient is a male who underwent laparoscopic-assisted colectomy. He used narcotics for 2 days post-surgery. His histology shows symptoms but he is still able to be ambulatory. The pathology report indicates that the cause of his symptoms is malignant.
5967,0,The patient is a 46-year-old white female with a BMI of 27.53. She is receiving the FOLFOX treatment regimen and has completed 10 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that the patient has a wild-type KRAS gene.
5968,0,The patient is a male who is undergoing conventional surgery. He has abdominal wall adhesion and bowel adhesion. He has been using narcotics for 4 days. His histology shows symptoms but he is still able to walk around. The pathology report indicates that the condition is malignant.
5969,0,"The patient is a 41-year-old white female with a BMI of 28.39. She is receiving treatment with FOLFOX and has been adherent to the treatment. She has experienced both bowel obstruction and bowel perforation. The patient has completed 12 cycles of chemotherapy. Histologically, the cancer is well-differentiated. Despite the bowel issues, her performance status is fully active. The KRAS biomarker shows that she has a wild-type status."
5970,0,"The patient is a 63-year-old white male with a BMI of 21.25. He is receiving the FOLFOX treatment arm and has completed 10 cycles of chemotherapy. His histology shows poorly differentiated cancer cells. Despite this, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS gene. The patient has experienced a hypersensitivity adverse effect."
5971,0,"The patient is a 49-year-old white female with a BMI of 28.58. She is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. Her histology shows well-differentiated cancer, and she has a fully active performance status. Additionally, her KRAS biomarker is wild-type."
5972,1,"The patient is a 61-year-old white male with a BMI of 29.42. He is fully active with a primary tumor diagnosis of rectal cancer. The patient's KRAS biomarker status is wild-type, and he is receiving treatment with the FOLFOX regimen."
5973,0,"The patient is a 55-year-old white male with a BMI of 29.26. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer, and he has a fully active performance status. The KRAS biomarker indicates he is wild-type. The patient has experienced an infection as an adverse effect during treatment."
5974,1,"The patient is a 74-year-old white male with a BMI of 24.25. He is receiving treatment with FOLFOX + Cetuximab and has been adherent to the treatment. Unfortunately, he experienced a serious adverse effect in the form of a bowel perforation. He has completed 9 cycles of chemotherapy and has a well-differentiated histology. Despite the adverse effect, his performance status remains fully active. The patient's KRAS biomarker is mutant. In addition to the bowel perforation, he has also experienced adverse effects in the form of diarrhea and infection."
5975,1,"The patient is a female who underwent laparoscopic-assisted colectomy. She has abdominal wall adhesions and bowel adhesions. There have been complications during her treatment. She used narcotics for 4 days post-surgery. Despite having symptoms, she is able to move around and is ambulatory. The pathology report indicates malignancy."
5976,0,The patient is a 61-year-old white male with a BMI of 25.76. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a primary colon tumor diagnosis. The KRAS biomarker indicates that the patient has a mutant KRAS status.
5977,1,The patient is a 60-year-old white female with a performance status indicating symptoms but still able to walk around. She is receiving treatment with 5FU/LV and radiation therapy. The histology shows poorly differentiated cells.
5978,0,"The patient is a 73-year-old white female with a BMI of 23.82. She is receiving treatment with the FOLFOX chemotherapy regimen and has completed 12 cycles. The histology of her cancer is well-differentiated. Despite her age, she has a fully active performance status. Her KRAS biomarker status is wild-type."
5979,0,"The patient is a 40-year-old white male with a BMI of 36.11. He is undergoing treatment with the FOLFOX chemotherapy regimen and is expected to complete 12 cycles. His cancer histology is well-differentiated, and he has a fully active performance status. Additionally, his KRAS biomarker status is wild-type."
5980,0,"The patient is a 74-year-old white male with a BMI of 29.1. He is receiving treatment in the FOLFOX + Cetuximab treatment arm and has completed 12 cycles of chemotherapy. His histology shows well-differentiated cancer cells. Despite his age, he has a fully active performance status. The KRAS biomarker analysis indicates that he has a mutant KRAS status."
5981,0,"The patient is a 67-year-old male of a race categorized as ""other"" with a BMI of 26.7. He is undergoing treatment with FOLFIRI + Cetuximab and has experienced a serious adverse effect. He has completed 12 cycles of chemotherapy. The histology of his condition is well-differentiated. Despite the adverse effect, his performance status is fully active. Additionally, the KRAS biomarker indicates that he has a wild-type status."
5982,1,"The patient is a male who underwent laparoscopic-assisted colectomy. He experienced complications post-surgery and required narcotic pain medication for 3 days. Despite the symptoms, he was still able to be ambulatory. The pathology report revealed a malignant condition."
5983,1,This patient is a 60-year-old white male with a BMI of 28.65. He is fully active and is receiving treatment with FOLFOX for a primary colon tumor. His KRAS biomarker status is wild-type.
5984,0,The patient is a female who underwent conventional surgery and has abdominal wall adhesions. She used narcotics for 3 days post-surgery. Her histology shows symptoms but she is still able to walk around. The pathology report indicates that the tumor is malignant.
5985,1,"The patient is a 64-year-old white male with a history of prior cancer. He is currently receiving treatment with 5FU/LV and radiation therapy. Despite experiencing symptoms, he is still able to be ambulatory. The histology of his cancer is poorly differentiated. He is experiencing adverse effects including low levels of neutrophils/granulocytes and leukocytes, as well as anorexia and fatigue."
5986,0,"The patient is a 42-year-old white male with a BMI of 23.8. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker indicates that he has a wild-type mutation."
5987,1,"The patient is a 74-year-old black male with a well-differentiated histology who is part of the treatment arm receiving ECF chemotherapy along with radiation. Despite experiencing symptoms, the patient is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes."
5988,0,The patient is a 58-year-old white male with a BMI of 30.12. He is receiving the FOLFOX treatment regimen and has experienced a bowel obstruction. He has completed 12 cycles of chemotherapy. The histology shows well-differentiated cancer cells. The patient has a fully active performance status. The KRAS biomarker indicates that he has a wild-type mutation.
5989,0,"The patient is a 68-year-old white male with a BMI of 22.82. He is enrolled in the FOLFOX + Cetuximab treatment arm. He is currently experiencing a bowel obstruction. The patient has not undergone any chemotherapy cycles yet. His histology shows well-differentiated cells. Despite the bowel obstruction, his performance status is fully active. The KRAS biomarker analysis indicates that he has a wild-type KRAS status."
5990,0,The patient is a female who underwent conventional surgery as part of her treatment. She used narcotics for 4 days following the procedure. Her histology shows symptoms but she is still able to walk around. The pathology results indicate that the condition is malignant.
5991,1,This patient is a 61-year-old white female who is receiving treatment with 5FU/LV + Radiation. She has a performance status of being in bed less than 50% of the time. The histology of her condition is poorly differentiated. She is experiencing an adverse effect related to neutrophils/granulocytes.
5992,1,"The patient is a female who underwent conventional surgery as part of her treatment. She experienced complications post-surgery and required narcotic pain medication for 2 days. Despite having symptoms, she is still able to move around and be ambulatory. The pathology results indicated that the condition is malignant."
5993,1,"The patient is a 69-year-old white female undergoing treatment with Cisplatin and Etoposide. She has completed 8 cycles of chemotherapy. Despite experiencing symptoms, she is still able to walk around (ambulatory). The patient is also experiencing adverse effects related to her granulocytes/bands and white blood cells."
5994,0,"The patient is a 47-year-old white female with a BMI of 25.26. She is receiving treatment with FOLFIRI for KRAS mutant cancer. She has completed 2 cycles of chemotherapy. The histology of her cancer is poorly differentiated. Despite her diagnosis, she has a fully active performance status. Her KRAS biomarker is wild-type."
5995,0,"The patient is a 56-year-old white female with a BMI of 28.68 who is fully active. She is receiving treatment with FOLFOX and Panitumumab for colon cancer with a wild-type KRAS biomarker. She is experiencing dermatitis acneiform as an adverse effect, which presents as a skin rash resembling acne."
5996,0,"The patient is a 47-year-old white male with a BMI of 26.45. He is receiving treatment with FOLFOX + Cetuximab and has completed 12 cycles of chemotherapy. His cancer histology is well-differentiated, and he has symptoms but is still able to walk around (ambulatory). The KRAS biomarker is wild-type. The patient has experienced hypersensitivity and diarrhea as adverse effects during treatment."
5997,1,The patient is a 50-year-old white male with a BMI of 26.57. He is fully active and is receiving treatment with FOLFOX and Panitumumab for a colon cancer diagnosis. The KRAS biomarker indicates that the patient has a mutant form of the gene.
5998,0,The patient is a 54-year-old white male with a fully active performance status who is receiving treatment with ECF chemotherapy and radiation. The histology of the cancer is well-differentiated. The patient is experiencing adverse effects related to low levels of neutrophils/granulocytes and leukocytes.
5999,0,"The patient is a 70-year-old white male with a BMI of 27.34. He is currently receiving treatment with FOLFOX chemotherapy combined with Panitumumab. Despite experiencing symptoms, he is still able to walk around (ambulatory). He has been diagnosed with a primary tumor in the colon, and his KRAS biomarker status is wild-type."
6000,0,"The patient is a 45-year-old white female with a BMI of 18.79. She is currently receiving the FOLFOX treatment regimen for her cancer. She is experiencing a bowel obstruction and has completed 7 cycles of chemotherapy. The histology of her cancer is well-differentiated. Despite her condition, she has a fully active performance status. Additionally, her KRAS biomarker status is wild-type."
6001,1,"The patient is a 50-year-old white male with a BMI of 30.62 who is currently receiving treatment with FOLFOX and Panitumumab for a rectal tumor. He has mutant KRAS biomarker status. Despite experiencing symptoms, he is still able to move around and be ambulatory."
